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Abstract 
 
The ‘smell’ of illness, disease or age has been known for many centuries, mainly created by 
volatile organic compounds (VOCs).  Dogs were first reported to detect cancer in 2004.  
Increasingly, the profiles of VOCs are being utilised as non-invasive diagnostic methods.   
The aim of the thesis was to develop and evaluate the performance of analytical methods to 
characterise the disease states of patients utilising selective discrimination, gas 
chromatography-mass spectrometry (GC-MS) and chemometrics.  The primary analytical 
technique investigated was GC-Time-of-Flight-MS coupled with headspace solid-phase 
microextraction (HS-SPME-GC-ToFMS).  A robust and sensitive method was developed by 
optimisation of all sample analysis parameters and was applied to clinical samples from 
bladder and prostate cancer patients and those with hepatic disorders.  This evidence was 
obtained by quantifying an internal standard, present in every sample and blank throughout 
the studies.  Based on these findings, large numbers of clinical samples were analysed with 
confidence. 
Statistically significant mathematical models were developed in partnership with Cranfield 
University to classify the diseased state of samples and clinically relevant controls.  PLS-
DA was determined as the best classifier.  The results from the HS-SPME-GC-ToFMS 
studies were highly promising.  Bladder cancer gave a mean accuracy of >80 % and even 
low-grade tumours gave a sensitivity of 73 %, superior to urine cytology.  Higher clinical 
performance was obtained in the prostate cancer study, with BPH distinguishable from 
cancer.  Hepatic disorders were better again (>86 %).  Preliminary studies on sepsis detection 
also showed promise. 
Several recommendations were made to enable significant clinical results in the future based 
on analytical rigour. 
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°C  degrees Celsius 
AES  atomic emission spectrometry 
ANN  artificial neural network 
ASTM  American Society of the International Association for Testing and Materials 
AUROC area under receiver operator characteristic 
β   phase ratio 
bp  boiling point 
Co  initial concentration 
Cg  concentration in the gas-phase 
Cs   concentration in the sample 
C∞f  concentration on the fibre at equilibrium 
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COW  correlation optimised warping 
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DC  direct current 
DI  deionised 
DI-SPME direct immersion solid-phase microextraction 
DVB  divinylbenzene 
EI  electron ionisation 
EIC  extracted ion chromatogram 
ek  kinetic energy 
EM  electron multiplier 
EPA  Environmental Protection Agency 
FA  fatty acid 
FAME  fatty acid methyl ester 
FDR  false discovery rate 
FN  false negative 
FP  false positive 
GC  gas chromatograph or gas chromatography 
GC-MS gas chromatograph hyphenated to a mass spectrometer 
GCxGC comprehensive two-dimensional gas chromatography 
GLC  gas liquid chromatography 
GNP  organically-stabilised spherical gold nanoparticle  
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H  height equivalent of a theoretical plate 
HCA  hierarchical cluster analysis 
HCV  hepatitis C virus 
HED  high energy dynode 
HETP  height equivalent of a theoretical plate 
HRMS  high resolution mass spectrometer 
HS  headspace analysis 
HS-SPME headspace solid-phase microextraction 
Hz  hertz (one cycle per second) 
i.d.   internal diameter 
IARTL indoor air toxic retention time locked 
IR  infrared 
IS  internal standard 
ISO   International Organisation for Standardisation 
K  partition coefficient 
Kfs  partition coefficient of analyte between coating and sample 
L  litre 
LC  liquid chromatography 
LC-MS liquid chromatograph hyphenated to a mass spectrometer 
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LOO-CV leave-one-out cross-validation 
LV  latent variable 
µL  microlitre 
µm  micrometre or micron 
m  mass 
mg  milligram 
min  minute 
mL  millilitre 
mm  millimetre 
ms  millisecond 
MCP  micro-channel plate 
MLR  multiple linear regression 
MS  mass spectrometer or mass spectrometry 
MTBE  methyl-tert-butyl ether 
m/z  mass to charge 
MW  molecular weight 
n  mass of analyte 
NCI  negative chemical ionisation 
NMR   nuclear magnetic resonance 
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NPV  negative predictive value 
o.d.   outside diameter 
OU  Open University 
PA   polyacrylate 
PAH  poly aromatic hydrocarbon 
PC  principal component 
PCA  principal component analysis 
PCI  positive chemical ionisation 
PDMS  polydimethylsiloxane 
PEG  polyethylene glycol 
PLS  partial least squares 
PLS-DA partial least squares discriminant analysis 
PNN  probabilistic neural network 
ppt   parts-per-trillion 
PPV  positive predictive value 
psi  pound per square inch 
PTR  proton transfer reaction 
PTV  programmable temperature vapouriser 
PVC  poly vinyl chloride 
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qMS  quadrupole mass spectrometer 
RFs  random forests 
RF  radio frequency 
ROC  receiver operator characteristic 
RNA  ribonucleic acid 
rpm  revolutions per minute 
RSA  reduced surface activity 
RSD (%) percentage relative standard deviation 
RTL  retention time lock 
s  second 
SN  signal-to-noise 
SPME  solid-phase microextraction 
STDDEV standard deviation 
SVM  support vector machine 
SVM-LIN linear support vector machine 
SVM-RBF radial basis function support vector machine 
SVOC  semi-volatile organic compound 
SWCNT single-walled carbon nano-tube 
TD  thermal desorption 
xi 
 
ToFMS time-of-flight mass spectrometer 
TN  true negative 
TP  true positive 
u  unified atomic mass unit 
u  velocity of the mobile phase 
UCLH  University College London Hospital 
UV-Vis ultraviolet-visible 
v  velocity 
V  volts 
Vf  volume of the coating 
Vg   volume of the gas-phase 
Vs  volume of the sample 
vs.  versus 
VOC  volatile organic compound 
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1. Aims 
The aim of the thesis is to develop and evaluate the performance of non-invasive methods to 
characterise the disease states of patients utilising selective discrimination, gas 
chromatography-mass spectrometry and chemometrics. 
The primary analytical method to be investigated is gas chromatography-time-of-flight mass 
spectrometry coupled with solid-phase microextraction. The hypothesis is: 
i) As previously demonstrated by dogs, the headspace above a urine sample will 
contain a profile of volatile organic compounds that can be utilised to diagnose 
the presence or absence of disease.  
ii) The sampling method parameters and the SPME fibre coatings can be optimised 
to reproducibly extract a wide range of volatile organic compounds from the 
headspace above complex matrices, such as urine.  
iii) Harnessing the separating power of gas chromatography will enable very similar 
compounds to be resolved temporally, enabling the wide range of volatile organic 
compounds to be characterised and their abundance to be compared between 
samples. 
iv) Coupling of the chromatography eluent with the fast acquisition rate of a time-
of-flight mass spectrometer further enhances the resolving power, by enabling 
the capture of the full mass spectrum at such a rate that peak deconvolution is 
also possible. 
v) Analysis of the rich data sets produced, by bespoke algorithms, will allow the 
disease state of a patient to be accurately determined. 
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1.1 Background 
The ‘smell’ of illness, disease or age has been known for many centuries, with some smells, 
such as stale sweat, mucus and cough medicine being easily identifiable as likely to be from 
someone with a bad cold or flu.  Whereas, other smells, much like those associated with 
decay, indicate that someone doesn’t smell ‘right’ without knowing the cause - illness or 
disease.  Some diseases and their associated smells are listed in Table 1-1 (Wilson & Baietto, 
2011). 
Until recently, malodour hasn’t been investigated for use in clinical medicine as a 
quantifiable diagnostic tool, to tell if someone is sick or to diagnose which illness or disease 
that person suffers from (Kusuhara, et al., 2010).  There are notes in medical textbooks 
referring to the fact that patient odour is useful, particularly in the diagnosis of congenital 
metabolic diseases in infants.  An example is Maple Syrup disease, where the urine is very 
sweet smelling, like maple syrup, after birth (NHS Choices information, 2015). However, it 
is mainly in the last couple of decades that ‘smell’ has been investigated as a diagnostic tool 
and clinicians have gathered evidence in a scientific manner (Wilson & Baietto, 2011).  The 
profiles of volatile organic compounds (VOCs) are increasingly being utilised as non-
invasive diagnostic methods for determining the presence, or absence, of an illness or 
disease.   
Smells are created by volatile compounds, usually with a low molecular weight of 350 g or 
less.  Olfactory detection is the term that covers the study of compounds responsible for 
smell and it has been widely applied in the food and fragrance sector, with over 8,000 
volatiles detected and identified; however, less than 5 % of these compounds contributed to 
the aromas of these foods (Grosch, 2001).   
  
4 
 
Table 1-1: Diseases and their associated smells 
Disease/ Disorder Body source Descriptive aroma 
Acromegaly Body  Strong, offensive
Anaerobic infection Skin, sweat Rotten apples
Azotemia (prerenal) Urine Concentrated urine odour
Bacterial proteolysis Skin Over-ripe Camembert
Bacterial vaginosis Vaginal discharge Amine-like
Bladder infection Urine  Ammonia 
Bromhidrosis Skin, nose Unpleasant
Darier’s disease Buttocks  Rank, unpleasant odour
Diabetic ketoacidosis Breath Rotting apples, acetone
Congestive heart failure Heart (portcaval shunts) Dimethyl sulphide
Cystic fibrosis Infant stool Foul
Diabetes mellitus Breath Acetone-like
Diphtheria Sweat Sweet
Empyema (anaerobic) Breath Foul, putrid
Esophageal diverticulum Breath Feculent, foul
Fetor hepaticus Breath Newly-mown clover, sweet
Gout Skin Gouty odour
Hydradenitis suppurativa Apocrine sweat glands Bad body odour
Hyperhydrosis Body  Unpleasant body odour
Hyperaminoaciduria  Infant skin Dried malt or hops
Hypermethioninemia Infant breath Sweet, fruity, fishy, boiled cabbage, rancid 
butter
Intestinal obstruction Breath Feculent, foul
Intranasal foreign body Breath Foul, feculent
Isovaleric academia Skin, sweat, breath Sweaty feet, cheesy
Ketoacidosis (starvation) Breath Sweet, fruity, acetone-like
Liver failure Breath Musty fish, raw liver, mercaptans, dimethyl 
sulphide
Lung abscess Sputum, breath Foul, putrid, full
Maple syrup urine disease Sweat, urine, ear wax Maple syrup, burnt sugar
Phenylketonuria Infant skin Musty, horsey, mousy, sweet urine 
Pneumonia (necrotizing) Breath Putrid
Pseudomonas infection Skin, sweat Grape
Renal failure (chronic) Breath Stale urine
Rotavirus gastroenteritis Stool Full
Rubella Sweat Freshly plucked feathers
Schizophrenia Sweat Mildly acetic
Scrofula Body Stale beer
Scurvy Sweat Putrid
Shigellosis Stool Rancid
Smallpox Skin Pox stench
Squamous-cell carcinoma Skin Offensive odour
Sweaty feet syndrome Urine, sweat, breath Foul acetic
Trench mouth Breath Halitosis
Trimethylaminuria Skin, urine Fishy
TB lymphadenitis Skin Stale beer
Tubular necrosis (acute) Urine Stale water
Typhoid Skin Freshly-baked brown bread
Uremia Breath Fishy, ammonia, urine-like
Vagabond’s disease Skin Unpleasant
Varicose ulcers, malignant Leg Foul, unpleasant
Yellow fever Skin Butcher’s shop  
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Volatile compounds can emerge from the body in several ways including: excretion in the 
breath; secretions from the skin as sweat; secretions from mucous membranes in the nose, 
mouth, ears and urogenital area; and excretion in the urine and faeces.  In the 1960s rats were 
trained to differentiate the sweat between schizophrenic patients and non-schizophrenic 
people (Smith, et al., 1969) and the compound was reportedly isolated and identified by gas 
chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance (NMR).  
Various reports followed, with a paper published in 2005 (Di Natale, et al., 2005) which 
reported that no single biomarker could be identified to differentiate between the three 
sample classes of schizophrenics, other mental disorders and controls using GC-MS and a 
chemical sensor array.  However, by considering the whole sample the classification could 
be achieved.  
There has been much research studying breath in recent years, with around 3,000 volatile 
organic compounds (VOCs) being detected in breath but only 20-30 of these being present 
in all humans (Phillips, et al., 1999).  Numerous examples of conditions which induce VOC 
changes, often manifested through odour in the breath, have been documented.  Arguably 
the most familiar breath analysis application is the diagnosis of diabetic ketoacidosis, where 
the breath acquires a characteristic ‘pear drop’ odour (Probert, et al., 2009).  However, lung 
cancer (Horvath, et al., 2009), breast cancer (Philips, et al., 2006), gastric cancer (Amal, et 
al., 2015), colorectal cancer (Amal, et al., 2016) and other diseases (Lourenco & Turner, 
2014) have also been studied, . 
The excreted or secreted odorous compounds causing the smell can be because of the intake 
of chemicals into the body. For example, eating garlic or smoking. They can also be caused 
by chemical reactions occurring inside the body caused by bacteria, cancers and diseases. 
Cancer is the largest cause of death in the world, with malignant neoplasms causing 7.87 
million deaths in 2011, compared to 7.02 million caused by ischaemic heart disease and 6.25 
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million caused by stroke (World Health Organization, 2014).  Cancer causes changes in 
genes, which results in changes to the proteins and enzymes within the cells that eventually 
produce modified metabolites.  These metabolites are then excreted from the body through 
urine or from the lungs in the patient’s breath, or can be secreted from the skin and mucous 
membranes.  Endogenous bacteria, within different organs within the body, can also 
metabolise some of these modified metabolites, producing different volatile organic 
compounds (VOCs).  These metabolites can differ, depending on which organ the cancerous 
cells are present in, and hence can be a route to determining which cancer type is present.  
Necrosis or tissue death from the cancer can also produce volatile compounds (Mazzone, 
2008). 
Bacterial cultures produce hundreds of volatile compounds.  In the past, the unique smells 
of different bacteria enabled identification, for example Pseudomonas aeruginosa smells 
like grapes, Streptococcus anginosus smells like caramel or butterscotch, Clostridium 
difficile like a ‘barnyard’ and other anaerobic and enteric bacteria (from the intestines) like 
Salmonella smell terrible (Bawdon, et al., 2015).  On the body, bacteria make humans smell 
‘bad’, for example Staphylococcus hominis is responsible for the body odour (BO) smell 
when sweat is digested by this bacterium on the skin (Bawdon, et al., 2015).   
In humans, olfactory detection of volatile compounds is through olfactory receptors in the 
nasal cavity.  The volatile compounds in the air dissolve into the mucus and bind with the 
receptors.  There are 390 known functional olfactory receptor genes in humans and 299 
subfamilies; however, in dogs there are 872 genes and 300 subfamilies (Niimura & Nei, 
2006).  Humans have around 10 million olfactory cells with 8-12 microvilli (microscopic 
cellular membrane protrusions) each, whereas dogs have around 200 million cells with 
around 125 microvilli each.  However, the number of receptors, cells and microvilli is 
reportedly not a definitive indicator of how good the species is at detecting smells (Shepherd, 
2004), as it is also attributed to the perception and recognition of the smell by the brain. 
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Dogs have been used in many roles, that rely on their excellent sense of smell.  ‘Sniffer’ 
dogs have been trained to detect explosives, illegal drugs, arson, food, human remains and 
even bed bugs (Lewis, et al., 2013). 
Dogs were first reported to be able to detect cancer in a report in the Lancet in 1989 
(Williams & Pembroke, 1989), where a dog discovered a malignant melanoma.  Since then, 
dogs have been trained to detect cancer by sniffing the headspace above the urine of bladder 
cancer patients.  Willis and colleagues (Willis, et al., 2004) trained six dogs of varying ages 
and breeds to distinguish between urine samples from 36 male and female patients suffering 
from new or recurrent transitional cell carcinoma of the bladder (TCC) and 108 male and 
female controls, who were healthy or were diseased but did not have bladder cancer.  
Twenty-seven of the TCC samples and 54 control samples were used in the training.  The 
remaining 9 TCC samples and 54 control samples were used in the evaluation.  The aim was 
to train the dogs to identify the urine from the bladder cancer patients based on the cancer 
status alone, rather than the secondary effects of bleeding, inflammation, infection and 
necrosis.  Six dogs of different breeds and ages were trained over 7 months.  For the 
evaluation, one TCC sample was placed amongst six control samples and each dog assessed 
for correctly selecting the TCC sample.  Nine test panels, each with one bladder cancer and 
six control samples, were run, giving a total of 54 assessments in all.  The dogs used their 
highly acute sense of smell and their ability to recognise complex patterns to correctly select 
the urine from bladder cancer patients on 22 out of 54 occasions giving a 41 % mean success 
rate.  With 95 % confidence intervals (CI) giving values of 23-58 % under assumptions of 
normality and 26-52 % from bootstrap methods.  This finding was much higher than a 
determined success rate of 14 %, based on chance alone.  Multivariate analysis indicated that 
the dogs could detect volatiles coming from the bladder cancer rather than other chemicals 
detectable by urinalysis.  Therefore, this seminal proof of principle study was deemed to be 
successful.   
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However, the accuracy, sensitivity and reproducibility is dog dependent and dogs can’t 
currently be used in a clinical setting.  Commercial analytical instruments can be configured 
to mimic the sampling and pattern recognition capabilities of dogs and distinguish between 
patients presenting with a disease and those without.  To replace dogs with an analytical 
instrument, capable of analysing the volatile organic compounds from urine samples, then 
we would need to develop a method that is: 
• Accurate and specific, to correctly identify the disease;  
• Reproducible, day in and day out with no ‘off’ days;  
• Sensitive, to obtain early diagnosis for a better prognosis;  
• A fast analysis, to obtain an answer quickly and at lower cost; 
• Suitable as a routine screen for diseases. 
There are now multiple different techniques reported for analysing VOCs for the detection 
of cancer (Haick, et al., 2014).  Cross-reactive nanoarrays combined with pattern recognition 
have been used for the detection of precancerous gastric lesions and gastric cancer (Amal, 
et al., 2015) and colorectal cancer (Amal, et al., 2016) through exhaled breath.  There are 
several problems, when using breath samples as a diagnostic tool for cancer and diseases, 
these include: the interferences from exogenous volatiles from the air, food and smoking 
(Horvath, et al., 2009); the low concentration of VOCs in breath and the level of water 
vapour within the samples.  Amal and colleagues collected two samples (750 mL GaSampler 
collection bag) of exhaled breath, after the patient had inhaled through a filter cartridge for 
3 minutes, to minimise exogenous VOCs.  The alveolar air from the lungs, was collected 
into a separate bag and then the contents were transferred and concentrated onto a thermal 
desorption (TD) tube containing two hydrophobic sorbents, so that the water vapour was not 
trapped.  One TD tube was analysed by GC-MS and the other by the cross-reactive 
nanoarrays.  The nanoarrays consisted of eight sensors based on either organically-stabilised 
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spherical gold nanoparticles (GNPs) or single-walled carbon nano-tubes (SWCNTs) covered 
with different ligands.  The TD tube was heated and the vapour stored in a heated metal 
column until it was sucked into a vacuum chamber containing the sensors.  The ligands on 
the different sensors then adsorbed different VOCs, generating different electrical signals 
that were recorded.  The data was then analysed using chemometrics. 
Selected-ion flow-tube MS (SIFT-MS) has recently been reported for the detection of 
cancers through breath analysis (Kumar, et al., 2015), along with other applications (Smith 
& Spanel, 2015).  SIFT-MS analyses the sample directly, in real-time, with no 
chromatographic separation.  It produces soft ionisation, with little fragmentation of the 
molecule and works well in a well-characterised matrix.  However, when analysing complex 
matrices there are many masses that overlap, resulting in isobaric interference and the 
incorrect quantification of compounds.  It is also believed that the sensitivity is not high 
enough for many trace compounds present in breath (Smith & Spanel, 2015).   
GC-MS is an analytical technique that has been successfully used for the separation and 
detection of volatile organic compounds for decades.  In more recent years, GC-MS is one 
of the fundamental techniques (Childs & Williams, 2014), along with LC-MS, that has been 
adopted and used in metabolomics profiling, the study of small molecule metabolites that 
are produced by and influence cellular processes. It is utilised to learn about cellular biology, 
systems biology and disease.  Metabolomics is mostly used in the study of plants in the agro-
biotechnology field (Hall & Hardy, 2012) and in the biomedical industry looking at health 
and disease in humans and animals  (Weckwerth, 2006).   
GC-MS is a highly sensitive and selective analytical technique for resolving and identifying 
large numbers of organic compounds present in complex samples.  By carefully choosing 
the sampling and sample introduction techniques, used to transfer the analytes into the GC, 
the volatility and nature of the compounds can be selected to only introduce the compounds 
10 
 
of interest while leaving behind matrix and any interferents within the sample. The flexibility 
of this capability is key when analysing urine and blood samples.  Analytes eluting from the 
GC are already in the gas-phase and are therefore compatible with the mass spectrometer for 
qualitative or quantitative analysis.  The parameters in the MS can be chosen to either detect 
target compounds selectively with high sensitivity or to rapidly collect large amounts of data 
looking at all the compounds separated by the GC, which may be many hundreds.   
Chemometric techniques are then used to extract information from the GC-MS or LC-MS 
data.  For example, to identify patterns or classes within a data set.  It is particularly useful 
where the data set is large or contains large amounts of information.  Clinical samples 
generally are complex, containing organic compounds with a wide volatility range as well 
as inorganic compounds.  
The potential of using GC-MS as a non-invasive, sensitive diagnostic method to characterise 
diseases will be investigated in this thesis, through the utilisation of a combination of: 
• Selective discrimination, to select the optimal sampling and sample introduction 
techniques;  
• Gas chromatography, to separate the selected analytes; 
• Mass spectrometry, to detect all the resolved analytes;   
• Chemometrics, to identify differences between the clinical samples  
The approach explored will include the development of the methodology to analyse the 
headspace above urine samples and its application and evaluation for the diagnosis of 
bladder cancer, prostate cancer and hepatic disorders and a separate method for the analysis 
of the headspace above bacteria, for the classification of septic infection. A brief introduction 
to each of the clinical areas of study will be provided in Section 1.2. 
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1.2 A background to the clinical areas of study in this thesis 
1.2.1 Bladder cancer 
There are over 200 different types of cancer; bladder cancer is the ninth most common cancer 
worldwide and the thirteenth most common cause of cancer death (World Health 
Organization, 2014).  In the UK, it is the eighth most common type (Office for National 
Statistics, 2014) and the seventh most common cause of cancer death (Cancer Research UK, 
2014).  Transitional cell carcinoma (TCC), also known as urothelial cell carcinoma (UCC), 
is the most common type of bladder cancer, accounting for >90 % of cases in 2014.   
1.2.1.1 Transitional cell carcinoma 
TCC begins in the cells, called transitional cells, of the bladder wall or lining called the 
urothelium (Bassi, et al., 2005).  These cells come into contact with waste products in the 
urine that may cause cancer, such as the chemicals in tobacco smoke which are a known 
cause of bladder cancer (World Health Organization, 2014).  Bladder cancer tumour staging 
is based on the extent of penetration into the bladder wall and adjacent structures.  
Superficial, otherwise known as early or non-muscle invasive, bladder cancer, is a cancer 
that has not invaded the bladder smooth muscle.  It includes the following stages: Ta is non-
invasive papillary carcinoma that appear as small, removable growths; Tis is carcinoma in-
situ (CIS) where the growths come back after removal; and T1 is where the tumour starts to 
grow into the sub-epithelial connective tissue beneath the bladder lining.  Stage 2 tumours 
and higher are muscle-invasive: T2 is where the cancer has grown into the muscle; T3 is 
where the cancer has grown through the muscle into the fat layer; and T4 is where the cancer 
has grown outside of the bladder.  Approximately 70-80 % of newly diagnosed TCCs present 
as non-invasive and low-grade tumours and after treatment 50-70 % of these tumours recur 
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and require further treatment, with 10-20 % progressing to invasive tumours, despite 
improvements in diagnosis and treatment.  Invasive tumours in the muscle quickly progress 
and metastasize, they have poor prognosis with only 30-40 % of patients surviving for longer 
than five years.  Therefore, the earlier bladder cancer can be diagnosed, if possible before 
symptoms appear, the better the prognosis. 
1.2.1.2 Bladder cancer diagnosis 
Usually, the first indication of bladder cancer is blood in the urine (haematuria).  This is 
confirmed by carrying out urinalysis that can detect small amounts of blood, at which point 
a cystoscopy is arranged.  Cystoscopy is the gold standard for the diagnosis of bladder cancer 
and is reliable.  However, it uses invasive techniques to obtain a biopsy, which is both a 
higher risk and causes discomfort for the patient.  It is also expensive, at around £400 per 
patient, when one considers that only around 20 % of haematuria patients have bladder 
cancer.  Infections are the most common causes of haematuria (NHS Choices, 2015).  
Urine cytology can also be used to look for cancer cells using a microscope.  It can be very 
specific to identify the type of cancer (90-96 %), but it suffers from low sensitivity (20-50 
%) (Bassi, et al., 2005).  It requires an expert to interpret the results, can take several days to 
get an answer and is not recommended for routine screening.  More recent tests have been 
approved; for example, looking for chromosome changes, various bladder tumour-
associated antigens, such as BTA (Glas, et al., 2003) or proteins in the urine (Poulakis, et 
al., 2001).  Although they are more sensitive, with reported sensitivities of 50-70 % and 50-
85 % respectively, they have poorer specificity (60-70 %) when compared to cytology.  This 
can result in false positives and false negatives and they are now not being recommended 
for routine screening (American Cancer Society, 2016).  Therefore, an early screening test 
is required that is sensitive, specific, non-invasive and is inexpensive.   
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1.2.1.3 Diagnosis of bladder cancer using analytical chemistry 
Since the publication by Willis and colleagues, there have been multiple studies published 
involving the diagnosis of bladder cancer using non-invasive urinary metabonomics - the 
quantitative measurement of the metabolic response to the pathophysiological stimuli.  
Pasikanti and colleagues analysed samples from 24 bladder cancer patients and 51 controls 
using a lengthy sample preparation method involving derivatisation followed by a liquid 
injection into a GC-ToFMS.  They reported 100 % sensitivity and specificity, compared to 
33 % sensitivity and 100 % specificity for urine cytology (Pasikanti, et al., 2010).  However, 
the study was unclear about the type of controls used, there was no mention of TCC and no 
retention time shift corrections were applied in the data analysis.  
The use of a metabonomic approach for liquid chromatography-mass spectrometry (LC-MS) 
has also been documented (Issaq, et al., 2008).  They compared 41 healthy controls to 48 
TCC patients and reported 100 % specificity and 100 % sensitivity.  However, urine samples 
were injected neat into the LC-MS and a scan range of m/z 100-2,000 u analysed less volatile 
analytes rather than investigating the olfactory profile given by urine and detected by the 
dogs.  
1.2.2 Prostate cancer 
Of the 200 different types of cancer, prostate cancer is the most common cancer in males 
and the second most common cancer in males in the UK. Overall, it is the fourth most 
common cause of cancer death in the UK and the second most common in males, accounting 
for 13 % of all cancer deaths in males in the UK in 2014 (Cancer Research UK, 2014).  
During their lifetime, 1 in 8 men will be diagnosed with prostate cancer.  Prostate cancer is 
incurable when diagnosed at a late stage; hence, an accurate method of detecting it early, 
when treatable, is key.  
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1.2.2.1 Prostate cancer diagnosis 
There are three tests used for prostate cancer screening and diagnosis.   When the patient 
first presents to the general practitioner (GP) they are given a Prostate Specific Antigen 
(PSA) test.  If this gives a positive result, a Digital Rectal Examination (DRE) is given by 
the GP and those with a positive result are referred to the consultant.  The consultant then 
also gives a DRE before progressing to a trans-rectal ultrasound (TRUS).  Both the DRE and 
TRUS are highly invasive, embarrassing and inconvenient and in the case of the TRUS it is 
also expensive.   
The least invasive test is the first conducted, the PSA test.  PSA is an enzyme produced by 
the prostate gland cells, which circulates the body in the blood, either bound to other proteins 
or on its own.  There are two different tests, the PSA test measures the total of both free and 
bound PSA, whereas the free-PSA test only measures the percentage of unbound PSA.  Their 
use is controversial, with this test being named as an unnecessary treatment by The Royal 
College of Pathologists in October 2016 (BBC News, 2016).  Unfortunately, factors such as 
age, obesity and the presence of benign prostatic hyperplasia (BPH) can also affect the levels 
of PSA (Banez, et al., 2007).  It suffers from a lack of sensitivity, at 30-35 %, with around 
15 % of men with a normal level of PSA having prostate cancer (Thompson, et al., 2004).  
It also suffers from a lack of specificity, at only 63 %, with other conditions such as BPH, 
prostatitis and lower urinary infections giving elevated levels of PSA (Selley, et al., 1997).  
This results in 66 % of men with elevated PSA levels going through the discomfort of DRE 
and the expense of TRUS but not having prostate cancer.  DRE itself only has an overall 
accuracy of around 59 % and TRUS will miss 13 % of cancers at the first test. 
1.2.2.2 Diagnosis using analytical chemistry 
In 2009, US researchers identified a possible biomarker in urine called sarcosine which could 
be used to identify the aggressiveness and the invasiveness of the prostate cancer 
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(Sreekumar, et al., 2009).  Sreekumar and colleagues profiled more than 1,000 metabolites 
in 2009, by analysing tissues, urine and plasma samples related to prostate cancer using GC-
MS and LC-MS.  Only 15 % of these metabolites were shared across the different types of 
samples.  Samples were compared between benign adjacent prostate (not dangerous to 
health), clinically localised prostate cancer (cancer only within the prostate) and metastatic 
prostate cancer (where the cancer has spread outside the prostate).  Sarcosine, an N-methyl 
derivative of glycine, was identified in urine.  The samples were derivatised using 
bistrimethyl-silyl-trifluoroacetamide (BSTFA) and sarcosine, cysteine, glutamic acid, 
thymine and glycine were quantified by isotope dilution GC-MS using selected ion 
monitoring.  The results showed that sarcosine levels were significantly higher in the 
clinically localised prostate cancer compared to benign adjacent prostate samples and there 
was an even larger increase when comparing metastatic prostate cancer compared to the 
clinically localised prostate cancer.  However, this result was disputed with a paper published 
in 2010 (Jentzmik, et al., 2010).  They determined that sarcosine in urine could not be used 
as a marker for prostate cancer diagnosis in their studies to compare sarcosine levels in 106 
prostate cancer patients, 33 patients with no prostate cancer and 12 healthy men and women. 
1.2.3 Hepatic disorders 
The liver is the second largest organ in the body and is responsible for removing toxins, 
controlling cholesterol levels, fighting infections and illnesses, helping to clot the blood and 
producing bile to break down fats and acids in the digestion system (Kuntz & Kuntz, 2008).  
The liver can regenerate itself by developing new cells after, for example, filtering alcohol.  
Unfortunately, serious damage to the liver through prolonged alcohol misuse or viral 
infection can cause permanent damage to the liver and reduce its ability to regenerate.  
Reduced functioning of the liver can lead to internal (variceal) bleeding, a build-up of toxins 
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in the brain (encephalopathy), fluid accumulation in the abdomen (ascites) that is associated 
with kidney failure and, liver cancer (LC). 
There are more than 100 different types of diseases that affect the liver (hepatic disorders) 
and reduce its ability to regenerate and function correctly (NHS Choices, 2014).  Hepatitis 
is the inflammation of the liver and can be virus-induced, caused by the hepatitis A, B or C 
virus, or caused by alcohol misuse (NHS Choices, 2016).  Alcohol-induced liver disease 
(ARLD) can lead to alcoholic fatty liver disease, alcohol hepatitis and eventually cirrhosis 
(NHS Choices, 2015).  Non-alcoholic fatty liver disease (NAFLD) is the build-up of fat 
within the liver cells and is often caused by obesity (NHS Choices, 2016).  NAFLD can lead 
to non-alcoholic steatohepatitis (NASH) a more serious condition where the liver is also 
inflamed.  NASH can lead to fibrosis and eventually cirrhosis. Primary biliary cirrhosis, 
otherwise known as primary biliary cholangitis (PBC) is the damage of the bile ducts in the 
liver caused by the immune system attacking them.  Bile builds-up in the liver and can lead 
to cirrhosis (NHS Choices, 2014).  Its cause is unknown.  The congenital disorder 
haemochromatosis causes the absorption of too much iron from food (NHS Choices, 2014).  
Iron levels gradually build up, usually in the liver and the heart, leading to heart failure, liver 
cirrhosis or liver cancer.  Liver diseases are a major health problem with high mortality rates, 
as the only cure is a transplant. 
1.2.3.1 Liver fibrosis and cirrhosis 
Fibrosis is the first stage of scarring of the liver, where healthy tissue is replaced by scar 
tissue that doesn’t perform its function or regenerate healthy cells.  Cirrhosis occurs when 
scar tissue builds-up and takes over most of the liver.  It is caused by long-term damage to 
the liver that cannot be reversed.  If too much of the liver is cirrhotic then the whole liver 
stops functioning, resulting in liver failure.  There is no cure for cirrhosis, therefore 
determining and treating the cause, whether that is anti-viral medication, losing weight or 
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reducing alcohol intake, slows the progression.  Approximately 4,000 people die in the UK 
each year from liver cirrhosis and 700 people are saved by liver transplants (NHS Choices, 
2015).   
1.2.3.2 Liver cancer 
Liver cancer (LC) is the eighteenth most common cancer in the UK and the ninth most 
common cause of cancer death, accounting for 3 % of all cancer deaths in the UK in 2014 
(Cancer Research UK, 2014).  Worldwide, it accounts for 6 % of all cancer cases and 9 % 
of cancer deaths (World Health Organization, 2014).  In Asia, chronic hepatitis B (HBV) 
and C (HCV) virus infections are the major cause of LC.  In North America and parts of 
Europe LC caused by HCV infection is increasing, along with NAFLD. 
The most common cause of a cancerous tumour in the liver is metastatic disease, where 
cancer has spread to the liver from elsewhere in the body, known as secondary LC (World 
Health Organization, 2014). 
Primary LCs mostly occur in the liver cells or the intrahepatic bile ducts and both are 
associated with cirrhosis.  Hepatocellular carcinoma (HCC) is the most common primary 
malignancy occurring in the cells or hepatocytes of the main liver tissue, which makes up 
70-85 % of the liver’s mass.  HCC represents around 80 % of liver tumours and 
cholangiocarcinoma or bile duct cancer that starts in the lining of the bile duct, is the second 
most common. 
1.2.3.3 Hepatitis and Hepatitis C 
There are three different types of hepatitis viruses, A (HAV), B (HBV) and C (HCV), all of 
which result in similar symptoms but are transmitted differently and have different effects 
on the liver.  HAV is usually transmitted by close personal contact or through contaminated 
food or drink.  HAV only results in an acute infection that doesn’t usually require treatment.  
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HBV and HCV can both remain in the body and result in chronic infection of the liver 
leading to long-term liver damage.  There are vaccines for HAV and HBV but not HCV 
(Immunization Action Coalition, 2014).   
The hepatitis C virus (HCV) causes hepatitis C disease, it is blood borne and can cause acute 
or chronic infection of the liver.  Usually infection of the hepatitis C virus is through blood, 
for example transfusions of unscreened blood and the use of unclean medical equipment.  
Acute HCV can cause a mild illness lasting for only a few weeks and requiring no treatment, 
but chronic HCV infection can be serious, causing a lifelong illness.  130-150 million people 
globally suffer from chronic hepatitis C, a significant number of whom will develop liver 
cirrhosis (15-30 % within 20 years) or LC (World Health Organisation, 2016).  Around 0.7 
million people die each year from hepatitis C-related liver diseases (Lozano, et al., 2012).  
There is currently no vaccine for hepatitis C but it can be cured in 90 % of cases by using 
direct antiviral agents (DAA) medicines.  The problem is that acute HCV infection is usually 
asymptomatic and therefore early diagnosis of HCV, which is easily treatable, frequently 
doesn’t occur.  Currently, a blood sample is taken and screened for anti-HCV antibodies.  A 
positive result leads to a nucleic acid test for HCV ribonucleic acid (RNA) to confirm chronic 
infection.  A positive result then leads to an assessment of the degree of liver fibrosis and 
cirrhosis through either a biopsy or a series of non-invasive tests.  Identification of the HCV 
genotypes, of which there are six possibilities, is determined as each genotype responds 
differently to treatment. 
1.2.3.4 The diagnosis of hepatic disorders 
Diagnosis of liver problems is first based on physical signs and a variety of symptoms, from 
nausea and vomiting to swelling of the abdomen and unintentional weight loss, itchy and in 
the later stages jaundice skin.  Unfortunately, signs of hepatic disorders are usually vague 
until the disorder becomes more advanced.   
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On presenting to the GP, the patient suspected of having a hepatic disorder will be sent for 
tests.  Individual tests often have limited sensitivity and specificity towards the exact cause 
of the problem, therefore a combination of tests is used to determine the cause and severity 
of the disorder.  A series of blood tests are used to determine if the liver is functioning 
properly and to distinguish between acute and chronic disorders and between hepatitis and 
cholestasis (where the bile duct from the liver is blocked).  Each test looks at a different 
enzyme or protein, therefore it can take several blood tests to determine if the liver has a 
problem and what it is.  For example, protein is made by the liver and therefore the albumin 
and total protein tests check how well the liver is functioning.   
Bilirubin is a waste product made from old blood cells.  Bilirubin conjugated with glucuronic 
acid is produced in the liver and is not usually detected in the urine of normal, healthy 
individuals.  This ‘direct’ conjugated bilirubin is water soluble and passes out through the 
bile duct and into the colon where it is metabolised into urobilinogen.  This is then oxidised 
to form urobilin and stercobilin which are then excreted in the faeces.  The presence of excess 
conjugated bilirubin in the urine is an early indicator of the liver not functioning properly, 
as it leaks out of the liver through the hepatocytes.  As bilirubin is yellow in colour, it is 
visible when present in increased amounts as dark urine and jaundice. The total bilirubin test 
measures all the bilirubin in the blood and the conjugated bilirubin test measures the form 
that is made in the liver.  If conjugated bilirubin is high in both blood and urine then this is 
indicative of liver disease (Lab Tests Online, 2015).    
Haemolytic anaemia is the abnormal breakdown of red blood cells, leading to higher levels 
of unconjugated bilirubin in the blood and can cause jaundice.  This doesn’t increase the 
amount of bilirubin in the urine, as unconjugated bilirubin isn’t water soluble, but it gets 
conjugated by the liver as usual, as it isn’t caused by a liver problem.  Urobilinogen is 
normally present in urine at low concentrations and by comparing the amount of conjugated 
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bilirubin against the amount of urobilinogen other disorders such as haemolytic anaemia can 
be determined.  
The levels of the liver enzymes alanine transaminase (ALT) and aspartate transferase (AST) 
indicate hepatitis if they are raised and at the same time alkaline phosphatase (ALP) levels 
are checked as this often increases when bile ducts are blocked (Lab Tests Online, 2015).  
Transferrin saturation and serum ferritin tests are performed to check the body’s iron 
metabolism and the amount of iron stored.  These tests are used in the diagnosis of 
haemochromatosis.   
An ultrasound scan; a transient elastography scan (also known as a Fibroscan) that is based 
on ultrasound; a computerised tomography (CT) scan; or magnetic resonance elastrography 
(MRE) scan, that is based on magnetic resonance imaging (MRI); all can also be carried out 
on the liver to produce detailed images and to look for abnormalities (Venkatesh, et al., 
2013).  For example, using the Fibroscan or MRE to look at liver stiffness can indicate 
scarring and be used to determine the extent of the fibrosis or cirrhosis (NHS Choices, 2015). 
A biopsy can be performed to remove a small sample of liver cells for testing to confirm 
cirrhosis or cancer and this can also be used to indicate the cause.  A Fibroscan is increasingly 
being used as an alternative to biopsy to diagnose cirrhosis in the UK.  An endoscopy can 
also be used to check for swollen vessels (varices) in the stomach that are a sign of cirrhosis.  
A laparoscopy can be used to examine the liver using an endoscope (NHS Choices, 2016).  
The information from these tests is then used to determine the nature of the hepatic disorder 
and if it is cirrhosis or cancer to grade it.  Cirrhosis is graded from A (meaning relatively 
mild and the liver is working normally), to C (meaning severe and liver function is poor 
using the Child-Pugh score) (Cancer Research UK, 2015).  In LC, it is graded to indicate 
how far the cancer has spread.  The Barcelona Clinic Liver Cancer (BCLC) staging system  
grades it from Stage 0 (where the tumour is less than 2 cm and the patient is well with normal 
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liver function) up to Stage D (where the cancer has spread through the lining of the abdomen 
or into organs close to the liver, the liver is barely functioning and the patient starts to have 
end-stage liver disease) (Cancer Research UK, 2015).   
Currently there isn’t a general screening method available for hepatic disorders and it is often 
only suspected when tests for other conditions show that there is a liver problem.  Patients 
identified as having liver cirrhosis, or other disorders that have a high risk of developing LC 
are regularly screened (known as surveillance).  Every six months, patients undergo 
ultrasound scans of the liver to look for abnormalities and blood tests to check for the alpha-
fetoprotein (AFP) that is an indicator of LC. 
1.2.3.5 Hepatic disorders diagnosis using analytical chemistry 
Patients with hepatic disorders often report dark urine and changes in the odour of their 
breath which may be sweet, musty or have a slight faecal aroma (Probert, et al., 2009). 
Exhaled volatile organic compounds have been detected in the breath of patients suffering 
from hepatic disorders and have been reported as sulphur containing VOCs for many decades 
(Kaji, et al., 1978), (Tangerman, et al., 1983), (Hisamura, 1979).  It is thought that the change 
in breath VOCs is caused by metabolic processes, inflammation and/or oxidative stress 
(Parola & Robino, 2001), (Nitti, et al., 2008).   
A range of analytical techniques including ion-molecular reaction-MS (Netzer, et al., 2009) 
and GC-MS (van den Velde, et al., 2008) have been used to study breath samples from 
patients with liver disease.  Van den Velde and colleagues, analysed the alveolar air of 52 
patients with liver disease and 50 healthy volunteers by GC-MS before analysing the data 
using discriminant analysis.  Dimethyl sulphide, acetone, 2-butanone and 2-pentanone were 
found to increase in concentration and indole and dimethyl selenide decreased when 
compared to the healthy patient samples, with a sensitivity of 100 % and specificity of 70 
%.   
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The results from the investigations of volatile metabolites in the blood of hepatic patients 
have been conflicting, with Goldberg and colleagues using a GC-MS method to identify a 
possible biomarker, 3-methylbutanal, at a raised level for hepatic cirrhosis (Goldberg, et al., 
1981); whereas, Marshall and colleagues found no difference between patients and controls 
(Marshall, et al., 1985).   
Hepatic encephalopathy (HE) is the change in the brain that occurs with chronic liver 
disease.  The volatiles from plasma samples, in particular isovaleraldehyde, have been 
studied using TD-GC-MS (Mardini, et al., 1987).  Although there were significant 
differences between healthy controls and patients with LC or liver failure, comparisons of 
patients with hepatic encephalopathy and those in a coma (with no encephalopathy) were 
similar.  The volatiles in the headspace above the blood of patients with hepatic disorders, 
to identify possible biomarkers, has also been studied using SPME-GC-MS (Xue, et al., 
2008).  A small study of 19 LC patients and 18 healthy patients were studied, with three 
potential biomarkers identified, being hexanal, 1-octen-3-ol and octane, each giving 
sensitivities of 84.2-94.7 % and specificities of 100 %. 
1.2.4 Classification of septic infection of intensive care patients 
Sepsis, otherwise known as blood poising or septicaemia, is a serious medical condition 
caused by a bacterial infection or injury.  When an infection spreads through the blood, the 
body’s immune system tries to fight the infection and can go into over-drive.  This can cause 
problems throughout the whole body, resulting in widespread inflammation, leaking blood 
vessels, abnormal blood clotting and it affects blood pressure, breathing and organ function 
due to reduced blood supply.  When the blood pressure drops to a dangerously low level, 
septic shock can occur resulting in multiple organ failure and death (NHS Choices, 2016).  
Unfortunately, the mortality rate of patients with severe septic shock is reported as 28-50 %, 
with the chance of survival depending on the cause of infection, the number of organs that 
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have failed and how soon treatment is started (Daniels, 2011).  There are estimated to be 
more than 100,000 cases of sepsis in the UK every year leading to approximately 31,000 
deaths (NHS Choices, 2016). 
Sepsis is caused by the body over-reacting to an infection. The most common sites of 
infection are the lungs, urinary tract, abdomen, pelvis or sites of surgery. The infection is 
usually caused by pneumonia, appendicitis, peritonitis (tissue lining the abdomen), urinary 
tract infection, cholecystitis (gall bladder), cholangitis (bile ducts), cellulitis (skin infection), 
osteomyelitis (bone infection), endocarditis (heart infection), influenza, meningitis, 
encephalitis (inflammation of the brain) and other bacterial infections such as MRSA.  
However, in one in five cases the infection type and source of the sepsis cannot be 
determined. 
1.2.4.1 Diagnosis of sepsis 
Sepsis is usually diagnosed through body temperature, heart rate, breathing rate and blood 
pressure.  The cause and source of the sepsis is diagnosed through several tests including: 
blood, urine and stool samples; a wound culture test from a visibly affected area; a 
respiratory secretion test to analyse saliva, phlegm or mucus; organ function tests; or a spinal 
tap.  X-ray, ultrasound and CT scans may also be used.  
Most of these tests involve culturing of the sample to determine the type of bacterial 
infection.  Blood samples for culture must be taken before antibiotics are administered to 
fight the infection to improve the chances of successful identification.  Treatment is 
recommended to be started within 1 hour of sepsis onset.  At least two blood cultures are 
recommended to be taken; however, with automated culture, two samples result in only 80 
% sensitivity and three samples in 96 %, therefore four samples are suggested to be necessary 
for reliable detection, which isn’t practicable (Daniels, 2011).   
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Unfortunately, identification of the bacteria causing the infection usually takes 48 hours and 
therefore a broad spectrum of antibiotics is prescribed to treat a wide range of known 
infectious bacteria, along with some fungal infections.  Once identified, specific antibiotics 
are given to fight that bacteria, or if the sepsis is caused by a virus, anti-viral medication may 
be given. 
The widespread use of antibiotics both within and outside of medicine is playing a significant 
role in the emergence of antibiotic-resistant bacteria (Goossens, et al., 2005) (Gootz, 2010).  
Therefore, the prescription of a broad spectrum of antibiotics in the treatment of sepsis and 
any bacterial infection, while awaiting identification, is of concern.  In addition, if the sepsis 
is caused by a virus or unknown bacteria the treatment may not help. 
The standard method for analysing bacteria in blood is to add between 3 and 10 mL of blood 
to a bottle containing a culture medium. There are several different bottles suitable for 
aerobic (containing CO2 and O2) or anaerobic (containing CO2 and N2) bacteria, usually at 
least two different culture bottles are used per patient.  The bottle is then incubated at 37 °C 
and readings made with a fluorescence detector, which is sensitive to the concentration of 
CO2, every 10 minutes.  The presence of microorganisms either increases the amount of CO2 
or decreases the amount of O2 present in the vial, the rate and amount the fluorescence 
changes determines if the vial is positive.  Positive samples then undergo a gram stain and 
subculture for identification of the bacteria.  It is recommended that samples are cultured for 
up to 4 days to confirm negativity, with detection taking 10 to 70 hours depending on the 
type of organism (Gopi, et al., 2011). 
1.2.4.2 Diagnosis using analytical chemistry 
The research into the diagnosis of anaerobic and aerobic bacterial infections using separation 
science has been gradually happening over many decades.  In the late 1970s and 1980s there 
was much research carried out into the identification of bacteria using headspace-gas 
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chromatography (HS-GC).  Amongst these, alcohols and volatile fatty acids (VFA) were 
studied from the headspace above three different anaerobic bacteria culture mediums and 
compared to the detection of these compounds against a direct injection of liquid culture 
medium and solvent extracts of (Larsson, et al., 1978).  All three methods could detect the 
volatile fatty acids, but only HS-GC could detect the alcohols.  The HS-GC method was also 
determined to be less laborious.  Larsson and colleagues then went on to publish multiple 
papers using this technique for anaerobic bacterial identification in culture mediums.  The 
technique was then used for the analysis of the headspace above 59 microbial isolates 
cultured in blood (Huysmans & Spicer, 1985).  HS-GC could detect the growth of 46 of 
these but it was concluded that it did not reduce the detection time when compared to visual 
inspection.  HS-GC was then used for the analysis of blood from patients with intraperitoneal 
and intrapleural infections (Vitenberg, et al., 1986).  Despite discrepancies between the HS-
GC and bacteriological analysis results, the method was reported as being reliable.  These 
findings were backed-up by a similar study, where 445 strains of common aerobic and 
anaerobic bacteria were cultured in blood and the volatiles analysed by HS-GC (Ho, 1986).  
The method reportedly characterised most strains for presumptive identification.  An earlier 
study by Watt and colleagues had claimed that, although GC analysis was of use in the rapid 
presumptive diagnosis of anaerobic infections with very few false-positives and false-
negatives and can sometimes distinguish between aerobic and anaerobic infections by the 
presence of acetic acid, there was poor correlation of volatile fatty acids (VFA) patterns to 
identify the type of bacteria, compared to the culture results (Watt, et al., 1982). 
In the 1990s, following on from the work by Larsson and colleagues, the direct GC injection 
of volatile fatty acids in the aqueous liquid-phase was compared to their liquid extraction 
using methyl-tert-butyl ether (MTBE) (Socolowsky, et al., 1990).  The aqueous method was 
found to be less sensitive, although it was much simpler.  At the same time, it identified 
some key VFAs in the detection of anaerobic microorganisms.   
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In another study, comparisons were made between three analysis methods for the 
identification of 52 clinical Clostridium difficile isolates and 17 non-C. difficile isolates after 
24 hours of culturing (Cundy, et al., 1991).  The traditional GC method performed a solvent 
extraction of the positive cultured sample with MTBE and injected the solvent extract into 
the GC for analysis.  The HS-GC method placed some of the positive cultured sample into a 
headspace vial with salt and acid to analyse the headspace above the culture.  The Microbial 
Identification System (MIS) GC method, cultured the microbes in special tubes followed by 
a laborious sample preparation method before solvent extraction and injection into the GC 
and identification through a special anaerobe library.  Both the HS-GC and MIS-GC methods 
gave equivalent accuracy against the traditional GC method, but the MIS-GC method 
incorrectly identified 8 of the 17 non-C. difficile strains.  It was concluded that the HS-GC 
method had by far the fastest sample processing time, simplest method with equivalent 
accuracy against the traditional GC method or the MIS-GC method.     
Liquid injection has then been used for a further study of 375 positive and negative blood 
cultures using solvent extraction and GC analysis (Julák, et al., 2000).  Blood samples were 
cultured in a BacT/AlertTM system which took between 6-24 hours.  After a positive signal 
alert, some blood culture was removed, acidified, internal standard (IS) added, extracted with 
MTBE, vortexed and the organic phase removed for liquid injection into the GC.  The data 
was analysed by measuring peak heights of eight VFAs and comparing to the IS.  VFAs 
were lower in aerobic samples than in anaerobic samples that had more distinctive profiles.  
The GC method also detected anaerobes in 11 % of blood cultures that were not determined 
by routine microbiological analysis. 
Other non-GC techniques have been used for the analysis of bacteria.  SIFT-MS was used 
to evaluate bacterial growth blood cultures and compared to the BacT/ALERTTM system 
(Scotter, et al., 2006).  Sixty infected samples were analysed and SIFT-MS gave positive 
results for 53 samples after 8 hours and 58 samples after 24 hours.  Matrix-assisted laser 
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desorption/ionisation couple with time-of-flight MS (MALDI-ToFMS) has been used for the 
rapid characterisation for Staphylococcus aureus (Goldstein, et al., 2013).  The culture 
conditions and sample preparation methods were found to have a large effect on the spectral 
quality and reproducibility for this technique.   
More recently, the improvements in analytical techniques, for example the development of 
solid-phase microextraction (SPME) and the widespread use of GC-MS, have enabled more 
sensitive methods with better detection and identification to be developed.  In 2005, SPME-
GC analysis was compared against HS-GC and traditional solvent extraction GC for the 
analysis of 375 blood cultures, 205 exudates and 210 bronchoalveolar lavages (BAL), MS 
was also used (Julák, 2005).  The study again looked at VFAs, which gave approximate 
agreement between the GC techniques, however 11.2 % of blood cultures, 20 % of exudates 
and 9-20 % of BALSs were not found by cultivation but were identified by GC.  SPME-GC 
found the most samples that gave false-negative cultivations, meaning that it was more 
sensitive.  Using MS as the detector also identified several other components that had not 
yet been studied in the identification of bacteria.   
SPME-GC-MS analysis has also used to analyse VOCs in human breath for the diagnosis of 
bacterial infections (Ulanowska, et al., 2011).  A small group of six patients, with 
Helicobacter pylori in their stomach, was studied and compared to 23 controls.  A 
Carboxen/PDMS SPME fibre was used to extract the volatiles with analysis by GC-MS, 
with data analysis using discriminant analysis and factor analysis.  Three potential markers 
were identified, however the statistical analysis didn’t support the speculation and the focus 
of the research group then moved onto the VOC breath analysis of patients, using SPME-
GC-MS, with lung cancer (Ulanowska , et al., 2011) and chemotherapy controls (Ulanowska, 
et al., 2012).   
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Breath has also been studied for bacterial infections in the cystic fibrosis (CF) lung (Scott-
Thomas, et al., 2010).  A carbowax SPME fibre was used to extract the volatiles from the 
breath from: 
• 16 CF patients, where Pseudomonas aeruginosa had colonised; 
• 13 CF patients, where Pseudomonas aeruginosa hadn’t colonised; and  
• 17 healthy controls.   
The fibre was desorbed in a GC-MS inlet and the data was analysed using chemometric 
techniques.  2-Aminoacetophenone (2-AA) was identified as a potential biomarker.  
Comparison of 2-AA in the breath to the isolation of Pseudomonas aeruginosa in sputum 
gave 93.8 % sensitivity and 69.2 % specificity.   
Recently, the successful analysis of Clostridium difficile, using a designer enzyme to create 
a unique VOC profile in stool samples that was subsequently analysed by HS-SPME-GC-
MS has been described (Dean, et al., 2014).  One hundred stool samples were tested, of 
which 77 were positive by culture.  After 18 hours of incubation, Clostridium difficile was 
confirmed with 83.1 % sensitivity and 100 % specificity (Tait, et al., 2014).   
1.2.5 The analysis of VOCs for disease diagnosis 
There are many techniques that could be used to analyse volatile compounds produced by 
bladder and prostate cancers, hepatic disorders and microbiology samples.  The key 
techniques for the extraction of volatile compounds are: headspace analysis (HS), solid-
phase microextraction (SPME) and thermal desorption (TD).  Gas chromatography (GC) is 
designed to separate volatile compounds that easily move into the gas-phase.  Mass 
spectrometry (MS) gives an additional dimension of separation when hyphenated to GC, 
along with the ability to identify compounds.  Chemometric techniques have been used in 
more recent years to analyse the data, enabling more complex chromatograms and data sets 
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to be compared and reducing the need to identify biomarkers or a small number of different 
peaks for the comparison between sample classes.  A more detailed explanation of these 
techniques is given in Section 1.3. 
1.3 A review of the analytical techniques applied in this thesis  
1.3.1 Gas Chromatography (GC) 
Gas chromatography (GC) is an analytical separation technique, used to separate chemical 
constituents in a sample mixture. It was invented in 1951 by Martin and James (Ettre, 1991).  
These chemical constituents are usually gases or organic compounds that must be volatile 
enough to be vapourised and move through the gas chromatograph at temperatures below 
480 °C.  They should also not decompose at the temperature required to vapourise the 
sample.  Gas chromatography is used to separate and detect organic compounds and gases, 
otherwise known as analytes, with molecular weights below 1250 g. 
1.3.1.1 Carrier gases 
The carrier gas transports the vapourised sample through the gas chromatograph, from the 
sample introduction device, through the analytical column (holding the stationary phase) and 
into the detector.  The most common type of carrier gas used in GC is helium, as: it is inert 
and therefore doesn’t react with the sample constituents or the stationary phase; it has good 
diffusivity and therefore is able to transport the analytes between the mobile and stationary 
phases at reasonably high flow rates, resulting inefficient and relatively fast separations; and 
it has a moderate viscosity, meaning that when the GC oven temperature is increased the 
pressure doesn’t need to be increased excessively to maintain a constant linear velocity 
through the analytical column.  
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Other carrier gases commonly used, include hydrogen and nitrogen.  Hydrogen has a higher 
efficiency of separation in shorter run times than helium, but is flammable and reactive.  
Nitrogen has a higher efficiency of separation than helium but only at low flow rates, due to 
its poor diffusivity.  It also has high viscosity and isn’t compatible with mass spectrometers, 
due to space charging effects within the ion source.   
1.3.1.2 Liquid stationary phase 
The most common type of gas chromatography, used to separate volatile organic compounds 
(VOCs), is gas-liquid chromatography (GLC).  In GLC, separation is achieved through 
partitioning of the analytes between the mobile phase and the stationary phase, which is a 
viscous liquid coated onto the inside of a very narrow tube.  This configuration is known as 
a Wall Coated Open Tube (WCOT).  The tube itself is a long narrow length of deactivated 
fused silica, coated on the outside with polyimide to protect the silica and to make it flexible, 
with internal diameters commonly ranging from 0.1-0.53 mm and lengths commonly 
between 10-150 m.  The most common dimensions are 0.25 mm internal diameter and 30 m 
long, enabling fast separations with good efficiency, peak shapes and sensitivity.   
The stationary phase itself is usually polydimethylsiloxane (PDMS), which is non-polar.  
Separation is through dispersion interactions and based on volatility of the analytes.  The 
GC oven temperature is started low (usually below 100 °C) and then ramped to higher 
temperatures to separate the less volatile analytes.   
The dimethyl groups can be replaced with different percentages of different functional 
groups, to change the interactions.  For example, 5 % diphenyl 95 % dimethylpolysiloxane 
is still deemed a non-polar column but 50 % diphenyl 50 % dimethyl polysiloxane is a mid-
polar column with separation primarily on volatility but also on π-π interactions between the 
analyte’s π bonds and those in the phenyl groups of the stationary phase.  Other polysiloxane 
based stationary phase functional groups include biscyanopropyl, trifluoropropylmethyl and 
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cyanopropylmethyl-phenylmethyl, with interactions dependent on the characteristics of the 
functional groups present in the analytes and those on the stationary phase.  These 
interactions include dipole-dipole and dipole-induced dipole as well as the dispersion and π-
π interactions.  Another common class of capillary column stationary phase is the 
unsubstituted polyethyleneglycol (PEG) that enables the additional interaction of hydrogen 
bonding of the –OH group with relevant functional groups in the analyte molecules.   
The type of stationary phase selected for the application is dependent on the chemistry of 
the analytes – their functional groups and their volatility.  To separate analytes in the sample, 
their volatility and/or their interaction with the stationary phase must differ.  The temperature 
required to elute all analytes from the analytical column, must always be a factor when 
selecting the phase type, as generally the more polar the analytical column, the lower the 
maximum temperature.  The maximum temperature of the column must not be exceeded, 
otherwise the stationary phase will be damaged causing excess column bleed and higher 
baselines, greater activity within the column and generally poor peaks shapes, resolution and 
sensitivity.   
The phase ratio is the ratio between the column internal diameter and the stationary phase 
thickness.  Columns with lower phase ratios have a greater retention of analytes within the 
analytical column and therefore longer retention times; conversely, higher phase ratios have 
a lower retention and result in shorter retention times.  Very volatile (low molecular weight) 
analytes are separated using columns with lower phase ratios which means they have thicker 
stationary phases to trap the analytes.  Less volatile (higher molecular weight) analytes are 
separated using thinner stationary phases, which allow faster mass transfer of the analyte 
between the mobile and stationary phases, resulting in sharper peaks and better resolution.   
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1.3.1.3 Band broadening and column efficiency  
The key to good chromatography is to maintain narrow sample bands throughout the 
analytical run, which means that all the molecules of the same analyte remain close together, 
eluting as a sharp, Gaussian-shaped peak.  If good separation and sensitivity are to be 
achieved, then band broadening needs to be minimised.   
Band broadening can be caused by many factors, including: poor introduction of the analyte 
onto the analytical column resulting in the analyte molecules spreading out; dead volumes 
within the system that are poorly swept by carrier gas, the analyte molecules diffuse into 
these areas making slower progress; and irregular residence time in the stationary and mobile 
phases for each molecule of an analyte.  Some may spend a greater than average length of 
time in the mobile or stationary phases, depending on whether they remain close to the 
mobile phase:stationary phase interface, or diffuse deeper into the stationary phase or into 
the centre of the analytical column.   
The Height Equivalent of a Theoretical Plate (HETP otherwise known as H) is a measure of 
the resolving power of a column.  A theoretical plate is a hypothetical concept, in which the 
two GLC phases establish an equilibrium with each other and is frequently put into context 
by thinking about a distillation processes.  This process can be seen as one movement of the 
analytes from the stationary phase into the mobile phase and back into the stationary phase 
again, as is shown in Figure 1.1 (a). 
The more theoretical plates, the greater the number of separate equilibrations of the analytes 
between the stationary and mobile phases, resulting in a greater separation of the analytes 
and hence better resolving power of the column.  As a metaphor, this can be seen as a group 
of sprinters running down a track, with equal speed.  However, if one hurdle is put in their 
way, this will separate them; if more hurdles are placed, one would get a much better 
separation of these sprinters, as they are not equally capable of jumping over hurdles! 
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Figure 1.1: Model of theoretical plates in an analytical column of fixed length (cm); (a) few 
theoretical plates and large plate height; (b) many theoretical plates and small 
plate height 
The number of theoretical plates (N) can be calculated chromatographically, by examining 
the retention time (tR in minutes) and the peak width at half height (w½ in minutes): 
ܰ = 5.55 ൬ ௧ೃమ௪½మ ൰  (1.1) 
From this, the HETP (H in mm) can be calculated from the length of the analytical column 
(L in cm): 
ܪ = ௅ே  (1.2) 
The column efficiency is a measure of an analyte’s dispersion band using N or HETP.  A 
completely efficient peak would be a single linear line, that is non-Gaussian, with all 
molecules of an analyte arriving at the detector at the same time.  However, in 
chromatography, there is always some band broadening, therefore a completely efficient 
peak is never possible.  The factors that contribute to band broadening within the column are 
described by the Van Deemter equation (Van Deemter & Zuiderweg, 1956), for the HETP 
(H in m): 
ܪ = ܣ +	ܤ ݑൗ +	(ܥ௦ +	ܥ௠)ݑ (1.3) 
Where: 
 u (m/s) is the average velocity of the mobile phase. 
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A (m) is the Eddy diffusion parameter.  For a packed column, the analyte molecules may 
take longer or shorter pathways, through the stationary phase packing.  To minimise this 
term, the diameters of the particles in the column packing should be as small as possible 
(although this increases back pressure); they should be consistent in size and shape; and be 
packed with a constant density, with no empty spaces.  
B (m2/s) is the longitudinal diffusion coefficient.  The process of migration from the 
concentrated analyte band centre to the more dilute regions on both sides. This is dependent 
on the diffusivity of the analyte in the mobile phase, being inversely proportional to the linear 
velocity and therefore later eluting peaks are the most affected.  To minimise band 
broadening from this term, peaks should be eluted from the column as quickly as possible. 
C (s) is the resistance to mass-transfer coefficient of the analyte between the mobile phase 
(Cm) and the stationary phase (Cs).  It is proportional to the thickness of the stationary phase: 
those molecules that travel deeper into the stationary phase to interact will take longer to 
reach the stationary/mobile phase interface than those interacting on the surface.  To 
minimise this term, the stationary phase should be as thin as possible.  
For WCOT columns, where a liquid is the stationary phase rather than particles, Eddy 
diffusion is not applicable.  Therefore, the Golay equation can be used instead:  
ܪ = ܤ ݑൗ +	ܥ௦ݑ + ܥ௠ݑ  (1.4) 
Each of these terms and their overall effect can be seen in the graph of HETP against linear 
velocity in Figure 1.2. 
To minimise band broadening from the longitudinal diffusion term, the column should have 
dimensions that allow a short run time to elute the analytes quickly before they broaden, 
whilst being just long enough to obtain the required separation.   
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Figure 1.2: Graph of HETP (H) against linear velocity for an uncoated capillary column 
To minimise broadening from the mass-transfer term, the column should have the minimum 
internal diameter but still be wide enough for the required capacity for the analysis, without 
overloading the column.  In addition, the stationary phase should be just thick enough to trap 
and separate the more volatile analytes. 
1.3.1.4 Resolution, selectivity and the capacity factor 
The number of theoretical plates or the HETP are a measure of the ability of the column to 
produce sharp peaks.  The selectivity measures how far apart the peak apexes are, as shown 
in Figure 1.3 (a).  This is particularly important for identifying that there are two peaks, even 
if they are co-eluting.  The resolution measures the difference between how far apart the 
peak bases are by considering the difference in the apexes and the peak widths, i.e. how well 
the two peaks are resolved, as shown in Figure 1.3 (b).  This is particularly important for 
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quantitation, to accurately determine the area under the peak.  Having good selectivity 
doesn’t mean that peaks are always well resolved, as shown in Figure 1.3 (c) and (d).  The 
column stationary phase may be capable of separating peaks, but other factors come into it, 
such as band broadening, which may also affect the analytes’ separation.  
 
Figure 1.3: Resolution and selectivity of chromatographic peaks 
The resolution (RS) can again be calculated from the chromatogram, as shown in Figure 1.4 
(a).  The difference in the retention times of the two peaks, ΔZ (minutes), is compared to the 
sum of the two peak widths at the baseline, WA and WB (minutes) using: 
ܴ௦ = 2	 ቀ∆ܼ ( ஺ܹ +	 ஻ܹ)ൗ ቁ  (1.5) 
A resolution of ≥1.5 means the peaks are baseline separated.  The resolution of a method can 
be improved by increasing the number of theoretical plates.  This can be achieved by: (i) 
lengthening the column, however this can also lead to longer analysis times and increased 
longitudinal diffusion; (ii) reducing the column internal diameter, which enables analyte 
molecules to reach the mobile to stationary phase interface faster and reduces the mass 
transfer term of the Van Deemter equation; (iii) by changing the selectivity of the column; 
or (iv) by controlling the capacity factor. 
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Figure 1.4:  Measurements on the chromatogram used in the calculation of (a) resolution, 
(b)selectivity and capacity factor  
The capacity (or retention) factor (k’) of the analyte, describes the analyte’s distribution 
between the two mobile and stationary phases and is a measure of its migration rate or 
retention on the chromatographic column.  It is independent of the column dimensions and 
the mobile phase flow rate.  The capacity factor is calculated from the retention time of the 
peak, (tR)A (minutes) and the retention time of an unretained peak or dead time of the column, 
tM (minutes), determined from the chromatogram, Figure 1.4 (b).   
݇′ = ((ݐோ	)஺ −	ݐெ) ݐெൗ    (1.6) 
The capacity factor optimal value is between 1-10.  By increasing the temperature of the 
analytical column, the capacity factor decreases, as the retention of the peak reduces and the 
analyte elutes earlier. 
Selectivity is the preference for the stationary phase (or for the mobile phase too, in HPLC) 
for one analyte over another in a separation, distinguishing those peaks ‘chemically’.  The 
selectivity factor, α, is calculated based on the retention times of the two peaks, (tR)A and 
(tR)B (minutes), and the retention time of an unretained peak, tM (minutes).  These values are 
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determined from the chromatogram, as shown in Figure 1.4 (b) and the selectivity factor is 
calculated using: 
ߙ = ((ݐோ	)஻ −	ݐெ) ((ݐோ)஺ −	ݐெ)൘   (1.7) 
The selectivity factor, α, is greatly affected by changing the stationary phase composition 
and this is one of the most powerful separation factors in gas chromatography.  The phase 
ratio, β, of the stationary phase thickness to the column internal diameter also has an impact, 
as this alters the distribution of the analyte between the two phases.  The diffusivity of the 
analyte in both the mobile and stationary phases, the radius of the column, the column 
temperature and oven temperature ramp rate all have an influence on the selectivity of some 
analytes.   
1.3.1.5 Carrier gas flow rate 
The flow rate of the carrier gas through the analytical column affects the separation of the 
analytes and the time taken for the analysis.  As shown in Figure 1.5, the Van Deemter plot 
is a visual representation of the respective equations and relate the HETP to the average 
linear velocity of the carrier gas through the column and allow the conditions for the optimal 
column efficiency to be determined.  To obtain the optimal column efficiency, the optimal 
mobile phase linear velocity is mostly dependent on the carrier gas type.  Helium has an 
optimum linear velocity of around 22 cm/s, with typical operating conditions of 20-25 cm/s.  
However, due to the broader curve for helium, a shorter GC run time can be obtained by 
using a faster velocity of up to 35 cm/s with a slight increase of the HETP value.  This 
increase in HETP results in a very slight decrease in the column efficiency, however it is 
still more than adequate for many applications.   
The linear velocity and the volumetric flow rate through the column are both calculated from 
the carrier gas type, the analytical column dimensions and the oven temperature and are 
controlled by adjusting the head pressure (the gas pressure at the head of the analytical 
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column) using an electronic pressure or flow control module within the GC.  The GC method 
can be run in constant pressure, ramped pressure or constant flow modes throughout the 
analysis, depending on the application.  Maintaining a constant flow through the column, 
while the oven temperature increases, reduces run times and longitudinal diffusion. 
 
Figure 1.5:  Van Deemter plot of HETP against average linear velocity through the column 
for nitrogen, helium and hydrogen carrier gases 
1.3.1.6 GC inlets 
The head of the analytical column connects to the GC inlet, which introduces the carrier gas 
and enables the transfer of the vapourised sample, in a narrow sample band, onto the column 
for separation.  There are three common methods of transferring the analytes onto the 
column: cold on-column, split and splitless injection.  
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Cold on-column injection is performed by injecting the sample directly into the analytical 
column using a narrow syringe needle.  The column is positioned into the inlet, that may be 
a cold on-column inlet, or a programmable temperature vapouriser (PTV) with an inlet liner 
insert that holds the head of the analytical column in position for the syringe needle to be 
inserted.  The inlet is held at a temperature of 10-20 °C below the boiling point of the solvent 
(hence it is known as a ‘cold’ injection).  Once injected, the inlet and the column oven are 
heated together to first evaporate the solvent and then perform the separation.  On-column 
injection is useful for: thermally labile compounds, as the sample is injected at a cool 
temperature before being gently heated; high molecular weight compounds, as they are not 
subject to mass discrimination when being transferred onto the column; and trace level 
analytes, as they are far less likely to suffer from losses.  However, on-column injection is 
unsuitable for dirty samples, as the dirt and unwanted matrix is also transferred to the 
column. 
Split and splitless methods are vapourising injections, the sample is in the gas-phase before 
it is transferred onto the column, leaving behind the dirt and unwanted matrix.  The inlet is 
installed with a removable inlet liner.  The sample is injected into the top half of the liner, 
the inlet heated and the vapourised sample is transferred into the head of the analytical 
column, positioned near the bottom of the inlet liner.  The whole, introduced sample may be 
transferred onto the column in splitless mode.  For higher concentration samples, only a 
portion of the sample may be introduced in split mode, while most of the vaporised sample 
is sent to waste through the split exit.  The split ratio is the proportion of the sample amount 
that goes to waste out of the split exit compared to the amount that is transferred to the 
analytical column.  For example, a 20:1 split ratio means that the flow through the split exit 
is 20 mL/min if the flow through the column is 1 mL/min. 
Samples may be immediately vapourised on introduction into a hot inlet; or they may be 
introduced into a cold inlet (below the boiling point of any solvent) which is then heated to 
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vapourise the analytes and transfer them to the column. This PTV technique is better for 
high molecular weight and thermally labile analytes, which may suffer from mass 
discrimination or thermal degradation by introducing into a hot inlet.   
Liquid injection volumes for split and splitless injections are usually between 0.1-3 µL.  If 
the injection volume is too large, the vapour volume may exceed the capacity of the inlet 
liner, causing contamination of the system.  Too much solvent condensing on the walls of 
the analytical column can also cause wide sample bands, resulting in poor peak shapes.  
Trace analytes in liquid samples may also be concentrated in the inlet when introducing 
larger volumes of solvent from 10-850 µL with a large volume injection (LVI).  The excess 
solvent is evaporated in the inlet and sent to waste out of the split exit when injected under 
cold conditions.  The large sample volume injected, is either held within a liner packed with 
an absorbent or adsorbent, that increases the surface area and can interact with the sample 
depending on the type, being called a rapid or at-once LVI; or the solvent is evaporated as it 
is slowly injected, this is called speed-controlled LVI.  Once most solvent has been 
evaporated and the analytes are concentrated in only 1-3 µL of remaining solvent, the split 
exit is closed and the inlet is heated to transfer the analytes in splitless mode onto the 
analytical column for separation.   
The temperature of the inlet is dictated by the volatility of the analytes of interest.  The inlet 
should be hot enough to obtain total transfer of the least volatile analyte of interest; while 
keeping it as low as possible, to minimise the likelihood of any thermal degradation and 
minimise the transfer of any unwanted matrix onto the column. This unwanted matrix can 
be more difficult and time consuming to remove, increasing the run times and the final oven 
temperature, but also causing potential damage to the column and dirtying the detector.  An 
inlet liner is cheaper, easier and faster to replace. 
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There are different styles of liners, depending on the type of inlet, the introduction technique, 
the nature of the analytes and the vapour volume.  Liquid samples are vapourised within the 
inlet for split and splitless injections and therefore the liner volume must be a third greater 
than the vapour volume produced for the solvent used at that temperature and pressure.  
Usually, gas-phase samples, especially those that contain higher amounts of water vapour, 
use a similar size of liner.  For splitless injection, the aim is to transfer all the sample onto 
the column and therefore a taper is used to direct the vapour onto the head of the analytical 
column.  Inversely, for split injections, especially those with high split ratios, most of the 
sample will go to waste and therefore the taper is not required.  The aim of a split injection 
is to obtain a homogenous mixture of sample vapour and carrier gas between the point of 
injection and the head of the analytical column where it is proportioned between the split 
exit and column, to obtain reproducible analyses.  On vapourisation, turbulent flow occurs 
that mixes them, however the flow through the liner in a split injection can be very high and 
therefore a liner with a plug of glass wool in the centre of the liner is used to improve the 
mixing and hence the reproducibility.  
Solventless injections, do not require a liner with a large volume.  Narrow liners vapourise 
the analytes faster and much improve the transfer to the analytical column, resulting in 
narrower sample bands and sharper peaks. 
Active compounds interact with active sites within the GC system, resulting in those 
molecules travelling slower than average and resulting in tailing peaks.  Active compounds 
are usually more polar in nature.  Those with an active hydrogen, for example in a hydroxyl 
group, form hydrogen bonds with silanol (-Si-O-H) groups on glass surfaces.  Glass is used 
through the GC system, from the autosampler vials, to the autosampler syringes, inlet liners 
and analytical columns.  After the column has been coated with the stationary phase, it is 
deactivated to remove the active silanol groups; however, damage to the column can result 
in it becoming active again.   
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The main place for activity is within the GC inlet.  The inlet liner is the site of sample 
injection, analyte evaporation and transfer onto the analytical column.  It is where dirt and 
unwanted matrix accumulates, becoming active sites for these active compounds.  For 
analyses of active compounds, especially those at trace levels, it is essential to use a 
deactivated inlet liner, to improve peak shapes and reduce analyte losses.  There are multiple 
different techniques for deactivation, but most of them include silanisation to remove the 
active hydrogen. 
Some solventless injection techniques do not use a GC inlet, but connect the source of the 
sample, such as a thermal desorption or headspace autosampler, through a heated transfer-
line directly to the head of the analytical column. 
1.3.1.7 GC detectors 
The separated analytes elute from the analytical column into the detector. Depending on the 
chemical composition and the quantity of the analytes eluting the detector produces a 
response and the signal produced is used to create a chromatogram – a graph of the detector 
response versus the retention time of the analyte.   
There are over 20 different types of detectors in gas chromatography that can respond to 
specific elements, bonds or functional groups in a molecule or its physical properties such 
as electronegativity or thermal conductivity.  As shown in Table 1-2, some GC detectors 
give a similar response to all analytes, others are selective to one or more classes of analytes. 
All detectors have varying sensitivities and dynamic ranges.  Universal detectors are good 
for seeing most organic compounds in a sample, whereas selective detectors can reduce 
matrix interferences and improve detection limits.   
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Table 1-2: GC detector types, what they respond to, their sensitivity and linear range 
Detector Known as Analytes/atoms/bonds Sensitivity Linear 
range 
Flame Ionisation Detector FID C-H bonds 100 pg C 107 
Pulsed Flame Photometric 
Detector 
PFPD Sulphur/Phosphorus/other 
elements 
S & P fg S:103 
P:103 
Photo Ionisation Detector PID VOCs 25-50 pg 105-7 
Vacuum Ultra-Violet VUV Functional groups, isomers pg 104 
Infra-Red Detector IRD Functional groups, isomers ng 103 
Sulphur/Nitrogen 
Chemiluminescence Detector 
SCD/NCD Sulphur/Nitrogen pg 104 
Thermal Energy Analyser TEA Nitrogen groups pg 104 
Atomic Emission Detector AED Heteroatoms & other 
elements 
<pg 104 
Thermal Conductivity 
Detector 
TCD Organic & inorganic <ng 105 
Nitrogen Phosphorus Detector NPD Nitrogen/Phosphorus 50-500 fg 105 
Barrier discharge Ionisation 
Detector 
BID Organic low pg 105 
Helium/Discharge Ionisation 
Detector 
HID/DID Gases 0.1 ppm 102 
Electron Capture Detector ECD Electron capturing, 
halides… 
<50 fg 104 
Electrolytic Conductivity 
Detector 
ELCD Halogens, sulphur, 
nitrogen 
5 ppb 103 
1.3.1.8 Qualitative and quantitative analyses 
For most GC detectors, the only information that they can give about an analyte is that they 
respond on that detector with a given response and the length of time that the analyte is 
retained by that column with that method, i.e. the retention time and signal response.  
Therefore, GC detectors are mainly used to determine if a known analyte is potentially 
present in a sample, by comparing the retention time of a peak in the sample to that of a 
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standard, analysed using the same method.  This mode of operation is known as qualitative 
analysis.  
If required, the amount of an analyte in the sample can be determined by comparing the area 
(or less commonly the height) of the peak in the sample and the same peak in the standard.  
This mode of operation is known as quantitative analysis.  Peaks must be well resolved and 
known, to ensure there are no co-eluting peaks which could give false results.  There are 
several different methods utilised to perform quantitation.  External standards are prepared 
at one, or more, concentrations around the expected concentration in the sample and are 
analysed separately to the samples. A calibration curve is then plotted of the target analyte 
response against the known concentration.  When the sample is analysed and the target 
analyte identified, the calibration curve is then used to determine the concentration using the 
response seen in the sample.  The standard addition method adds the standard solution at 
different concentrations to portions of the same sample, these are then plotted and the trend 
line is extended to determine the concentration of the analyte in the original sample. This is 
the most accurate determination of concentration, especially for sample with high matrix 
interferences; however, each sample must be analysed a minimum of three times.   
The internal standard (IS) method analyses standards in the same way as external standards; 
however, compound(s), chosen as internal standard(s), must not be present in the sample.  
The same concentration of the IS is added to all external standards and samples.  The 
response of the target analytes are then normalised against the IS response before calibration 
to correct for any potential problems with the specific analysis. This approach can reduce 
the percentage relative standard deviation (RSD (%)) down to 1-2 % or less.  GC detectors 
cannot be used to identify unknown peaks in the sample, or identify or quantify closely co-
eluting peaks.  MS can be used for this and can be hyphenated to GC to give us GC-MS. 
46 
 
1.3.2 Mass spectrometry (MS) 
Mass spectrometry (MS) is an analytical technique that can be used to identify unknown 
analytes, quantify known analytes and determine the structural and chemical properties of 
molecules, usually organic.   
1.3.2.1 The vacuum system 
The separated analytes elute from the GC as neutral molecules and pass through a heated 
transfer line into the mass spectrometer which is under a vacuum, at around 1 x 10-5 to 1 x 
10-7 mbar, depending on the vacuum pumps.  The vacuum provides a collision-free path for 
the ions generated from the analyte molecules, thus reducing ion-molecular reactions, 
background interferences and electrical discharge, thereby improving sensitivity and the 
lifetime of the MS components.  The type and size of the vacuum pumps limits the upper 
column flow rate and total volume of carrier gas into the MS, with typical maximum flow 
rates of 1.5 to 4 mL/min and maximum column internal diameters of 0.25 mm.  Too much 
carrier gas compromises the vacuum system and severely reduces the sensitivity and the 
resolving power of the MS. 
1.3.2.2 Ionisation 
The neutral analyte molecules first enter the ion source, where they undergo ionisation.  The 
most common ionisation technique, which produces good structural and library searchable 
information is electron ionisation (EI).  Here, a platinum or rhenium filament generates 
electrons which are accelerated to 70 eV and hit the neutral analyte molecules.  The electron 
interaction energy is higher than the bond energy and so an electron is knocked out to 
produce a positive molecular ion in the excited state: M + e- → M+• + 2e-. 
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The excited molecular ion can be unstable and the excess energy present breaks chemical 
bonds predictably.  Depending on the structure of the ion, it can either fragment, to lose a 
neutral, or undergo molecular rearrangements to become more stable.  The steps of ionisation 
are shown in Figure 1.6.  For some analytes, where they have no structural features to 
disperse the excess energy, such as saturated hydrocarbons, all the molecular ions produced 
will undergo fragmentation with no molecular ions passing through the remainder of the MS.   
 
Figure 1.6: Neutral molecules elute from the GC column and are hit by an electron with 
70eV, knocking out an electron. The radical cation may then fragment. 
The fragmentation pattern produced along with the molecular ion (if present) is called the 
mass spectrum and is a characteristic fingerprint for the molecule.  This mass spectrum can 
be interpreted to determine the molecular formula and structure of the analyte, or compared 
to large libraries of EI mass spectra, produced using 70 eV, to identify the unknown analyte.  
Electron impact sources can also utilise lower potential differences (eVs) or softer ionisation 
techniques, such as positive or negative chemical ionisation (PCI & NCI), to produce mass 
spectra that usually have less fragmentation and stronger molecular ions, for confirmation 
of the molecular weight or for targeted analysis. 
Once the molecular ions and fragment ions are formed in the ion source, they are extracted 
through a series of lenses (Einzel) to produce a tight ion beam and to remove unwanted ions, 
before being separated in the mass analyser according to their mass-to-charge ratio (m/z).   
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There are several different mass analysers that work in different ways to perform the 
separation. Some use electric or magnetic fields others use direct current (DC) and radio 
frequency (RF) voltages.   
1.3.2.3 The quadrupole mass analyser (qMS) 
The most common (and cheapest) MS for GC is the single quadrupole.  This has four parallel 
rods arranged in a square cuboid, to which a positive DC voltage is applied to two opposing 
rods and a negative DC voltage is applied to the remaining two.  A RF voltage is applied to 
all the rods.  The DC & RF voltages are varied to allow a certain m/z value to have a stable 
trajectory through the space between the rods to the detector. The remaining ions hit the rods 
and are not detected, hence the systems are commonly known as mass selective detectors 
(MSD).   
The quadrupole instrument is a scanning instrument.  Once one m/z value is recorded, the 
voltages are then varied to allow the next m/z ions through, and so on.  One of the drawbacks 
with single quadrupoles, is the time taken to scan through all the voltages to allow all the 
ions through to produce a single mass spectrum of sufficient quality for identification of the 
peak.  If the scan speed is too slow, peaks may be missed or there may not be sufficient data 
points across the GC peaks to produce a high-quality chromatogram and insufficient 
information to enable quantitation.  Conversely, if the scan speed is too fast, then sensitivity 
is lost as the number of ions reaching the detector reduces before the voltage is changed to 
allow a different m/z through.  Stabilisation time is also needed for any large changes in 
voltages, for example between scans, before signal collection can begin.  Therefore, the more 
frequent the scans, the longer the time is spent stabilising rather than collecting.    
If the mass range acquired is too narrow, important information such as the molecular ion or 
low mass ions, used for identification, may be lost.  Conversely, a wide mass range, which 
would allow these parameters to be collected, will take longer with the result that the number 
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of data points output per second will be smaller and this could result in a poorer 
representation of the chromatographic peak shapes.   
The desired scan or acquisition rate is dependent on the average peak widths in the 
chromatogram.  Ideally, 15-25 data points across the peak from baseline to baseline are 
required for good qualitative and quantitative analysis.  In standard GC-MS, the average 
peak width is usually around 3 s, therefore for an average of 20 data points across the peak, 
the desired acquisition rate would be approximately 7 scans/s.  Once optimised, the scan 
range is usually fixed, therefore how long the ions are allowed through to the detector before 
the voltages are changed is adjusted to reach the desired acquisition rate.  How this is done 
depends on the manufacturer of the MS, for example it could be the sampling rate or the 
event time (ms). 
With qualitative and quantitative target analysis, the ions of interest are known and therefore 
a MS method can be optimised to only look for the target ions at the expected retention 
times.  The use of selected ion monitoring (SIM) mode, rather than a full scan method, 
improves sensitivity and the chromatographic peak shapes as less time is spent jumping 
between the voltages and more time detecting the ions of interest.  In each timed group, only 
the 2-4 key ions are acquired for each analyte that elute in close proximity.  A space in the 
baseline enables a different timed group to be acquired.  Larger numbers of timed groups 
result in less ions to be acquired for each group, enabling the voltages to be held for longer 
(dwell times), to allow more ions of that m/z to reach the detector and therefore improve 
sensitivity for each ion.   Identification is based on the retention time, presence and ratios of 
the 2-4 ions collected for each analyte.  It is common for this mode to lead to an order of 
magnitude reduction in the baseline noise for targeted species, when compared to the full 
scan mode. This SIM mode is not applicable when analysing unknown compounds.   
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1.3.2.4 The time-of-flight (ToF) mass analyser 
Another type of mass analyser is the time-of-flight (ToF) mass spectrometer, which enables 
the simultaneous acquisition of all the ions and is therefore not a scanning instrument.  All 
ions, of varying m/z values, are pulsed out of the ionisation source in packets, with 
effectively the same kinetic energy, and are accelerated and focused into a flight tube.  With 
the ions having the same kinetic energy (ek = ½ mv2), ions with different mass (m) will have 
different velocities (v).  The lighter ions travel through the flight tube faster and will arrive 
at the detector first, whereas the heavier ions are slower, hence the name given to the type 
of analyser, as shown in Figure 1.7.   
 
Figure 1.7:  Time-of-Flight mass analyser 
Depending on their proximity to the push plate in the ion source, when the voltage was 
applied, ions of the same m/z may have slightly different kinetic energies, giving them very 
slightly different flight times.  This variability is corrected by an ion mirror or reflectron 
further down the flight tube, where a series of metal plates with increasing voltages create 
an electric field.  Those ions with slightly higher kinetic energy travel further into the 
reflectron before being deflected.  Having a longer path length, than those ions with slightly 
lower kinetic energy, means that all ions with the same m/z will arrive at the detector 
simultaneously. 
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1.3.2.5 MS detectors 
The detector in a MS responds to the ions reaching it, this produces a signal which is 
amplified and recorded, then used to create a mass spectrum and consequentially a 
chromatogram.  Single quadrupole mass spectrometers usually use electron multipliers (EM) 
and ToFMS systems micro-channel plates (MCP).  Both are coated with a high secondary 
electron yield material, but the EM is a funnel or horn shape whereas the MCP has two plates 
in a chevron shape with many tiny slots, each one a continuous-dynode electron multiplier.  
When the ion (or electron, if the ion has been converted to an electron on exiting the mass 
analyser by, for example, a high-energy dynode (HED)) hits the material, secondary 
electrons are liberated. These then go on to liberate more electrons and so on, until there is 
a cascade of electrons that produce a signal by hitting a metal anode that measures the total 
current.  The number of electrons liberated is proportional to the voltage applied to the 
detector, however higher voltages doesn’t necessarily mean better sensitivity, as they also 
respond to chemical noise such as column bleed too. 
1.3.2.6 Accurate mass or high resolution MS 
The ability of a mass spectrometer to distinguish between two ion peaks of slightly different 
m/z ratio in a spectrum depends on the type of MS.  Quadrupoles have unit mass resolution, 
for example being able to distinguish between 50 and 51 u, or slightly better to 0.1 u.  ToFs 
can be configured to have unit mass or high resolution (HRMS).  ToFs with high acquisition 
rates of 250 spectra/s or higher, accelerate the ions into the flight tube with high velocities, 
which prevents such a good separation of the masses and therefore are usually unit mass 
instruments.  To obtain high mass resolution, the ions must have slower velocities and 
therefore the acquisition rate is not as high, limited by the refresh rate of the detector.  High 
mass resolution has the added advantages of more accurate identification of analytes with 
the same nominal mass but different molecular formula.   
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Atomic masses are not whole numbers.  Based on carbon-12, where 12C = 12.0000 g, 
hydrogen and oxygen have masses of 1H = 1.00794 g and 16O = 15.9994 g respectively.  The 
mass defect is the difference between the nominal and exact or accurate masses. 
Small differences in the accurate mass of molecular and fragment ions can be used to resolve 
co-eluting compounds and to minimise the influence of background interferences, but this 
can often be at the expense of reduced dynamic range, reduced sensitivity and higher cost, 
as well as lower acquisition rates.  High acquisition rates enable narrower peaks from the 
GC to be detected, enabling fast GC separations to be performed and therefore shorter 
analysis times.  The number of data points across peaks can also be higher which can aid in 
the detection of co-eluting peaks with spectral resolution, this can be useful when analysing 
complex samples containing hundreds of different compounds. 
1.3.2.7 Deconvolution 
Spectral resolution can only be used as an additional separation method where a mass 
spectrometer is hyphenated to a GC, not with GC detectors.  Analytes only partially 
separating on a GC column can usually be identified and quantified by the differences in 
their mass fragmentation patterns. The exceptions are isomers, as they have the same or 
similar mass spectra and ions.  If all the ions in a mass spectrum belong to the same peak 
(analyte), then their concentration will increase and decrease at the same rate, after spectral 
deskewing of the data. 
Scanning instruments such as the quadrupole MS, allow ions of different m/z through the 
mass analyser and into the detector at slightly different times.  If all the ions acquired were 
overlaid, it would be noticed that the ions, even if belonging to the same peak, would go up 
and down at very slightly different times, in the order that they were acquired, for example 
high to low mass or low to high mass depending on the manufacturer.  Deskewing is the act 
of aligning all the ions to remove the acquisition time differences.  
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After deskewing, the ions belonging to the same peak will have the same apex and peak 
shape. Therefore, if an ion has a different apex or shape, it is very likely to come from a 
different analyte, the matrix or baseline that has a similar retention time on the analytical 
column. 
The act of monitoring the rate of the rise and the fall of all the ions collected and then putting 
together a cleaned-up mass spectrum for each analyte, that is also library searchable, is called 
deconvolution.  Analyte peaks that have the same apex and shape cannot be deconvoluted 
and will result in a mixed mass spectrum that is difficult to interpret and will make the 
compounds difficult to correctly identify.  This situation could arise due to a lack of 
chromatographic resolution and therefore the GC separation conditions should be optimised.  
Alternatively, there may not be enough data points across the peaks for accurate 
determination of the apex, in which case the mass spectral method must be optimised.  The 
use of deconvolution is critical in: fast GC analyses, where total chromatographic resolution 
is not always achieved; in the analysis of samples with complex matrices, especially with 
large differences in the concentration of peaks, where small peaks of interest can often be 
masked by large, overloaded matrix components which cannot be chromatographically 
separated on a single column stationary phase; and for finding small peaks under the 
baseline.  For good deconvolution, the chromatographic peaks should be sharp, giving a 
good signal-to-noise (SN) ratio and peak shape; and there must be enough data points across 
the peaks to enable the deconvolution of closely co-eluting peaks.  In practice, 15 to 25 data 
points across the peak is optimal. 
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1.3.3 Comprehensive two-dimensional gas chromatography 
(GCxGC) 
Gas chromatography is a powerful separation technique, but for samples containing many 
hundreds or thousands of peaks a single dimension column doesn’t have enough resolving 
power to separate all the components with a single type of stationary phase. 
Multi-dimensional chromatography is the act of using more than one type of separation step, 
or stage, based on different mechanisms that are linked. For example, using volatility, 
polarity, shape selectivity or linking two different separation techniques such as liquid 
chromatography (LC) and GC to give LCxGC.  GCxGC is usually achieved by using 
columns with two different stationary phases, each with different selectivities for separation, 
in a single analytical run. 
Heart cutting has been used for decades in the petroleum industry to take a small fraction, 
otherwise known as ‘cut’, of partially resolved analytes eluting from the primary column 
and transfer them to a second column of a different selectivity.  Multiple cuts can be taken 
across the run, depending on the separation time on the second column – for simplicity, 
separation should be complete before transferring the next cut.  A switching device, most 
commonly a Deans’ switch, switches the primary column effluent (only during the heart cut 
times) away from the primary detector and into the secondary column, from where it elutes 
into a secondary detector (Deans, 1968).  With developments in technology resulting in the 
availability of commercial solutions, heart cutting is now used in many industries, when 
there are multiple groups of partially resolved analytes that need further separation with a 
different stationary phase selectivity. 
However, there are many samples that have partially resolved analytes throughout the 
primary separation and continuous heart cutting is required. Comprehensive two-
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dimensional gas chromatography (GCxGC) continuously traps, focuses and re-injects 
aliquots of the primary column effluent into the secondary column, usually at 1 to 10 s 
intervals, using a modulator.  The technique was originally described by Phillips and Liu, in 
1991 (Liu & Phillips, 1991).  It has been extensively applied to solve complex problems 
such as separating thousands of peaks in diesel or meteorite samples or for the trace analysis 
of analytes in high matrix samples such as drugs of abuse (Watson, et al., 2007), (Guthery, 
et al., 2010).  Two columns are placed in series, with the primary column connected between 
the GC inlet and the secondary column. The connection is made using a press-fit connector 
or a similar low-thermal mass, low-dead volume, leak tight union.  The outlet of the 
secondary column is connected to the detector, this must have a low internal volume to avoid 
band broadening and have a fast acquisition rate of 100 Hz or higher to be able to detect the 
narrow peaks eluting from the secondary column, which can have peak widths down to 30-
40 ms, depending on the modulator.   
1.3.3.1 GCxGC detectors 
There are many universal and specific GC detectors that are fast enough for GCxGC and 
some mass spectrometers.  Slower scanning quadrupole and high resolution ToFs can be 
used with GCxGC, but mainly for identification of well separated peaks, as they may not 
give enough data points across the peaks for quantitation and deconvolution. Their 
applicability will depend on the application, modulator and MS.  Fast scanning ToFs are 
more suited due to their high acquisition rate, with the added advantage of deconvolution 
should any peaks not give total separation even with GCxGC.  Unlike heart cutting, only a 
single detector is required, as all the transferred sample moves through the primary column 
and through the secondary column into the same detector. 
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1.3.3.2 GCxGC modulators 
The modulator is the key to successful GCxGC.  It is a repetitive injector for the secondary 
column and is usually configured with the head of the secondary column passing through it.  
This enables it to refocus the sample band, should band broadening occur between the 
primary and secondary columns.  The modulator continuously collects, or traps, small 
fractions of effluent from the primary column; focuses and with some modulators refocuses 
the fraction into a narrow band; then very quickly it transfers the whole focused fraction into 
the secondary column before collecting or trapping the next fraction.  This modulation cycle 
is repeated every 1-10 s.  With some modulators, some effluent goes to waste as the fraction 
is transferred to the secondary column. 
Modulators should have: 
• a high sampling frequency, in that they have fast heating and cooling;  
• good sampling efficiency or focusing effect;  
• a high temperature range that matches the GC oven temperature;  
• no dead volumes, to maintain peak shape; and  
• been designed to be robust and easy to maintain.   
There are two main groups of thermal modulators.  Those that use a non-cryogenic coolant 
system, operating at -90 °C, or those that use a cryogenic liquid to trap and focus the cut.  
The former release the analytes using heaters whilst the latter use hot air to release the 
analytes.   
The modulator with the highest sampling efficiency (i.e. the highest secondary column peak 
capacity) uses liquid nitrogen (LN2) cooling to trap at around -180 °C.  It is dual stage and 
can modulate down to C3 compounds.  It uses either two cold & hot jets to trap and then 
release the cut, or the secondary column loops around and passes through the hot & cold jets 
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a second time. A sample path of 50-100 cm, between the upper and lower modulation points, 
allows further focusing.   
Air for the hot jet is heated through the modulator. The thermal modulators are usually 
operated at 30-100 °C above the primary oven temperature, to heat the air sufficiently and 
to prevent cold areas forming around the columns that could cause band broadening.  
Valve-based or capillary flow modulators trap and compress the cut in a collection loop or 
tube that is quickly flushed onto a secondary column with the same or a slightly larger 
diameter, so that there is no back pressure.  The flow through the primary column is low, at 
around 1 mL/min, to trap the cut in the wide i.d. collection tube under almost stop flow 
conditions. Typically, a very high flow rate (~20 mL/min) is diverted through the collection 
tube, for the sweep time. The peaks are compressed and the cut is swept onto the secondary 
column.  It performs the secondary separation at high flow, making it unsuitable for the total 
flow of the secondary column effluent to directly enter a mass spectrometer for detection.  
Therefore, when a GC-MS is used with a capillary flow modulator the effluent is split or 
more usually a GC detector is also used.  This splitting of the flows results in lower 
sensitivity for the MS output.   
1.3.3.3 GCxGC column sets 
For GCxGC, two columns must be chosen with different selectivities.  The most 
conventional set, where most of the separation can be performed based on the volatility of 
the analytes, is a non-polar primary column, followed by a polar secondary column (Turner, 
2002).  Separation on this second column is based on the polarity and functional groups of 
the analytes.  A reversed phase column set, using a polar primary column followed by a non-
polar secondary column can be selected for specific applications, usually those that contain 
a large proportion of more polar analytes and are separated in 1D on a polar column.  For 
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the separation of stereo or positional isomers, the chiral column is usually installed as the 
primary column, followed by a non-polar or PEG secondary column (Hilton, 2008).   
Columns with different selectivities can have large differences in their maximum operating 
temperatures; for example, non-polar columns could have a maximum temperature of 350-
370 °C, whereas, polar PEG columns have a maximum temperature of 260-280 °C.   These 
differences can cause a problem if the sample has a wide volatility range, thus the oven 
temperature needs to ramp high to elute the least volatile analytes.  Therefore, for some 
applications, although not optimal, a mid-polar column with 50 % diphenyl 50 % dimethyl 
polysiloxane must be chosen instead of a PEG column, due to the higher column temperature 
limits of 360-370 °C.  This enables lower volatility analytes to be separated by GCxGC for 
example in diesel analysis.  
1.3.3.4 GCxGC column ovens 
Both columns can be heated in the same GC oven.  Alternatively, the secondary column can 
be heated in a second GC oven or even in a small oven sited within the main GC oven.  A 
second oven provides the maximum flexibility as it enables the secondary column to be 
heated above the temperature of the primary oven, to speed-up the separation in the second 
dimension. For example, an increase of 15 °C would ensure that the separation on the 
secondary column, of a conventional column set, would be purely based on the interaction 
of the functional groups and not volatility.  Use of a separate GC oven would enable the 
secondary column separation to be at a higher or lower temperature than the primary 
separation, but it significantly increases the cost of the instrument and the bench space 
required. 
Both thermal and flow modulators use a conventional column for the first-dimension 
separation, with a length of 20-30 m and an i.d. of 0.18-0.25 mm.  A lower flow rate of 0.6-
1 mL/min is combined with a slow oven temperature program of 2-10 °C/min, to broaden 
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the eluting peaks so that multiple cuts can be taken across the peak but still get good 
resolution.  For thermal modulators, the second column is much shorter (0.5-2 m) and 
narrower (0.1 mm i.d.) with a thin stationary phase film thickness (usually 0.1 µm).  This 
allows the modulator to efficiently cool and heat a small area of the column, trapping the 
analytes into a very narrow sample band and efficiently releasing them.   
Coupling the narrow bore secondary column with the primary column also results in a faster 
flow rate through the secondary column and a fast analysis of the cut before the next cut is 
transferred. The coupling also results in a high back pressure, greatly increases the pressure 
required to obtain an average flow rate of 1 mL/min through the column set and making it 
more difficult to get a leak-free connection at the press-fit.  The volumetric flow rate of gas 
eluting from the secondary column is low enough for the column to be installed directly into 
an MS, although a high-performance vacuum system is recommended for maximum 
flexibility in flow rate and stability.   
Flow modulators use a secondary column of the same, or a slightly wider i.d., than the 
primary column.  Usually they are 5 m in length, with a 0.25 mm i.d. and with a 0.15 µm 
stationary phase film thickness.  Having the same diameter there is no increase in the back 
pressure, the primary column usually has a flow rate of 0.8-1 mL/min, to slow the separation; 
whereas, a fast separation is performed on the secondary column using a high flow rate of 
around 20 mL/min, making it unsuitable for direct installation of the column into an MS, as 
previously discussed. 
1.3.3.5 GCxGC chromatograms 
GCxGC with a GC detector produces data that is three dimensional: retention time on 
column 1; retention time on column 2; plus, the intensity of the signal.  If coupled to an MS, 
the data is four dimensional: retention time on column 1; retention time on column 2; 
intensity of the signal; plus, the m/z ratio.  
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The instrument acquisition software produces three-dimensional data that can be viewed as 
a conventional two-dimensional chromatogram that the detector sees, of the intensity against 
the total retention time from the start of the run, as shown in Figure 1.11 (b).  However, 
GCxGC data is easier to visualise through the GCxGC software, either as a 2D contour plot, 
as shown in Figure 1.8, or as a 3D surface plot, as shown in Figure 1.9.   
 
Figure 1.8: Example of a 2D contour plot of diesel by GCxGC-FID: x-axis 1st dimension 
retention time (s); y-axis 2nd dimension retention time (s); colour represents 
response: from no response (dark blue) to highest response (red). 
In the 2D contour plot, the 1st dimension (non-polar column) retention time is shown on the 
x-axis, the 2nd dimension (polar column) retention time on the y-axis and the intensity of the 
ion signal is represented by colouration.  The horizontal green line that is increasing in 
intensity (bottom right) is the modulated column bleed from the 1st dimension column; above 
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this are non-polar alkanes, moving up in bands to polycyclic aromatic hydrocarbons (top 
right).  In the 3D surface plot, the 1st dimension retention time is shown on the x-axis, the 
2nd dimension retention time on the y-axis and the intensity of the ion signal is clearly seen 
on the z-axis.   
 
Figure 1.9: Example of a 3D surface plot of diesel by GCxGC-FID 
The additional separation abilities of GCxGC compared to conventional 1D GC can be seen 
from the examples of diesel analysis using GC-FID shown in Figure 1.10; and diesel by 
GCxGC-FID as contour and surface plots are shown in Figure 1.8 and Figure 1.9 
respectively. 
 
Figure 1.10: Example of a 2D chromatogram of diesel by GC-FID 
Peaks eluting from the primary column are modulated into multiple slices. Optimally, a 
minimum of 3 slices are required for small peaks and possibly dozens for wide peaks.  When 
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producing the contour and surface plots from the conventional chromatogram the slices of 
the same analyte must be aligned and for quantitation the areas of these slices must be 
summed; although, not all slices are needed if they are representative of the total peak area 
and the same method is used for all samples and standards.  To produce 2D contour and 3D 
surface plots and to perform quantitation, sophisticated software is required, containing more 
method parameters for data analysis than when comparing to handling 1D data.  Each of 
these individual parameters must be optimised.  The steps of creating a 2D contour plot are 
shown in Figure 1.11. 
 
Figure 1.11:  The stages of GCxGC. Acknowledgements to JSB UK for their kind permission 
to use their diagram 
First, unresolved peaks elute from column 1 (a); these are modulated and the slices of each 
peak elute from column 2 into the detector (b); the software transforms the data from the 
detector into a surface plot where chromatograms from each modulation are stacked side-
by-side (c); each ‘slice’ of a peak are then combined and are shown as a contour plot (d) or 
converted to a surface plot. 
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1.3.3.6 Summary of GCxGC 
GCxGC is very good for solving complex separation problems and is also good for 
improving sensitivity, with very sharp peaks of approximately 30-40 ms wide, whereas 
standard 1D GC produces peaks 2-3 seconds wide.  However, thermally labile, active and 
high molecular weight analytes can still be a problem. Matrix compounds can still cause 
frequent maintenance of the instrument and enantiomers can still only be separated with the 
use of a chiral column, therefore the sample preparation, sample introduction and detection 
techniques must still be carefully selected and optimised. 
1.3.4 Headspace (HS) analysis 
1.3.4.1 Background to HS analysis 
Headspace (HS) can be defined as the gas space above a sample when placed in a 
chromatography vial and therefore HS analysis is the analysis of the analytes present within 
that gas.  Samples that can be analysed by HS analysis include anything that can fit in the 
vial and release volatile compounds, these include liquids and solids.  Usually, heat is applied 
to the vial to assist in the release of the compounds. How much heat can be applied depends 
on the boiling point of any solvent in the sample and the maximum temperature of the 
instrument and the vial.  For most HS analyses, it is always in the thermal desorption region, 
below 350 °C, where carbon-carbon bonds are not broken. 
1.3.4.2 Static HS 
Static HS analysis takes place in a sealed vial.  The sample plus any matrix modifier are 
placed into the vial, which is then sealed with a septum and cap.  Volatile analytes migrate 
from the sample into the headspace and reach equilibrium, where the rate of analyte 
molecules leaving the sample is equal to the rate of analyte molecules re-entering the sample. 
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A portion of the equilibrated headspace is then taken and injected into the GC for analysis.  
Not all analytes are distributed equally between the sample phase and the gas-phase. The 
equilibrium will depend on the volatility of the analyte, the temperature and matrix 
properties and its affinity for the sample phase.  The ratio of the analyte in the headspace to 
the sample, under the chosen conditions, at equilibrium, is given by the partition coefficient 
(K), where Cs is the concentration of the analyte in the sample phase and Cg is the 
concentration of the analyte in the gas-phase: 
ܭ =	 ஼ೞ஼೒   (1.8) 
If K is large (>1) then analytes prefer the sample and a good recovery will not be obtained 
in the analysis; if K is small (<1) then there is a higher concentration of analytes in the 
headspace, resulting in a more sensitive analysis.  For example, if the sample is hexane in 
water, at 40 °C the partition coefficient is 0.14.  A good recovery can be obtained, as the 
hexane moves easily into the headspace as it is a non-polar analyte in a very polar 
environment.  Whereas, for methanol the partition coefficient is 1670, meaning that a very 
low proportion of the analyte molecules will migrate into the headspace and be available for 
analysis. Methanol is a very polar molecule in a very polar environment and as hydrogen 
bonding is a very strong interaction it will keep the analyte molecules in the matrix, resulting 
in an analysis with poor sensitivity. 
There are several techniques to improve the detection limits of analytes with poor K values, 
by increasing the concentration of the analytes in the headspace and thus lowering their K 
values. 
Raising the equilibration temperature reduces the solubility of analytes in the sample matrix 
as well as reducing the time to reach equilibrium.  For example, ethanol in water at 40 °C 
has a K value of 1355, but at 80 °C the K value is reduced to 328, which would give a large 
improvement in sensitivity (factor of ~4).  The boiling point of the solvent should always be 
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considered, as a high concentration of solvent vapour in the headspace can reduce analyte 
concentration in the gas-phase and affect the GC(-MS) separation and detection.  For 
example, the concentration of water vapour doubles with each 10 °C increase and therefore 
an equilibration temperature of 60-80 °C is fine for most applications, but needs to be 
optimised. 
Another method of reducing the K values is to modify the matrix.  The addition of salt to 
aqueous samples decreases the analyte solubility by reducing hydrogen bonding.  However, 
there isn’t an equal effect on all analytes.  The largest effect is on polar analytes with high K 
values, but for those analytes with low K values it has little effect.  There are several different 
salts that can be used, including sodium chloride, sodium sulphate, sodium citrate, 
ammonium chloride or sulphate and potassium carbonate.  Which salt to use depends on the 
properties of the analyte and the matrix. For example, in aqueous samples, at 60 °C, the 
addition of ammonium chloride makes the ethanol peak area two times larger than with no 
salt; whereas, the addition of potassium carbonate makes the peak area eight times larger 
(PerkinElmer, Inc., 2014).  The salt should not react with the sample or analytes, for example 
sodium chloride reacts with brominated analytes, and it must be readily available with high 
purity so as not to contaminate the sample. 
Another example of matrix modification is changing the pH, which can minimise the 
solubility of some analytes.  Acidic analytes are more effectively extracted at acidic pH and 
basic compounds are more effectively extracted at basic pH.  For example, an acid present 
in a sample at a basic pH with insufficient protons will dissociate into its conjugate base: 
ܴܥܱܱܪ	 ⇋ 	ܴܥܱܱି + ܪା	   (1.9) 
The acidic analyte will become ionised, which makes it more polar, and therefore it will be 
more difficult to move into the headspace in a polar environment.  In an acidic sample, there 
will be enough protons in solution for the acidic analyte to retain its proton, so it will be ion-
66 
 
suppressed and remain in the neutral form.  It is still polar in a polar environment, but less 
polar than in its dissociated form.  Partially ionised analytes do not have constant K values 
and therefore the sample must be buffered to be either suitably acidic (pH 2-3) or basic (pH 
8-9). 
The addition of a co-solvent is a third matrix modification method used to enhance or 
suppress the response of one analyte in comparison to another.  For example, the addition of 
dimethylformamide (DMF) to a water sample increases the recovery of acetonitrile, up to a 
certain concentration.  This is a useful method where there are only a few analytes that are 
of interest, as it is difficult to find a co-solvent that only enhances and doesn’t suppress any 
analytes of interest in the sample. 
Analytes with reactive hydrogen atoms, such as acids, alcohols and amines can be 
derivatised to improve their volatility, reactivity and solubility and thereby improve their K 
values.  For example, fatty acids (FAs) can be esterified in methanol with boron trifluoride 
to become fatty acid methyl esters (FAMEs) or the acetylation of glycerol in acetic anhydride 
with sodium carbonate.  Derivatisation can be performed offline or automatically online, 
using a GC autosampler as part of the HS analysis prior to analysis by GC.   
After optimisation of the HS temperature and matrix modification, another parameter to 
improve the sensitivity of the static HS method is to consider the phase ratio, β.   β, is defined 
as the relative volume of headspace (Vg) compared to the volume of sample (Vs) in the HS 
vial: 
ߚ = 	 ௏೒௏ೞ    (1.10) 
Larger sample sizes result in lower β values and yield higher responses for volatile analytes, 
however this is dependent on their K value.  The impact of both β and K on the concentration 
in the gas-phase, Cg, can be described by: 
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ܥ௚ = 	 ஼బ(௄ା	ఉ)   (1.11) 
The concentration of an analyte in the gas-phase is directly proportional to the initial 
concentration (Co).  If K is large then β is unimportant, the analyte molecules will stay in the 
sample no matter what the phase ratio.  If K is small, then β dominates and increasing the 
amount of sample not only increases the concentration of analyte molecules in the headspace 
but also the number of analyte molecules placed in the HS vial.  Also, a larger proportion of 
the headspace is removed for injection into the GC for analysis, overall resulting in a higher 
concentration injected.  Therefore, the key to a sensitive HS method is to obtain low K values 
for all analytes by optimising the method and performing matrix modification.   
Environmental and biological samples can contain variable amounts of salt and have variable 
pH before any matrix modification is performed.  Variable pH and salt content can have a 
significant impact on the partition coefficient, partially ionised analytes don’t have constant 
K values, therefore it is necessary to normalise samples to ensure consistency.  It is relatively 
easy to check the pH and adjust, but salt content is more difficult to determine, therefore it 
is better to add salt to saturation.  The volume of sample plus matrix modifier in the vial 
must always be constant, to make sure β is reproducible, therefore care must be taken when 
changing the pH to ensure a constant sample volume is maintained.  These principles were 
applied in Chapter 3. 
1.3.4.3 The instrumentation available for static HS analysis 
There are three types of instruments available to perform automated HS analysis into a GC: 
• The gas-tight syringe instrument is an XYZ robot that uses an incubator to heat and 
shake the HS vial for a given time and temperature.  The heated syringe, which is at 
a temperature higher than the sample to prevent condensation, takes an aliquot of the 
headspace from the vial, moves to the GC inlet and injects the sample.  Some sample 
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can be lost between the incubator and inlet due to pressure differences between the 
vial and atmosphere. This loss can be reduced by minimising the syringe 
temperature.   
• The balanced pressure system heats the HS vial in a thermostatted oven before a 
needle is inserted and the vial is pressurised with carrier gas.  After equilibration, a 
valve is switched for a fixed time, allowing the sample from the vial onto the column 
through a heated transfer line. The total volume transferred is unknown.   
• The pressurised loop system is similar to the balanced pressure system, however after 
pressurisation the valve is turned and a loop of fixed volume is filled.  The valve is 
then turned again and the loop contents flushed onto the column with carrier gas 
Both the valve systems have multiple connections with a complicated flow path that can 
cause problems and can only be used for HS analysis. Whereas, in the gas tight syringe 
system the sample pathway is very simple and the syringe can be changed to enable the XYZ 
robot to perform other sample preparation and injection techniques, for example liquid 
injection or SPME analysis. 
Even with careful optimisation of the parameters, static HS is not a very sensitive technique, 
as multiple dilutions occur between the sample and the column.  Even with low K values, 
not all the analyte molecules will be present in the headspace at equilibrium.  In addition, 
only a portion of the headspace is taken for injection, not the whole of it.  Finally, the 
headspace aliquot is injected under split conditions, to ensure a fast transfer to the column 
and obtain narrow sample bands and therefore sharp peaks for the very volatile analytes.  
This inevitably results in most of the sample making its way down the split-line and not 
being available for analysis. As discussed in the following section, other techniques can 
concentrate the headspace, where the analysis of species at trace level is necessary. 
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1.3.4.4 Dynamic HS 
Dynamic HS takes place in a purged vial.  A flow of carrier gas is purged over the sample 
and continuously transfers the volatile analytes emerging from the sample to a trap, where 
they are concentrated.  Equilibrium is never reached and after a fixed period the purging 
stops and the trap is thermally desorbed, to transfer the analytes to the GC column for 
analysis. Alternatively, it can be eluted with an organic solvent for analysis using different 
techniques.  As most the analyte molecules are recovered, dynamic HS is more sensitive 
than static HS, but only for those analytes with low partition coefficients.  The sample is 
treated in the same way as for static HS, with heating of the sample vial and matrix 
modification to release the analytes from the sample matrix.  This approach requires a further 
step to be optimised.  Namely, the selection of the optimal trap adsorbent(s) that both traps 
and releases the analytes quantitatively with no break-through, irreversible adsorption or 
catalytic breakdown, while providing the best recovery of the analytes.  It is also 
advantageous to choose a selective adsorbent that doesn’t trap the matrix, for example a 
hydrophobic adsorbent for aqueous samples.  The optimal adsorption and desorption 
temperatures and flows must also be determined and care taken to minimise activity, dead 
volumes and cold spots through the more complicated flow path and valve. 
1.3.5 Solid-Phase MicroExtraction (SPME) 
1.3.5.1 Background to SPME 
Solid-phase microextraction (SPME) is a separation method that uses a solid phase to extract 
analytes from a sample, based on their preferential affinity for the phase over the sample 
matrix.  It was developed in 1989, at the University of Waterloo, by R.P. Belardi and J. 
Pawliszyn (Pawliszyn, 2011).  It uses a fibre that is coated with a stationary phase that is 
similar to the GC column stationary phase and can be a liquid polymer or a solid sorbent.   
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It can be used to extract and concentrate analytes from both liquid and gas-phase samples, 
which includes the headspace above liquid and solid samples.  The fibre is then inserted into 
the GC inlet where it is thermally desorbed directly onto the analytical column, or it can be 
desorbed with a liquid solvent, including within an HPLC interface.  It is primarily a 
solventless technique, therefore the vapour volume from a liquid injection and the solvent 
vapour from a headspace injection are not problematic, if the correct fibre phase is selected 
for the application.  It can be a manual or an automated process and onsite sampling is 
possible, if the fibres are appropriately stored for transport back to the laboratory.  It is a fast 
and simple technique for both rapid screening and quantitative analysis.  For most methods, 
it is recommended to use an IS for quantitation or semi-quantitation to reduce errors. 
There is a linear relationship between the initial concentration of the analyte in the sample 
and the amount adsorbed or absorbed by the fibre.  The amount of analyte extracted is not 
related to the sample volume, which means that the technique can be used for field sampling 
in e.g. lakes, air, trees.  VOCs require a thick phase, semi-volatile organic compounds 
(SVOCs) and less-volatile analytes require a thin phase.  By selecting the correct fibre, 
analytes can be sampled with a precision of <12 % and certain analytes have parts-per-
trillion (ppt) detection limits.  With headspace SPME (HS-SPME), any sample type can be 
analysed that fits in a HS vial.  With direct immersion SPME (DI-SPME), where the fibre is 
inserted into the sample for extraction, the sample can be any liquid or slurry that is placed 
into the HS vial and doesn’t damage the fibre when extracting. 
1.3.5.2 Headspace-SPME 
HS-SPME is more sensitive for volatile analytes that are predominantly in the headspace 
above the sample.  Prior to analyses, the fibre must be conditioned at the recommended 
temperature and for the specified time for the phase type and thickness.  The sample is pre-
shaken at high rpm and heated to establish an equilibrium between the sample and 
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headspace.  The needle is then inserted into the vial and the fibre exposed to the sample 
headspace while the vial continues to be heated and is shaken gently for 2-30 minutes to 
concentrate the analytes onto the fibre phase.   
The analytes form an equilibrium between the sample and headspace and between the 
headspace and the fibre, respectively.  It is a tri-phase system.  As with HS analysis, the 
release of the analytes into the headspace is improved with matrix modification, increasing 
the temperature and by optimising the phase ratio.  The fibre phase must be carefully selected 
so that there is preferential affinity for it rather than the analytes returning to the sample at 
equilibrium.   
At the end of the extraction time, the fibre is retracted inside the needle, removed from the 
sample vial and inserted directly into the hot GC inlet installed with a very narrow liner of 
0.75 mm i.d. as it is a solventless injection and this also aids in a fast transfer onto the column.  
The fibre is exposed and the analytes are quickly desorbed onto the column within 1-2 
minutes.   
1.3.5.3 Direct Immersion-SPME 
DI-SPME is more sensitive for analytes predominantly in the liquid-phase.  The fibre is 
again pre-conditioned and the sample pre-shaken and heated.  This time the needle is inserted 
into the vial and the fibre exposed directly into the liquid sample to extract the analytes.  The 
analytes form an equilibrium between the liquid and fibre and between the liquid and 
headspace.  Unlike in HS analysis, there is no need for matrix modification, if there is 
preferential affinity, through correct phase selection, for the fibre over the sample.  The loss 
of the analytes to the headspace is minimised by keeping the temperature low. Although, it 
needs to be reproducible and therefore the lowest programmable temperature for the 
instrument is set. Maximising the sample volume in the vial also minimises losses to the 
headspace volume.  After 2-30 minutes, depending on the application and the sample matrix, 
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the fibre and then the needle are retracted and quickly desorbed directly in the GC inlet.  HS-
SPME keeps the fibre cleaner, minimises interferences and prolongs the life of the SPME 
fibre versus DI-SPME. 
For SPME, the distribution constant (Kfs) of the analyte between the fibre coating and the 
sample is defined as:  
ܭ௙௦ = 	 ஼೑
ಮ௏೑
஼ೞಮ௏ೞ
   (1.12) 
Where C∞s is the concentration in the sample at equilibrium, C∞f is the concentration on the 
fibre at equilibrium, Vs is the volume of the sample and Vf is the volume of the fibre coating.  
Nernst’s partition law for liquid polymeric coatings states that the mass of analyte absorbed 
(n) by a single, homogenous liquid-phase coating at equilibrium where no headspace is 
present is linearly proportional to the initial concentration (Co) in the sample, given as: 
݊ = 	ܥ௙ஶ ௙ܸ = 	௄೑ೞ௏೑௏ೞ஼బ௄೑ೞ௏೑ା	௏ೞ    (1.13) 
Where there is headspace present, the equation becomes:  
݊ = 	ܥ௙ஶ ௙ܸ = 	 ௄೑ೞ௏೑௏ೞ஼బ௄೑ೞ௏೑ା	௄೒௏೒	ା	௏ೞ   (1.14) 
 
The amount of an analyte extracted by the fibre coating doesn’t depend on the location of 
the fibre, whether it is in the liquid-phase in DI-SPME or gas-phase in HS-SPME, if the 
volumes of the two phases are the same in both sampling modes.  Analytes can diffuse more 
rapidly into the coating in HS-SPME than DI-SPME, with diffusion coefficients up to four 
times higher in the gas-phase. Therefore, equilibrium is reached more rapidly in HS-SPME, 
especially for volatile analytes that are already significantly in the headspace prior to 
extraction. 
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1.3.5.4 The SPME fibre and coatings 
The SPME fibre is 1-2 cm of fused silica bonded to a stainless-steel plunger or a length of 
flexible metal alloy on which the phase is coated.  The plunger is held within a needle which 
is retracted to protect the fibre, especially when piercing a vial and the GC inlet septa.  The 
fibre is then exposed to extract the analytes from the headspace above or directly from the 
sample. The phase coated onto the fibre can be non-bonded or bonded. Non-bonded fibres 
are stable with some water-miscible organic solvents but swelling may occur and they can’t 
be used with non-polar organic solvents.  Bonded phases are more stable with all organic 
solvents, although slight swelling with non-polar solvents is possible.  The most stable 
coating is cross-linked with bonding to the fibre core, these are stable in most solvents, with 
slight swelling possible in some non-polar solvents. 
The phase type and thickness are selected to absorb or adsorb the target analytes, the amount 
of analyte extracted is dependent on the thickness of the phase and the partition coefficient 
of the analyte.  The SPME phase should be selected to match the chemistry of the analytes 
to be extracted, i.e. their molecular weight (MW) and polarity.  Unlike GC columns, small 
changes in stationary phase polarity doesn’t give large selectivity differences, but the 
addition of a sorbent onto a coating, for example strongly polar carbowax PEG onto a divinyl 
benzene (DVB) polymer, increases the surface area and improves the extraction efficiency 
of polar molecules.   
Absorption describes the process of analytes dissolving into the coating or diffusing into the 
bulk phase. The absorbent takes in the analytes in a non-competitive process and quantitative 
analysis is usually unaffected by matrix composition.  Absorptive fibres have a greater 
capacity and broad linearity, as extraction is through partitioning of the analyte between the 
two immiscible phases, e.g. the sample/liquid and the fibre/liquid-phase coating, which 
could be PEG, PDMS or polyacrylate (PA).   
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Adsorption is the process of analytes interacting with the surface of a solid, usually through 
physisorption, chemisorption or electrostatic attraction, depending on the analytes. The 
analytes do not diffuse into the sorbent, unless there are pores.  Adsorption is a competitive 
process, as there are a limited number of surface sites, and the matrix composition and 
extraction conditions affect the amount of analyte extracted by the fibre.  Adsorptive-fibres, 
such as Carboxen (CAR) and DVB, are better for extracting low concentration analytes, 
Quantitation is linear only in narrow concentration ranges.   
There are two main types of fibres: homogeneous pure polymer coatings or fibres with 
porous particles embedded in the partially cross-linked polymeric phase.  Homogeneous 
pure polymer coatings, include PDMS, which is available in three different thicknesses to 
match the volatility of the analytes, PEG and PA.  Fibres with porous particles embedded in 
the partially cross-linked polymeric phase have lower stability but high selectivity and are 
usually a PDMS or PEG polymer with either Carboxen, DVB or a template resin porous 
particles embedded.  It is also possible for both DVB and CAR to be embedded in a PDMS 
fibre.  A fibre containing a mixture of different phases with different polarities benefits from: 
a higher extraction selectivity, to increase recovery of specific analytes with a matched 
polarity fibre; a reduced possibility of extracting interferences; enabling the extraction of 
polar analytes from organic matrices.   
Coating the fibre with a mixture of polymer and porous particles increases the porosity of 
the fibre coating and hence its total capacity and its ability to retain analytes more tightly, as 
well as increasing the pore size in the coating, thus increasing the analyte selectivity.   
Thick phase coatings are selected to give higher sensitivity, as more molecules can be 
extracted, or to retain VOCs without loss.  However, the thicker phase has longer desorption 
times for higher molecular weight (MW) analytes, carryover is also more likely to occur and 
the phase bleeds more.  Thin phase coatings ensure a faster diffusion and release of higher 
75 
 
MW analytes, have lower bleed but also results in lower sensitivity.  The efficiency of the 
analyte extraction and desorption from the fibre depends on several factors including: the 
MW and size of analyte molecules; boiling point and vapour pressure of the analyte; polarity 
and functional groups present in the analyte molecules and fibre phase(s); concentration in 
the sample and the instrument used for separation and detection.  Different fibres have 
different operating temperatures and are conditioned for different lengths of time at different 
conditioning temperatures, depending on the stability and thickness of the phase. 
1.3.6 Thermal Desorption (TD) 
1.3.6.1 Background to TD 
Thermal desorption (TD) is a physical separation process, where heat is applied to a sample 
to transfer analytes, that are adsorbed or absorbed in the sample, into the gas-phase so that 
they can be analysed using gas chromatography.  TD only uses temperatures up to 350 °C 
and therefore no chemical bonds are broken in the process, only interactions.  TD can be 
used to analyse a range of species, from those as volatile as acetylene (with two carbon 
atoms) up to molecules with forty carbons, such as polyaromatic hydrocarbons (PAHs) and 
phthalates.   
Small solid or viscous liquid samples can be directly thermally desorbed by placing in a 
conditioned TD tube. Gas-phase analytes can be concentrated by drawing the gas-phase 
sample through a conditioned TD tube packed with a sorbent.  For example, parts-per-trillion 
(ppt) levels of PAHs can be detected in air analysis, by drawing 100 L of air through a packed 
TD tube.   
After placing the sample in the tube, or concentrating the gas-phase sample in a packed tube, 
the tube is placed in the TD instrument and leak checked.  On passing, it is pre-purged with 
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carrier gas, usually helium, to remove atmospheric oxygen and to prevent oxidation of the 
sample on heating.  The TD tube is then heated to a temperature dependent on the maximum 
temperature of the sorbent, the volatility of the analytes and the nature of the sample.  It is 
then held at that temperature, for usually 5-30 minutes, to fully desorb the sample or sorbent.  
The TD tube is continuously purged while heated and the emerging analytes are back-flushed 
off the TD tube and selectively concentrated on a narrow cold trap, containing a small 
amount of sorbent. During this process, unwanted gases, water and matrix are removed.   If 
the sample is very concentrated, the analytes can be transferred to the cold trap in split, rather 
than the usual splitless mode.  After the TD tube is fully desorbed, the cold trap is rapidly 
heated and the concentrated analytes are back-flushed through a heated transfer line, usually 
as a split injection, onto the GC analytical column in a narrow sample band for separation 
and detection.  
1.3.6.2 Sampling for TD analyses 
Gas-phase samples can be sampled in-situ by drawing the sample through a conditioned, 
packed TD tube using a constant pressure or constant flow pump.  The tube is then sealed, 
to prevent the loss of analytes and the ingress of contaminants, and returned to the lab for 
analysis.  Tubes can be stable for several weeks.   
Passive sampling is frequently used for occupational hygiene to monitor indoor and ambient 
air, by using a packed TD tube with an axial diffusive sampler to enable exposure of the tube 
sorbent to the sample.  Radial diffusive samplers, after sampling, can also be analysed by 
TD-GC by placing them in an empty TD tube for analysis.   
On-line instruments continuously pump the sample directly onto a pair of cold traps, 
switching between collection and analysis as frequently as required.  No TD tubes are 
required for this mode of operation.   
77 
 
Gas-phase samples can also be sub-sampled by filling Tedlar, Teflon, polyvinyl chloride 
(PVC), charcoal-filled or multi-layer foil bags, or canisters, with the sample.  Which type of 
container is used depends on the nature of the sample and the field site.  It is important to 
ensure that the container has low permeability and has high inertness to the sample.  It must 
be leak-tight and shouldn’t be damaged in the sampling location, to ensure analytes do not 
become stuck or lost.  The container should also not contaminate the sample.   
1.3.6.3 Important parameters for TD analyses 
Before use, TD tubes must be conditioned and sealed before taking to the sampling location.  
Those packed with a sorbent, must be conditioned at the optimal temperature for the required 
time for the specific sorbent(s) used.   
The break-through volume for the samples and analytes to be sampled must be determined 
before sample collection, so that a known volume of sampled gas can be taken that is below 
the break-through volume.  Break-through volume can simply be checked for by attaching 
two sampling tubes in series; if the first tube becomes saturated any analytes breaking-
through will be trapped by the second tube, this can then be analysed to determine if the 
break-through volume has been exceeded.   
When sampling, the optimal flow rate through the tube affects the interaction of the analyte 
with the sorbent and therefore the amount that can be trapped.  The optimal sampling rate 
through a standard 5 mm i.d. packed TD tube is 50 mL/min, with a working range of 10-200 
mL/min which can increase to 500 mL/min for a maximum of 10 to 15 minutes.  Sample 
volumes range from 500 mL to 100 L.   
There are improved adsorption efficiencies at lower temperatures, however the ambient 
temperature during sampling must be considered when selecting the sorbent(s).  Where there 
is a wide range of analyte physical and chemical properties, a tube can be packed with 
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multiple sorbent beds, usually up to three, so that there can still be enough mass of each 
sorbent for the capacity required.  The weakest sorbent is packed closest to the sample, with 
the strongest sorbent packed furthest from the sampling end of the tube to enable the fast 
and efficient release of the analytes in the reverse direction.  The analytes are back-flushed 
to the next stage of the TD process.   
Where replicate sample aliquots are required, a manifold sampling system can be used where 
there are multiple tubes, either containing the same sorbent(s) for repeatability checks or 
containing different sorbents to sample for different analytes. These are set-up in parallel 
and are all connected to the same pump, but with flow control valves for each, to either 
balance the flows or to set individual flows for each TD tube.   
1.3.6.4 TD Tubes 
The TD tube itself can be made from: glass, which is good to see the position of samples 
placed directly into the tube; stainless steel which makes it very robust, especially for those 
tubes sampled away from the lab; or coated (silco) steel, which makes the tube very inert 
and is much better for active analytes such as those molecules containing sulphur.   
The tubes vary in size depending on the manufacturer, but the industry standard TD methods, 
such as ISO, CEN, ASTM and EPA, use 3.5 inch x ¼ inch outside diameter (o.d.) tubes.  
Tubes should have a unique identifier, which enables the sample to be matched to the tube 
and the sampling direction must be known so the tube is desorbed in the reverse direction to 
ensure that all the sampled analytes are recovered.  
1.3.6.5 Sorbents for TD 
Similar to SPME, the sorbents placed into the TD tube and the cold trap can either interact 
with the analytes through absorption or adsorption.  The sorbent(s) selected is dependent on 
the target analytes.  It must trap the target analytes at the ambient temperature of the sampling 
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location and easily release them again when rapidly heated. This temperature must be no 
higher than the maximum temperature of the sorbent, with no irreversible ad/absorption or 
catalytic breakdown.   
Common sorbents are polymers such as Tenax ®, Porapak, Hayesep or Chromosorb, a styrene 
DVB polymer; carbon molecular sieves such as Sulficarb, Carbosieve or Carboxen; zeolite 
molecular sieves; graphitised carbon black such as Carbopack, Carbotrap or Carbograph.  
Tenax® and graphitised carbon blacks are hydrophobic and therefore good for ‘wet’ samples. 
Carbon molecular sieves are mostly hydrophilic with Carboxen being the most hydrophobic.  
Zeolite molecular sieves are very hydrophilic and can collect water up to mg levels, in a 
typically sized TD tube.   
Different types of sorbents are good for different volatilities and polarities of analytes and 
have different retention volumes and maximum temperatures (ranging from 190-400 °C).  
Even when the maximum temperatures are not exceeded, some sorbents can produce 
artefacts – the release of molecules, that are focused, separated and detected by GC.  Carbon 
molecular sieves have minimal artefact levels, whereas Tenax® has a low artefact level when 
new; however, as the sorbent ages the artefact level increases.   
Porous polymers and carbonised molecular sieves are more inert than graphitised carbon 
blacks such as Carbograph 1TD.  Generally, the more volatile the analyte(s), the stronger the 
sorbent must be.  For analytes with a boiling point (bp) > 100 °C a weak sorbent such as 
Tenax® TA is used.  Those analytes with a boiling point of between 30-100 °C require the 
use of a medium strength sorbent such as Carbograph 1TD and very volatile analytes with a 
boiling point between 30-50 °C require the of use a strong sorbent such as Sulficarb or 
Carboxen 1000. 
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The mesh size of the packing material affects the packing density and the back pressure that 
it creates.  A mesh size of 20/40 has larger particles than 60/80 and therefore can be sampled 
using higher flow rates.   
The sorbent life of the tube is dependent on the type of sorbent(s) used, the maximum and 
routine desorption temperatures it has been exposed to and the number of desorption cycles, 
which includes conditioning of the tubes.  Tenax® and carbon-based sorbents are usually 
good for 100-200 cycles, whereas porous polymers are less stable, usually with a life of 100 
cycles. 
A trap is used to collect and focus analytes between the TD tube and the GC analytical 
column. Without it, the long TD tube desorption times would result in long transfer times to 
the column, producing broad sample bands and poor chromatographic resolution and peak 
shapes.  The analytes can be trapped through cryofocusing in the inlet liner or on a GC pre-
column using cryogens or through cold trapping with a Peltier cooled trap (cold trap).  The 
cold trap enables the use of a small amount of sorbent in a narrow tube to selectively 
concentrate the analytes, but unlike the TD tube, the cold trap is cooled below ambient 
reducing the likelihood of breakthrough even though less sorbent is used.  With 
cryofocusing, everything released from the TD tube is trapped, but with the cold trap the 
sorbent can be selected to not trap unwanted gases such as water, solvents, etc.  Like with 
the TD tube sorbent, it must trap the target analytes at the (lower) temperature chosen and 
then easily release them with no catalytic breakdown when the trap is rapidly heated.  As the 
cold trap is backflushed, multiple sorbents can be chosen, usually up to three, to match the 
target analytes.  On rapidly heating the narrow cold trap, the analytes are usually transferred 
to the GC column in split mode to increase the flow through the cold trap when desorbing, 
resulting in a faster transfer to the GC column and therefore a narrow sample band.  Even 
with a low split ratio, the sample flow to waste is higher than that onto the column.  More 
recent instrumentation can automatically enable the split flow effluent from the cold trap 
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desorption to pass back through the original sample TD tube or through a new, conditioned 
TD tube to re-collect the sample.  This means that TD samples are no longer one-shot, where 
if something went wrong with the analysis of that sample it could not be re-analysed.   In 
addition, the recovery is quantitative, therefore if the sample does have to be re-analysed the 
original concentration can be determined based on the split ratio.  Sample re-collection can 
also be achieved through the trapping of the split effluent from the TD tube desorption onto 
a new, conditioned TD tube if a split method was used.   
Quantitation can be performed, as in other techniques, by analysing the standards using the 
same method as the samples.  A maximum of 1-2 µL of standard solution, preferably in a 
solvent that is not trapped by the sorbent and has a low vapour expansion coefficient, or its 
headspace is directly spiked onto the TD tube using a spiking rig.  The rig enables the 
standard to be injected into a carrier gas so that the analytes are blown through the TD tube 
sorbent and then any solvent is purged before analysis.  The automatic addition of IS to the 
TD tube and/or the cold trap is possible and is instrument dependent. 
1.3.7 Bioinformatics and Chemometrics 
Analytical techniques, such as GC-MS, can generate large volumes of information and can 
be thought of as a method of data generation and collection.  Several chromatograms can 
manually be compared to identify patterns, but multiple complex chromatograms or 
hundreds of simple chromatograms can be far more difficult.  The processing of large data 
sets of complex chromatograms can take as long as, if not even longer than the sample 
analyses.  This can happen, especially, when making sense of and trying to find the answer 
to the question(s) asked, when there are many variables generated for each sample and large 
numbers of samples analysed.  There are multiple steps to the processing of that data, 
including data preparation or pre-processing, extraction of the information, processing of the 
information, interpretation and then reporting of the result.  It is very important to both 
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design and evaluate experiments, there are multiple different techniques used to validate 
results throughout the process (Broadhurst & Kell, 2006).  
1.3.7.1 Bioinformatics and cheminformatics 
Bioinformatics and cheminformatics are general terms that describe the use of computer 
programming as part of the methodology in the analysis of biological or chemical data.  They 
develop methods and software tools using computer science, mathematics, statistics and 
engineering to process, analyse and interpret the data that can come from a variety of sources, 
not just for one-off investigations but also in routine analysis.  Bioinformatics uses 
computation to better understand biology by analysing biological data rather than building 
theoretical models of biological systems and therefore relies on the generation of sometimes 
large amounts of high quality data.  This data is inputted to the computer system that uses 
algorithms generated from artificial intelligence and data mining that depend on discrete 
mathematics and statistics to process that data.  Originally, bioinformatics was invented by 
Paulien Hogeweg and Ben Hesper in 1970 to describe the study of information processes in 
biotic systems parallel to the biophysics field and biochemistry.  Today, bioinformatics is 
used in many areas of biology, including molecular biology, genetics and genomics.  
Bioinformatics can use a variety of techniques to understand the biological processes and is 
mostly involved in the study of genes and large proteins, whereas cheminformatics has its 
roots in chemometrics, chemical information and computational chemistry focusing on the 
study of small molecules.   
1.3.7.2 Data mining 
Data mining, otherwise known as knowledge discovery, is a sub-field of computer science 
that appeared around 1990.  It is the automatic or semi-automatic analysis of large data sets 
to discover previously unknown patterns of interest, the extraction of the information and 
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the presentation of it for further use, for example in machine learning.  Data mining methods 
and tasks can be artificial neural networks (ANN), support vector machines (SVM), outlier 
detection, association rule learning to discover interesting relationships between variables, 
cluster analysis and classification, regression to find a model with the least error and 
summarisation. 
1.3.7.3 Machine learning 
Machine learning is also a sub-field of computer science that enables the computer to learn 
without being explicitly programmed, by using algorithms that can learn from and make 
predictions with the data.  The algorithm builds a model with the data that it is given and 
uses this to make the predictions or decisions. The accuracy of these are very dependent on 
both the quality and the quantity of the data that is used to generate the model, plus the 
testing of the hypothesis.  The algorithms used can be very complex, generating very 
complex models which can then be used to produce reliable, repeatable decisions and results. 
1.3.7.4 Artificial Neural Networks (ANN) and Probabilistic Neural 
Networks (PNN) 
Artificial neural networks (ANN) were created to process information and there are a wide 
variety of ANNs to model, for example, behaviour and control in animals and machines, but 
they are also used in pattern recognition, forecasting and data compression.  They were 
inspired by the human central nervous system and are used in machine learning to describe 
relationships in a network of variables where there are many, usually unknown inputs which 
the estimated functions depend on.  The architecture of the ANN is similar to a neural 
network, an interconnected group of nodes (neurons) that specify the variables involved in 
the network and their relationships.  For each neuron, there are large number of inputs, these 
are similar to synapses, which are multiplied by weights, for example the strength of the 
84 
 
respective signals, and then a mathematical function is applied to determine the activation 
of the neuron or to compute the output.  The weights can be adjusted to obtain the output 
that is wanted for the specific inputs.  The higher the weight the stronger the input, or a signal 
can be inhibited by a negative weight.  An ANN can have hundreds to thousands of neurons, 
the activities of which will affect each other, therefore algorithms are required to adjust the 
different weights to obtain the desired total output. 
Probablistic neural networks (PNNs) are used for classification and they are much faster to 
train.  The radial base layer makes PNNs different to other networks, which calculates the 
distances between the input vectors and the input weights.  If these are very close together 
the output is 1.  All outputs are then summed to attain a vector of probabilities.  A competitive 
layer is then applied where the maximum of the probabilities is selected to produce a total 
of 1 for a target class and 0 for all others. 
1.3.7.5 Support Vector Machines (SVM) 
Support vector machines (SVM) are used for classification and regression analysis by 
constructing a hyperplane, or set of hyperplanes, in a high or infinite dimensional space. 
However, they are only directly applicable for two-class tasks rather than multi-class.  They 
are supervised learning models that can use a SVM training algorithm to build a model based 
on a given set of labelled training data with, for example, assigned classifications.  The 
classifications are then mapped in the space, as far apart as possible.  When new samples are 
mapped into the same space they can then be correctly classified.  Unlabelled data cannot be 
modelled with supervised learning by SVMs.  Unsupervised learning, called support vector 
clustering, attempts to find natural clustering within the data, it splits them into groups and 
maps them in the space, which can then be used to map and classify new, unknown data.  
There are multiple different types of SVM kernels, the linear (SVM-LIN) and radial basis 
function (SVM-RBF) kernels were used in this thesis. 
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1.3.7.6 Random forests (RFs) 
In machine learning, the random forests or random decision forests algorithm uses many 
uncorrelated decision trees for the training in regression, classification and other 
bioinformatics tasks.  These are used to combine learning models and output the mode (most 
frequent value) in classification or the mean prediction in regression to increase the accuracy 
of the classification or prediction by averaging noisy and unbiased models to create a model 
with low variance and that doesn’t overfit the training set.   
1.3.7.7 Pattern recognition 
Pattern recognition focuses on the similarities – patterns and regularities - in the data and is 
a branch of machine learning.  Supervised learning is when labelled ‘training’ data is used 
in the machine learning, for example if the data from ‘good’ samples and ‘bad’ samples is 
used to generate the model.  This model can then be used to classify if an unknown sample 
is statistically ‘good’ or ‘bad’.  Unsupervised learning is when there is no labelled data and 
therefore other algorithms must be used to discover previously unknown patterns in the data.  
Semi-supervised learning is when there is a combination of labelled and unlabelled data.   
All models created must be tested and therefore the data is usually split into a training set 
and a test set.  Once a model has been created with the training set, the test set can then be 
used to test the model and check for model error, this is called cross-validation.  Overfitting 
happens where the statistical model describes the random error or noise, rather than the 
underlying relationships and can occur where there are far too many parameters relative to 
the number of samples, resulting in a very complex model that has poor predictive 
performance and exaggerates the minor differences in the training data.  By testing the model 
on unused data, these exaggerations can be ruled out, a different selection of training data 
and test data can be chosen from the data set, a new model created and tested.  Multiple 
rounds of cross-validation are performed to reduce variability and the validation results are 
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averaged.  With very large data sets, the data can be partitioned with usually 70 % for training 
and 30 % for testing, however for smaller data sets cross-validation is better as it ensures 
enough data for significant modelling and testing. 
1.3.7.8 Cluster analysis 
Cluster analysis is the organisation of samples into groups that are more similar to each other 
than other samples in different groups, it is also known as unsupervised classification.  It is 
a significant task in data mining and is used in machine learning and pattern recognition.  
Cluster analysis isn’t a single algorithm, there are many algorithms that could be used.  The 
cluster models presented in the data depend on the algorithm used to define a cluster and 
how it finds them.  Cluster models include models based on distance connectivity such as 
hierarchical cluster analysis (HCA); centroid models where a cluster is represented as a 
single mean vector; distribution and density models; subspace and group models; and graph-
based models.  Clustering can be ‘hard’, where each sample either belongs to a cluster or 
not; or ‘soft’, where the sample belongs to each cluster by a certain degree.  Clusters may 
have: strict partitioning, where each sample belongs to one cluster; overlapping clustering, 
where samples may belong to more than one cluster; hierarchical clustering, where samples 
belonging to a child cluster also belong to a parent cluster; or subspace clustering, where 
samples are not expected to overlap in a uniquely defined subspace, even though there is 
overlapping clustering.  Outliers are those samples that do not belong to any cluster.  Cluster 
analysis isn’t an automatic task, as the algorithm chosen or algorithm’s parameters may need 
to be changed or the data pre-processing or model parameters modified to obtain the optimal 
result. 
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1.3.7.9 Multivariate statistics 
Multivariate statistics is the simultaneous analysis of more than one statistical outcome 
variable and has always been a large part of chemometrics, as the data from these analytical 
techniques is multivariate with potentially thousands of data points per sample.  Multivariate 
techniques construct a mathematical model that relates the multivariate data to the sample.  
There are different approaches in the analysis of the data - those which are good at describing 
the measured analytical response, known as the classical methods, or those that are good at 
predicting the property of interest, known as the inverse methods. 
1.3.7.10 Principal Component Analysis (PCA) 
Principal component analysis (PCA) was invented in 1901 by Karl Pearson.  It reduces the 
number of dimensions of a data set, the predictive variables, by building a new set of co-
ordinates known as principal components (PC).  The number of PCs cannot exceed the 
number of variables or samples, whichever is smaller.  PCs are linear combinations of the 
original variables which are orthogonal to each other and therefore uncorrelated, which can 
be used to summarise the data without loss of too much information.  The first principal 
component, PC1, accounts for the greatest amount of variability within a data set.  PC2 
accounts for the second largest amount of variability and is orthogonal to PC1, and so on for 
PC3, PC4, etc.  PCA analysis is mostly used in exploratory data analysis and for making 
predictive models to identify outliers, determine patterns of association – natural groups 
(clusters) within a data set and to determine variability.  The results of PCA analysis can be 
visualised with a scatterplot, for example a two-dimensional scatter for PC1 vs. PC2, or a 
three-dimensional scatter plot for PC1 vs. PC2 vs. PC3 in which it is easy to see clusters of 
data, if they are present.  PCA is an unsupervised dimension reduction method that doesn’t 
consider the correlation between the dependent and independent variables.  It is the most 
widely used multivariate statistical technique (Brereton, 2007). 
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1.3.7.11 Regression and Partial Least Squares Discriminant Analysis 
(PLS-DA) 
Statistical regression analysis is a generic name for all methods that attempt to fit a model to 
observed data so that a relationship between two groups of variables can be quantified.  This 
model can then be used to describe their relationship or predict new values.  The two data 
matrices are usually denoted X and Y, regression attempts to build a model Y = f(X) to 
explain or predict variations in the dependent variable(s) Y, from variations in the 
independent variable(s) X, by applying the function f.  Univariate data has a single predictor 
X, whereas multiple linear regression (MLR) simultaneously considers multiple predictive 
X variables resulting in a more accurate model. 
Partial least squares (PLS) Regression combines the output from PCA with multiple 
regression and is particularly useful when multiple dependent variables need to be predicted 
from a very large set of independent variables.  PLS is a supervised dimension reduction 
method as it looks at the correlation between the dependent and independent variables and 
unlike PCA, all variance in the data is explained and it is considered to be better at explaining 
complex relationships (Maitra & Yan, 2008).  PLS is good when there are more predictor 
variables than observations and when there are multiple predictor variables with high 
correlation, meaning that one can be correctly predicted from the others. 
Partial least squares-discriminant analysis (PLS-DA) (Barker & Rayens, 2003) replaces the 
dependent variable with a categorical one that describes the cluster.  The clusters are already 
known and therefore PLS-DA is used to determine if the clusters are actually different and 
what features best describe the differences between the groups.  It can improve the resolution 
between clusters by rotating the PCA components to obtain maximum separation between 
the classes and determine the variables that can separate those classes.  This is particularly 
useful in analytical chemistry to identify the experimental variables that contribute to the 
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difference.  However, PLS-DA is prone to overfitting the data and therefore must be properly 
validated (Westerhuis, et al., 2008). 
The key information that can be gained from PLS-DA are the scores and weights of the 
model.  The score describes the position of each sample in each determined component, 
otherwise known as a latent variable (LV).  Latent variables are not observed but are shared 
variance from other variables that are directly measured and that can be grouped together in 
a model representing an underlying hypothesis, they are good at reducing the dimensionality 
of the data.  The most important information or characteristics should typically be held in a 
low number of LVs, such as important chromatographic peaks, for example in LVs 1-4.  The 
less important information, such as noise, is held in the higher LVs, for example in greater 
than 20 LVs.  The weights describe the contribution of each variable to each LV.  The PLS 
loadings plot enables visualisation of the most significant features of the sample data file 
from the PLS-DA.   
1.3.7.12 Hierarchical Cluster Analysis (HCA) 
Hierarchical cluster analysis (HCA) is also an exploratory algorithm that is used to assure 
the validity of raw data by finding outliers and to show clusters of data.  It arranges the 
network into a hierarchy of groups, usually a dendrogram is produced that shows the 
hierarchy of the individual samples and clusters those samples according to their similarities.  
Agglomerative HCA starts at the bottom in a cluster and then pairs of clusters are merged 
while moving up the hierarchy.  Divisive HCA starts in the cluster of all samples and then 
the clusters are split while moving down the hierarchy.  The splitting or combining of clusters 
relies on a measure of dissimilarity between the samples, usually in HCA this is the 
connectivity distance. 
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1.3.7.13 Correlation Optimised Warping (COW) 
There are multiple methods for data alignment, including dynamic time warping (DTW), 
local warping and parametric time warping (PTW).  Correlation optimised warping (COW) 
(Tomasi, et al., 2004) is the preferred route for aligning data from analytical instruments that 
has suffered drift, such as shifts in retention time, as it preserves the peak shape and area.  
One data file is chosen to be the reference and is used to align the whole data set.  The 
reference data file and the sample data file are both divided into segments.  Each segment of 
the sample data file is then compressed or extended compared with interpolation and 
converged to the reference data file.  The two parameters optimised in this procedure are the 
segment length (the number of data points in each segment), and the slack size (the number 
of data points that can move between the segment boundaries).  The parameters can be 
selected using an automated method to compute a ‘simplicity’ value for each segment and 
slack parameter combination for a discrete number of chromatograms.  This is used to 
measure how accurately those chromatograms are aligned.  The best combination can then 
be used to align the full data set using the optimal parameters.  
1.3.7.14 Data Scaling 
Data within a data set can be scaled to normalise the range of independent variables or 
features.  For example, with GC-MS data the abundance can be normalised against the 
internal standard.  Several different methods (and therefore equations) can be used for 
scaling, including auto-scaling, mean-centring, range scaling between 0 and 1 and range-
scaling between -1 and +1 (Otto, 2007). 
1.3.7.15 Feature selection and t-tests 
Feature selection is a filter method that selects the variables that are most distinctive for each 
class of samples or deselecting the features that are not at all significant.  It is a crucial step 
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before sending data to a classifier algorithm, so that only the most significant data is sent 
and therefore a higher classification accuracy can be achieved.  A decision rule is applied to 
decide if two variables belong to the same population (Glantz, 2005) or not.  The Student t-
test tests the hypothesis about the mean of a small sample drawn from a normally distributed 
population, when the population standard deviation is unknown.  The Wilcoxon test is non-
parametric, meaning that it doesn’t assume the data is normally distributed. 
1.3.7.16 Cross-Validation, Leave-One-Out Cross-Validation (LOO-CV)  
Cross-validation, otherwise known as rotation estimation is a way of validating a model to 
estimate how accurately a predictive model performs in practice.  When an algorithm is 
trained with a training dataset it is then usually tested with a testing data set.  Cross-
validation, defines a validation dataset to test the model while it is being trained, to minimise 
problems such as overfitting of the data and to see how the model will generalise to 
unknown, real data.   
Leave-one-out cross-validation (LOO-CV) (Hastie, et al., 2009) uses one sample as the 
validation set and the remaining samples for the training set.  For a dataset of n samples the 
learning and validating process then occurs n times to classify 1 sample against a model built 
using n-1 samples and therefore n models are built.  Data is then produced about the true 
positive rate (if the 1 validation sample is positive and is predicted as positive in the 
validation) and the true negative rate (if the 1 validation sample is negative and is predicted 
as negative in the validation). 
Where there are very large data sets, leave-five-out cross-validation (LFO-CV) may also be 
used to speed up the validation process. 
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1.3.7.17 Bootstrapping or resampling methods  
Bootstrapping is a resampling technique that is good at determining accuracy, for example 
variance, bias, confidence intervals or prediction error.  It is a test or metric that relies on 
random sampling with replacement, where it selects a subset from the dataset or statistical 
population, called the resample or bootstrap sample, to estimate characteristics of the whole 
population.  As the randomly selected sample is replaced before the next random sample is 
selected, it is probable that at least one sample is reselected.  The process is repeated many 
times and, for each subset generated, the standard errors can be calculated. 
1.3.7.18 Monte Carlo simulation and null hypothesis model 
A Monte Carlo simulation (Brereton, 2009) carries out repeated random sampling by 
assigning a random class (in this work, disease positive or disease negative) to each sample, 
generating many data sets, each is then used to produce a null model.  The null model is 
generated from a set of data that is statistically similar, but from which a meaningful 
classification model is not expected.  For a disease discriminant model using the real sample 
classes to be considered significant, it must achieve a classification accuracy far higher than 
that produced by the null models. 
1.3.7.19 Sensitivity & specificity 
When evaluating clinical data, the sensitivity and the specificity are calculated and reported 
for the test (Lalkhen & McCluskey, 2008).  These values are independent of the population, 
the defined groups of patients, and do not consider the cut-off point for a particular test.   
To calculate the sensitivity and specificity, the following must be determined: 
• Number of true positives (TP): those patients with the disease and the test results in 
a positive outcome. 
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• Number of true negatives (TN): those patients who do not have the disease and the 
test results in a negative outcome. 
• Number of false positives (FP): those patients who do not have the disease but the 
test results in a positive outcome. 
• Number of false negatives (FN): those patients with the disease but the test results in 
a negative outcome.  
Sensitivity is defined as the ability of the test to accurately identify patients with the disease:   
ܵ݁݊ݏ݅ݐ݅ݒ݅ݐݕ	(%) = 100	ݔ	 ቀ ்௉்௉ାிேቁ   (1.15) 
A sensitivity of 100 % means that all patients with the disease were correctly identified.  A 
sensitivity of 75 % means that 75 % of the diseased patients were correctly identified as 
positive.  However, 25 % of the diseased patients were not identified as having the disease, 
resulting as false negatives.  A high sensitivity test result means that patients that have or 
might have the disease will be identified for further tests and it is unlikely that patients with 
the disease will be incorrectly identified as being negative. 
Specificity is defined as the ability of the test to accurately identify patients who do not have 
the disease: 
ܵ݌݂݁ܿ݅݅ܿ݅ݐݕ	(%) = 100	ݔ	 ቀ ்ே்ேାி௉ቁ   (1.16) 
A specificity of 100 % means that all patients without the disease were correctly identified.  
A specificity of 75 % means that 75 % of the non-diseased patients were correctly identified 
as negative.  However, 25 % of the non-diseased patients were identified as possibly having 
the disease, resulting as false positives.  A low specificity test results in many patients that 
do not have the disease being identified as possibly having it.  This results in further worry 
and discomfort for the patient who is then sent for further tests at more expense, when they 
do not have the disease. 
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A test with high sensitivity and low specificity results in few patients with the disease being 
mis-diagnosed, but many disease-free patients being sent for unnecessary further tests.  With 
a high cut-off point, there are fewer FPs but more FNs resulting in a highly specific but not 
very sensitive test.  With a low cut-off point, there are less FNs but more FPs resulting in a 
highly sensitive but not very specific test. 
1.3.7.20 Overall classification 
It is useful to know the overall number of samples that are correctly classified (CC) either as 
TP or TN with a model: 
ܥܥ	(%) = 100	ݔ	 ቀ ்ேା்௉்ேା்௉ାிேା	ி௉ቁ   (1.17) 
If the sensitivity and the specificity values are similar, then the overall classification will 
give a similar, mean value.  If sensitivity is low and specificity is high, or vice versa, the 
overall classification is higher than the average of the two values. 
1.3.7.21 Positive Predictive Value (PPV) and Negative Predictive Value 
(NPV) 
The positive predictive value (PPV) is useful for judging the likelihood that the patient has 
the disease if the test result is positive: 
ܸܲܲ	(%) = 100	ݔ	 ቀ ்௉்௉ାி௉ቁ   (1.18) 
The negative predictive value (NPV) is useful for judging the likelihood that the patient does 
not have the disease if the test result is negative: 
  ܸܰܲ	(%) = 100	ݔ	 ቀ ்ே்ேାிேቁ   (1.19) 
The higher the PPV or NPV, the more believable the result.  However, both the PPV and 
NPV are also dependent on the prevalence of the disease in the population.  If the population 
has equal numbers of diseased and non-diseased patients and the sensitivity and specificity 
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are very high, the PPV is very high.  If the number of diseased patients is low compared to 
the number of non-diseased patients, then the PPV falls.  Therefore, the prevalence of the 
disease in the population must also be considered when examining PPV and NPV values.  
1.3.7.22 False Discovery Rate (FDR) 
The false discovery rate was formally described by Yoav Benjamini and Yosi Hochberg in 
1995.  It is used when conducting multiple comparisons to hypothesise the rate of false 
positives in null hypothesis testing.  This is important to check that significant features are 
not rejected in any filter methods such as feature selection using the Wilcoxon test 
(Motulsky, 2010).   
The FDR is a measure of the overall number of diseased samples that have been incorrectly 
classified as diseased (FPs) out of all samples that have been classified as diseased: 
ܨܦܴ	(%) = 100	ݔ	 ቀ ி௉்௉ାி௉ቁ = 100 − ܸܲܲ	(%)   (1.20) 
1.3.7.23 Area Under Receiver Operating Characteristic (AUROC) 
Receiver operator characteristic (ROC) curves were originally produced by radio receiver 
operators to determine the reason why US radar had failed to detect the Japanese aircraft 
after the attack on Pearl Harbour (Ekelund, 2012). 
The receiver operating characteristic is a graphical plot of true positive rate (TPR) against 
false positive rate (FPR) at various threshold settings, that is used to illustrate the 
performance of a classifier, as shown in Figure 1.12.   
It is used to determine the best cut-off for a test, with the highest TPR and lowest FPR.  The 
TPR is the equivalent of sensitivity and FPR is calculated as (1 – specificity).  The area under 
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the receiver operating characteristic (AUROC) curve measures the test’s discriminative 
ability. 
 
Figure 1.12: Receiver Operator Curves (ROC) showing AUROC values and significance  
When using normalised units, the AUROC curve is equal to the probability that a classifier 
will rank a randomly chosen positive instance higher than a randomly chosen negative one.  
It is equivalent to the Wilcoxon signed-rank test.   
The AUROC curve can be calculated using the trapezoid rule, meaning the region under the 
graph is approximated using the equation for a trapezoid. 
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A perfect test results in an AUROC value of 1.0.  Whereas, a test that is not at all useful 
results in an AUROC value of 0.5, meaning the test is as likely to produce the correct result 
as flipping a coin, see Table 1-3. 
Table 1-3: Significance of AUROC values for receiver operator characteristic curves  
Category Fail Poor Fair Good Very good 
AUROC 0.5-0.6 0.6-0.7 0.7-0.8 0.8-0.9 0.9-1.0 
1.4 Thesis Overview 
All analyses were performed at the School of Physical Sciences, (formerly Planetary and 
Space Sciences Research Institute (PSSRI) in the Faculty of STEM), at The Open University. 
Prior to the work reported in this thesis, there was no tradition of utilisation of GC-MS for 
medical diagnostics.  
The foregoing chapters describe a journey from the initial challenges of developing the 
methods to a solution which combines the selectivity of a HS-SPME and the separation 
capabilities of GC-ToFMS.  The optimised method will be evaluated for its suitability for 
detecting patients with bladder cancer, prostate cancer and hepatic disorders.  Separate 
methods were developed for the identification of the causative agents of sepsis, from the 
profile of the volatile compounds present in the headspace above culture samples.  
Chapter 2: Outlines the optimised experimental methods, the chemicals and reagents, the 
instrumentation and the preparative procedures used for clinical studies reported in this 
thesis.  
Chapter 3:  Summarises the development of the optimised methods reported in Chapter 2. 
The extraction methods and instrument operating conditions have been developed by a 
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mixture of experience, critical review of published literature, personal communications and 
a degree of trial and error.  
Chapter 4: The optimised HS-SPME-GC-ToFMS method developed in Chapter 3 and 
reported in Chapter 2 was applied to the study of a cohort of urine samples collected from 
patients with bladder cancer or controls.   
Chapter 5:  The optimised method HS-SPME-GC-ToFMS developed in Chapter 3 and 
reported in Chapter 2 was then applied to the study of a cohort of urine samples collected 
from patients with prostate cancer.  A mathematical model was then developed to determine 
if the cancer positive samples could be distinguished from those from patients with benign 
prostate hyperplasia (BPH) and controls. 
Chapter 6:  The optimised HS-SPME-GC-ToFMS method developed in Chapter 3 and 
reported in Chapter 2 was also applied to the study of a cohort of urine samples collected 
from patients with hepatic disorders.  A model was then developed to determine if the 
samples could be distinguished from those controls. 
Chapter 7:  Reports on a pilot study that utilised the HS-GC-MS and HS-TD-GC-MS method 
reported in Section 2.3.  The method was applied to the study of the profile of volatile organic 
compound present in the headspace above a range of bacteria that are known to cause sepsis. 
A model was then developed to determine if the bacteria samples could be distinguished 
from each other and from controls. 
Chapter 8:  Conclusions and future work 
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2.1 Introduction  
This chapter is divided into three sections, based on the individual studies conducted within 
this thesis and the methodologies used.  Section 2.2 summarises the optimised methods 
applied to the analysis of the headspace of clinically relevant urine samples by SPME, 
followed by analysis by GC-MS (SPME-GC-MS).  The section is organised to provide a full 
description of materials and equipment used in each study, any sample handling or 
preparative methods applied and the instrumental settings used. This section is the basis of 
the studies on clinical samples reported and discussed in Chapters 4, 5 and 6, respectively. 
It should be noted that it is Chapter 3, the Method Development chapter, which summarises 
how the parameters reported in this chapter were initially conceived, developed and 
optimised. 
Section 2.3 describes the materials, apparatus and methods used as part of a pilot study to 
evaluate the detection and quantitation of the volatiles present in the headspace above 
bacterial samples, for the classification of septic infection.  The analysis was performed by 
HS-GC-MS and TD-GC-MS. The results of this pilot study are reported and discussed in 
Chapter 7. 
The final section in this chapter (Section 2.4) describes the statistical analysis performed on 
the data reported in the clinical studies in Chapters 4, 5, 6 and 7, respectively. 
2.2 Urine analysis by SPME-GC-MS 
2.2.1 Sample handling 
Urine is not generally regarded as being hazardous; however, when it visibly contains blood 
the same measures must be taken for its handling as for tissue and whole blood.  The clear 
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majority of urine samples in the three studies were not blood-stained; however, a few of the 
more advanced bladder cancer samples were.  Thus, all samples were regarded as potentially 
hazardous and a detailed risk assessment was performed and independently evaluated, prior 
to conducting any experimentation.  Although all samples arrived as lab codes and hence 
were analysed ‘blind’, the codes were readily traceable back to the original patient should 
an incident happen. 
Prior to handling the human urine samples, a risk assessment was performed and biological 
agents were categorised against the human pathogen hazard group according to the Health 
and Safety Executive (HSE) (Advisory Committee on Dangerous Pathogens, 2016).   
The risk assessment identified the following potential hazards:  
• Hepatitis B - classified as a Group 3* risk (vaccine available and I was vaccinated); 
• HIV - classified as a Group 3* risk; 
• Cytomegalovirus - classified as a Group 2 risk; 
• Hepatitis C – classified as a Group 3* risk even though there is no vaccine or effective 
immediate prophylaxis.  However, there is no clinical evidence of transmission of 
Hepatitis C from urine specimens. 
The HSE definitions for Groups 2 and 3 (Advisory Committee on Dangerous Pathogens, 
2016) are as follows: 
• Group 2: Can cause human disease and may be a hazard to employees; it is unlikely 
to spread to the community and there is usually effective prophylaxis or treatment 
available. 
• Group 3: Can cause severe human disease and may be a serious hazard to employees; 
it may spread to the community, but there is usually effective prophylaxis or 
treatment available.  
• Group 3*: As for Group 3, but not normally infectious by the airborne route. 
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All samples were handled in fume cupboards in a Containment Level 2 (CL2) facility, 
wearing gloves, wrap-around safety glasses and a lab coat.  Prior to sample preparation and 
post sample disposal the fume hood was cleared and cleaned, with a 1% Virkon solution 
(Antec International, Sudbury, Suffolk, UK) and finally with isopropyl alcohol.  All items 
encountering the urine were also neutralised with 1% Virkon solution prior to disposal in the 
sharps bins or before further cleaning for re-use. As soon as possible after sample analysis, 
samples were flushed to waste in the fume hood with plenty of water followed by Virkon 
solution.  After sample preparation or sample disposal the fume hood was again cleared and 
cleaned as above.  
The addition of salt and acid to the sample followed by heating at 70 °C for 22 minutes 
should have inactivated any agents in the sample HS vial and therefore disposal to waste was 
deemed acceptable. 
2.2.2 Sample collection and storage 
Urine samples were collected by Amersham Hospital or the John Radcliffe Hospital, 
depending on the project.  Please see Chapters 4, 5 and 6 for further details.  Following 
urinalysis (Multistix 10 SG, Bayer Corporation, NY, USA) by Wycombe hospital or the 
John Radcliffe Hospital, fresh urine specimens were refrigerated immediately. Within 24 
hours, they were divided into 0.5-1 mL aliquots and placed in vials (2 mL glass, screw-top, 
source unknown) then stored in a freezer at -80 °C until required.  Where possible, 10 
aliquots of each sample were stored.  Samples were then transported in ice packs to The 
Open University. 
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2.2.3 Materials 
The night before analysis, anhydrous sodium sulphate (≥99 %, Sigma-Aldrich, Gillingham, 
UK) was prepared by placing approximately 70 g in a 10 mL beaker.  It was baked in a 
muffle furnace above 100 °C overnight.  On removal from the oven, it was sealed with clean 
foil and allowed to cool, in a clean environment. 
A 0.1 M solution of hydrochloric acid (HCl) was prepared by placing around 50 mL of 
deionised (DI) water, from a Synergy 185 Water Purification System (Merck Millipore Ltd., 
Watford, Hertfordshire, UK), into a clean volumetric flask.  8.5 mL of 36 % HCl (Fisher 
Scientific UK Ltd., Loughborough, Leicestershire, UK) was carefully added.  The 
volumetric flask was then topped up to the line with DI water.  The contents were transferred 
to a clean DURAN® (Duran Group, Mainz, Germany) bottle (100 mL) and stored in the 
refrigerator. 
The internal standard (IS) solution of 100 µg/mL of phenol-d6 was prepared by carefully 
weighing 2.5 mg of phenol-d6 (> 98 % ISOTEC, Miamisburg, Ohio, USA) into a clean foil 
weighing boat using a 4-decimal place BP211D high sensitivity balance (Sartorius AG 
Gottingen, Germany).  The contents of the foil weighing boat was then transferred into a 25 
mL volumetric flask.  Pesticide residue grade methanol (Fisher Scientific, Loughborough, 
Leicestershire, UK) was then carefully added up to the mark.  The flask was sealed and 
shaken gently, to dissolve the IS.  The top was sealed with Parafilm (Bemis Flexible 
Packaging, Oshkosh, Wisconsin, USA) and the flask stored in the fridge.   
Prior to batch sample preparation, the volumetric flask was removed from the fridge and 
transferred to a fume cupboard.  The flask was thoroughly mixed and 1 mL of IS was 
transferred to a clean 2 mL screw-top vial and immediately capped.  The stock solution was 
then sealed and returned to the fridge along with the 2 mL vial; unless it was for immediate 
use, in which case it was placed in a cool box with ice packs. 
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2.2.4 Sample preparation 
Screw-top, 10 mL headspace vials (VWR International, Lutterworth, Leicestershire, UK) 
were used for the sample analysis.  The vials were sealed with screw-top silver caps with an 
8 mm central hole (VWR International, Lutterworth, Leicestershire, UK).  The caps were 
fitted with a 1.5 mm thick, silicone (white) / PTFE (blue) septum (VWR International, 
Lutterworth, Leicestershire, UK) making them suitable for use with the SPME fibre 
assembly.   
Enough vials and caps for the batch, including blanks, were placed in clean glass jars in a 
GC oven and heated to 80°C for 1 hour, along with a 2 mL vial and cap for the IS solution 
for that batch.  The oven was then cooled to 30°C and the glass jars sealed with a cardboard-
lined lid. 
To each HS vial, 1.00 ± 0.01 g of conditioned, anhydrous sodium sulphate was weighed, 
using a PT210-000V1 balance (Sartorius AG, Gottingen, Germany).  The vial was sealed 
(not tightly) with a cap and placed into a removable autosampler tray for transport to the 
fume hood in the CL2 facility. 
The chilled 2 mL vial of IS solution and 0.1 M HCl were removed from the fridge and placed 
in a cool box containing ice packs.  The bag containing the urine samples for that batch were 
removed from the -80 °C freezer and placed on the ice packs in the cool box for transport to 
the CL2 fume hood.  At the fume hood, a bucket containing Virkon solution was prepared 
(2 x 5 g tablets into 1 L of lukewarm water) ready for the empty sample vials and used 
pipettes.  The sample vials were then removed from the cool box and placed upright in the 
fume hood to defrost. If the batch size was large then only half of the sample vials were 
removed to ensure that all samples could be processed in the time available, enabling the 
urine samples to defrost but remain very cold, to minimise losses of VOCs into the 
headspace. 
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Each of the samples were prepared by: 
• Labelling the HS vial with the sample name;  
• Removing the cap of the HS vial containing the salt;  
• Accurately adding 1.5 mL of 0.1 M HCl with an adjustable pipette (Acura 835, 0.5-
5 mL Macro pipette with Pasteur pipette adapter, Socorex Isba S.A., Switzerland) 
fitted with a disposable glass Pasteur pipette (Fisher Scientific UK Ltd., 
Loughborough, Leicestershire, UK);  
• Adding 1 µL of the IS solution using a 10 µL glass syringe (SGE, Milton Keynes, 
UK);  
• Adding 0.5 mL of the urine sample with a new disposable glass Pasteur pipette.   The 
sample had just defrosted but was still very cold and was lightly shaken to mix the 
contents before the cap was removed; 
• Immediately capping and sealing the vial - to ensure no leaks would occur;  
• Placing the used urine vial and cap and the pipette tip into the Virkon bucket, before 
moving onto the next vial.   
Once an autosampler tray was full, it was placed back into the cool box before continuing 
with the sample preparation.  Once sample preparation was complete, all the samples were 
stored in the cool box while the fume hood was cleaned, before immediate transportation to 
the instrument laboratory for analysis.  A summary flow chart is shown in Figure 2.1. 
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Figure 2.1: Flow diagram of sample vial preparation 
2.2.5 SPME-GC-MS instrumental parameters 
2.2.5.1 Preparation of the instrument for analysis 
The SPME-GC-MS analyses, for the bladder and prostate cancers and hepatic disorder 
studies, were performed with a CombiPAL autosampler (CTC Analytics AG, Zwingen, 
Switzerland) injecting into an Agilent 6890 gas chromatograph (GC) (Agilent Technologies, 
Santa Clara, California, USA) hyphenated to a Leco Pegasus® IV time-of-flight mass 
spectrometer (ToFMS) (Leco Corporation, St Joseph, Michigan, USA) fitted with a high 
performance (10 mL/min) vacuum system.  The autosampler was equipped with a SPME 
fibre syringe holder and a SPME fibre conditioning station (CTC Analytics AG, Zwingen, 
Switzerland) connected with a helium purge gas.  The GC was equipped with a split/splitless 
inlet.  Data acquisition and instrument control was through the Leco ChromaToF® software 
(Leco Corporation, St Joseph, Michigan, USA).   
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A new SPME fibre was used for each batch of samples.  Prior to use, it was conditioned in 
the fibre conditioning station at the recommended temperature and for the recommended 
time.  For this method, a 75 μm polydimethylsiloxane-Carboxen (PDMS/Car) SPME fibre 
(Sigma-Aldrich, Gillingham, UK) was used and it was conditioned at 300°C for 2 hours. 
The GC-ToFMS was leak checked and an instrument blank was run, to check for 
contamination.  The ToFMS was then tuned with an Autotune method before a SPME fibre 
blank was analysed using the new, conditioned SPME fibre.  The fibre blank was to check 
that the fibre was also clean and that it did not require any further conditioning.  In a fibre 
blank, only the fibre was desorbed in the GC inlet, no sample was extracted.  If the blanks 
failed, then further blanks were run following maintenance or further conditioning. 
2.2.5.2 SPME-GC-MS method 
The autosampler placed the HS vial into the incubator, heated at 70°C, and the sample was 
agitated at 750 rpm for 10 minutes, with a duty cycle of 10 seconds on and then 2 seconds 
off.  The analytes were extracted from the headspace with a 75 μm Polydimethylsiloxane-
Carboxen (PDMS/Car) SPME fibre that was inserted into the headspace above the liquid 
sample with a 22 mm vial penetration and 12 mm needle penetration. The volatile analytes 
were extracted for 12 minutes, at 70°C, with agitation at 100 rpm and with a duty cycle of 
10 seconds on and 2 seconds off. 
The SPME fibre was desorbed by penetrating the injector by 54 mm along with a needle 
penetration of 32 mm.  The GC inlet was fitted with a SPME liner (0.75 mm i.d.) and o-ring 
(Supelco, Sigma-Aldrich, Gillingham, UK) and a pre-pierced Thermogreen septum (11 mm, 
Thames Restek, Saunderton, Buckinghamshire, UK).  It was heated to 280°C in splitless 
mode for 3 minutes.  The fibre was then withdrawn and baked out in the SPME conditioning 
station, set at 300 °C, for 15 minutes with an injector penetration of 44 mm and needle 
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penetration of 25 mm.  The GC inlet split exit opened at 3 minutes with a purge flow of 40 
mL/min before going into gas saver mode at 5.5 minutes with a flow of 20 mL/min. 
The analytes were separated on an Rxi-624Sil (30 m x 0.25 mm i.d. x 1.4 μm film thickness) 
column (Thames Restek, Saunderton, Buckinghamshire, UK).  The column was held at 30°C 
for 2 minutes and then ramped to 300°C at 20°C/min.  The column was not held at the upper 
temperature.  The carrier gas used was helium with a constant flow rate of 1 mL/min.  
The separated analytes entered the ToFMS ion source, held at 230°C, through a heated 
transfer line held at 280°C. After a 60 second solvent delay, the ToFMS collected data at 10 
spectra/s over the mass range m/z 33 to 350 u.  The detector voltage was set at 1,650 V. 
Once the batch had been acquired, the data files were converted to NetCDF (network 
common data form) format and uploaded to Cranfield University servers for analysis using 
chemometric techniques. 
2.2.6 Sample analysis 
2.2.6.1 Replicates 
Where possible (if there was enough sample) all samples were analysed in triplicate. This 
approach checks sample, sample preparation and instrument variability and should an 
individual analysis of a sample fail, then the sample should not need to be re-analysed later. 
The replicates took place either:  
• In-batch together (one after the other) 
• In-batch scattered (throughout the batch randomly) 
• Between batches (randomly) 
Further information on the method for randomisation is provided in Section 2.2.6.4. 
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2.2.6.2 Fibre and matrix blanks  
After every 10 samples a blank analysis was carried out. The blank alternated between a 
fibre blank and a matrix blank.   
Using the fibre blank method, the fibre was desorbed in the GC inlet only, with no extraction 
in the HS vial, but the remainder of the method was the same as for the sample analysis.  
This was used to check for any carryover on the fibre, fibre bleed and to check if any 
contaminants were ad/absorbed from the laboratory air above the instrument between the 
end of the fibre bake out and being inserted into the HS vial for the next analysis.   
Matrix blanks were prepared at the same time as the samples and in the same way.  Instead 
of 0.5 mL urine being added to the HS vial, 0.5 mL of deionised water was added instead.  
The matrix blank was used to check for contamination or carryover in the sample preparation 
procedure, including: contamination of the reagents used in the HS vial; contamination of 
the tools and consumables used for the sample preparation; air contamination in the 
environment the sample preparation took place in; as well as contamination or carryover 
during the sample analysis. 
2.2.6.3 Procedural blanks  
Procedural blanks took a sample of DI water through the whole analytical procedure, from 
sample collection, sample storage, sample preparation and sample analysis.  Procedural 
blanks were mainly used to check for contamination from the sample collection and storage 
parts of the procedure.  One or two procedural blanks were analysed per batch, where 
possible, as limited numbers had been collected by the hospitals. 
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2.2.6.4 Batches and randomisation 
The autosampler could hold a maximum of 64 HS vials in two sample trays, including blanks 
and replicates; therefore, the samples were analysed randomly in multiple batches.  
Each batch contained 69 runs, as the fibre blanks did not require a vial.  Each batch included: 
• 1 procedural blank;  
• 3 matrix blanks (although if no procedural blanks were available, 4 matrix blanks 
were analysed);  
• 5 fibre blanks; 
• 60 samples, including any replicates.   
The first and last injections in the batch were always fibre blanks with a matrix or procedural 
blank immediately after or before them.  Fibre blanks were therefore runs 1, 13, 35, 57 and 
69.  Matrix or procedural banks were therefore runs 2, 24, 46, 68.  Where possible, each 
batch was prepared and then analysed one after the other, without any instrument 
reconfiguration except for leak check, tuning and a new conditioned fibre for each batch. 
To randomise the samples being analysed, one vial of each sample was placed into a bag 
called the ‘mixed sample bag’.  Separate bags were labelled for each batch, with the batch 
number.  A template of the sequence for each batch was printed out showing the positions 
of the different blanks within the sequence and where the samples would be analysed.  The 
sequence tables were then completed with the order that the samples were withdrawn in 
(randomised) and which type of replicate they would be (same batch together/same batch 
scattered/different batches).   
The first random sample was withdrawn from the mixed sample bag and placed into Batch1 
bag, a note was made of the sample’s name and if there were enough aliquots of the sample 
it was noted that a further 2 replicates were required and these were in-the-batch and 
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analysed together.  If there were not enough aliquots of this sample, then this type of replicate 
would pass to the next sample.   
The second random sample was then withdrawn from the mixed sample bag, placed into the 
Batch1 bag, notes made, and if there were enough aliquots of the sample it was noted that a 
further 2 replicates were required but these should be scattered through the same batch.  The 
position of those further replicates was then noted in the Sequence Template by evenly 
spacing them throughout the rest of the batch. 
The third random sample was then withdrawn from the mixed sample bag, placed in the 
Batch1 bag, notes made and if there were enough aliquots of the sample it was noted that a 
further 2 replicates were required and that these should be scattered between the batches.  
The batch now had 7 samples. The process was repeated until all 60 sample places were 
completed on the Sequence Template for the batch.  The mixed sample bag and batch bag 
were then returned to the freezer.  Those samples with replicates in the same batch were 
located and two additional aliquots were added to the batch bag for each.  Those samples 
with replicates scattered between the batches had 1 new sample vial each added into the 
mixed sample bag.  The process was then repeated for the next batch and when a sample was 
withdrawn that was already a different batches replicate, a note was made to place the final 
aliquot vial into the mixed sample bag after completion of the batch. 
The allocation process was performed quickly to ensure the samples didn’t melt, the samples 
being placed back into the -80°C freezer after the completion of each batch to allow the 
samples to completely freeze.  Bags with completed batches were placed back into the 
freezer immediately. 
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2.3 Bacterial analysis by HS-GC-MS and TD-GC-MS 
2.3.1 Sample preparation and handling 
BACTECTM (Becton, Dickinson and Company (BD), is a blood culture system for microbial 
growth from blood samples.  An optimum of 8-10 mL of a blood sample is added to a sealed 
BACTECTM bottle that contains 30-40 mL of the optimum medium for growing any bacteria 
present in the blood.   
BD BACTECTM Lytic/10 Anaerobic/F and BD BACTECTM Plus + Aerobic/F (Becton, 
Dickinson and Company (BD), New Jersey, USA) bottles containing positive samples that 
had been cultured and identified in the Microbiology Department of University College 
London Hospital (UCLH) were analysed.  At the time of sampling and analysis by HS-GC-
MS and TD-GC-MS the microbiological results were unknown, and so analyses were 
preformed blind. 
All TD tubes were heat treated in a GC oven at 65°C for 1 hour to sterilise them prior to 
transport back to The Open University for analysis, as recommended by a microbiologist at 
UCLH. 
2.3.2 Sample analysis by HS-GC-MS  
2.3.2.1 Sample analysis 
Unfortunately, replicate samples were not analysed during the pilot study, due to the small 
number of samples available and the limited time available on the GC-MS instrument at 
UCLH.  
Headspace syringe blanks were analysed to check for carryover and contamination of the 
syringe, filter and GC-MS system.  Procedural blanks (containing the medium but no blood) 
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were also analysed to check for interferences and contaminants from the two different types 
of BACTECTM bottles, aerobic and anaerobic.  As the number of samples were small, all 
samples were analysed in one batch. 
Positive sample bottles and procedural blank bottles were collected from the Microbiology 
Department of UCLH, where they had been stored in an incubator after microbial analysis. 
The BACTECTM bottles were transferred to the Biochemistry Department of UCLH in 
insulated bags.  The headspace was sampled at ambient temperature, as a heated HS system 
was unavailable.  Samples were also analysed after incubation at 37°C for 1-3.25 hours and 
after incubation at 56°C in a water bath. 
A 2.5 mL headspace aliquot, from near the top of the BACTECTM bottle, was withdrawn 
using a 2.5 mL gas-tight HS syringe (Hamilton, Bonaduz, GR, Switzerland) and immediately 
injected into the heated injection port of the GC, using the parameters detailed in Section 
2.3.2.3.  The syringe was then immediately placed into a separate GC oven heated to 80°C. 
After the first sample, the syringe was removed from the oven and while still hot an air 
sample was drawn into the syringe and immediately injected to check for carryover.  This 
was known as a ‘hot’ blank.  After four samples, the procedural blank for an anaerobic 
sample was analysed, followed by another ‘hot’ blank.  
2.3.2.2 HS-GC-MS instrument preparation  
The HS-GC-MS analyses for the bacterial samples, were performed with a Shimadzu 
QP2010 gas chromatograph (GC) hyphenated to a single quadrupole mass spectrometer 
(MS) (Shimadzu UK Ltd., Milton Keynes, UK).  The GC was equipped with a split/splitless 
inlet.  The data was acquired and the instrument controlled using GCMS solution version 
2.53 software (Shimadzu UK Ltd., Milton Keynes, UK).   
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The GC-MS was leak checked and an instrument blank run to check for contamination.  The 
MS was then tuned with an Autotune method.  Further blanks were run following 
maintenance or further conditioning, if the initial blanks failed. 
The HS syringe plunger was removed from the barrel and both were heated in a GC oven, at 
80°C for 15 minutes, to remove any carryover and to sterilise them.  This procedure was 
carried out between samples and before the start of analysis. 
2.3.2.3 The HS-GC-MS method 
The 2.5 mL of headspace was injected into the GC inlet, held at 220°C, with either a 10:1 or 
a 5:1 split ratio and a purge flow of 3 mL/min. 
The analytes were separated on a BP624 (30 m x 0.25 mm i.d. x 1.4 μm film thickness) 
column (SGE, Milton Keynes, UK), held at 50°C for 0.5 minutes, and then ramped to 240°C 
at 15°C/min and held for 1 minute.  The carrier gas used was helium at 54.7 kPa, resulting 
in a column flow of 0.98 mL/min.  
The separated analytes entered the MS ion source, held at 220°C, through a heated interface 
held at 220°C.  There was no solvent delay and the run was acquired with a threshold value 
of 10 (arbitrary units) and an event time of 0.25 ms across a mass range of 33 to 300 u. 
The data was exported in NetCDF format and uploaded to servers at Cranfield University 
for analysis using chemometric techniques. 
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2.3.3 Sample analysis by TD-GC-MS  
2.3.3.1 Materials 
Samples were trapped and concentrated using standard sized stainless steel TD tubes packed 
with Tenax® TA (35/60) / Carbograph 5TD (40/60) (Markes International, Pontyclun, 
Wales) sorbent.  New pre-conditioned tubes were ready for analysis and used as received.  
Used TD tubes were reconditioned and sealed with a Swagelok fitting at the OU, before 
visiting UCLH.   
Reconditioning of the TD tubes was performed, per the manufacturer’s parameters (Markes 
International Ltd., 2014) for the sorbent types, using the ULTRA 50:50 thermal desorption 
autosampler (Markes International, Pontyclun, Wales).  DiffLok caps were placed onto the 
end of each TD tube and they were placed into the ULTRA autosampler.  After purging with 
helium carrier gas, each TD tube was heated to 335 °C for 30 minutes.   
Any tubes that showed increased signs of artefacts, of contamination or that hadn’t been 
used for a month or more, were conditioned using the full tube conditioning cycle.  This 
cycle required 2 hours at 320 °C followed by a further 4 hours at 335 °C. 
Following conditioning, the DiffLok caps were removed one at a time and immediately 
replaced with a ¼-inch brass storage cap with a ¼-inch combined PTFE ferrule to completely 
seal the TD tube.  These are better for long term storage and for transportation both before 
and after sampling onto the tube, especially after sampling complex samples.  Any storage 
caps that had previously been used on a tube containing a sample, were first heated to 100 
°C in a GC oven to ensure they were clean before re-use. 
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2.3.3.2 Sample Analysis 
Unfortunately, replicate samples were not analysed in the pilot study, due to the small 
number of samples available and the limited number of TD tubes available.  As the aim was 
for this pilot study to be a proof-of-principle study for a larger follow-on study this was not 
considered an issue. 
TD-GC-MS blanks were analysed to check for carryover and contamination of the TD and 
GC-MS system. Procedural blanks were analysed to check for interferences and 
contaminants from both aerobic and anaerobic BACTECTM bottles. 
As the number of samples available were small, all samples were analysed in one batch with 
samples (aerobic and anaerobic) and blanks analysed randomly.  After the analysis of two 
sample tubes, each was analysed twice more to check for carryover, artefacts from the TD 
tubes after sampling and the stability of the sorbents. 
Positive aerobic and anaerobic sample BACTECTM bottles plus blank BACTECTM bottles 
containing the aerobic or anaerobic medium, but no blood, were collected from the 
microbiology department, transferred to the biochemistry department in insulated bags and 
then re-heated to 37 °C for a minimum of 10 minutes prior to sampling in a water bath. 
Sampling method   
The headspace was extracted by connecting the sampling end of the TD tube to a needle 
(Terumo Europe N.V., Leuven, Belgium), using medical grade tubing.  A 0.22 µm filter unit 
(Merck Millipore, Billerica, Massachusetts, USA) was installed between the needle and the 
TD tube.   The needle was inserted into the BACTECTM bottle.  The other end of the TD 
tube was connected to a sampling pump (AirChek 2000, SKC Inc., Eighty Four, 
Pennsylvania, USA) via low flow tubing.  
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While the BACTECTM bottle was still in the incubator, the headspace was extracted under 
static conditions pumping at 20 mL/min for 10 minutes.  A second, 5 micron filter needle 
(B. Braun Medical Inc., Bethlehem, Pennsylvania, USA) was then inserted through the 
septum of the BACTECTM.  This allowed for air replacement, while keeping bacteria within 
the bottle.  The system set-up is shown in Figure 2.2.  The sample was then extracted under 
dynamic HS conditions for a further 10 minutes.  The TD tubes were then immediately sealed 
with brass storage caps. 
 
Figure 2.2: Diagram of the sampling set-up for the BACTECTM bottle 
The TD tube fittings, between the TD tube and BACTECTM bottle were sterilised between 
analyses by placing them into a GC oven set at 80°C.  The needles and filters were disposed 
of in the microbial waste and new ones were used for each BACTECTM bottle. 
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Sterilising method  
The TD tubes were placed into the GC oven and heated at 65 °C, for 1 hour, to sterilise prior 
to returning them to The OU for analysis.  The tubes were not purged with inert gas prior to 
heating and therefore contained air.  Heating to higher temperatures could have damaged the 
sorbent inside the TD tube through oxidation; whereas, 65 °C was advised to be high enough 
to kill any live bacteria that potentially could have been trapped on the tube. 
2.3.3.3 TD-GC-MS Instrumental parameters 
The TD tubes were analysed at The OU using a Unity Thermal Desorber (Markes 
International Ltd., Pontyclun, Wales) and an 7890A GC coupled with a 5975C MS detector 
(Agilent Technologies, Santa Clara, California, USA) following a standard Indoor Air 
Toxics method for this instrumentation set-up (Wylie, et al., 5989-5435EN).   
The instrument was controlled by and the data acquired using MSD Chemstation with 
Deconvolution Reporting Software and the Indoor Air Toxics Library (Agilent 
Technologies, Santa Clara, California, USA).  Later, analyses were performed using the 
Ultra Autosampler (Markes International Ltd., Pontyclun, Wales) coupled to the Unity TD 
and a 6890N GC with a 5973N MS (Agilent Technologies, Santa Clara, California, USA). 
Instrument preparation for analysis 
The GC-MS was leak checked and an instrument blank run to check for contamination of 
the TD cold trap, GC and MS.  This procedure included a pre-trap fire and trap heat in the 
Unity TD, followed by analysis by GC-MS.  The MS was then tuned with an Autotune 
method.  Repeat blanks were run followed by maintenance or further conditioning, if the 
initial blanks failed.   
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The retention time locked Indoor Air Toxics method was loaded and a run was acquired to 
analyse the retention time locking compound, toluene, that had been spiked onto a TD tube 
using the spiking rig.  On identifying the retention time of the toluene peak, the software 
could then calculate the pressure required to enable the toluene peak to elute back at the 
locked retention time of 12.468 minutes and the pressure was automatically updated in the 
method.  A second run using the updated method confirmed that the toluene peak did elute 
at the locked retention time of 12.468 minutes. 
2.3.3.4 TD-GC-MS method 
TD Tube desorption:  The tube was pre-purged in the Unity (or Ultra) under helium for 1 
minute with the trap inline and the split on.  A general purpose cold trap was used containing 
hydrophobic Tenax® TA (Markes International Ltd., Pontyclun, Wales), held at -10 °C to 
trap and concentrate the analytes released from the TD tube.  The flow path temperature was 
set at 150 °C.  The TD tube was desorbed at 300 °C for 10 minutes with the trap inline and 
no split, meaning that all the analytes from the TD tube were trapped on the cold trap. The 
desorption flow was set at 20 mL/min.  There was a pre-trap fire purge for 1 minute before 
the trap was heated from -10 °C to 300 °C at the maximum heating rate for the instrument 
and held for 3 minutes.  The split was set at 40 mL/min, to transfer the analytes directly onto 
the GC column as a narrow sample band, giving an overall method split ratio of 18.6:1.  The 
split effluent was unable to be automatically re-collected using the Unity. 
GC-MS analysis:  The analytical column used was the same as the Indoor Air Toxic method 
(Wylie, et al., 5989-5435EN), a J&W DB-VRX (60 m x 0.25 mm x 1.4 μm film thickness) 
column (Agilent Technologies UK, Ltd).  The carrier gas used was helium, at a constant 
pressure of 33.21 psi. The pressure was calculated from retention time locking for toluene 
to elute at 12.468 minutes, giving an initial flow of 2.21 mL/min.  The oven temperature was 
initially held at 45 °C for 3 minutes before heating at 10 °C/min to 190 °C, then 20 °C/min 
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to 250 °C where it was held for 8 minutes, the maximum ramping temperature of this column 
is 260 °C.  This gave a GC-MS run time of 28.5 minutes and a GC cycle time of 31 minutes 
with the 7890A GC and 34 minutes with the 6890A GC. 
The analytes eluted from the GC into the MS through a heated transfer line set at 220°C, to 
minimise column bleed into the ion source.  The ion source temperature was set at 230°C 
and the quadrupole temperature set at 150°C.  The MS acquired data from 0 minutes with 
no solvent delay, across a mass range of 33-300 u with a threshold value of 10, sampling 
rate of 1 and the detector set with a gain factor of 5, with trace ion detection (TID) on and 
using the autotune. 
The data files (.csv) were then uploaded to the servers at Cranfield University for analysis 
using chemometric techniques. 
Instrument data analysis 
The data files from the TD-GC-MS analyses were analysed using MSD Chemstation with 
DRS and the IARTL retention time locked library.  Identification of the target compounds 
was checked using AMDIS and peaks not in the IARTL library were library searched using 
the NIST algorithm against the NIST14 library (National Institute of Standards and 
Technology, USA). 
2.4 Statistical Analysis by Cranfield University 
At Cranfield University, the NetCDF data files were processed and analysed using 
MATLAB (MathWorks Inc, USA).  Each data file contained the information from the 
analysis of one sample, including the full spectral information stored as a data matrix of size 
m/z_values x scans x intensity.   
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2.4.1 Data reduction 
GC-MS data files are three dimensional (3D) with the x-axis displaying the scan number, 
the y-axis displaying the abundance or intensity (arbitrary units, value is manufacturer 
dependent) and the z-axis displaying the mass to charge ratio (m/z), the charge for GC-MS 
data is +1 and therefore this is the mass (u), as shown in Figure 2.3.   
 
Figure 2.3:  A visual representation of the 3-dimensional (3D) GC-MS data: x-axis = scan 
number or retention time (min or s); y-axis = intensity (arbitrary units, value 
manufacturer dependent); z-axis = m/z (u)  
Taking a single scan number from the x-axis, a two-dimensional (2D) plot can be extracted 
of the mass spectrum from the z- and y-axis, as shown in Figure 2.4.  Depending on the 
software, the y-axis may be the intensity of the ion (arbitrary units, value manufacturer 
dependent) or the mass spectrum may be normalised to the most abundant ion called the base 
peak, where this ion is 100% and therefore the y-axis units are %.  The mass spectrum is in 
effect the fragmentation pattern of each compound eluting from the GC column. 
122 
 
 
Figure 2.4:  Extraction of a 2D mass spectrum from the 3D data matrix for a certain scan 
number or retention time: x-axis = m/z (u); y-axis = intensity (arbitrary units, 
manufacturer dependent or can be normalised to the most abundant ion (%)) 
A single m/z value from the z-axis can be extracted.  The intensity of this ion can then be 
plotted against the scan number or retention time.  This is useful to see which peaks this ion 
is present in throughout the GC run.  This produces a 2D extracted or single ion 
chromatogram (EIC or SIC), as shown in Figure 2.5.   
 
Figure 2.5:  Extracted Ion Chromatogram (EIC) of the intensity of a certain m/z plotted 
against the scan number or retention time (min or s) 
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Most multivariate data analysis techniques require only 2D data; therefore, data reduction is 
required to reduce the 3D GC-MS data down to two dimensions.  Having evaluated the 
various options as discussed, this is achieved by summing the abundances of all ions present 
at each scan number, as shown in Figure 2.6 to produce a total ion chromatogram (TIC).  
 
Figure 2.6:  Creation of a 2D Total Ion Chromatogram (TIC) from the 3-D GC-MS data, 
where the abundances of all ions for each scan number are summed to produce 
a TIC: x-axis = scan number or retention time (min or s); y-axis = intensity of 
summed ions (arbitrary units, manufacturer dependent) 
All data files processed by Cranfield University, underwent data reduction to produce a 2D 
data matrix before further processing.  Where the data could be normalised, through use of 
an IS, data reduction was applied after normalisation, as discussed in Section 2.4.2. 
2.4.2 Data normalisation and reduction 
On receipt of each data file, the data matrix was reconstructed to the order of m/z_values x 
scans (scan number).  To ensure that each data matrix was the same size, zero values were 
inserted where appropriate into the EIC chromatograms.  Phenol-d6, had been used as an IS.  
All the abundance values were normalised against the abundance values of the deuterated 
phenol using m/z 99 u, the most unique (i.e. not present in coeluting peaks or baseline noise), 
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and the highest abundance ion for this compound and therefore used as the quantitation ion.  
This allowed any variations in the analysis method to be accounted for. 
Scaling was also explored for the data set, with auto-scale, mean-centred scaling, no scaling, 
range-scaling (-1 to 1) and range-scaling (0 to 1) being applied.  This allowed differences in 
the concentrations of the individual samples to be accounted for. 
The intensities of the m/z values were then summed to generate a row vector of length equal 
to the number of scans, i.e. the TIC.  Finally, all row vectors (TICs) were combined into a 
data matrix of the order samples x scans.    
2.4.3 Alignment 
Slight retention time shifts can be seen in GC chromatograms due to very slight differences 
in sample introduction and when the instrument starts acquiring data; instrumental drift for 
example very slight differences in pressure and flow in the control of the carrier gas, 
temperature differences and a gradual reduction in the amount of stationary phase left in the 
analytical column; and matrix effects from different samples, where large concentrated 
matrix peaks shifts the retention time of neighbouring small peaks, or less volatile matrix 
builds-up on the analytical column, shifting retention times.  This can be particularly 
apparent over larger periods of time when analysing large batches and from batch-to-batch.  
Each scan represents 1/10th s and so very small variations in instrument performance are 
detected.  Therefore, it is necessary to align each chromatogram before any comparisons 
between them can be made, Figure 2.7.   
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Figure 2.7: Alignment prior to chromatogram comparison 
Correlation optimised warping (COW) was applied to the data sets to align corresponding 
peaks.  COW was used, rather than other warping methods, as it preserves peak shape and 
the areas under the peaks, plus optimal parameters for alignment can be determined easily.  
The segment (the number of data points per interval) and the slack (the extent of 
warping/shifting of the peaks in any direction) were optimised and applied for each data file. 
2.4.4 Exploratory data analysis 
After data reduction, normalisation and alignment, exploratory data analysis was performed 
to reveal any natural groupings of the data set, based on the characteristics that caused the 
greatest variance.  The most widely used techniques principal component analysis (PCA) 
and hierarchical cluster analysis (HCA) were performed on the data sets to accomplish this. 
PCA analysis was also used to detect any outliers in the data set. 
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2.4.5 Pattern recognition  
Three different pattern recognition techniques were used, partial least squares discriminant 
analysis (PLS-DA) and the machine learning algorithms random forests (RFs) and support 
vector machines (SVMs).  To train the algorithms, the known characteristic of each sample 
was used, for example the cancer status, the hepatic disorder type or the type of bacteria.  
Classification models were built through using custom-written scripts for each technique, 
PLS Toolbox 3.5 (Eigenvector Research Inc., USA) for PLS-DA, libsvm3.20 toolbox for 
SVMs and the RandomForest package in R (3.0.2) in MATLAB for RFs. 
For RFs, the number of trees were varied from 50 to 450 in steps of 100, to ensure that the 
optimum number of trees were used.  For SVMs, the linear kernel was used and optimised 
by applying cost values of 0.5, 1.0, 2.0, 4.0 and 8.0. 
PLS-DA is prone to overestimating the accuracy of the classification, therefore the number 
of latent variables (LV) was varied from 1 to 20 for each test run.  The performance of the 
PLS-DA classifier was also assessed. 
2.4.6 Evaluation process 
The accuracy of the PLS-DA was validated and the machine learning approaches were 
integrated into the procedures of using bootstrapping with optimisation by leave-one-out 
cross-validation (LOO-CV) or leave-five-out cross-validation (LFO-CV), depending on the 
size of the data set.  For each bootstrap evaluation, the data set was randomly split into two 
subsets:  
• Subset one: the bootstrap training set.  This was used to determine the optimum 
model parameters using LOO-CV.  Subset one was made up of 70 % of the original 
data set. 
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• Subset two: the bootstrap testing set.  This was used to evaluate the model at the 
determined optimum number of LVs.  Subset two was made up of 30 % of the 
original data set. 
This whole process was repeated for multiple bootstrap evaluations, with up to 300 
repetitions. 
2.4.7 Model performance  
The performance of the models generated were assessed by calculating the overall accuracy, 
specificity, sensitivity and the area under the receiver operating characteristic (AUROC) 
curve, which uses the trapezoid rule.  Using a model that excludes the data from the sample 
ensured that validation was sequentially performed on each sample.  
2.4.8 Statistical significance 
The final step in the data analysis procedures was to determine the statistical significance of 
the results.  Permutation testing with a Monte Carlo simulation was used, involving repeated 
random sampling.  A data set was created that was statistically similar to the data under 
study, but for which it was not expected to be able to build a meaningful classification model.  
Each sample in the data set was assigned a random class assignment and the data set was 
then used to generate the null model, which was subjected to the bootstrap procedure.  This 
was carried out hundreds of times.   
A good null hypothesis model should produce a mean percentage correctly classified (%CC) 
of 50 %.  For random assignment, there is a 50/50 chance of getting the answer correct, like 
when tossing a coin.  Therefore, a null model that is not biased, when repeated many times, 
should generate a distribution around the 50 %CC mark.   
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For a disease discriminating model that is trained on the data with real sample classes to be 
statistically significant, it needs to achieve a classification accuracy that is at the farthest 
point from that produced from the null models.  
The percentage of samples correctly classified (%CC) by the null models and the 
classification models are plotted as permutation density plots.  They show the distribution of 
the %CC against the frequency and are useful for visualising how broad or how narrow the 
null or classification distributions are, plus how close the classification models distribution 
is to the null models distribution. 
The statistical significance of the overlapping null and classification distributions is 
determined by using the Z-test or the t-test.  Where there are less than 30 samples for each 
of the distributions the t-test is used.  Where there are more than 30 samples for each of the 
distributions the Z-test is used to compare the means of the distributions. 
2.4.9 Identification of potential biomarkers 
A PCA or PLS loadings plot is used for interpreting relationships among the variables in the 
data.  It is a graphical plot of the relationship between the original variables and the subspace 
dimensions.   
The PLS-DA loadings were used to identify scan numbers from the data that showed the 
greatest variance between the data sets, for example the diseased data set against the non-
diseased data set.  Once the scan numbers were known from these plots, the mass spectrum 
could be extracted and library searched against the NIST (National Institute of Standards 
and Technology, USA) library and/or the MassBank (National Institute of Biomedical 
Innovation, Japan) library.  The results of which, were used to suggest possible biomarkers 
– compounds that could be used to differentiate between diseased and non-diseased samples. 
129 
 
2.4.10 Data processing workflow  
A summary of the data processing work flow can be seen in Figure 2.8. 
 
Figure 2.8: Workflow of the chemometric data processing 
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2.4.11 Summary of terms used in the discussion chapters 
A summary, description and calculation of the terms used in subsequent chapters is presented 
in Table 2-1. 
Table 2-1:  Definition of the statistical terms employed in determining the performance of 
the classification 
Terms Description Formula 
True 
Negatives 
The number of healthy samples correctly 
classified as healthy 
TN 
False 
Negatives 
The number of diseased samples incorrectly 
classified as healthy 
FN 
True Positives The number of diseased samples correctly 
classified as diseased 
TP 
False 
Positives 
The number of healthy samples incorrectly 
classified as diseased 
FP 
Correctly 
classified 
(CC) (%)  
The overall number of samples correctly 
classified out of all the samples: 100 % = perfect 
test 
100×(TN+TP)/ 
(TN+TP+FP+FN) 
Specificity   
(SPEC) (%) 
The overall number of healthy samples correctly 
classified out of all the would-be healthy 
samples: 100 % = perfect test 
100×TN/(TN+FP) 
Sensitivity   
(SENS) (%) 
The overall number of diseased samples correctly 
classified out of all the would-be diseased 
samples: 100 % = perfect test 
100×TP/(TP+FN) 
Negative 
predictive 
value (NPV) 
(%) 
The overall number of healthy samples correctly 
classified out of all samples classified as healthy: 
100 % = perfect test 
100×TN/(TN+FN) 
Positive 
predictive 
value (PPV) 
(%) 
The overall number of diseased samples correctly 
classified out of all samples classified as 
diseased: 100 % = perfect test 
100×TP/(TP+FP) 
False 
discovery rate  
(FDR) (%) 
The overall number of diseased samples 
incorrectly classified as diseased out of all 
samples classified as diseased: 0 % = perfect test 
100×FP/(TP+FP)  
or                 
100 % - %PPV 
LV Number of latent variables for the optimum 
model 
LV 
AUROC The area under the receiver operating 
characteristic (ROC) curve; a further indication 
of how good the classification system is: 1.0 = 
very good test; 0.5 = very poor test. 
Trapezoid Rule  
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3.1 Introduction 
The method to analyse the headspace above urine samples was developed over a long period, 
starting before my PhD.  The results from those preliminary studies very much influenced 
the method development, final analysis methods and the data analysis process used during 
the period of study.  Therefore, in this chapter, I will discuss those early studies and the 
methods developed during my PhD. 
This chapter on method development is divided into three sections. The first section will 
discuss the preliminary and pilot studies I undertook for the analysis of the headspace above 
urine, carried out prior to my PhD.  The second section will discuss the development of the 
HS-SPME-GC-ToFMS method, which was subsequently used to analyse the bladder cancer, 
prostate cancer and hepatic disorders projects urine samples. The final section will discuss 
the selection of the techniques and method development carried out for the analysis of the 
headspace above bacterial cultures by HS-GC-MS and TD-GC-MS. 
A summary of the studies and their timeline is shown in Table 3-1. 
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Table 3-1: A timeline and summary of the studies for urine and bacterial analyses 
Date Projects 
2006-2007 HS-SPME vs. HS analysis of urine comparison. 
GC-ToFMS vs. GCxGC-ToFMS comparison. 
Batch of 7xC1, 3xC2, 3xTCC1, 1xTCC2 & 1xTCC3 analysed by HS-
SPME-ToFMS 
Data processing via ChromaTOF then SIMCA-P. 
2008 February Analysis of batch of 30xTCC3, 20xC1, 20xC2, 19xC3 & 10xBPH 
samples by HS-SPME-ToFMS. 
Data processing initially attempted using ChromaTOF. 
Collaboration resulted in data being analysed late 2008 by Christina 
Weber at Cranfield University. 
2008 Late The eNose was used by Dr Claire Turner and colleagues to analyse 
the headspace above the urine samples.  The data was also processed 
by Christina Weber at Cranfield University and the eNose and HS-
SPME-GC-ToFMS results were compared. 
2008 December Faster HS-SPME-ToFMS method developed.  
Batch of 11xC1, 7xC2, 7xC3, 5xBPH, 2xTCC1, 1xTCC2, 8xTCC3. 
Data processed by Michael Cauchi at Cranfield University, TCC 
samples combined.  
2009 January Batch of 5xC1, 5xC2, 5xC3, 3xBPH, 6x TCC3 samples analysed by 
HS-SPME-GCxGC-ToFMS. 
Data processed by Michael Cauchi at Cranfield University. 
2009 May PhD started. 
2009-2011 HS-SPME-ToFMS method further developed for urine samples. 
2010 Method developed for bacterial analysis by HS-GC-MS and TD-GC-
MS. 
 
2011 Hundreds of bladder & prostate cancer samples analysed – the results 
are discussed in Chapters 4 and 5. 
2011 Bacterial samples analysed by HS-GC-MS and TD-GC-MS – the 
results are discussed in Chapter 7. 
2012 Hepatic samples analysed by HS-SPME-GC-ToFMS – the results are 
discussed in Chapter 6. 
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3.2 Preliminary Studies on Urine 
3.2.1 Preliminary studies on HS vs. HS-SPME and GC-ToFMS 
vs. GCxGC-ToFMS 
In 2004 Willis and colleagues published a study that dogs can be trained to detect bladder 
cancer from the odour of urine samples (Willis, et al., 2004).  Following discussions between 
Dr Morgan and Dr Willis, The Open University began to explore the development of 
analytical methods aimed at identifying markers or patterns of volatile organic compounds 
as indicators of bladder cancer, utilising the same samples as analysed by the dogs. 
In 2006, I was engaged by Dr Morgan to carry out a preliminary study to determine the 
profile of volatile organic compounds in the headspace above bladder cancer and control 
samples.  The study compared the results from a 0.5 mL headspace injection to a headspace-
solid phase micro-extraction (HS-SPME) injection using a Carboxen/PDMS fibre.   The 
separation and detection of the extracted analytes was also compared for comprehensive 
multi-dimensional gas chromatography with time-of-flight mass spectrometry (GCxGC-
ToFMS) against the more usual one dimensional GC with ToFMS (GC-ToFMS) separation 
for some samples. 
At that time, data analysis was performed manually using the Leco ChromaTOF software 
comparison feature.  A C1 healthy control sample was selected as a reference.  The data file 
was processed by ChromaTOF using the Peak Find and Deconvolution algorithms to define 
coeluting peaks and to deconvolute their mass spectra, before performing a library search 
against the NIST library.  Identified peaks were added to a reference file within the software.  
Other samples were then processed and compared to this reference, any additionally 
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identified peaks found were then added and this larger reference file was then used to process 
the next data file, and so on, until all data files had been processed.   
3.2.1.1 Preliminary study results 
Far more peaks were identified using HS-SPME than using headspace as the extraction 
technique and therefore all future studies used HS-SPME.  In this way, 972 compounds were 
identified as possible markers in one-dimension of GC separation (1D GC) and over 3,000 
compounds in two-dimensions (2D GC).   
After all new peaks in all data files had been found and added to the reference file, each data 
file was then re-analysed and compared against this final reference file.  The results for each 
HS-SPME data file, containing the peak retention times and abundances, was then exported 
in .CSV format for further evaluation.  Automated processing using MZmine (open source 
software originally by Matej Oresic) and Umetrics SimcaP (MKS Data Analytics Solutions, 
Umea, Sweden) was originally attempted on the data files directly from the ChromaTOF 
software.  The ChromaTOF raw (.peg) or processed (.smp) data file formats could not be 
used and therefore they were exported in a common format as NetCDF files.  However, the 
size of the NetCDF data files generated by the GC-ToFMS (~15 MB) and especially 
GCxGC-ToFMS (~900 MB), plus the large number of files in the data sets for these 
comparatively small studies, crashed both software programs on the computer and were 
unable to be used.   
The exported .CSV files were used instead, but even then, the processing took three days for 
the 1D GC data alone!  The 2D GC data files could not be processed and therefore even 
though the HS-SPME-GCxGC-ToFMS analyses gave very large amounts of information 
that could potentially give very good results, the data could not be used with the computers 
and software available at the time. 
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Some useful data was obtained from the PLS-DA analysis of the HS-SPME-GC-ToFMS 
data using Simca-P, as shown in Figure 3.1.   This shows that there is a natural grouping of 
the cancer status, where the five positive cancer samples in the circle bottom left are clearly 
separated from the ten negative cancer samples, when using the pre-processed data and 
considering the 972 compounds identified.  No further information could not be obtained as 
to possible biomarkers when using this software.    
 
Figure 3.1: Scores scatter plot after PLS-DA analysis of 5 bladder cancer positive and 10 
bladder cancer negative samples from the preliminary work. Score t1 (first 
component) explains largest variation in the data set, followed by t2, etc. Red 
circle shows the aggregation of the 5 positive samples. 
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3.2.1.2 Preliminary study summary 
Based on the results from these preliminary studies it can be concluded that: 
• HS-SPME was far more sensitive and more peaks were identified than when using 
HS analysis. 
• Although GCxGC-ToFMS gave much better separations and sensitivity, enabling 
three times more peaks to be identified than GC-ToFMS, the data could not be 
processed using the available computers and software.   
• GC-ToFMS data was still difficult, but more manageable to handle. 
• The extensive data processing using ChromaTOF software, taking many months for 
this comparatively small study along with the difficulty in analysing the processed 
data, indicated that an alternative method for future studies was required.  
Therefore, Cranfield University were enlisted to help on the chemometrics side for data 
processing as they could use the exported NetCDF format with no pre-processing through 
ChromaTOF.  
3.2.2 Pilot studies using HS-SPME-GC-ToFMS and eNose 
3.2.2.1 HS-SPME-GC-ToFMS technique 
Following on from the preliminary study, a pilot study, to further evaluate the effectiveness 
of the HS-SPME-GC-ToFMS analysis, was carried out from 2008-2009.  Samples were 
provided by Dr Carolyn Willis (Amersham Hospital).  Diseases classifications of the 
samples were conducted by Dr Michael Cauchi and Christina Weber, from Dr Conrad 
Bessant’s Bioinformatics Group at Cranfield University.  At the same time, a parallel study 
was performed by Dr Claire Turner and colleagues on the same batch of urine samples. The 
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analyses utilised an eNose rather than HS-SPME-GC-ToFMS.  Once again, the data 
generated was analysed using the same techniques at Cranfield University by Dr Michael 
Cauchi and Christina Weber. 
The studies analysed samples from a total of 30 patients aged between 50-88 with new or 
recurrent transitional cell carcinoma (TCC) bladder cancer, graded as TCC1-3.  In addition, 
59 control samples, divided into three control groups of 20 C1 (healthy individuals aged 
between 18-31 with no positive urine dipstick test); 20 C2 (individuals aged between 18-32 
who had any non-cancerous condition or disease that produced a dipstick reading that was 
positive for leucocytes, blood and/or protein, including menstruating women and those with 
suspected urinary tract infections); and 19 C3 (patients aged between 24-89 with a confirmed 
non-cancerous urological disease including renal and ureteric stones, renal cysts and 
polypoid cystitis that did or did not produce a positive dipstick test result).  All participants 
over the age of 32 had a recent cystoscopy to check for visible signs of bladder cancer and 
all men over 50 were also checked for prostate cancer, as prostate cancer could give a false 
positive.  Those with other urological cancers or bladder cancers other than TCC were 
excluded; whereas, those with a history of other cancers that had been disease free for more 
than 5 years were included.  Data had also been collected on the participant’s age, smoking 
habits, medication, menstrual cycle, diet, alcohol consumption and chemical exposure, in 
case this influenced the odour or composition of the urine.   
The headspace above the urine samples was analysed using HS-SPME-GC-MS using the 
optimised method I had previously developed.  The 0.5 mL urine sample was placed into a 
headspace vial with sodium sulphate and 0.1 M hydrochloric acid.  This vial was then heated 
for 10 min at 60 °C before the Carboxen/PDMS SPME fibre was inserted into the headspace 
above the sample and the VOCs extracted for 5 minutes.  The fibre was then desorbed in the 
GC inlet and analytes were transferred for separation on the GC analytical column with 
detection by ToFMS.   
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Initially, an attempt was made to process the data using ChromaTOF software, as described 
in the previous experiment.  However, there was far too much data.  It was at this point that 
it was decided to exploit a recently established collaboration with Cranfield University, to 
use their expertise and computers to develop methods to process the data and to compare the 
data sets in a more statistically rigorous manner. 
The data was exported in NetCDF (network common data form) format and uploaded to 
Cranfield University servers, ready for chemometric analysis.  The methodology for 
processing the data was developed at the same time as the comparative study discussed in 
Section 3.2.3.  In this section, I will just discuss the final data processing method and the 
results produced from its application. 
At Cranfield University, the data files were analysed using MATLAB by first summing the 
abundances of the m/z at each data point to produce a total ion chromatogram (TIC), as 
previously discussed in Chapter 2 (Weber, et al., 2011).  Correlation optimised warping 
(COW) was then applied to align the data on the x-axis, to consider any shifts in the retention 
time while maintain the peak shape and peak area (Tomasi, et al., 2004).  The effect of data 
scaling was explored to normalise the data.  Exploratory data analysis was performed by 
principal component analysis (PCA), to determine the characteristics that caused the greatest 
variance within the data set.  Feature selection was then performed to extract the most 
significant features, using univariate statistics, the Wilcoxon test, followed by the false 
discovery rate (FDR) statistical method to correct for the multiple comparisons performed 
by the Wilcoxon t-test.   
Partial least squares discriminant analysis (PLS-DA) was then used to build a classification 
model, using the clinical status of the patient providing the sample to train the algorithm to 
differentiate between the classes.  Differentiating between those samples from bladder 
cancer patients and those with no bladder cancer and which compounds could be used to 
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separate the classes.  Due to overfitting of the data by PLS-DA, the classification was 
validated by varying the number of latent variables and by performing leave-one-out cross-
validation (LOO-CV).  A Monte Carlo Simulation was finally used to validate the results 
and to determine their significance.  These statistical techniques are described in Section 2.4. 
3.2.2.2 eNose technique 
The eNose or gas sensor array, used by Dr Claire Turner and colleagues, was made up of 
twelve metal oxide semi-conductor (MOS) sensors along with an array of ten individual 
metal oxide semi-conductor field-effect transistor (MOSFET) sensors, a capacitance-based 
humidity sensor and an infrared-based CO2 sensor.   
The urine samples, that had been stored in a freezer at -80 °C were randomised and allowed 
to defrost.  2.5 mL of urine from each patient was placed into two HS vials for duplicate 
analysis and the vials incubated for 1 hour at 38 °C before being analysed by the eNose.  The 
24 sensors responded to the compounds in the urine headspace and eight characteristic signal 
parameters were estimated from the raw data by the eNose software.  The data for 178 
samples, including duplicates, were then exported into Microsoft Excel ready for 
chemometric analysis. The interpretation of this data was published in 2011 (Weber, et al., 
2011). 
For the method using the gas sensor array, a total of 152 sensor variables were used in the 
data analysis, after the removal of some noisy sensors.  Models were built on the data from 
the full array, as well as from only the MOS or the MOSFET sensors.  PCA analysis did not 
produce any natural groupings related to the cancer status, even though the first three 
principal components captured 98 % of the variance.  The data from the full sensor array, 
rather than the MOSFET or MOS sensors, gave better results for the classifications using 
PLS-DA, after data scaling between zero and one, performing feature selection and LOO-
CV for all sample categories.  The results from PLS-DA classification of the different sample 
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categories using eNose with the data from the full sensor array are presented in Table 3-2.  
As expected, the C1 healthy controls vs. TCC gave the best results with a total accuracy, 
sensitivity and specificity all at 70.0 %.  C2 vs. TCC gave similar sensitivity but lower 
specificity.  C3 vs. TCC gave lower performance, but this is to be expected, as the C3 control 
samples are the most similar to the TCC samples and therefore would be more difficult to 
differentiate.  Using all the data from samples C1-3 vs. TCC gave lower sensitivity but higher 
specificity than the C3 controls alone.  The Monte Carlo simulation to assess the significance 
of the results of the four experiments, each attained with 250 random runs, showed that C1 
vs. TCC was very significant; C2 vs. TCC and all sample classes were all deemed significant, 
and C3 vs. TCC was just below the 95.0 % confidence limit of 62.5 %. 
Table 3-2:  PLS-DA best performing model results from the eNose full sensor array and HS-
SPME-GC-ToFMS sample analyses 
 eNose: full sensor array HS-SPME-GC-ToFMS 
 Sensitivity 
(%) 
Specificity 
(%) 
Total 
accuracy 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
Total 
accuracy 
(%) 
C1 vs. TCC 70.0 70.0 70.0 90.0 89.5 89.8 
C2 vs. TCC 71.7 60.0 67.0 90.0 80.0 85.0 
C3 vs. TCC 68.3 52.6 62.2 86.7 68.4 79.6 
All C vs. TCC 60.0 66.9 64.6 73.3 82.8 79.6 
Data from the HS-SPME-GC-ToFMS method, did not produce any natural groupings related 
to the cancer status when PCA data analysis was performed by Cranfield University.  The 
metadata such as diet could have been responsible for the largest variance in PCs 1-3, within 
the dataset.  The data was very much multivariate rather than univariate and therefore 
univariate feature selection was not used on this dataset.  The results from PLS-DA 
classification of the different sample categories from the analysis of the samples by HS-
SPME-GC-ToFMS are presented in Table 3-2.  The PLS-DA classifier showed that the two 
most dissimilar groups, as expected, were C1 versus TCC samples.  A total of 90.0 % of 
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cancer patients (sensitivity) and 89.5 % of non-cancerous patients (specificity) were 
correctly classified using PLS-DA, with range-scaling [0 to 1], feature selection and 8 latent 
variables, producing a total accuracy of 89.8 %.  
It was predicted that it would be relatively easy to differentiate between healthy participants 
and those with tumours in the late stage, but more difficult to differentiate between patients 
with bladder cancer and those controls with haematuria (C2) or other urological non-
cancerous diseases (C3).  C2 versus TCC patients were classified with a total accuracy of 
85.0 %, a sensitivity of 90.0 % and a specificity of 80.0 % again using range-scaling [0 to 
1], feature selection and with 14 latent variables.   
C3 versus TCC patients were more difficult to classify.  PLS-DA with mean centred scaling, 
feature selection and 2 latent variables was used, producing a total accuracy of 79.6 %, a 
sensitivity of 86.7 % and a specificity of 68.4 %.  Using this data analysis technique and all 
the sample categories: C1, C2, C3 and TCC; classification models were built using PLS-DA, 
with mean centred scaling, feature selection and 12 latent variables to produce a total 
accuracy of 79.6 %, sensitivity of 73.3 % and 82.8 % specificity.   
The Monte Carlo simulation to assess the significance of the results of the four experiments, 
each attained with 500 random runs, showed that C1 vs. TCC was very significant; C2 vs. 
TCC, C3 vs. TCC and the combined sample categories were all deemed significant, 
comfortably exceeding the 95.0 % confidence limit at 62.5 %. 
3.2.2.3 Pilot study summary 
The conclusions from this pilot study were: 
• There was a clear relationship between the profile of VOCs in the headspace above 
the urine samples and the clinical status of the patient (presence or absence of bladder 
cancer).   
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• The HS-SPME-GC-ToFMS sample analysis method could extract and analyse the 
VOCs quickly and reproducibly.  
• Compared to the eNose, the HS-SPME-GC-ToFMS sample analysis used less 
sample, the sample preparation time was shorter, and the sample analysis 
methodology produced data for the controls and TCC samples that gave better 
classification results.   
• The specificity from the HS-SPME-GC-ToFMS method was slightly lower than 
urine cytology but the sensitivity was much higher.   
These positive results led to further development in the methodology and larger studies 
through my PhD. 
3.2.3 Development of a faster GC-ToFMS method 
Even though sample preparation time was shorter for HS-SPME-GC-TOFMS than eNose, 
the sample analysis time was longer.  Therefore, an attempt was made to shorten the GC-
MS runtime, by increasing the oven temperature ramp rate. 
The original method had an oven temperature program of 30 °C (2 minutes hold) then 
ramped at 20 °C/min to 240 °C and held for 2.5 minutes.  The faster method had an oven 
temperature program of 50 °C (1 minute hold) then ramped at 50 °C/min to 240 °C and held 
for 1.2 minutes.  The original method had a column flow of 1 mL/min and the faster method 
a flow of 4 mL/min.  This resulted in the GC-ToFMS analysis reducing from 15 to 6 minutes.  
From here on this is referred to as the ‘Fast Method’ compared to the original ‘Standard 
Method’. 
By reducing the analysis time, the peaks eluted faster and were narrower.  To maintain the 
number of data points across the peaks, for accurate quantitation, the ToFMS acquisition 
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rate was increased from 10 to 15 spectra/s.  Ultimately, this resulted in each data file 
containing around 6,300 scans rather than around 8,390 scans, from the Standard Method. 
A batch of eleven C1, seven C2, seven C3, five BPH, two TCC1, one TCC2 and eight TCC3 
urine samples were analysed using the Fast HS-SPME-GC-ToFMS Method. 
3.2.3.1 Development of the chemometric methods 
The data was uploaded to the servers at Cranfield University and processed by Dr Michael 
Cauchi.  The data produced from the Fast Method was compared to the data produced from 
the Standard Method, acquired in the pilot study covered in Section 3.2.2.1.  Both sets of 
data were processed together using the same techniques.  These sets of data were also used 
in the development of the processing method by Cranfield University. 
The GC-MS data files are effectively three dimensional (3D), with each scan number 
containing information on the intensity of the signal for each fragment ion.  An attempt was 
made to import and process these files using PCA and HCA; however, their hardware 
restrictions were encountered with a lack of physical memory preventing processing of this 
more complex 3D data.   
It was also found that each data file generated using the same acquisition method had very 
slightly different mass ranges and number of scans.  This led to the development of the best 
way to create the data matrix for each file to be the same size. 
To reduce the complexity of the data files, the data could be reduced to two-dimensions 
(2D): 
• m/z vs. intensity: resulting in no chromatographic resolution 
• scan number vs. intensity: resulting in a total ion chromatogram (TIC)  
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PCA and HCA were initially used to compare the 2D data.  The intensity vs. scan number 
was found to give better results than the intensity vs. m/z.  This fits in well with the results 
of the HS-SPME-GC-TOFMS vs. eNose experiment, where the chromatographic method 
gave better results than the eNose.  One of the main differences is that it uses 
chromatographic separation of the compounds in the analysis.   
Next, the removal of the noisy background air and hydrocarbon mass ions, m/z 36, 40, 43 
and 44 u, were investigated, along with the use of scaling, PLS-DA for classification and 
LOO-CV.  Null models were generated with and without removing ions and using no scaling 
against auto-scaling.  Outlier removal and cropping of ions up to/from m/z 170 u were also 
tried.  The results from cropping implied that more representative ions, as potential 
biomarkers, were in the mass range of m/z 170 to 350 u.  Outlier removal occasionally led 
to improved classifications.  Alignment was identified as being necessary to greatly improve 
results.   
3.2.3.2 Fast method results 
The results of PLS-DA classification of the C1, C2 and TCC samples are shown in Table 
3-3.  The results are shown for the data sets from both methods, analysed in the same way 
(comparative), using the TIC with auto-scaling, no outlier removal and no cropping plus the 
results using the optimal processing method for the data set from each method.  
As can be seen, when comparing the results from the two different GC-ToFMS methods 
using the same data processing methods, the standard method gives better results than the 
Fast Method.  The TN/FP and TP/FN are very similar and are therefore consistent when 
using the standard method.  Whereas the Fast Method, although being very good at 
classifying the TN/FP, is poor in comparison at classifying the TP/FN.  Even when 
optimising the data processing methods by removing noisy ions and, as in the case of the 
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Fast Method, cropping ions and removing outliers, with LOO-CV the results are still better 
for the standard method than the Fast Method. 
Table 3-3: PLS-DA results of the Standard Method vs. the Fast Method 
 Standard Method Fast Method 
 Comparative Optimal* Comparative Optimal** 
Overall % 77.14 82.86 72.41 81.48 
TN % 77.5 85 88.9 82.4 
FP % 22.5 15 11.1 17.6 
TP % 76.7 80 45.5 80 
FN % 23.3 20 54.5 20 
Classification of the C1, C2 and TCC samples, using TIC and auto-scaling; *LOO-CV and 
ions m/z 36, 40, 43, 44 u removed; ** LOO-CV, ions m/z 36, 40, 43, 44 u removed, cropping 
m/z 170-350 u; plus, outliers removed. 
3.2.3.2 COW alignments 
Alignment of the data using COW was also investigated using the data from the Standard 
Method.  The results of alignment using PLS-DA for C1 vs. TCC samples is presented in 
Table 3-4.  COW did improve the percentage classification.    
Table 3-4: PLS-DA results of the Standard Method with and without COW 
 No COW COW aligned 
Overall % 78 81.63 
TN % 75 84.2 
FP % 25 15.8 
TP % 80 80 
FN % 20 20 
Classification of the C1 and TCC samples; using TIC and auto-scaling; no outliers removed. 
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3.2.3.3 Fast analysis summary 
To summarise, the reduction in chromatographic separation, from a 15 minute Standard 
Method to a 6 minute Fast Method, although partially compensated for by increasing the 
ToFMS acquisition rate to maintain the number of data points across the peak, resulted in 
poorer classification results.  Therefore, from this point on, the amount of chromatographic 
resolution was maintained and deemed important to the classification of bladder cancer 
samples.  This was also backed up in the data processing optimisation, when the 2D m/z vs. 
intensity was compared to the 2D scan number vs. intensity data. 
The optimisation of the chemometric data processing methods using this data showed how 
important it was: 
• to investigate and implement alignment, scaling and LOO-CV; 
• to import data into the same size matrix and to produce null models; and  
• to consider cropping of fragment ions and removal of noisy ions.   
Optimised data processing techniques were then used to analyse the full standard method 
data set, as previously discussed in Section 3.2.2.1 HS-SPME-GC-ToFMS technique. 
3.2.4 Analysis of GCxGC-ToFMS data 
The previous studies had shown that chromatographic separation was an important factor in 
the quality of the disease state classification of the patient samples.  In gas chromatography, 
the ultimate chromatographic or temporal resolution is obtained using comprehensive 
(GCxGC) chromatography.  The preliminary studies reported in Section 3.2.1 had shown 
that the 2D GC method produced far more peaks than the 1D method, but the data processing 
had inhibited its use.   
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From previous experience of using comprehensive chromatography (GCxGC), to separate 
and detect 5-6,000 analytes in diesel and meteorite samples, amongst others, I used my 
default volatiles method for the analysis.  The aims of the analyses were to produce enough 
data files for Cranfield University to attempt classification of the 2D data. 
The primary column was the same as that used in the 1D GC separation, the SGE BP624 (30 
m x 0.25 mm x 1.4 µm film), a mid-polar column.  For the secondary column, a more polar 
SGE BP20 (2 m x 0.1 mm x 0.1 µm film) was selected.  The main oven temperature program 
had the same initial temperature and hold time as the 1D method; however, the ramp rate 
was set at 5 °C/min to slow the separation on the primary column to produce more 
modulation ‘slices’ for separation on the secondary column.  The final main oven 
temperature was 230 °C and initially held for 6 minutes, this ensured that the secondary 
column in the secondary oven did not exceed its maximum temperature.  The final hold time 
was then increased to 10 minutes to ensure all peaks eluted.  This produced a 52 minute total 
run time and a 95 minute cycle time, as the secondary oven and modulator take a long time 
to cool.  The secondary oven had a +15 °C offset to the main oven, to produce a fast 
separation that was not related to volatility and the modulator had a +15 °C offset to the 
secondary oven, to ensure fast transition of the molecules from the modulator into the 
secondary oven.  An initial modulation frequency of 4 seconds with a hot pulse time of 0.4 
seconds was used.  This was then reduced to 3 seconds, which enabled separation of the 
analytes on the secondary column without wrap-around, while producing as many 
modulations as possible.  The remaining GC parameters were the same as the 1D method. 
The peaks eluting from the secondary column are much narrower than for a 1D separation.  
Initially, a ToFMS acquisition rate of 100 spectra/s was used.  After the first analysis, on 
inspection of the peak width, this was increased to 150 spectra/s to obtain the optimal number 
of data points across the peak (~20).  The remaining ToFMS parameters were the same as 
the 1D method. 
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This 2D HS-SPME-GCxGC-ToFMS method was used to analyse a batch of five C1, five 
C2, five C3, three BPH and six TCC3 urine samples.  The data files were exported in 
NetCDF format and uploaded to the servers at Cranfield University. 
Due to the size of the 2D data files (~900 MB) compared to the 1D data files (~15 MB), the 
departmental computers at Cranfield University could not be used.  ‘The GRID’, Cranfield’s 
super computer was used, but even importing the data into memory was very slow.  The 
number of scans (mass spectra) in the 2D data file was ~312,000 compared to ~8,400 in the 
1D data files. 
3.2.4.1 Results from 2D GC 
A simple PLS-DA classification was performed on six 2D samples: one C1, one C2, two C3 
and two TCC resulting in 100 % correctly classified.  The same classification when 
performed on the same 1D samples produced a 66.67 % correctly classified result.  The PCA 
scores plot is shown in Figure 3.2. 
However, this data set was too small for statistically representative results, plus the pre-
processing had not been carried out, as had been found to be important with the 1D data in 
previous studies.  A larger number of sample data files were successfully imported and 
processed making a total of eleven samples (two C1, two C2, four C4 and three TCC).  The 
simple PLS-DA classification with auto-scaling for 8 control and 3 TCC sample results are 
shown in Table 3-5. 
Table 3-5: Classification results from simple PLS-DA for 8 control & 3 TCC samples 
Data set Correctly classified (%) 
2D* 63.64 
1D Standard* 63.64 
1D Fast 72.73 
* one data file cropped 
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Figure 3.2: Simple PCA score plot for 2 TCC and 4 control samples by GCxGC 
The results show the comparison between the three different analysis methods, which 
indicate that the 2D method gives no better classification result than the 1D standard method, 
but only three of these samples were diseased and no alignment had been carried out.   
The next step was alignment of the 2D data files using COW.  Alignment using COW but 
with no optimisation produced no further improvements in the classification results.  
Attempts to optimise the segment and slack combination for the 2D data files using the 
GRID, resulted in the system crashing, even when employing all eight cores.   
3.2.4.2 2D GC Summary 
Owing to the limitations of the hardware, the classification using 2D data was abandoned.  
In the future, this will be re-visited as the memory in computers has greatly improved in the 
last eight years. 
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From these preliminary studies, it was concluded that the best techniques available for the 
analysis of the headspace above urine samples was HS-SPME-GC-ToFMS and this is what 
was employed for my PhD studies.  
3.3 Further development of the HS-SPME-GC-ToFMS 
method for urine analysis 
The purpose of method development is to determine the optimal combination of parameters 
that will result in a robust method that will produce analytically sensitive and reproducible 
results and ultimately produce results that have high clinical sensitivity and specificity and 
enable informed decisions to be made by clinicians.  Many people believe that method 
development is, for example, solely selecting and optimising the temperatures for the 
analysis.  However, it starts before that, in selecting the best instrumentation and techniques 
and should be considered at every step, including data analysis. 
3.3.1 Selection of the sampling technique and instrumentation 
Dogs have been trained to sniff the headspace above urine samples to detect patients who 
have cancer. This ability would suggest that the compounds that are indicative of cancer 
must be volatile or semi-volatile.  There are several techniques that are available to sample 
the headspace above a liquid prior to analysis, including: static and dynamic headspace, HS-
SPME, purge-and-trap, thermal desorption and thermal extraction techniques.  The relative 
merits of each technique, in the context of the clinical application under consideration, will 
now be explored: 
Thermal extraction techniques, where the sample is placed in a TD tube or micro-chamber 
and heated, with the volatile analytes being trapped and concentrated before transfer to a 
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GC-MS for analysis, is better for solid samples with low solvent content and is not applicable 
to liquid samples.   
TD tends to be more of a manual process, with the volatile analytes purged and trapped onto 
a TD tube sorbent before transfer to an autosampler.  This is a very useful technique for 
sources of samples that cannot be taken to the lab, as once analytes are trapped on the 
sorbent, the TD tube can be shipped anywhere for analysis.  Very large volumes, >100 L of 
gases, can also be sampled.  In contrast, urine samples can be easily stored and transferred 
to the laboratory for automated analysis, the sample volume can be optimised and the 
headspace above the sample should be reasonable concentrated, therefore TD is not the first 
method to try for this analysis.   
Purge and trap is a highly sensitive technique, where an inert gas is bubbled through the 
sample to sweep out the volatiles and concentrate them on a trap.  The technique is fully 
automated after placing the sample in a vial; however, it can easily be overloaded producing 
carryover from high concentration samples, including those with high amounts of volatile 
matrix and samples that foam, which could be the case with urine samples.   
Static HS is a less sensitive technique; whereas, dynamic HS is more sensitive, as the 
analytes are trapped and concentrated on a trap before being rapidly heated to transfer them 
to the GC-MS for analysis.  The technique can also be completely automated.   
During the urine analysis project, dynamic HS wasn’t a readily available technique.  
Therefore, HS-SPME was selected as:  
• The fibre phase can be chosen to selectively trap a wide range of volatilities and 
polarities of analytes, with higher molecular weight, semi-volatile compounds more 
detectable than with HS analysis;  
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• After placing the urine sample in a HS vial, the whole sample analysis process can 
be automated;  
• The fibre extracts the analytes quickly (< 30 minutes) and is desorbed rapidly (~2 
minutes) in the GC inlet;  
• Splitless mode can be used for analyte transfer to the column due to the fast 
desorption and the use of a very narrow inlet liner, unlike HS analysis that must use 
a split injection to obtain sharp peaks;  
• It is a solventless injection, therefore large amounts of vapour in the headspace are 
not transferred to the GC column where it can interfere with the analytical separation, 
although it can still interfere with the extraction. 
The GC-MS selected for the urine analysis work was an Agilent 6890 GC with a Leco 
ToFMS capable of GCxGC-ToFMS analysis.  The reasons that this instrument was selected 
for this study are: 
• ToFMS is not a scanning instrument, therefore full mass spectra can be acquired 
across the mass range required without compromising the sensitivity. 
• ToFMS has very little spectral skewing, unlike scanning instruments.  Therefore, for 
deconvolution and chemometric analysis the data doesn’t have to be deskewed. 
• The Leco ToFMS has a high acquisition rate of up to 500 spectra/s, therefore fast 
chromatography with narrow peaks and GCxGC separations could both be acquired 
without compromising the number of data points across the peak or the sensitivity. 
• It was available in the laboratory. 
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3.3.2 Development of the sample preparation method 
3.3.2.1 Optimisation of sample buffering 
In any HS analysis, whether the headspace above a sample is sampled by heated syringe (HS 
analysis) or fibre (HS-SPME analysis), the release of analytes out of the sample matrix, when 
they have similar polarities, is difficult.  Urine samples are mostly aqueous. Water is the 
most polar solvent and therefore polar analytes that can undergo hydrogen bonding with the 
sample makes the extraction of these analytes very difficult and results in low recoveries.  
Matrix modification can break or reduce these interactions to release the analyte molecules 
from the aqueous matrix, enabling them to form an equilibrium with the headspace above it, 
from where they can be extracted.  The exact classes of analytes of interest in the urine 
sample is not completely known; therefore, the aim was to consistently extract as wide a 
volatility and polarity range of analytes as possible.   
The two main methods of improving the partition coefficient, for the extraction of polar 
analytes from water, is the addition of salt and the changing of the pH.  The addition of acid 
and heating of the sample would sterilise the sample.  From previous experience, as well as 
a review of multiple methods published on the headspace analysis of aqueous samples, an 
adjustment to pH 2 was selected.    
The urine samples were provided in 0.5 mL aliquots.  The addition of salt to the vial increases 
the volume, as well as affecting the pH; therefore, pH adjustment and salt addition had to be 
optimised simultaneously.  For HS-SPME there needs to be sufficient space in the headspace 
vial for the fibre to be inserted to extract the VOCs without touching the vial septum, fibre 
needle or the liquid sample, while it is being gently shaken.  In addition, the phase ratio 
needs to be considered, as excessive headspace reduces the analyte concentration in the 
headspace and therefore the extraction efficiency.   
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The autosampler takes 10 and 20 mL HS vials, 2 mL vials were deemed too small and 
although 4 mL vials fit in a tray, there are not enough positions for the large quantities of 
samples that needed to be analysed.  When taking all these factors into consideration, a 10 
mL HS vial was chosen, as the sample volume was small, and the pH adjustment would 
sufficiently increase the sample volume within the vial, for a more efficient extraction. 
A concentration of 0.1 M HCl was chosen to adjust the sample pH, as it was sufficiently 
dilute to adjust the pH of the sample with the addition of only a moderate volume.  A control 
sample was prepared and the volume of 0.1 M HCl solution required to adjust to pH 2 was 
recorded and the pH checked with pH indicator paper (pH-Fix 0-14, Fisher Scientific UK 
Ltd., Loughborough, Leicestershire, UK).  Ideally, each sample should have the pH checked 
after preparation; however, the sample volume is very small and the risk of losing VOCs 
from the sample once prepared is high; therefore, it was concluded that it was better to add 
a fixed volume of acid to all samples and blanks. 
Different salts can increase the concentration in the headspace by different amounts, 
however it was unknown which analytes were of interest.  Sodium sulphate was chosen 
rather than sodium chloride, to reduce the likelihood of unwanted reactions, it was readily 
available in high purity and has been proven to give a good increase in peak area for alcohols, 
amongst other compounds (PerkinElmer, Inc., 2014).  For samples to be reproducible they 
should be normalised to have the same concentration of salt; however, biological samples 
can slightly vary in their salt concentration, as well as pH; therefore, it is easier to add a fixed 
mass of salt until it is just past the saturation point.   
Anhydrous sodium sulphate was gradually weighed and shaken into a vial containing 0.5 
mL of deionised (DI) water plus the volume of 0.1 M HCl determined from the above 
experiment.  It was added to past saturation point at room temperature and then was heated 
and shaken (60 °C for 15 minutes) to ensure that the sample was still just saturated at the 
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higher temperature and adjustments were made.  The same mass of salt was then added to 
the vial containing the control sample and acid solution and the pH checked and the 0.1 M 
HCl solution volume adjusted.  Back to the blank sample and the volume of acid was 
adjusted and then the mass of salt.  This process was repeated until it was determined that 
the addition of 1.5 mL of the 0.1 M acid solution to the 0.5 mL urine sample plus 1.0 g of 
sodium sulphate saturated the 2 mL of sample to pH 2 when heated to 60 °C.  Two different 
control samples were then prepared, the pH checked and then the vials heated and shaken to 
check saturation to ensure this matrix modification amounts would work for other samples.  
After the incubation temperature was raised to 70 °C during the method development, the 
pH and salt saturation were checked again and the volume and mass were still found to be 
applicable. 
3.3.2.2 Internal standard 
In quantitative analysis, the addition of a fixed known concentration of an internal standard 
(IS) to every standard and sample enables normalisation of the data to the IS’s response to 
account for errors.  For example, problems in sampling such as a leak, problems in 
transferring the method sample volume into the GC and transferring to the column, retention 
time drifts and detector drift.  Use of an IS can reduce the RSD for an instrument or reduce 
the method error down to 1-2 %.  IS can also be used in semi-quantitation, where analytes 
detected in a sample can be semi-quantified against the internal standard. This may not be 
very accurate in determining the absolute concentration of a specific analyte, but is useful 
for comparing the relative concentration of the analyte between samples in large data sets. 
In HS-SPME-GC-MS there are many steps where analytes could be lost, resulting in a loss 
in sensitivity for that analysis.  Addition of an internal standard can be used to normalise the 
responses of analytes, for comparison between the patient samples. Thus, reducing the 
likelihood of data from runs that had even a small problem being unusable and the number 
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of outliers from a poor injection.  They can also be used to monitor the robustness of the 
method within a batch and between batches, helping to identify instrument trends; for 
example, the gradual loss of sensitivity from the SPME fibre becoming less effective at 
extracting analytes and the IS throughout a batch. 
When selecting a suitable internal standard, it should: 
• have similar chemical and physical properties to the analytes, 
• have a similar extraction efficiency to the analytes, 
• elute towards the centre of chromatogram,  
• give a similar response to the detector,  
• not react with the sample or degrade any differently in the GC than the analytes,  
• be distinguishable from the other analytes and matrix compounds in the sample, 
• have a good peak shape and be relatively easy to determine the retention time and 
peak area,  
• not be present in any of the samples.   
When analysing biological samples, it is difficult to identify a compound with a similar 
volatility to the analytes that is not present in the sample; therefore, isotopically labelled IS 
are frequently used, as they are chemically and physically similar but are not present in 
nature.  However, they are expensive to purchase and therefore only one IS was selected.  
Common isotopically labelled IS for VOC analyses include toluene-d8, 1,4-
dichlorobenzene-d4 or chlorobenzene-d5; however, an IS was needed that could identify 
errors for the more difficult polar analytes with a molecular weight of around 100 g.    
Phenol-d6 was selected as it isn’t present in nature, has a similar volatility and was probably 
slightly more polar than the compounds of interest and therefore was good for optimising 
the extraction from the sample and the separation on the column.  It can easily be identified 
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with the mass spectrometer with an abundant fragment ion at m/z 99 u and does not interfere 
with co-eluting analytes.  It also eluted towards the far end of the middle of the 
chromatogram and therefore was more likely to suffer from poor peak shape if activity within 
the system occurred. 
The internal standard was prepared and added to the sample vials, as previously described 
in Section 2.2.4. 
3.3.2.3 Optimisation of sample preparation 
Sample preparation of biological samples, particularly those for analysis by LC-MS, usually 
use plastic disposable autosampler vials and pipette tips.  Plastics usually contain 
plasticisers, which are additives to increase the plasticity or viscosity of the material, the 
most common plasticisers being phthalate esters.  Unfortunately, phthalate esters can leach 
into samples and they are very GC-amenable, being easily detected.  Therefore, from the 
sample collection and storage to the transfer of the sample to the headspace vial, high quality 
glass consumables were used.  These included the 2 mL sample vials for storage of the urine 
samples in the freezer to the use of headspace vials, disposable glass pipette tips and a glass 
syringe for the transfer of the internal standard.  Glass itself has its problems, with the 
potential for breakages and injury during the sample preparation stage and needle pricks 
from the IS syringe. It goes without saying that great care was taken.  It also has silanol 
groups that can form strong hydrogen bonding interactions with polar species such as 
alcohols and amines and can be particularly problematic if these are trace analytes in the 
sample.  At the time of method development and sample analysis, reduced surface activity 
(RSA) glass vials were not readily available, they have significantly reduced surface silanol 
groups and surface ions that reduces the interaction.  Future studies should use these sample 
and HS vials and if possible glass pipette tips should be deactivated, as I have suggested to 
the UK distributor Hichrom, Theale, UK.    
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The 2 mL sample vials and HS vials were selected with screw-top caps.  This enabled the 
caps to be easily fitted and the vial sealed after filling.  The cap could also be easily and 
safely removed for sample transfer to the HS vial or for sample disposal.  The alternative 
was to use crimp caps, that can be more difficult to seal consistently, particularly without 
spillage.  They are difficult and time consuming to remove with the possibility of breaking 
the vial when removing increasing the risk of cuts, sample loss and sample contamination.  
The screw-top HS vials are generally easier to seal than crimp-top vials, leaks result in 
sample loss particularly for vials that are heated with water-based samples that result in a 
pressure build-up within the vial.  The CTC autosampler also transfers the HS vials from the 
sample tray to the incubator and back using magnets.  It requires a cap that is made of steel 
or has a steel insert, which can make it more difficult to crimp.  In addition, if the cap is not 
horizontal then the vial will not be vertical, making it difficult to insert the vial into the 
incubator or the tray without an error.  
The septa for the sample and HS vials must be inert to the sample, seal in the -80 °C freezer 
or warm incubator and be thin enough not to damage the SPME fibre on insertion of the 
blunt, fibre needle (23 Gauge) without coring.  PTFE is very inert but is not good at sealing, 
silicone is good at sealing but will absorb the sample or volatile analytes from the vial.  
Therefore, PTFE lined silicone septa were carefully selected and used. 
3.3.3 Optimisation of the HS-SPME sampling method  
There were a limited number of clinical sample aliquots available for method development.  
Therefore, it was not possible to perform all the optimisation on clinical control samples.  As 
much method development as possible was performed on matrix blanks.  The method 
parameters and the optimised values chosen are summarised later in the chapter in Table 3-9.  
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When beginning method development, the initial method sensitivity is relatively poor, 
because the parameters have not yet been optimised.  Matrix blanks were prepared as 
described in Section 2.2.6.2, however 10 µL of the IS solution, rather than 1 µL, was spiked 
into the vial, to be able to see the peak clearly.  From here on the matrix blank spiked with 
10 µL of the IS solution is referred to as the Test sample. 
Most the method development and as many parameters as possible were optimised by 
comparing the response of the IS for a wide range of values for each parameter and selecting 
the value that gave the best response.  Once completed and the conditions selected, many of 
these parameters were then checked by analysing a control sample spiked with 1 µL of the 
IS.  
3.3.3.1 Initial conditions 
HS-SPME method parameters and initial values 
A CAR/PDMS SPME fibre was used for the pilot studies, this was selected by considering 
the chemistries of the potential analytes, matrix and fibre, as discussed later in this chapter.   
For the SPME method an incubation temperature of 60 °C was selected based on previous 
experience, as this was moderately hot but was also not too close to the boiling point of the 
aqueous matrix that would produce excessive amounts of water vapour in the headspace.   
A pre-incubation time of 10 minutes had been used in the pilot studies; however, for the 
initial method development 5 minutes was used to speed up the first method development 
parameters.   
In the pilot studies an incubation speed of 500 rpm had been used; however, for the initial 
method development runs 750 rpm was used, as the pre-incubation time had been reduced.   
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The default values for the mixing function of the incubator are 5 seconds on and 2 seconds 
off; however, previous studies indicated that this was not long enough to get substantial 
mixing.  Based on these previous experiences, the incubator was run for 10 seconds and then 
switched off for 2 seconds, prior to changing direction. These parameters did not require 
further optimisation.   
An initial fibre extraction time of 5 minutes was used at the instrument default setting of 100 
rpm and the fibre was desorbed in the GC inlet for 2 minutes.  The manufacturer recommends 
a desorption time of between 1-2 minutes.  2 minutes was selected as it would ensure total 
desorption of the fibre.  This assumption was checked by analysing a fibre blank directly 
after the first analysis to check for carryover, no carryover was detected.   
A vial penetration of 22 mm and a needle penetration of 12 mm were determined as being 
optimal and checked by extracting from a vial in the autosampler tray, where the depth of 
the needle and fibre could be seen above the sample.  A GC inlet (injector) penetration of 54 
mm and a needle penetration of 32 mm were determined as optimal by removing the top of 
the inlet, holding the liner in place, inserting the SPME fibre manually and measuring the 
depth with a ruler to ensure that the fibre had been exposed and was being desorbed in the 
centre of the SPME liner, to avoid the temperature gradient of the inlet.    
The pilot studies used a bakeout time of 20 minutes at 300 °C, the manufacturer 
recommended fibre conditioning temperature for the CAR/PDMS fibre.   However, for the 
initial method development, with only the IS and co-extractives on the fibre, this period was 
reduced to 10 minutes for the earlier experiments. This was checked with a fibre blank after 
the first extraction and this period was further optimised with the C1 controls in later 
experiments. 
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A summary of the initial SPME method conditions is presented in Table 3-6.  This table 
shows which parameters which were fixed throughout method development and 
optimisation. 
Table 3-6: Initial SPME method conditions 
Method parameter Parameter value 
SPME fibre type CAR/PDMS 
Incubation temperature 60 °C 
Pre-incubation time 5 min 
Incubation speed 750 rpm 
Extraction time 5 minutes 
Desorption time 2 minutes 
Bakeout time 10 minutes 
Incubator on / off * 10 s / 2 s 
Extraction speed * 100 rpm 
Vial/needle penetration * 22 mm / 12 mm 
Injector/needle penetration * 54 mm / 32 mm 
Bakeout temperature * 300 °C 
Bakeout/needle penetration * 44mm / 25 mm 
* Those parameters that were fixed throughout method development and optimisation. 
The stationary phase selected for the pilot studies was a 624 GC column, which is mid-polar 
and therefore was a good compromise for both non-polar and polar analytes.  The column 
phase separates using a range of different interactions, it is also the most common column 
used for VOC analysis.   An SGE BP624 was used with a length of 30 m, as a short runtime 
was required but this also gave good separation.  An internal diameter of 0.25 mm was 
selected so that it was applicable for use with MS.  A 1.4 µm phase thickness was chosen, 
as it is thick enough to trap the more volatile compounds, but not too thick, which could lead 
to longer run times and band broadening of semi-volatile analytes.   
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The initial oven temperature was set to 30 °C, as this was the lowest temperature that could 
be routinely reached in a reasonable timeframe, with the type of gas chromatograph used at 
ambient temperature.  The initial hold time was 2 minutes to match the SPME desorption 
time.  The oven was ramped at 20 °C/min as it gave a reproducible rate of increase in 
temperature, up to the final oven temperature used.  The GC was fitted with a GCxGC 
module and therefore had extra mass within the GC oven, that limited the maximum ramp 
rate.  The selected ramp rate also separated the analytes relatively quickly within a total run 
time of 15 minutes.  A final oven temperature of 240 °C was used, which is the maximum 
ramped temperature recommended by the manufacturer for this column. This temperature 
was held for 2.5 minutes to ensure that all peaks had eluted from the analytical column.   
Helium carrier gas was used, as it is inert, suitable for the GC-MS and gives good resolution 
of the analytes.  The flow rate was set at 1 mL/min constant flow to obtain optimal resolution.  
The GC inlet temperature was set at 230 °C, the maximum isothermal temperature of the 
analytical column.  The inlet was installed with a SPME liner of 0.75 mm i.d.  This narrow 
liner is suitable for solventless injections and it maximises the efficiency of the analyte 
transfer from the SPME fibre to the GC column.  The analytes were transferred in splitless 
mode, to obtain the optimal sensitivity, with a splitless time of 2 minutes.  The split line was 
then opened at 40 mL/min to flush the liner for 3.5 minutes to prepare for the next injection.  
Once the inlet had been flushed, the split flow was reduced to 20 mL/min in gas saver mode 
for the remainder of the sample run.  The transfer line to the MS was set at 220 °C to 
minimise column bleed into the MS, while ensuring the peaks didn’t broaden. 
A summary of the initial GC method conditions is presented in Table 3-7.  This table also 
shows which parameters were fixed throughout method development and optimisation. 
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Table 3-7: Initial GC method conditions 
Method parameter Parameter value 
GC column SGE BP 624 30 m x 0.25 mm x 1.4 µm 
Carrier gas type * Helium 
Carrier gas flow * 1 mL/min constant flow 
Inlet liner type * Supelco 0.75 mm i.d. 
Inlet temperature 230 °C 
Inlet mode * Splitless 
Split open time 2 minutes 
Purge flow * 40 mL/min 
Gas saver flow * 20 mL/min 
Gas saver time * 5.5 minutes 
Initial oven temperature * 30 °C 
Initial hold time 2 min 
Ramp rate  20 °C/min 
Final hold time 2.5 minutes 
Total run time 15 minutes 
Transfer line temperature 220 °C 
* Those parameters that were fixed throughout method development and optimisation. 
MS method parameters and initial values 
The ion source was set at 230 °C, the default temperature for EI ion sources.  A solvent delay 
of 60 seconds was used, as no peaks would be seen during this time as the hold-up time of 
an unretained compound on this column, under these conditions was longer than 60 seconds.  
This solvent delay reduced the data file size, but by switching the MS on after this selected 
period, allowed it to stabilise before any peaks eluted.   
The mass range acquired was m/z 33 to 350 u, with the low mass selected to avoid m/z 28 u 
for nitrogen and m/z 32 u for oxygen, which would increase the baseline noise.  The optimal 
acquisition rate was calculated as being 10 spectra/s, which gave 15-30 data points across a 
peak, for the range in peak widths seen in a test run using the method.  A detector voltage of 
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1650 V was used, 50 V above the tuning voltage which meant the peaks doubled in size and 
therefore was better for trace analysis.   
A summary of the initial MS method conditions is presented in Table 3-8.  These parameters 
were fixed throughout method development and optimisation. 
Table 3-8: Initial MS method conditions 
Method parameter Parameter value 
Ion source temperature  230 °C 
Solvent delay  60 seconds 
Mass range 33-350 u 
Acquisition rate  10 spectra/s 
Detector voltage  1650 V 
3.3.3.2 Further optimisation with the Test sample 
SPME is an equilibration technique.  For HS-SPME, equilibration initially occurs between 
the sample and the headspace and then when the fibre is inserted, between the headspace 
and the fibre.  For the analytes to be extracted, they must move into the headspace first.  
Matrix modification was covered in the previous section, where the pH and addition of salt 
improves the partition coefficients of the more polar species from the polar matrix.  As also 
previously discussed, the phase ratio (volume of headspace compared to the volume of 
sample) also affects the efficiency of the extraction of VOCs by the fibre.  These parameters 
were optimised before moving onto the instrument parameters.  As summarised in Table 3-9, 
many parameters directly influence each other and so they were optimised sequentially.  
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Table 3-9: A summary of the parameters optimised and values chosen using the Test samples  
Parameter optimised Pre-inc. 
time 
(min) 
Inc. 
temp. 
(°C) 
Inc. 
speed 
(rpm) 
Extrac. 
time 
(min) 
Desorp. 
time 
(min) 
Bakeout 
time 
(min) 
Extraction time 5 60 750 3 2 10 
5 60 750 5 2 10 
5 60 750 10 2 10 
5 60 750 15 2 10 
Desorption time 5 60 750 10 5 10 
5 60 750 10 3 10 
5 60 750 10 2 10 
5 60 750 10 1 10 
Incubation speed 10 60 500 10 2 10 
10 60 750 10 2 10 
Incubation time and 
temperature 
5 60 750 10 2 10 
10 60 750 10 2 10 
15 60 750 10 2 10 
Incubation time and 
temperature 
5 50 750 10 2 10 
10 50 750 10 2 10 
15 50 750 10 2 10 
Incubation time and 
temperature 
5 70 750 10 2 10 
10 70 750 10 2 10 
15 70 750 10 2 10 
Bakeout time 10 70 750 10 2 5 
10 70 750 10 2 10 
10 70 750 10 2 15 
Parameter values selected are highlighted in yellow.  
Parameters optimised: Pre-incubation (Pre-inc.) time; Incubation (Inc.) Incubation (Inc.) 
speed; Extraction (Extrac.) time; Desorption (Desorp.) time; Bakeout time.   
Sample: Test sample spiked with 10 µL of phenol-d6. 
  
169 
 
Extraction time 
The first step in the optimisation was to optimise the extraction time of the sample by the 
SPME fibre.  If the fibre wasn’t inserted into the headspace for long enough, the IS peak 
would not be as large and it would make determining the results from subsequent 
experiments more difficult.  The Test sample was analysed with extraction times of 3, 5, 10 
and 15 minutes.  As shown in Figure 3.3, the response increased up to 10 minutes from 
where it levelled off, therefore ten minutes was chosen as the optimal value.   
 
Figure 3.3: Optimisation of analyte extraction time from Test samples 
Desorption time 
The next step was to optimise the desorption time of the fibre in the GC inlet.  Desorption 
times of 1, 2, 3 and 5 minutes were used.  The initial oven temperature hold time and inlet 
splitless time parameters are related to the desorption time and to get the best results these 
both need to match the desorption time, as illustrated in Table 3-10.   
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Table 3-10: Values used in the optimisation of the desorption time 
Desorption time 
(min) 
Oven initial temperature hold 
time (min) 
Splitless (split open) time 
(min) 
1 1 1 
2 2 2 
3 3 3 
5 5 5 
As can be seen in Figure 3.4, the response rapidly increased from 1 to 2 minutes and then 
started to plateau, therefore two minutes was selected for the next series of experiments.   
 
Figure 3.4: Optimisation of fibre desorption time from Test samples 
Sample pre-incubation  
An increase in the sample temperature reduces the solubility of analytes in the matrix and 
by agitating the sample equilibration can be reached faster.  When the fibre is inserted into 
the sample vial the agitation speed must be low, as the fibre is quite delicate and fast agitation 
is more likely to break the SPME fibre.  Also, as the fibre extracts analytes from the 
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headspace in this method, fast agitation speeds risk the fibre becoming exposed to liquid 
sample.  The instrument default agitation speed of 100 rpm was used when extracting the 
sample with the fibre in the vial; however, at this speed reaching an equilibrium between the 
sample and the headspace, and the headspace and the fibre would take a long time.  It is 
preferably to pre-incubate the sample, heating it for a fixed time at a faster speed to reach 
equilibrium, before the fibre is inserted for extraction, thus reducing the total duty cycle for 
the analysis.   
Incubation (agitation) speed 
Next, the incubation speed was optimised.  The pilot studies used an incubation speed of 500 
rpm; however, the agitator can go up to a maximum of 750 rpm.  Ideally, when agitating, 
the sample shouldn’t touch the septum because artefacts could occur through extraction of 
the septum material.  Although, the impact depends on the sample and the septum type.  A 
test was run by placing a piece of paper inside the cap with the Test sample and agitating at 
750 rpm, without heating, for a couple of minutes.  On removal, the paper was not wet and 
therefore it was concluded that the volume of sample, even with matrix modification 
reagents, did not touch the vial septum.  The Test sample was then extracted with agitation 
speeds of 500 rpm and 750 rpm.  As shown in Figure 3.5, a larger response was achieved at 
750 rpm.  An incubation speed of 750 rpm was therefore selected. 
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Figure 3.5: Optimisation of incubation speed from Test samples 
Pre-incubation time and temperature 
The next step was to optimise the pre-incubation time and temperature.  These are dependent 
on each other, therefore for each incubation temperature of 50, 60 and 70 °C samples were 
pre-incubated for 5, 10 or 15 minutes.  As shown in Figure 3.6, at both 50 and 60 °C a pre-
incubation time of 15 minutes gave the highest response.  At 70 °C the response plateaued 
at 10 minutes.   
Comparing each temperature with the optimal pre-incubation time, the pre-incubation time 
and temperature that gave the highest response was 10 minutes at 70 °C.  A pre-incubation 
temperature of 80 °C was not considered in this experiment.  Previous experience with 
aqueous samples had indicated that at this temperature too much water vapour is present in 
the headspace and this interfered with the extraction. 
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Figure 3.6: Optimisation of pre-incubation time and temperature from Test samples 
Bakeout time 
The final experiment with the Test sample was to optimise the bakeout time.  Following Test 
sample extractions, using the optimised conditions above, the fibre was baked out for 5, 10 
or 15 minutes before a fibre blank was analysed.  As shown in Figure 3.7, the IS peak was 
seen after a 5 minutes bakeout (orange), but not after a 10 (green) or 15 (blue) minutes 
bakeout time.  Therefore, a 10 minute bakeout time was selected to minimise the overall 
cycle time while ensuring carryover was not likely. 
 
Figure 3.7: TICs of the fibre blanks from Test sample bakeout time optimisation  
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A summary of the method optimisation with the Test sample 
Optimisation, using the Test sample (IS spiked matrix blank), resulted in the parameter 
values summarised in Table 3-11.  
Table 3-11: Summary of optimised parameter values for the Test sample 
Parameter Optimised value 
Incubator speed 750 rpm 
Incubation temperature 70 °C 
Pre-incubation time 10 minutes 
Extraction time 10 minutes 
Desorption time 2 minutes 
Bakeout time 10 minutes 
These parameter values gave the best sensitivity for the matrix blank (DI) spiked with IS 
solution; however, matrix effects may also affect the extraction and desorption of analytes 
from urine samples.  The next step was to re-evaluate sub-sets of these parameters using 
urine samples rather than the matrix blank. 
3.3.3.3 Method optimisation using the C1 control sample 
More C1 control samples were obtained than other sample types.  Therefore, aliquots of two 
C1 control samples, called Reyba and Goutr, were selected for use in the optimisation of the 
method parameters using urine samples.  These urine samples were prepared as described in 
Section 2.2.4, by spiking them with 1 µL of the internal standard solution.  The optimised 
parameters from the Test sample experiments, as summarised in Table 3-11, were used as 
the starting point.  The phenol-d6 peak was used, as before, to quantify the change in 
response; however, the whole chromatogram was also used to evaluate the effect of the 
parameter values on the extraction of all volatile peaks appearing in the chromatogram, by 
overlaying their TICs.  The parameters optimised with the Reyba C1 control samples are 
summarised in Table 3-12. 
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Table 3-12: Summary of parameter optimisation: values used & chosen using the C1 control 
Reyba samples 
Parameter 
optimised 
Extraction 
time (min) 
Desorption 
time (min) 
Bakeout time 
(min) 
Oven initial 
hold time (min) 
Extraction time 5 2 10 2 
10 2 10 2 
15 2 10 2 
Bakeout time 12 2 5 2 
12 2 10 2 
12 2 15 2 
Desorption time 12 5 15 5 
12 3 15 3 
12 2 15 2 
Oven initial hold 
time 
12 3 15 2 
12 3 15 3 
Parameter values selected are highlighted in yellow.  
Extraction time 
The first parameter optimised was the extraction time, with C1 control samples analysed 
using extraction times of 5, 10 or 15 minutes.  Fibre blanks were analysed between each 
sample to check for carryover.  The response of the IS at each extraction time is shown in 
Figure 3.8. 
The response plateaued for 10 and 15 minutes, however there was steep rise in response from 
5 to 10 minutes.  From previous experience, a 10 minute extraction might be on the ‘cliff 
edge’ meaning that slight fluctuations in instrument stability could cause a large drop in 
response.  However, a 15 minute is 50 % longer, resulting in significantly longer SPME 
analysis time.  Therefore, an extraction time of twelve minutes was chosen, to be away from 
the ‘cliff edge’ whilst minimising extraction time.   
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Figure 3.8: Optimisation of extraction time using the C1 control Reyba samples  
Complex sample carryover 
The next part of the optimisation was to ensure there was no carryover from the most 
complex urine samples.  Although desorption of the fibre was optimised to transfer the 
analytes onto the GC column for most samples, the occasional very high concentration 
sample could cause carryover and reduce the sensitivity of extraction of the next sample.  
Use of the fibre conditioning station, which is held at a higher temperature than the GC inlet, 
reduces the likelihood of this.  
C1 Reyba control samples were extracted and analysed with post-desorption bakeout times 
of 5, 10 and 15 minutes.  As seen in Figure 3.9, a ten minute bakeout (green) still left very 
small traces of some analytes from a particularly dirty sample, whereas fifteen minutes (blue) 
did not.  Therefore, a fifteen minute bakeout time was selected, which didn’t affect the 
overall GC cycle time (GC run time plus oven cool-down time). 
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Figure 3.9: TICs of the fibre blanks from Reyba C1 control sample bakeout time optimisation  
Desorption time 
Once all the analytes of interest are extracted with the fibre, it is important to ensure it is 
fully desorbed and that all the analytes are transferred onto the GC column for separation 
and detection.  C1 Reyba control samples were analysed with desorption times of 2, 3 and 5 
minutes and the equivalent increases in oven initial hold time and inlet splitless time.   
As shown in Figure 3.10, more peaks were visible with a desorption period of three (green) 
rather than two (orange) minutes; however, increasing to five minutes did not produce any 
increase in peak sensitivity, but at the front of the chromatogram the peaks were broader. 
This broadening was most likely caused by longitudinal diffusion and migration of the more 
volatile analytes due to the long initial hold time.  Therefore, a desorption time of three 
minutes was selected, with a matching inlet split open time of three minutes. 
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Figure 3.10: TICs of the C1 Reyba control samples from the desorption time optimisation 
GC oven initial temperature hold time 
Usually, the oven initial hold time will be the same length of time as the splitless time.    
During the splitless period analytes are being transferred onto the GC column and if this is 
increasing in temperature the transferred analyte molecules, especially those that take longer 
to vapourise and transfer such as semi-volatile analytes, will not condense in the same place.  
This results in band broadening of those analyse at the front end of the column before they’ve 
started to be separate.   
Due to the band broadening seen in the earlier experiment, the chromatograms produced 
from an initial oven temperature time of two or three minutes were compared and for three 
minutes the mid-later eluting peaks were no narrower than for two minutes, but the early 
eluting peaks were slightly broader.  Therefore, an oven initial hold time of two minutes was 
chosen. 
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Summary of optimisation with the C1 Reyba control sample 
A summary of the parameters optimised using the C1 Reyba control sample and used in 
subsequent analyses is given in Table 3-13. 
Table 3-13: Summary of optimised parameter values for the C1 Reyba control sample 
Parameter Optimised value (minutes) 
Extraction time 12 
Desorption time 3 
Bakeout time 15 
GC inlet split open time 3 
Oven initial hold time 2 
3.3.3.4 Selection of SPME fibre type 
Previous method development and experience, prior to my PhD, had determined that the 
CAR/PDMS was the SPME fibre that extracted the largest range of volatilities and polarities 
from aqueous samples that could be seen using this analytical column.  However, as will be 
discussed in Section 3.3.4.1, a change in the analytical column manufacturer enabled the 
maximum oven and the inlet temperatures to be raised, enabling the separation and detection 
of less volatile analytes.  Therefore, it was decided to compare the range of analytes that 
could be extracted with three different fibres, using the conditions that had been optimised 
up until this point, but with the new Restek Rxi-624Sil column. The new column enabled 
the final oven temperature to be increased to 300 °C (rather than 240 °C); where it was held 
for 0 minutes (rather than 2.5 minutes); making a total run time of 15.5 minutes (rather than 
15 minutes).    
Before experimenting with different fibre types, the chemistries of the fibre coatings and the 
potential analytes were considered to determine the best three phases to try, as there are ten 
different SPME fibres commercially available.  A phase was required that could extract a 
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wide volatility range, a wide polarity range and extract analytes at trace levels.  All the 
commercially available SPME fibres were considered: 
• 75/85 µm Carboxen/Polydimethylsiloxane (CAR/PDMS) is an adsorption type fibre, 
which is better for trace-level analysis and good for the adsorption of volatiles with 
a MW 30-225 u.  This was selected as the first choice of fibre and is what had been 
used in previous studies. 
• 30 or 7 µm Polydimethylsiloxane (PDMS) are good for non-polar semi-volatile 
analytes (Sigma-Aldrich, 2009), but a thicker coating can be used to trap any volatile 
analytes, therefore a 100 µm PDMS coating was selected to extract volatile analytes 
with a molecular weight (MW) between 60-275 u 
• 60 µm Carbowax (CW) and 85 µm Polyacrylate (PA) are good for extracting polar 
analytes such as alcohols with a MW of 40-275 u and 80-300 u.  However, since the 
extraction of a wide range of polarities was required, these fibres were considered 
but were not tried. 
• 65 µm Polydimethylsiloxane/Divinylbenzene (PDMS/DVB) is good for the analysis 
of polar volatiles, amines and nitro-aromatic compounds with a MW 50-300 u.   
• 50/30 µm Divinylbenzene/Carboxen on Polydimethylsiloxane (DVB/CAR/PDMS) 
is good for the analysis of flavour compounds with a MW of 40-275 u.  
The three fibres selected for comparison were: 
• 75/85 µm CAR/PDMS 
• 100 µm PDMS 
• 65 µm PDMS/DVB 
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For each fibre, the first step was their conditioning in the fibre conditioning station.  The 
PDMS/DVB and PDMS fibres were conditioned at 250 °C for 30 minutes and the 
CAR/PDMS at 300 °C for 1 hour (SUPELCO, 1999).   
The inlet temperature previously had been limited to 230°C, by the maximum isothermal 
temperature of the analytical column.  As the fibre optimisation was carried out after the 
analytical column was changed from the SGE column to the Restek column, the GC inlet 
temperature could be increased to the optimal desorption temperatures for the different 
fibres.  They each had different maximum and recommended desorption temperatures of 270 
°C (PDMS/DVB), 280 °C (PDMS) and 310 °C (CAR/PDMS), respectively.  The maximum 
isothermal temperature for the new column was 300 °C and to minimise bleed, a final oven 
temperature of 300°C had been chosen.  The inlet temperature should be below the final 
oven temperature, to ensure that any higher MW analytes desorbed onto the column can 
easily be eluted.  Therefore, an inlet temperature of 280 °C was used for the CAR/PDMS 
fibre and the PDMS fibre and a slightly lower temperature of 270 °C for the PDMS/DVB.  
A summary of the fibres can be seen in Table 3-14.   
After conditioning, each fibre was analysed twice, except for the PDMS/PVB that was 
desorbed thrice, as it had higher bleed.  No sample was extracted.  The last fibre blank for 
each SPME fibre was overlaid and is shown in Figure 3.11.   
Table 3-14: Summary of the SPME fibre types and parameters 
Parameter 
optimised 
SPME fibre 
type 
Conditioning 
temperature 
(°C) 
Conditioning 
time          
(min) 
GC inlet 
temperature 
(°C) 
Fibre type: 
PDMS/DVB 
PDMS/DVB 250 30 270 
Fibre type: 
PDMS 
PDMS 250 30 280 
Fibre type: 
CAR/PDMS 
CAR/PDMS 300 60 280 
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Figure 3.11: Overlaid TICs of the fibre blanks for the three SPME fibres 
The chromatograms were used to compare each fibre for artefacts and background noise 
levels, which add extra peaks to the chromatogram and reduce the method sensitivity, 
therefore a fibre with a low bleed and background was preferred.  As shown in Figure 3.11, 
the PDMS/DVB fibre showed by far the highest background signal throughout the 
chromatogram, even after three desorptions, compared to two desorptions for the other two 
fibres.  The CAR/PDMS had fewer artefact peaks and they were present at much lower levels 
than the PDMS/DVB.  The PDMS fibre had artefact peaks present at lower concentrations 
than the CAR/PDMS, but there were a few more of them.  From this experiment, the 
PDMS/DVB was the worst performing fibre. 
Next, each fibre was used to analyse a blank, this was a prepared vial with matrix modifiers, 
but the urine sample was replaced by an equivalent volume of DI water and no IS solution 
was added.  The chromatograms were compared between fibres and with the fibre’s fibre 
blanks to check for further artefacts that could be caused by the matrix modifiers and water 
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vapour.  The chromatograms from the analysis of these matrix blanks (with no IS solution), 
for each of the three different fibres are overlaid in Figure 3.12. 
 
Figure 3.12: Overlaid chromatograms of blanks (with no IS added) for the SPME fibres 
The source of the additional peaks was tricky to determine, as additional peaks could have 
been additional fibre artefacts or the fibre being very sensitive and picking up traces from 
the matrix blank.  The known artefacts from the fibre blanks were compared to see if they 
were larger in the matrix blank.  Although the peaks seen in the fibre blanks, for example 
the two peaks between 425-450 seconds, were present in the matrix blank, they appeared to 
be comparable in size.  Some peaks, for example the peak at 900 seconds in the PDMS/DVB 
fibre blank was much smaller in the matrix blank, this could be because repeated desorptions 
had reduced the bleed.   
Comparing the chromatograms in Figure 3.12, the PDMS/DVB extracted analytes around 
the middle of the chromatogram, mostly from 550-860 seconds.  This fibre also gave the 
largest peaks between 700-800 seconds.  The PDMS fibre mainly extracted analytes that 
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eluted later in the chromatogram from 740-1020 s, overall this fibre produced the smallest 
peaks of the three.  The CAR/PDMS extracted the most volatile analytes, producing large 
peaks, with most peaks eluting between 200-800 seconds.  This fibre seemed to extract the 
largest range of volatilities, although it didn’t give large peaks for analytes eluting after 800 
seconds compared to the PDMS fibre.  If it was impurities in the matrix blank that were 
being extracted, then the CAR/PDMS or PDMS/DVB fibre were better. 
Finally, each fibre was used to analyse two aliquots of a clinical control sample, labelled 
Goutr.  These duplicates for each fibre were compared against each other for reproducibility 
(there were a limited number of replicate samples from each patient and therefore further 
replicates could not be analysed).  The overlaid replicates for PDMS/DVB is shown in Figure 
3.13; PDMS in Figure 3.14 and CAR/PDMS in Figure 3.15.  
The overall reproducibility was good for all fibres, with all analytes extracted in both 
replicates.  There were some slight variations in response for some peaks for each fibre, but 
these didn’t show a significant trend. 
As seen before with the matrix blanks, CAR/PDMS appeared to extract the more volatile 
analytes more effectively, with higher responses than the other two fibres.  The PDMS/DVB 
did not extract many volatile peaks, with the majority eluting between 500-800 s.  The profile 
of peaks between 500-800 s was very similar for all three fibres, this could be because all 
contained PDMS.  However, this is more difficult to see for the CAR/PDMS replicate 
overlays, because the scale is very different.   
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Figure 3.13: TICs from the PDMS/DVB fibre analysis of a C1 Goutr control  
 
Figure 3.14: TICs from the PDMS fibre analysis of a C1 Goutr control 
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Figure 3.15: TICs from the CAR/PDMS fibre analysis of a C1 Goutr control 
The maximum response for an analyte extracted with the PDMS/DVB fibre was just over 
8x10-7; PDMS just over 1x10-7; and for CAR/PDMS 1.4x10-8(all measured in arbitrary 
units).  This variation in response is more easily seen in the overlays of the first replicate for 
each fibre, as shown in Figure 3.16. 
 
Figure 3.16: TICs of the e analysis of C1 Goutr control samples using different SPME fibres 
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Summary 
To summarise, the PDMS was good for analysing non-polar analytes but gave very poor 
sensitivity for other, more polar analytes, especially the more volatile components of the 
sample.  PDMS/DVB gave good sensitivity for analytes with a wide range of polarities, 
however it gave a high amount of fibre bleed and could only analyse a limited volatility 
range.  The CAR/PDMS fibre, used in the previous study, extracted analytes with a wide 
range of volatilities and polarities but also had a high maximum temperature of 310 °C 
making it more stable and less prone to bleed, resulting in a lower background and making 
it more suitable for longer use. Therefore, it was decided to continue with the Car/PDMS 
fibre as determined in previous studies. 
3.3.4 Development of the HS-SPME-GC-TOFMS method 
3.3.4.1 GC analytical column and oven temperature program   
Initial studies had suggested that the SGE BP 624 (30 m x 0.25 mm x 1.4 µm film) gave 
good separation of the analytes indicating that the stationary phase type selected was correct 
for the proposed method.  However, the column maximum temperature of 240 °C was being 
reached and held to elute all analytes extracted with the SPME fibre.  This resulted in a high 
amount of column bleed at the end of the analysis and the temperature hold meant that any 
less volatile analyte peaks broadened, reducing their sensitivity. After the method 
development phase and first study of 4 batches of samples, but before the large study of 22 
batches of samples, the column had deteriorated significantly and was causing excessive 
bleed.  An alternative manufacturer of the same column phase and dimensions was 
identified.  A column was purchased from Thames Restek (Saunderton, Buckinghamshire, 
UK) and evaluated.  With a maximum temperature of 320 °C, this enabled the column 
temperature to be ramped to elute all the analytes desorbed by the fibre before the final 
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temperature was reached.  This minimises the band broadening of peaks towards the end of 
the run and ensures maximum sensitivity, if there isn’t excessive column bleed.   
The bleed profile of the two columns, when new and after conditioning were compared and 
it was found that the Restek column had lower bleed even though it was being heated to a 
higher final oven temperature.  After being used for the analysis of 22 batches of samples 
for the bladder and prostate cancer projects, the Restek column was still found to have low 
bleed.  It was then used for the hepatic disorders project and is still in use today for relevant 
projects. 
With optimisation, a final column temperature of 300 °C was selected with no final hold, 
which ensured that all extracted and desorbed analytes were separated and detected.  No 
sample analyte peaks were seen above this temperature and this allowed the column to be 
kept at a temperature that minimised column bleed.  The analysis of fibre blanks on the SGE 
(orange) and Restek (green) columns is shown in Figure 3.17.  Even though the Restek 
column final oven temperature was higher temperature, there was still significantly lower 
bleed than the previous column used.  The final run time was 15.5 minutes.  
 
Figure 3.17: Comparison of column bleed between the SGE and Restek columns  
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3.3.4.2 GC inlet temperature 
The GC inlet and MS transfer line temperatures are limited by the maximum temperature of 
the stationary phase, as the column passes into them and the temperature is held constant.  
The maximum isothermal temperature of the SGE column was 230 °C which meant that the 
GC inlet temperature could not be raised to the optimal desorption temperature for the SPME 
fibre chosen.  Ideally, the SPME fibre should be desorbed as quickly as possible and all 
analytes that had been extracted from the sample with the fibre should be desorbed into the 
GC, with a volatility range that can then be eluted by the column.  The maximum temperature 
the CAR/PDMS SPME fibre could be desorbed at was 310 °C.  By changing to the Restek 
column, the maximum isothermal temperature was now 300 °C.  
The GC inlet temperature was optimised to fully desorb all the analytes extracted while 
keeping all temperatures at a minimum, to minimise both fibre and column bleed.  A value 
of 280 °C was chosen, as at higher temperatures there were no noticeable improvements to 
the number or size of the peaks detected.   
After changes to the inlet temperature were made, there was a final check of the optimal 
fibre desorption time.  This was kept at three minutes, with a splitless time of three minutes. 
3.3.4.2 Transfer line temperature 
With an increase in the final oven temperature from 240 °C to 300 °C it is important that the 
less volatile analytes eluting through the analytical column do not condense or slow their 
progress when passing through the transfer line into the MS, as band broadening will occur. 
As discussed in the previous section, the Restek column has a higher maximum isothermal 
temperature.  Subsequently, the transfer line temperature was increased from 220 °C to 280 
°C to ensure all analytes eluted into the ToFMS with minimal band-broadening.  
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3.4 HS-GC-MS and TD-GC-MS of Bacterial Samples 
3.4.1 Selection of the sampling technique and instrumentation 
The method of sampling from BACTECTM bottles was developed at The Open University 
using clean BD BACTECTM Lytic/10 Anaerobic/F and BD BACTECTM Plus + Aerobic/F 
bottles (Becton, Dickinson and Company (BD), New Jersey, USA), containing only the 
medium and no blood sample.  Due to the difficulty in obtaining samples, especially any 
replicates for the pilot study, the parameters were not optimised but were selected based on 
calculations and available information. 
Due to the nature of the samples, a sampling technique for the pilot project was required that 
could sample directly from the BACTECTM bottles that had been prepared and analysed 
using conventional methods for identification of the bacteria type, rather than taking a sub-
sample of this for analysis.  The BACTECTM bottles are too large to fit into the autosampler 
without modification, therefore a more manual technique was required.   
Manual headspace, SPME and TD sampling were the three techniques evaluated for volatiles 
analysis.  Manual SPME analysis can be more difficult, as the sample needs to be heated and 
shaken for a period with the SPME fibre inserted in the sample, before being retracted and 
inserted into the GC inlet.  Manual HS, in some ways is more simple, as the headspace can 
be removed and injected directly into the GC inlet; although, if the sample is at a higher 
temperature the syringe would need to be at a higher temperature to prevent condensation of 
less volatile analytes.  HS analysis would require the sample to be next to the instrument, 
whereas sampling with SPME fibres enables sampling in a remote location before being 
thermal desorbed in the GC inlet.   
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Due to the nature of the samples and the fact that the instrument was not in a fume hood, nor 
could a filter be employed to prevent sampling of bacteria directly onto the fibre, it was 
decided that SPME should not to be used for the pilot study.   
TD uses active sampling onto a tube, through a filter to prevent the sampling of bacteria into 
the tube.  Sampling can also be carried out at a remote location away from the instrument, 
as the TD tubes can be sealed and heat treated to sterilise any live bacteria, which could 
possibly have transferred to the tube during the sampling process.  Two different candidate 
sampling methods were developed, HS and TD. 
The Unity TD system was connected to an Agilent 7890-5975C GC-MS for the initial pilot 
project.  The Unity TD was evaluated with the addition of an ULTRA autosampler and these 
were then semi-permanently installed on an Agilent 6890-5973 GC-MS.  The Leco GC-
ToFMS was unavailable for the pilot project as it was being used for the urine projects. 
3.4.2 Development of the sampling methods  
3.4.2.1 HS analysis 
At the Open University (OU), the first method was developed using HS analysis.  The aims 
were to see if volatile analytes could successfully be removed and analysed by the technique 
and to see if there were any large interference peaks from the sampling technique or the 
BACTECTM bottle, such as plasticisers.   
Sampling method 
A 2.5 mL gas-tight HS syringe fitted with a 0.22 µm filter (Merck Millipore, Billerica, 
Massachusetts, USA), was used to withdraw 2.5 mL of the headspace from the blank 
BACTECTM bottle.  It was directly injected and analysed using the same method for HS-
GC-MS as described in Section 2.3.2.3.   The same column was used as at UCLH.  The only 
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difference was that the injections were made into the injection port of an Agilent 7890-
5975C GC-MS instead of a Shimadzu QP2010 GC-MS.   
Analysis of blank BACTECTM bottles 
Comparisons were made between sampling the headspace in the BACTECTM bottle and the 
laboratory air.  As is shown in Figure 3.18, there is a clear difference with more peaks from 
the BACTECTM bottle headspace (blue), but fortunately there are no large interfering peaks.  
This result meant that we were successfully removing VOCs from the BACTECTM bottle 
with both the bottle and the syringe at ambient temperatures.   
 
Figure 3.18: TICs of the HS sampling of laboratory air vs. BACTEC bottle 
Microbial filter contamination check 
Comparisons were also made between sampling the laboratory air with and without a 
microbial filter to check for contaminants such as phthalates, from the filter.  The m/z 149 
ion, the common fragment ion for phthalates, was extracted from the chromatogram (an EIC) 
to look for these contaminants.  As can be seen in Figure 3.19, none were visible.   
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Figure 3.19: EIC m/z 149 of HS sampling of laboratory air with & without a microbial filter  
The key ions for hydrocarbons, m/z 43 (black) and 57 (blue), were also extracted.  As can 
be seen in Figure 3.20 some hydrocarbons were present, as expected, but not in large, 
problematic amounts.  Also, not all peaks are hydrocarbons, for example the peak at 6.6 
minutes is acetone from the laboratory air. 
 
Figure 3.20: EIC m/z 43 u for the HS analysis of laboratory air with microbial filter 
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3.4.2.2 TD analysis 
Sorbent selection 
The second method involved concentrating a sample using a TD tube packed with a sorbent.  
The sorbent was selected by considering the volatility and polarity of the analytes and the 
nature of the matrix.  Blood contains water and on heating of the sample to 37 °C, the 
incubation temperature of the bacterial samples, would cause a humid environment.  
Therefore, the best sorbent type would be hydrophobic.  We had no idea what the volatility 
range of the analytes present would be, at 37 °C they would be volatile to semi-volatile 
compounds and therefore would require more than one sorbent.  Analytes could have a range 
of polarities, with likely compound classes being more polar species such as acids, 
aldehydes, ketones, etc. (Schulz & Dickschat, 2007).  The main two options for sorbents, 
were Tenax® TA/Unicarb or Tenax® TA/Carbograph 5TD.   
Unicarb is a carbonised molecular sieve that has been subsequently replaced by Sulficarb, it 
is good at trapping light VOCs from C3-C8 with boiling points of -30 to 150 °C and sulphur 
species as it is inert.  It is a stronger sorbent than Carbograph 5TD, giving better 
breakthrough volumes, but it also absorbs water as it is slightly hydrophilic.  Carbograph 
5TD is a medium-strong sorbent, suitable for the light hydrocarbon range of analytes from 
C3/4-C8 with boiling points of 50 to 150 °C, but is also good for trace-level applications as it 
gives minimum artefacts on heating and is hydrophobic.  However, it can have some activity 
with labile compounds.  Tenax® TA is a porous polymer that has a weak strength with low 
inherent artefacts.  It is inert and is hydrophobic and it is good for trapping and releasing 
analytes from C6-C26 with boiling points from 100 to 450 °C (Markes International Ltd., 
2012).  After considering the possible analytes and matrix and with advice from the 
manufacturer (Markes International Ltd., Pontyclun, Wales), for the preliminary studies a 
dual-sorbent TD tube was selected.  This contained Tenax® TA with a mesh size of 35/60 to 
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ensure small particles of Tenax® didn’t leak through the retaining gauze at the 
sampling/desorption end of the TD tube, and Carbograph 5TD with a mesh size of 40/60 
sorbents were selected.  The sorbents were held in stainless steel TD tubes.  These were 
originally purchased as pre-conditioned tubes from the manufacturer, due to the urgency of 
the project at the time and the fact that no autosampler was available for automated 
conditioning.  After use, the tubes were re-conditioned ready for re-use by following the 
manufacturer’s recommendations. 
Sampling system set-up 
In the OU laboratory, various ways were tried to successfully connect the pump to the TD 
tube and then the sampling end of the TD tube to the syringe, via a filter, without any 
leakages occurring.  Medical grade tubing was used between the needle and the TD tube, as 
this produces low artefacts and should be inert.  The final set-up, as shown in Figure 2.2, 
included the pump connected to the TD tube using low flow tubing, as only small volumes 
of headspace would be collected, unlike other TD applications where litres of gas-phase 
samples are frequently collected.  The sampling end of the TD tube was then connected to a 
disposable filter system using a short length of medical grade tubing which was connected 
to the disposable needle.  The needle was then inserted into the BACTECTM bottle.   
Selection of sampling parameters 
After incubation of the BACTECTM bottle there would be a high concentration of volatiles 
in headspace above the medium, therefore it was decided to extract these under static HS 
conditions but drawing out the headspace through the TD tube using the pump, to ensure no 
volatiles were lost to the atmosphere.  Once the pump was drawing out the headspace, a 
second needle could be inserted to replace the air being withdrawn from the bottle and 
therefore now the sampling would be dynamic HS, where volatile analytes emerging from 
the sample would immediately be swept away to the TD tube.  The volume of the 
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BACTECTM bottle is 80 mL.  It is filled with 30 mL of aerobic bacteria growing medium or 
40 mL of anaerobic bacteria growing medium.  With a maximum sample of 10 mL, this 
leaves 30-40 mL of headspace, depending on the type of bottle.   
This is a small volume for TD sampling and sampling is through a narrow i.d. needle.  
Usually, the optimal sampling rate through a standard 5 mm i.d. packed TD tube is 50 
mL/min, with a working range of 10-200 mL/min for sample volumes of 500 mL and higher.  
The minimum flow for trapping is 10 mL/min, therefore a flow rate of 20 mL/min was 
selected, to allow for any variation in pump flow, sampling set-up, etc.  The amount of time 
sampling under static flow conditions needs to exceed the time taken to remove the volume 
of headspace, again to account for any variability.  40 mL of headspace sampled at 20 
mL/min would take 2 minutes to evacuate, therefore a time of 10 minutes was selected, for 
both the static HS and then the dynamic HS sampling.  These values were not optimised for 
the pilot study, but were on the list for optimisation for the full study.  This method was then 
applied to check that volatiles were extracted from the blank BACTECTM bottles. 
Analysis of blank BACTECTM bottles 
As shown in Figure 3.21, comparisons were made between sampling the headspace in the 
BACTECTM bottle (black) and the laboratory air (blue).  A clear difference can be seen with 
more peaks present than in the headspace method and some different peaks which were 
identified as TD tube artefacts, by comparison with a conditioned TD tube that had not been 
exposed to samples.     
The TD method was, as expected, more sensitive than the HS method for concentrating 
peaks from the BACTECTM bottle.   
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Figure 3.21: TICs of the TD sampling of laboratory air vs. BACTEC bottle 
Tubing and microbial filter contamination check 
Comparisons were also made between sampling the laboratory air with and without the 
tubing and microbial filter, to check for contaminants such as phthalates, etc. from the tubing 
and filter.  No ions of m/z 149 u were seen, the EICs for m/z 43 and 57 u are shown in Figure 
3.22 .  Some small hydrocarbon peaks were seen, but again these peaks from the tubing and 
filter were minimal. 
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Figure 3.22: EICs m/z 43 and 57 u for the TD analysis of laboratory air with the microbial 
filter 
3.4.3 Development of the HS-GC-MS analysis method 
The HS-GC-MS method needed to have a fast analysis time, as we only had access to the 
Biochemistry Department GC-MS instrument for 1 day, which had to include the HS and 
TD sampling methods too. 
3.4.3.1 HS-GC-MS column selection 
The standard 624 column phase for VOCs analysis was chosen again.  A spare SGE BP624 
column (30 m x 0.25 mm i.d. x 1.4 µm) from the urine sample work was sent down in 
advance for installation into the Shimadzu GC-MS at UCLH.   
3.4.3.2 HS-GC-MS method development 
A fast method was developed at the OU for the analyses at the same time as the sampling 
method was developed.   
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Ion  43.00 (42.70 to 43.70): TD_LabAir2.D\data.ms
Ion  57.00 (56.70 to 57.70): TD_LabAir2.D\data.ms
199 
 
GC inlet mode and parameters 
HS analyses uses a split injection to transfer the volatile analytes very quickly onto the 
analytical column for separation.  The higher the split ratio, the faster the transfer but also 
more of the sample goes to waste and therefore sensitivity drops.  A split ratio of 10:1 was 
selected as a compromise but this could not be tested at The OU as there were no ‘real’ 
samples.  During the sample analysis at UCLH, the sensitivity of the first sample analysed 
was low and so the split ratio was reduced to 5:1 to help improve the sensitivity of the 
method, through an increase in the sample transferred on to the column. 
GC oven temperature program 
With split injections, the transfer to the column is very fast and therefore the focusing of the 
more volatile analytes on the front end of the column is less necessary.  An initial oven 
temperature of 50 °C with a hold time of 0.5 minutes was long enough to give more than 
two flushes of the liner volume and to separate the more volatile analytes on the column, 
while minimising the run time and the oven cool-down time.  A ramp rate of 15 °C was a 
compromise between getting a good separation of the analytes while minimising the run 
time, this value was selected based on previous experience.  The maximum ramping 
temperature of the SGE BP624 column is 240 °C and therefore during the run, the oven 
temperature was ramped to 240 °C and held for 1 minute. 
A column flow of 1 mL/min in helium was selected to give an average velocity of around 
36 cm/s, the optimal velocity range for helium is 20-40 cm/s and therefore 36 cm/s would 
still give a good resolution while minimising run time.  On inputting this method into the 
Shimadzu instrument, the software preferred 0.98 mL/min calculating the pressure to be at 
54.7 kPa. 
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MS transfer line (interface) temperature 
The GC-MS interface temperature was selected as 220 °C to give minimal bleed into the 
MS, while not allowing condensation of the analytes while moving through the transfer line.  
MS method 
The low mass of m/z 33 u was selected to be as low as possible to see more ions in the mass 
spectra of the more volatile analytes, while avoiding acquiring the oxygen molecular ion at 
m/z 32 u and nitrogen molecular ion at m/z 28 u.  Both of which are abundant when analysing 
samples that can contain air (as these were used BACTECTM bottles).  Their exclusion avoids 
saturating the MS and causing noisier baselines.  Also, a solvent delay of 0 was selected, due 
to the lack of a solvent peak, the scan range starting higher than the sample matrix (air) and 
to ensure no very volatile analytes were missed with the higher initial oven temperature.  A 
high mass of 300 u was selected, as this was believed to be the maximum MW of analytes 
sampled by HS analysis.  Dr John Honour, the operator of the Shimadzu GC-MS, 
recommended an ion source temperature of 220 °C, a threshold value of 10 and event time 
of 0.25 s for the mass range acquired and for the chromatographic peak widths of the analytes 
as seen during the method development at the OU laboratory.  
HS injection volume 
A maximum of 2.5 mL of headspace was injected, as this was the maximum volume of the 
HS syringe and a larger headspace injection volume would also increase the volume of water 
vapour injected into the GC, that could cause interferences with the separation of the 
analytes. 
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3.4.4 Development of the TD-GC-MS analysis method 
The analysis of volatile analytes by TD-GC-MS is a common application.  The GC-MS 
separation suffers little from matrix effects, if the TD tube sorbent is carefully selected for 
the application and the amount of sample transferred to the GC column is optimal.  
Therefore, matrix effects affecting retention time reproducibility should be relatively low.  
Alignment of the GC-MS traces is one of the first steps in chemometric analyses and is 
important for detecting differences between the samples.  Therefore, reproducible retention 
times can minimise the effort required and make the alignment easier. 
3.4.4.1 Retention Time Locked (RTL) method and database 
RTL 
The TD-GC-MS analyses were performed on a Markes International TD system, hyphenated 
to an Agilent GC-MS system.  The accuracy of the EPC pressure control, in psi, is 2 decimal 
places on the older 6890N GCs and 3 decimal places on the newer Agilent 7890 GC.   
One of the key features of the Agilent acquisition software is the ability to retention time 
lock (RTL) the method to one analyte (RTL compound), preferably eluting around the 
middle of the chromatogram.  The method is then always locked to that analyte eluting at 
that retention time enabling all the other analytes to have the same retention times from run-
to-run, batch-to-batch, instrument-to-instrument and after maintenance by relocking the 
method.  The method is retention time locked by acquiring five runs in constant pressure 
mode, which is more accurate than constant flow mode as flow is a calculated value whereas 
pressure is absolute.  In each run the pressure is changed and an analysis is performed of a 
conditioned TD tube, spiked with the RTL compound using the spiking rig.  This results in 
the generation of a 5-point calibration of the retention time of the RTL compound versus 
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pressure.  From that, the software can then calculate the pressure required to enable the 
locking compound to elute at the locked retention time.   
RTL library 
Agilent has developed multiple libraries for different industries using a locked method and 
therefore the retention times of the compounds along with the mass spectrum can be used 
for the identification of target analytes in screening and quantitative analyses.  This is 
particularly useful when analysing suites of compounds containing isomers, that have the 
same mass spectra and therefore the exact isomer must be identified by its retention time. 
A locked method and library for use with TD-GC-MS is the indoor air toxics retention time 
locked library (IARTL) (Wylie, et al., 5989-5435EN) containing 171 compounds.  This RTL 
database was available for use on the TD-GC-MS instrument used for the bacteria samples.  
The library was designed for the analysis of indoor air toxic volatiles, however many of the 
analytes present are common VOCs and I have used it for many applications during my 
work.   
RTL compound 
The method is retention time locked to toluene-d8 or toluene.  I chose toluene as this was 
available in the laboratory.  The method was locked to toluene at 12.468 minutes.  This 
means that the remaining 170 compounds in the IARTL library will then elute at the retention 
times suggested in the library, if the same analytical column and analysis parameters are 
used.   
3.4.4.2 TD-GC-MS method 
As the IARTL method was being followed, the GC separation and MS detection parameters 
were taken from this and therefore did not require optimisation.  These parameters are 
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specified in Section 2.3.3.4.  This includes the DB-VRX column that is a manufacturer 
specific modified version of a 624 column for VOC analysis.   
Many parameters were taken from the TD method, however the IARTL method uses a TD 
tube packed with Tenax® TA only, whereas the best sorbents for this application were 
determined to be Tenax® TA/Carbograph 5TD.  
Optimisation of the TD method 
The Tenax® TA/Carbograph 5TD sorbent combination has a maximum desorption 
temperature of 350 °C and a maximum recommended temperature of 320 °C (Markes 
International Ltd., 2014).  Lower desorption temperatures reduce artefacts and extend 
sorbent lifetime.   
For the method, a TD tube desorption temperature of 300 °C was set and held for 10 minutes 
to ensure the tube was fully desorbed onto the cold trap, while minimising the temperature.  
The cold trap desorption split ratio was a comprise between ensuring a rapid transfer to the 
analytical column to obtain narrow sample bands and therefore sharp peaks and a large 
proportion of the sample going to waste and reducing sensitivity.  An optimal 15:1 to 20:1 
split ratio should ensure good sensitivity and fast transfer through the long transfer line from 
the TD instrument to the column, however on the Unity the flows are set using a flow meter 
and needle valves and therefore it is easier to set the cold trap desorption split flow at a 
rounded up or down number to ensure reproducible set-up batch-to-batch.  The split flow 
was set at 40 mL/min, resulting in an 18.6:1 split ratio.  
Summary of the TD-GC-MS RTL method 
The reasons for using this RTL method rather than developing a separate method based on 
the urine methods are that the RTL reduces data alignment in chemometric analysis.  This is 
especially useful if batches of samples were to be analysed periodically, with the analytical 
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instrument used for other applications with different set-ups in-between.  Also, if after 
chemometric analysis peaks were highlighted that could be potential biomarkers, these could 
quickly be identified if they were either already within the library, or they could be easily 
added to the library for subsequent routine screening and quantitation.  As this was a pilot 
study, using the RTL method saved lots of time rather than developing the GC-MS method.  
The RTL method had already been developed, optimised and proven for VOCs in TD-GC-
MS analysis using a single quadrupole MS.  The method I had developed for urine analysis 
by HS-SPME-GC-MS was using a ToFMS that has a higher acquisition rate then SQMS and 
therefore can detect narrower peaks and produce more data throughout a shorter run time.  
Therefore, the use of the urine method for this study was not applicable for the instruments 
used. 
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 Bladder Cancer Study 
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4.1 Introduction 
Dogs have been trained to recognise specific volatiles from the headspace above urine 
samples to detect bladder cancer (Willis, et al., 2004), but their use for routine clinical 
analysis is limited.  GC-MS is an analytical technique that is already used in hospital 
laboratories that is also good at separating and detecting volatile organic compounds 
(VOCs).  SPME is a technique that is good at extracting and concentrating VOCs for 
desorption into a GC-MS (Pawliszyn, 2011).   
Following on from the promising results of the preliminary trial described in Chapter 3, a 
much larger study of the samples was analysed by HS-SPME-GC-ToFMS using the 
optimised method described in Chapter 2.   
4.1.1 Participant selection 
Participants were recruited for both the bladder cancer and prostate cancer studies at the 
same time.  Patients presented with new or recurrent transitional cell carcinoma (TCC) of 
the bladder or prostate cancer at Buckinghamshire Healthcare NHS Trust.  The study was 
given favourable ethical opinion by the Mid and South Buckinghamshire Local Research 
Ethics Committee (04/Q1607/65) and all participants gave written informed consent.  
Participants completed a Case Report Form (CRF) providing considerable detail about their 
medical, personal and social histories to enable any medical or lifestyle factors to be taken 
into consideration that might influence the chemical composition of their urine.  
The co-ordination of taking, processing and storing the samples and patient details was 
undertaken by Dr Carolyn Willis and Mrs Lezlie Britton at Amersham Hospital.  Samples 
were taken in the Urology Department before any surgical or therapeutic intervention.  Urine 
cytology and biochemistry tests were conducted at Wycombe Hospital.  This process was 
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described in Section 2.2.2.  The data was then anonymised before information and samples 
were sent to The Open University for analysis. 
4.1.2 Bladder cancer and control sample types 
The samples for the bladder cancer study were divided into two classes, those with 
transitional cell carcinoma bladder cancer (TCC) and controls (C) with no bladder cancer.  
Each of the classes were sub-divided into categories.   
For the study, samples from all TCC participants were used.  Participants from each of the 
three control categories were randomly selected to match the total number of TCC 
participants, as advised by Cranfield University to reduce any bias in the data analysis. 
For all the samples analysed, I extracted the metadata by highlighting the range of values 
from each data type or highlighting those that tested positive for a feature.  A screenshot of 
the sex, age, smoking status and dipstick measurements for some of the TCC2 and TCC3 
participants can be seen in Figure 4.1.  A screenshot of the diagnosis and the medication 
taken up to 48 hours before the study sampling, for some of the C2 participants, can be seen 
in Figure 4.2.  A screenshot of the food and drink intake up to 48 hours before the study 
sampling for some of the C3 participants can be seen in Figure 4.3.  
Some of the participants had drunk alcohol within 24 hours, most had eaten cooked garlic, 
raw garlic, cooked onion, raw onion, brassicas, mustard, mint, fish, strong cheese or other 
strong food, for example ginger and spices.  A handful of participants across all classes had 
eaten asparagus, aniseed or liquorice in the previous 48 hours. 
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Figure 4.1: A snapshot of the metadata for TCC2 and TCC3 participants, showing sex, age, smoker and urinalysis results 
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Figure 4.2: A snapshot of the metadata for Control 2 participants, showing diagnosis and medication taken within 48 hours prior to study 
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Figure 4.3: A snapshot of the metadata for Control 3 participants, showing food and drink intake during 48 hours prior to study
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TCC samples were taken from patients with new or recurrent bladder cancer and included 
male and female patients aged over 18 years.  TCC samples can be divided into three 
categories by the stage of the cancer with TCC1 being early stage and TCC3 being late stage: 
• TCC1 – low grade or well differentiated transitional cell carcinoma.  These were 
male and female patients aged between 58-87; the majority were non-smokers.  
TCC1 patients had no positives on the urine dipstick test for glucose, bilirubin or 
nitrite; some had trace amounts of ketones and some tested positive for leucocytes; 
most tested positive for protein and/or blood; they had normal urobilinogen levels 
except for one patient; their urine ranged from pH 5-7; the majority were taking 
prescription medication; half were taking over the counter medication pain relief or 
indigestion; some were on vitamin or mineral supplements; no one had taken 
recreational drugs. 
• TCC2 – moderately differentiated transitional cell carcinoma.  These were male and 
female patients aged between 49-86; a mixture of smokers and non-smokers.  TCC2 
patients had no positives on the urine dipstick test for nitrite; some had trace amounts 
of ketones and some tested positive for glucose and/or leucocytes; most tested 
positive for protein and/or blood; one tested positive for bilirubin and two for high 
urobilinogen levels; their urine ranged from pH 5-7.5; the majority were taking 
prescription medication; most were not taking over the counter medication, a few 
had pain relief or indigestion medication; some were on vitamin or mineral 
supplements; no one had taken recreational drugs. 
• TCC 3 – high grade or poorly differentiated transitional cell carcinoma.  These were 
male and female patients aged between 49-91; a mixture of smokers and non-
smokers.  Some TCC3 patients had trace amounts of glucose and ketones in their 
urine; some tested positive for bilirubin and nitrite; the majority tested positive for 
leucocytes, protein and blood; two had high urobilinogen levels; their urine ranged 
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from pH 5-7.5; the majority were taking prescription medication; most were not 
taking over the counter medication but a few had pain relief medication; some were 
on vitamin or mineral supplements; no one had taken recreational drugs. 
For the control samples, it was important to include patients with inflammation, infection 
and necrosis that did not have bladder cancer, so that samples were classified purely based 
on the cancer volatiles rather than volatiles that were symptoms but not specifically 
attributed to the cancer.  The control samples for bladder cancer included male and female 
participants aged over 17 years who had a non-malignant urological disease or were healthy.  
The control (C) class was divided into three categories:   
• C1 – male and female healthy individuals aged between 18-34; a mixture of smokers 
and non-smokers.  C1 controls had no positives on the urine dipstick test for glucose, 
bilirubin, ketones, protein, nitrite; leucocytes were negative but there were a few with 
a trace and one with a moderate amount; they had normal urobilinogen levels; their 
urine ranged from pH 5-8; most were not taking prescription medication, but some 
were on asthma medication or contraceptives; most were not taking over the counter 
medication but some were on pain relief; some were on vitamin or mineral 
supplements; a few had taken recreational drugs. 
• C2 - male and female individuals aged between 17-31; a mixture of smokers and 
non-smokers. C2 controls had normal levels of urobilinogen; were negative for 
bilirubin; but their urine had produced a dipstick reading that was positive for 
glucose, ketones, leucocytes, nitrite and/or blood; or who had trace amounts of 
protein; their urine ranged from pH 5-8; many were not taking prescription 
medication the rest were on contraceptives or antibiotics; most were not taking over 
the counter medication but some were on pain relief; some on vitamin or mineral 
supplements; a few had taken recreational drugs. This category included any non-
cancerous condition or disease, including menstruating women, pregnancy, eczema, 
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irritable bowel syndrome, psoriasis, penile warts, thrush and those with suspected 
urinary tract infections.  
• C3 - male and female patients aged between 24-88; a mixture of smokers and non-
smokers.  Except for 2 patients, all C3 controls had normal levels of urobilinogen.  
Their urine had produced a dipstick reading that was positive for glucose, bilirubin, 
ketones, leucocytes, nitrite, protein and/or blood; their urine ranged from pH 5-8.5; 
most were taking prescription medication; most were not taking over the counter 
medication but some were on pain relief; some on vitamin or mineral supplements; 
a few had taken recreational drugs.  This category included patients with a confirmed 
non-cancerous urological disease including renal and ureteric stones, renal cysts, 
renal colic, urethral stricture, nephrectomy, polypoid, interstitial or catheter cystitis 
or stress incontinence and some were diabetic.   
Control participants over the age of 32 were required to have been screened with a recent 
cystoscopy to check that there were no visible signs of bladder cancer, otherwise they were 
excluded. 
For both control and TCC participants, men over the age over 50 were only included in the 
study if they had recently been checked for prostate cancer and received a negative result.  
Participants with current history of malignancy or pre-malignancy elsewhere in the body, a 
pre-malignant urological disease or a history of bladder cancer other than TCC were 
excluded from the study.  Participants who had suffered from a different cancer elsewhere 
in the body more than five years previously and were considered disease-free were included 
in the study.  Participants with mental incapacity or who had participated in another clinical 
trial during the study period and three weeks prior to inclusion were also excluded.   
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4.1.3 Participant urinalysis results  
Control 1 samples showed no urine abnormalities on dipstick.  However, C2, C3 and TCC 
categories did show urine abnormalities.  These urinalysis abnormalities can indicate a range 
of problems.  The presence of: 
• Blood could be caused by several disorders, including menstruation, trauma, 
infection, inflammation, infarction (blood supply obstruction), neoplasia (abnormal 
tissue growth).  Transient blood could also be due to recent strenuous physical 
activity. 
• Leucocytes and/or nitrites could indicate an infection, whereas blood, leucocytes, 
protein and nitrites could indicate a urinary tract infection. 
• Protein could be from a range of causes, including high urine concentration, the use 
of antibiotics, renal problems or recent sexual activity. 
• Glucose is usually caused by diabetes or certain drugs. 
• Ketones could be caused by diabetes, pregnancy, a high fat diet or starvation. 
• Bilirubin and/or high urobilinogen indicates various liver problems. 
The normal urine pH range is 5.5 – 6.5, but can vary from 4.5 – 8.5.  High pH (alkaline) can 
be caused by diet, certain drugs and several conditions, including: 
• A vegetarian diet which is rich in citrus fruits, most vegetables and legumes. 
• Urinary tract infections. 
• Pyloric (or gastric outlet) obstructions. 
• The use of certain prescription drugs that make the urine more alkaline to help 
prevent kidney stones. 
• Kidney failure. 
• Certain metabolic disorders. 
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Low pH (acidic) can be caused by diet and several conditions, including: 
• A high protein diet or certain fruits like meat and cranberries. 
• Certain metabolic disorders. 
• Diabetes. 
• Kidney stones. 
• Dehydration, starvation, diarrhoea or malabsorption. 
• Certain rare conditions. 
In the Control 1 group the urine pH ranged from 5 to 8.  All those participants with acidic 
urine of pH 5, were taking salbutamol or a similar prescription medicine.  Those participants 
with an alkaline urine of more than pH 6.5 had no other metadata that could explain the high 
pH, therefore this could be assumed to be due to diet. 
The other two control categories C2 and C3 both showed a similar trend, with pH ranging 
from 5 to 8 or 8.5, respectively.  Those with acidic pH had urinary tract infections, kidney 
problems or were taking prescription medicines.  Those with alkaline pH could not be 
explained by the metadata and so this was also assumed to be due to diet. 
The three TCC categories, showed a narrow range of pH, from 5 to 7.5.  Acidic pH can be 
explained as before.  The pH neutral urine samples showed no match to the metadata and 
therefore again was assumed to be diet related.   
The specific gravity measures the ability of the kidney to concentrate or dilute the urine.  It 
measures the amount of solute dissolved in urine and is compared to the density of water 
(1.000).  A normal range is 1.002 to 1.035 for adults, if kidney function is normal (Fischbach, 
2004). 
A low specific gravity can be caused by: 
• An inability to concentrate urine or excessive hydration. 
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• A range of conditions, including diabetes, renal diseases, kidney infections. 
• Alkaline urine. 
A high specific gravity can be caused by: 
• An inability to dilute urine or dehydration. 
• A range of conditions, including diabetes.  
• Protein in the urine. 
Across all the categories there was only one sample outside of the normal range.  This was 
a Control 1 participant with a specific gravity of 1.  This could be assumed to be a typo in 
the data or be caused by excessive hydration.  However, the sample was alkaline, at pH 7.5, 
with a moderate amount of leucocytes and blood.  This patient was excluded in the outlier 
removal. 
4.1.4 HS-SPME-GC-ToFMS study samples and analysis 
4.1.4.1 Samples used in the study 
A total of 86 bladder cancer samples and 219 control samples were analysed in triplicate, 
where the quantity of sample allowed.  Analyses were conducted in 22 batches, including 
fibre blanks, sample blanks and procedural blanks.  The samples were prepared and analysed 
using HS-GC-MS as described in Section 2.2.  The total number of participants and total 
number of samples analysed, including replicates for each category, along with the metadata 
is presented in Table 4-1 and Table 4-2.   
The data was processed using the methods described in Section 2.4.  In brief, a consistency 
test was initially performed on the data files to ensure that they had roughly the same number 
of scans.  Any files that had too few scans for alignment, were removed.  Generally, these 
data files were from samples that had failed to acquire on the GC-MS instrument.  This 
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consistency test was performed when importing the data files into the data analysis software.  
The total number of sample data files data processed beyond this step is shown in Table 4-1. 
Next, the data was standardised against the IS, phenol-d6, quantitation ion.  Exploratory 
PCA analysis was performed and outliers were removed.  Outlying samples were identified 
visually and statistically, leaving the total number of participants for each category as shown 
in Table 4-1.   
Table 4-1: TCC and Control participants used in the study, no age-matching 
 Category 
Number: C1 C2 C3 TCC1 TCC2 TCC3 
Participants 73 73 73 21 32 33 
Total samples analysed 218 212 208 53 90 83 
Males 26 13 26 15 21 20 
Females 47 60 47 6 11 13 
Smokers 23 17 25 2 11 6 
With blood detected 4     
(*) 
41       
(*-***) 
52     
(*-***) 
9      
(*-***) 
14       
(*-***) 
31     
(*-***) 
With glucose detected 0 2       
(**-***) 
3       
(*-***) 
0 3       
(**-***) 
1       
(*) 
With protein detected 3     
(*) 
17       
(*) 
25     
(*-***) 
8      
(*-***) 
11        
(*-***) 
22     
(*-**) 
With bilirubin detected 0 0 5       
(*) 
0 1         
(*) 
5       
(*-***) 
With high urobilinogen 0 0 2 1 2 2 
With nitrite detected 0 4        
(*-***) 
8       
(*) 
0 0 6       
(*-***) 
With leucocytes detected 3     
(*-**) 
31       
(*-***) 
36     
(*-***) 
3      
(*) 
5         
(*-**) 
24     
(*-***) 
With ketones detected 0 3        
(*) 
7       
(*) 
3      
(*) 
2         
(*) 
6       
(*-**) 
Total samples data 
processed  
210 204 195 53 84 80 
Participants after outlier 
removal 
70 71 64 17 28 27 
* = trace or small amount, ** = moderate amount, *** = large amount 
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The chromatographic peaks were aligned using COW.  Different types of scaling and feature 
selection were investigated.  Classification was performed using PLS-DA, SVM-LIN and 
RFs with cross-model validation through bootstrapping with LOO-CV and LFO-CV.  Each 
of these approaches were previously described in detail in Chapter 2. 
Generally, the control samples included a higher proportion of females to males, whereas 
the TCC samples had a higher proportion of males to females.  Most participants in each 
category were non-smokers.  The percentage of smokers in each category ranged from 9 to 
34 %. 
Table 4-2: Participants used in the study age, pH and specific gravity, no age-matching 
Category Age range (years) pH range Specific gravity range 
C1 18-34 5-8 1.005-1.030 
C2 17-31 5-8 1.005-1.030 
C3 23-88 5-8.5 1.005-1.030 
TCC1 58-87 5-7 1.005-1.030 
TCC2 49-86 5-7.5 1.005-1.030 
TCC3 49-91 5-7.5 1.005-1.030 
As shown in Table 4-2, C1 and C2 controls were all under the age of 35, as they were far 
less likely to have a urological disorder.  C3 controls with non-cancerous urological 
disorders had a much wider age range. 
It can also be seen that the pH range of the samples for each category was similar.  The most 
acidic pH for each category was pH 5, whereas the most basic samples ranged from pH 7 to 
8.5, with controls pH 8-8.5 and TCC samples pH 7-7.5.  The specific gravity for each 
category had the same range of 1.005-1.030. 
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4.1.4.2 Age-matched sample set 
A paper was submitted for publication about this work.  Following feedback from one 
reviewer, it was decided to reduce the C3 data set to only classify samples from participants 
in the C3 category within the same age range as the TCC class of samples.  Information on 
the age-matched data set (C3(AM)) used for pattern recognition is presented in Table 4-3 
and the results are discussed in Section 4.2.3.  The paper, utilising the age-matched C3(AM) 
data set, was subsequently accepted for publication in May 2016 (Cauchi, et al., 2016) by 
Analytical Methods.  This paper is in Appendix A. 
Table 4-3: Participants used in the age-matched data set 
Category: C1 C2 C3 TCC1 TCC2 TCC3 
No. of participants after 
age-matching 
70 71 46 17 28 27 
Age range (years) 18-34 17-31 50-88 58-87 49-86 49-91 
4.2 Results and Discussion 
The results and discussion section is divided into four sections: 
• The raw data that was processed using the Leco ChromaTOF software and was not 
processed by Cranfield University will be discussed in Section 4.2.1.  This data was 
used to assess the reproducibility of the analytical method across all 22 batches of 
samples and to evaluate the importance of using an IS.  Different types of blanks 
were also used to look for carryover within the analytical instrument and the sample 
preparation.  As both the bladder cancer study and prostate cancer study samples 
were analysed together, the results for both studies will be presented here, as they 
cannot be separated for certain tests.  Where possible, any data that could be 
separated for the prostate cancer samples, will be presented in Chapter 5. 
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• The results obtained by Cranfield University on the statistical analysis of the disease 
classification models, developed using the above analytical data, will be shown and 
discussed in Section 4.2.2.  This section will give the results from each step of the 
development of the data processing algorithms. 
• The statistical analysis results from the use of the age-matched C3 samples will be 
shown and discussed in Section 4.2.3. 
• Finally, the results from biomarker discovery by Cranfield University will be shown 
and discussed in Section 4.2.4. 
4.2.1 Robustness of HS-SPME-GC-TOFMS analysis method in 
the bladder and prostate cancer samples batches 
As previously determined by HS-SPME-GCxGC-MS, in the method development chapter, 
there are thousands of VOCs present in the headspace above urine.  The GC method was 
optimised to get the best resolution of all peaks seen.  However, as to which peaks are the 
most important ones is unknown, the calculation of the resolution of those peaks was not 
possible, as would be carried out in target analysis.  In this study, the analytes of clinical 
interest present in the samples are unknown; therefore, standards could not be prepared to 
check the linearity of the instrument for those analytes, their reproducibility nor their limits 
of detection.   
However, the quality control checks that could be carried out for this analysis method for 
‘unknowns’ included: making sure that the instrument operated reproducibly, with similar 
sensitivity between batches as well as across batches; checking that carryover was not 
present or was at a very low level that didn’t interfere with the next analysis; ensuring that 
any differences between samples was due to the characteristics of the sample rather than the 
analysis method.  In order to achieve this, an IS was used. 
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4.2.1.1 Internal standard use  
The purpose of the IS is to normalise the data to correct for error in the HS-SPME-GC-
TOFMS sample analysis, both run-to-run and batch-to-batch.  These errors could include 
variability in analyte extraction, desorption, separation, retention time or detector drift.  Any 
of these can result in shifts in retention time of the analyte and method sensitivity, causing 
increases or decreases in abundance that is not related to the clinical sample. 
As discussed in Chapter 3, the IS, phenol-d6, was chosen as it is not present in nature and 
therefore will only be detected after spiking of the sample or blank or is due to carryover 
from the previous sample.  Phenol is polar; therefore, the peak shape can also be used to 
check for activity within the analysis system.  The IS was added to every sample and every 
sample blank.  The only analyses that did not contain phenol-d6 were the fibre blanks, where 
the SPME fibre was desorbed in the GC inlet without extracting a sample.  This was used to 
test for carryover from the SPME fibre through to the MS. 
4.2.1.2 IS identification 
The IS was looked for in all 69 injections in every batch of samples, resulting in 1,454 data 
files including: bladder cancer and prostate cancer samples, C1-C4 controls, matrix, 
procedural and fibre blanks.  Only data from the extracted ‘samples’, which excludes the 
fibre blanks, is presented in this section.  The presence of IS in fibre blank analyses, from 
carryover, is discussed later. 
Some of the data files failed to acquire.  This is a known intermittent problem with this 
instrument.  The autosampler triggers the GC at the start of desorption of the SPME fibre; 
however, the MS fails to be triggered to acquire the data.  Fortunately, this does not result in 
a mis-matched sequence (where the data files do not match the samples), not carryover to 
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the next run as sample extraction, desorption and separation is still performed.  A data file 
is created by the software for that analysis, but it contains no data from the ToFMS.  
The automatic peak find, deconvolution and library search was used to find peaks, extract 
their mass spectra and search them against the NIST library.  This was performed for all data 
files on all peaks eluting around the expected retention time of phenol-d6.  In this method, it 
was expected to elute at 610-611 s.   
The similarity match criteria of the deconvoluted mass spectrum against the NIST library 
was 600 out of a maximum of 1,000.  This is the equivalent of a 60 % similarity match and 
is normal for this instrument, as the Leco ToFMS gives lower similarity matches against the 
NIST library than other types of MS.  This is partly due to the ToFMS’ bias against the 
higher mass ions and it is partly due to a difference in the library search algorithm that the 
Leco software uses in the matching.    
The highest similarity match of the IS mass spectrum against the NIST library for a matrix 
blank, with no sample, was 885, the equivalent of 88.5 %. The average identification 
similarity match, of the IS for all data files (samples and sample blanks) in each batch, is 
given in Table 4-4.  As is shown, for most batches the average similarity match is in the mid-
to-high 80 % range, which is narrow enough to produce low RSD (%) of 5 % or less for 
most batches.  Batches 3 and 8 did have lower average similarity match across the batch with 
a higher RSD (%), this will be discussed later.  The average value across all data files was 
85 % with a RSD (%) of 9 %.  This reproducible similarity match shows that the 
concentration of the phenol-d6 was high enough to reduce the likelihood of data analysis 
error when processing the phenol-d6 peak.   
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Table 4-4: Summary of the IS identification results for all samples  
Batch 
number 
No. of 
sample* 
data files  
Average 
similarity 
match 
Similarity 
RSD       
(%) 
Average 
retention 
time (s) 
Retention 
time RSD 
(%) 
1 64 858.8 1.700 610.55 0.0363 
2 60 858.6 3.648 611.85 1.2534 
3 64 589.8 20.781 611.47 0.0242 
4 64 864.7 1.444 611.10 0.0507 
5 64 870.2 1.555 611.34 0.0928 
6 64 858.9 8.171 611.16 0.0482 
7 62 860.1 2.362 611.04 0.0328 
8 48 789.5 18.835 610.85 0.0138 
9 64 878.1 1.422 610.73 0.0184 
10 64 852.6 1.616 610.67 0.0195 
11 60 841.7 1.386 610.70 0.0504 
12 63 859.2 4.865 610.81 0.0755 
13 63 861.1 4.854 610.49 0.0531 
14 60 869.1 1.294 610.52 0.0515 
15 53 859.2 2.122 610.78 0.0694 
16 55 866.1 1.236 610.47 0.0508 
17 64 870.8 0.983 610.47 0.0637 
18 59 875.4 1.055 610.24 0.0213 
19 63 877.1 1.110 610.66 0.0689 
20 62 866.4 3.806 610.48 0.0310 
21 61 875.2 1.059 610.54 0.0548 
22 3 849.7 1.155 610.47 0.0473 
Average of 
all samples
1284 848.17 9.0153 610.809 0.28096 
* Refers to bladder cancer, prostate cancer, control samples, matrix and procedural blanks 
The average retention time across each batch, along with the RSD (%), is shown in Table 
4-4.  Batch 2 shows a much higher average retention time of 611.85 seconds than the other 
batches with a much higher RSD of 1.25 % when the others have <0.1 %.  The scatter plot 
of the retention times for all sample data files, as shown in Figure 4.4, reveals an IS retention 
time outlier in Batch 2, with a retention time of 670 seconds.   
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Figure 4.4: Plot of IS retention time for all samples 
The similarity match of the IS is very high in this data file at 87.5 %.  On closer inspection, 
the chromatogram shows lower abundance compared to the other two replicates for this 
sample and the retention time has greatly shifted.  This shows the importance of using an IS 
to monitor retention time shifts and the use of replicates to monitor reproducibility of 
injection.  Large retention time shifts, as in this case, is usually due to a flow inconsistency 
or the MS starting to acquire data later than the GC starts. 
Removal of this outlier from the batch, shifted the average retention time to 610.86 s with a 
RSD of 0.0257 %, in line with the other batches. 
The plot of the IS retention time for all samples, excluding fibre blanks, across the 22 
batches, with this outlier removal, is shown in Figure 4.5.  Examination of the plot shows no 
major outliers, with the IS peak eluting between 610-613 s.  The earlier batches 4-6 show 
the latest retention times whereas the later batches 17-22 show the IS eluting at the earliest 
time and there is an overall downward trend in IS retention time, as shown in Figure 4.6.   
610
620
630
640
650
660
670
0 5 10 15 20 25 30 35 40 45 50 55 60 65
Re
te
nt
io
n t
im
e (
s)
Sample injection number
Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 Batch 6 Batch 7 Batch 8
Batch 9 Batch 10 Batch 11 Batch 12 Batch 13 Batch 14 Batch 15 Batch 16
Batch 17 Batch 18 Batch 19 Batch 20 Batch 21 Batch 22
225 
 
 
Figure 4.5: Plot of the IS retention time for all samples after outlier removal 
This is as to be expected, because, over time and after lots of temperature cycling of the 
analytical GC column the amount of retentive stationary phase reduces.  In this study, 
column maintenance, in the form of trimming of the front end, was not performed.  There 
were several reasons including: the fact that the column was not changed during the study; 
the analytes were not of high molecular weight; neither dirt nor involatile material was 
expected to be transferred to the column using SPME; the injection was solventless.  
Therefore, the gradual overall reduction in retention time, as highlighted by the trend across 
the batches, is essentially due to thermal loss of stationary phase, a process known as column 
bleed. 
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Figure 4.6: The IS retention time for batches after outlier removal, showing the downward 
linear trendline 
There is little retention time drift across the samples and batches considering the number of 
injections performed, with a maximum of 2.8 seconds across 1,283 sample runs.  However, 
with a method acquisition rate of 10 spectra/s, this equates to a shift of 28 mass spectra or 
data points, meaning that COW alignment is necessary to compare all the data files against 
each other. 
If this method was to be used for routine cancer diagnosis, it is likely that the column would 
be changed and maintenance performed on the instrument on a regular basis, resulting in 
much larger shifts in retention time.  Therefore, the development of a robust method would 
require the use of an IS to monitor retention time, along with retention time alignment in the 
chemometric analysis. 
4.2.1.3 IS response, all samples 
After the IS had been identified in each data file, the peak area and signal-to-noise (SN) ratio 
were calculated.  The base peak in the mass spectrum of phenol-d6 is the m/z 99 u ion and 
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in most data files this was also the unique mass for this compound, meaning that it was the 
most abundant ion not found in co-eluting peaks.  Therefore, this ion was also used as the 
quantification ion.  A summary of the IS abundance and SN ratio for the quantitation ion, 
for all samples, matrix and procedural blanks in each batch, is shown in Table 4-5.   
Table 4-5: Summary of the IS abundance and SN ratio data for all samples 
Batch number Average peak area 
(arbitrary units) 
Area RSD 
(%) 
Average SN 
ratio 
SN ratio 
RSD (%) 
1 35344381 38.09 44367 32.43 
2 32540156 38.22 44266 39.70 
3 134710 48.66 177 44.01 
4 29561562 20.71 37407 25.38 
5 33260033 13.68 38954 23.92 
6 33355195 28.19 44264 30.43 
7 23180898 26.55 32067 30.07 
8 23653266 76.45 33099 76.91 
9 42486961 25.49 61819 25.74 
10 31323911 19.57 46863 19.15 
11 24939740 19.82 35698 24.35 
12 25097664 29.05 31892 33.39 
13 32319314 28.64 41514 34.76 
14 31991051 37.92 44062 35.47 
15 27454555 26.52 42382 30.95 
16 36685661 31.70 56401 32.07 
17 37329101 23.86 53480 27.49 
18 43604237 24.30 59528 26.48 
19 58404767 22.18 71210 33.49 
20 66108808 30.27 91603 36.23 
21 61623368 24.06 78013 34.00 
22 33972063 12.54 37993 18.76 
Average of all 
samples 
34876693 50.89 47112 52.99 
When looking at the IS average peak area and RSD (%) for each batch, immediately, Batch 
3 jumps out as having a much lower average peak area and a high RSD (%).  Batch 8, 
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although having a similar average peak area to Batch 7, has a much higher RSD (%).  The 
relationship between the average IS area and the RSD (%) of the area can be more clearly 
seen in Figure 4.7. 
 
Figure 4.7: Plot of the average IS area and RSD (%) for each batch 
There is clearly a problem with the area of the IS in Batch 3, which is probably causing the 
high RSD (%).  From Batch 3 onwards, the RSD (%) generally stabilises, except for the high 
RSD (%) in Batch 8.  Batches 1, 2 and 14 also show RSD (%) above 30% and warrant a 
closer look.  The variation in the IS area across Batch 1 can be seen in Figure 4.8.   
 
Figure 4.8: The IS quantitation ion peak area for Batch 1 
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Injections 2, 15 and 16 show low responses, whereas 45 appears to be abnormally high.  
Removal of these four outliers improved the RSD to 21.46 %.  The remainder of the plot 
shows a very slight upward trend in area, this will be discussed later.  The variation in the IS 
area across Batch 2 can be seen in Figure 4.9.   
 
Figure 4.9: The IS quantitation ion peak areas for Batch 2 
Injections 1, 27, 41, 43, 44, 48 and 49 show low responses, whereas 12, 50 and 60 appear to 
be abnormally high.  Removal of these ten outliers, improved the RSD to 13.49 %.  Again, 
the remainder of the plot shows a very slight upward trend.  In real world applications, 
removal of these outliers may not be feasible, depending on replicates analysed and whether 
it is possible to analyse further aliquots of those samples.  The variation in the IS area across 
Batch 3 can be seen in Figure 4.10.   
Although the variability can be seen, there are no clear outliers, as was the case with Batches 
1 and 2.  The high RSD (%) is more likely to be caused by the low abundance in the area 
counts.  Adding a trendline shows there is a gradual downward trend in the IS area, which 
occurred from the beginning of the batch.  The first IS injection, within the procedural blank, 
had shown a much higher abundance; however, this was still around forty times lower than 
other batches. 
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Figure 4.10: The IS quantitation ion peak areas for Batch 3 showing a linear trendline 
Removal and examination of the SPME fibre after the batch had finished acquiring and the 
problem had been identified, revealed a fibre that appeared to have less stationary phase than 
other fibres in the batch.  It was also discoloured.  These would affect the extraction of the 
analytes from the sample and result in a large drop in sensitivity.  A damaged fibre would 
also give a decline in extraction efficiency throughout the batch. Due to the use of an IS this 
problem could easily be identified, even though this was post-batch analysis.  The samples 
were prepared again and re-analysed as Batch 21.  Method validation by running many 
batches, helps to identify what is a ‘typical’ response for analytes such as the IS.  Therefore, 
this can be used to quickly identify when there is a problem, by running the IS in a typical 
matrix, such as a system suitability check, before the batch is analysed, reducing the 
likelihood of having to re-run it.  This procedure could easily be introduced in to any future 
standard operating procedure.  Through the analysis of all these batches, the typical response, 
typical retention time, along with the following data can be determined.  The variation in the 
IS area across Batch 8 can be seen in Figure 4.11. 
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Figure 4.11: The IS quantitation ion peak areas for Batch 8 
From the beginning of the batch, just like with Batches 1 and 2, there is a gradual increase 
in response.  Looking at Injections up to 31, Injections 23 and 24 show a large drop in 
response, not to 0 as it appears, but to a value around 200 times lower and these could be 
considered outliners.  However, from Injection 32 onwards, the response drops again and 
remains low, with occasional blips of increased response, but nowhere near the response 
seen earlier in the batch.  This is most likely to have been caused by a SPME fibre failure or 
an instrument leak.  The final batch to be checked was Batch 14, shown in Figure 4.12. 
 
Figure 4.12: The IS quantitation ion peak areas for Batch 14 showing the linear trendline 
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Looking at the data, again there appears to be no obvious outliers, with just an upward trend 
in response that plateaus from around Injection 41, with possibly an outlier at Injection 49.  
There is also a general increase in variability, particularly from Injection 29 onwards.  
Reviewing the remainder of the batches, as shown in Figure 4.13, the majority follow a 
horizontal, linear trend.  In Batch 9, Injection 57 appears to be an outlier; in Batch 6 
Injections 27, 60 and 61 are very low.  Batches 19, 20 and 21 appear to have consistent 
higher responses across the batches, which corroborates the conclusions drawn for Figure 
4.7 and Table 4-5.  
The variability in the IS response could be caused by several problems, including: incorrect 
addition of the IS or a problem in the sample preparation; the IS extraction or desorption 
using HS-SPME; or the separation and detection.   
The variability of the IS response, highlights the importance of using an IS for normalisation.  
It is recommended to use an IS when performing quantitation with SPME (Pawliszyn, 2011), 
due to the potential variability in the extraction of analytes from sample to sample.   In 
November 2016, Chris Mussell from the Laboratory of the Government Chemist (LGC) gave 
a presentation on measurement uncertainty in clinical analysis at the Advances in Clinical 
Analysis meeting (RSC, 2016).  Although he focused on LC-MS analysis rather than GC-
MS, he concluded that the mass spectrometer alone can introduce variability around the 22 
% level.  
It should also be remembered that this method is not being used to perform quantitation on 
individual samples; rather, they are being compared to each other.  With one batch taking 
over 12 hours to acquire and many batches taking many weeks.  To compare the peak 
responses and identify potential biomarkers, the data files must be normalised to take into 
account any variation in the analytical method performance; therefore, an internal standard 
must be used. 
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Figure 4.13: The IS quantitation ion peak areas for the remaining batches 
The signal-to-noise ratio is a measure of the sensitivity of the instrument.  As the name 
suggests, both the response of the analyte and the noise level affect the SN ratio.  A plot of 
the average SN ratio for the IS quantitation ion for each batch is plotted, along with the 
average RSD (%) in Figure 4.14.  
 
Figure 4.14: Plot of the IS average SN ratio and RSD (%) for each batch 
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The average SN ratio for Batch 3 is not visible in the graph and this is understandable from 
the numbers presented in Table 4-5.  The SN ratio is only 177, compared to 44,000 in Batch 
2, approximately 250 times smaller.  Just as for the IS area, the highest RSD (%) is from 
Batch 8, where, as previously discussed, there was a large drop in sensitivity part-way 
through the batch.  Batches 19-21 also show an increase in SN ratio, as was seen when 
considering the IS area response for the quantitation ion. 
The batch-to-batch profile of the average SN variation, for each batch, is very similar to the 
batch-to-batch profile of the average area response (Figure 4.7).  This would suggest that the 
average SN variation is most likely to be from variation in the signal response, rather than 
any change in the noise. 
4.2.1.4 Performance checks of procedural and matrix blank samples 
There were two types of sample blanks used in the study: matrix blanks, that replaced the 
urine with deionised water during the sample preparation process; and procedural blanks, 
that were taken when the urine samples were collected and treated in the same manner.  
There were a limited number of procedural blanks; therefore, these were distributed 
throughout the batches.  Matrix blanks were used when procedural blanks weren’t available. 
Four sample blanks were analysed throughout each batch, comprising a total of 69 injections. 
The blanks were always performed as the second, twenty-fourth, forty-sixth and sixty-eighth 
injections in a batch.  The sample blanks contained internal standard but no matrix; therefore, 
they were the best type to check the performance of the internal standard, throughout the 
batch and between batches, as they shouldn’t have any sources of matrix interferences. 
The results for the IS in all sample blanks, for each batch, and all injections, is shown in 
Table 4-6 and Table 4-7.   
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Table 4-6: Summary of the sample blanks IS identification results for all batches 
Batch 
number 
Number of 
Sample 
blanks 
Average 
Retention 
time (s)  
Retention 
time RSD 
(%) 
Average 
Similarity 
Similarity 
RSD       
(%) 
1 4 610.53 0.008 858.8 0.77 
2 4 610.85 0.021 859.3 2.75 
3 4 611.55 0.041 619.5 25.25 
4 4 611.23 0.077 860.5 2.56 
5 4 611.43 0.118 863.5 2.14 
6 4 611.08 0.016 871.0 2.40 
7 4 611.08 0.047 873.5 0.38 
8 4 610.90 0.013 693.5 30.22 
9 4 610.73 0.008 868.5 1.82 
10 4 610.63 0.008 860.5 1.22 
11 4 610.63 0.025 846.5 1.01 
12 4 610.70 0.098 864.5 1.37 
13 4 610.48 0.025 856.0 1.46 
14 4 610.48 0.008 864.5 2.29 
15 3 611.23 0.093 853.0 1.06 
16 4 610.40 0.013 860.8 1.38 
17 4 610.33 0.008 866.3 1.29 
18 3 610.30 0.016 875.0 0.82 
19 4 610.50 0.019 876.0 0.77 
20 4 610.60 0.013 876.0 0.75 
21 4 610.63 0.008 878.5 0.53 
22 1 610.30  844.0  
Average of 
all sample 
blanks 
83 610.77 0.070 844.6 9.65 
Within a batch, the trend of variability in the retention times and similarity matches of the 
IS in the matrix blanks follows very similar trends to the variability seen for all samples 
including the blanks that was discussed in Section 4.2.1.2.  This implies that the variability 
in these performance parameters for the IS, is systematic and caused by the analysis rather 
than being matrix related.   
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A plot of the IS retention time in all sample blanks across all batches is shown in Figure 
4.15. 
 
Figure 4.15: The IS retention time in all sample blanks  
At the beginning, there is a gradual increase in retention time.  The first four batches were 
analysed slightly earlier, with maintenance performed between batches four and five. From 
Batch 7 onwards, these is a gradual reduction in retention time, which is to be expected and 
is discussed previously.      
The IS peak area and SN ratio for the sample blanks also follows similar within a batch and 
batch-to-batch trends as was previously discussed for all samples.  For example, the peak 
area reproducibility in Batch 8 is very poor for the sample blanks, as it was for all samples, 
due to the fibre failure, part-way through the batch.  A comparison of the IS mean peak area 
and RSD (%) between the sample blanks and all samples is shown in Figure 4.16.  There are 
far more data files used in the generation of the results for all samples (up to 64) compared 
to the sample blanks (up to 4). 
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Table 4-7: Summary of the IS response in all sample blanks for all batches 
Batch number Average peak 
area 
Area RSD 
(%) 
Average SN 
ratio 
SN ratio 
RSD (%) 
1 29353789.8 35.10 38154.3 33.43 
2 37450877.3 55.22 50015.3 54.06 
3 236042.5 47.59 241.2 61.08 
4 28893720.5 36.79 34903.0 38.20 
5 30060449.3 23.52 37332.5 20.83 
6 28291069.8 29.68 39256.5 24.07 
7 24110379.8 20.09 33035.5 19.52 
8 14098898.0 115.61 19104.8 114.39 
9 36215496.3 42.01 50691.8 38.22 
10 27066494.8 11.93 38949.0 7.64 
11 22880135.5 17.95 31826.8 19.06 
12 23218796.5 19.84 30657.8 23.08 
13 21558153.8 8.40 25784.3 11.46 
14 22643104.5 34.46 28544.5 25.67 
15 17447033.0 32.37 23481.0 24.02 
16 32933970.0 21.10 46005.8 26.54 
17 32325063.5 23.77 43547.5 16.32 
18 22463154.7 21.95 26148.0 18.46 
19 49420796.5 19.76 57295.0 13.17 
20 46214074.8 25.97 49882.0 23.52 
21 48421301.5 20.05 48094.5 21.75 
22 29773796.0  29902.0  
Average of all 
sample blanks 
28567166.5 49.04 36049.1 45.35 
The IS mean peak area for all samples is slightly higher than for the sample blanks only for 
most batches, but they both follow the same trend.  The RSD (%) is slightly higher for all 
samples than the sample blanks only, but again they both follow the same trend.  This again 
indicates that errors are systematic rather than caused by matrix interferences.  Generally, 
reproducibility improved batch-to-batch which is most likely, particularly after the first three 
batches, the result of practice of preparing samples and analysing the samples.  This could 
also have resulted in improved sensitivity of the method as is shown from batch 16 onwards. 
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Figure 4.16: The IS peak area average and RSD (%) for all samples and sample blanks 
There is a correlation between the IS peak area and similarity match, as shown in Figure 
4.17.  This is to be expected, as small peaks generally have a poorer quality mass spectrum.  
When library searching that mass spectrum, the similarity match will therefore not be as 
high.  This plot is helpful in determining the minimum area that is required to obtain a mass 
spectrum for the IS that is of high enough quality to obtain a library search match that is 
deemed high enough to have confidence that the peak is that which has been identified.  For 
this method and using this instrument, a similarity match of 600, which is the equivalent of 
a 60 % match, would require an area count of 42,000,000 (arbitrary units).  This information 
could then be used for quality control, as one of the parameters, to determine if a sample or 
matrix blank has been analysed correctly. 
0
20
40
60
80
100
120
0
10000000
20000000
30000000
40000000
50000000
60000000
70000000
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
RS
D 
(%
)
Pe
ak
 ar
ea
 o
f I
S (
ar
bi
tra
ry
 un
its
)
Batch number
Sample blanks average Average all samples Sample blanks RSD RSD all samples
239 
 
 
Figure 4.17: Plot of IS peak area and similarity match for all sample blanks 
To summarise, there is variability of the IS in sample blanks, both within a batch as well as 
batch-to-batch.  Again, this highlights the importance of using an IS even in non-quantitative 
studies, to normalise the data generated so that comparisons can be made between data files 
acquired both within a batch as well as between batches. 
4.2.1.5 Comparisons between different blanks 
Within the study three different types of blanks were acquired: 
• Fibre blanks, to check for carryover or contamination within the SPME-GC-ToFMS 
system. 
• Matrix blanks, to check for contamination through sample preparation and analysis. 
• Procedural blanks, to check for contamination from sample collection through 
analysis. 
By comparing these blanks, analysed at different times, sources of contamination can be 
determined.  Before a new batch of samples was analysed, any instrument maintenance was 
performed and a couple of fibre blanks were then analysed to purge the system and check 
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for contamination before the sequence was started.  At the start of a sequence, the first 
analysis was a fibre blank followed by a sample blank (Matrix or Procedural).  The overlaid 
total ion chromatograms (TICs) for Injection 1 (Fibre blanks) is shown in Figure 4.18. 
 
Figure 4.18: Overlaid TICs of Injection 1 Fibre blanks for all batches  
All the fibre blanks were consistent, with the same main peaks seen in each data file.  These 
were identified as different types of siloxanes, for example hexamethyl-cyclotrisiloxane, 
dimethylsilanediol and octamethyl-cyclotetrasiloxane.  There were also additional siloxanes 
towards the end of the run for some fibres.  Siloxane peaks are to be expected, as the 
CAR/PDMS fibre will bleed to produce these peaks.  The levels of each varied, as some 
fibres produced more bleed than others.  The first large peak is air that was trapped within 
the fibre phase.  The amount of air desorbed was slightly different for different fibres.  Some 
smaller peaks in some fibre blanks, between the air peak and main siloxane peak at ~450 
seconds, were identified as solvents, including acetone, pentanol, dichloromethane, hexane 
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and acetonitrile.  The source of these is most likely to be the laboratory air, which the fibre 
extracts before injection.   There were also a few tiny other peaks, most of which could not 
be identified, but one was identified as benzaldehyde.  The source of these is unknown but 
could be from either of the sources discussed above, particularly fibre bleed.  
After conditioning of the SPME fibre for each batch, the amount of bleed produced by a 
fibre was stable at the start of that batch, as shown in Figure 4.19, where two fibre blanks 
were analysed at the start of the batch for Batch 9.   
 
Figure 4.19: Overlaid TICs of Injection 1 (orange) & 2 (green) Fibre blanks from Batch 9 
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Of course, contamination from the sample matrix, along with repeated heating could cause 
excess bleed to be produced later in the batch.  Also, the amount of bleed could reduce as 
the fibre becomes more ‘conditioned’, as shown in Figure 4.20, where the Injection 1 and 
Injection 69 Fibre blank chromatograms are overlaid. 
 
Figure 4.20: Overlaid TICs of Injection 1 (orange) & 69 (green) Fibre blanks from Batch 
19 
The additional contamination peaks from the matrix blank samples can be seen in the 
overlaid chromatograms of the Injection 2 Matrix blanks for each batch, as shown in Figure 
4.21.  The reproducibility of the matrix blanks and the peaks present, are similar for most 
batches.   
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Figure 4.21: Overlaid Injection 2 Matrix blank TICs from Batches 2, 4-6, 8-9, 12, 14, 16-22 
The matrix blank can then be compared to the fibre blank to determine and identify the 
additional peaks from the sample preparation steps, as shown for the most contaminated 
matrix blank from Batch 21 (green) in Figure 4.22. 
The additional peaks found in the matrix blanks were identified as various methyl, ethyl, 
butyl and larger esters; larger amounts of solvent than were seen in the fibre blanks, for 
example acetone, ethyl-alcohol, isopropyl-alcohol, dichloromethane, methyl-propanol, 
pentane, n-hexane, heptane, decane, ethylacetate, benzene, toluene, ethylbenzene, xylenes; 
larger siloxane peaks, for example trimethyl-silanol, dimethyl-silanediol, octamethyl- 
cyclotetrasiloxane; some additional peaks for example propenenitrile, tetrahydrofuran, 
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hexanal, nonanal, p-tert-butyl phenol, various ketones like butanone and pentanone and of 
course the IS, that was not present in the fibre blank.   
 
Figure 4.22: Overlaid Injection 1 Fibre blank & Injection 2 Matrix blank TICs in Batch 21 
These contamination peaks can come from several different places in the sample preparation 
process, including: glassware used; matrix modification reagents; consumables, for example 
HS vials, caps and septa; facilities used for the sample preparation.  The presence of higher 
amounts and different types of solvents, is most likely from the sample preparation stages.  
The contaminant peak p-tert-butyl-phenol is most commonly used as a flame retardant.  
Aldehydes and methyl esters are most commonly linked as contaminants from plastics, along 
with some of the additional solvents identified, especially on heating of the plastic (Bach, et 
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al., 2012).  The HS vial cap inserts were lined with PTFE and the vial was heated.  Future 
work would be to analyse an empty HS vial to identify if these were the source of some of 
these contaminant peaks found.  The sample vials also had PTFE lined cap inserts and some 
of the reagents used were sourced in plastic containers. 
The procedural blanks can be used to determine additional compounds that come from the 
sample collection, urinalysis, transport and storage.  The overlaid chromatograms of the 
Injection 2 Procedural blanks for the batches are shown in Figure 4.23. 
 
Figure 4.23: Overlaid Injection 2 Procedural blank TICs in Batches 1, 3, 7, 10-11, 13 & 15 
The procedural blanks mostly had the same peaks present as the matrix blanks.  The most 
contaminated Injection 2 Procedural blanks from Batch 7 and Batch 11 were compared to 
the most contaminated Injection 2 Matrix blank from Batch 21, as shown in Figure 4.24. 
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Figure 4.24: Overlaid Injection 2 Batch 7 & 11 Procedural & Batch 21 Matrix blank TICs 
Most peaks present in the procedural blanks (green and blue) were also present in the matrix 
blank (orange), but the peak sizes were slightly different. 
The additional peak found in the procedural blank from Batch 11 (green) was identified as 
2-nitrobutane with a 97% similarity match, the source is unknown.  Ethanol and acetone 
were also found in much higher concentrations in the procedural blanks than seen in the 
matrix blank.  These could be a result of the higher levels of these solvents present in the 
laboratory air or glassware used in the collection of the samples. 
This concludes that most contamination occurs from the sample preparation and analysis 
steps, rather than the sample collection, urinalysis, sample transport and storage.  In the 
sample preparation, efforts were made to ensure that the matrix modification reagents, 
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glassware and sample preparation areas were clean as clean as possible.  However, the 
technique is very sensitive and therefore some background will always be generated.   
Figure 4.25 shows the overlaid chromatograms from a sample (blue), a matrix blank (orange) 
and a procedural blank (green). There is clearly a large difference in the number and size of 
the peaks when extracting a sample compared to a blank. 
 
Figure 4.25:  Overlaid Batch 13 C3 sample with Injection 2 Batch 11 Procedural and Batch 
21 Matrix blank TICs 
Ideally, any contamination peaks that vary in response should be excluded in the data 
analysis.  Those contamination peaks that have a constant value should automatically be 
ignored by the chemometrics techniques.  Any potentially identified biomarkers should be 
looked for in these sample blanks to ensure they are not a result of contamination but are 
coming from the urine.  
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4.2.1.6 Fibre blanks and carryover 
A fibre blank is an injection where the fibre is desorbed directly in the GC inlet without 
extracting a sample.  It checks for carryover and contamination coming from the SPME fibre, 
GC inlet, column and detector.  Another source of contamination is the laboratory air around 
the instrument, as between injections the fibre is not sealed and can extract any solvents, etc. 
that are present. 
As previously discussed, before a batch was analysed the system was purged by analysing 
two fibre blanks.  As well as a final check that there is no contamination, the fibre blank at 
the start of a batch can also be used to check for bleed, including fibre bleed and inlet septum 
bleed.  These usually appear as discrete peaks through cold trapping at the front of the 
analytical column at the start of a run; also, column bleed that raises the baseline, particularly 
towards the end of the run when the oven is hot.  Bleed levels indicate if maintenance is 
required; for example, fibre, septum or column replacement.   
The overlaid chromatograms of the Injection 1 Fibre blanks were shown and discussed in 
Figure 4.18.  As is expected, there was no presence of the IS in the Injection 1 fibre blanks.  
Further fibre blanks were analysed as Injections 13, 35, 57 and 69.  These were used to check 
for carryover from the previous sample analysis.  Injection 69 was also used to check the 
system cleanliness at the very end of the batch and was used to indicate how much 
maintenance was required before the next batch was analysed. 
The chromatograms of each of these fibre blanks were compared to the chromatograms from 
the previous injection, as well as against the Injection 1 Fibre blank.  Any IS peaks identified 
indicated the presence of carryover.  The details of where carryover was detected, along with 
the calculated percentage carryover, is summarised in Table 4-8. 
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Table 4-8: IS carryover detected in the fibre blanks 
Batch number Injection no. Injected after: Carryover (%) 
1 13 Sample 0.330 
1 35 Sample 0.261 
1 57 Sample 0.162 
1 69 Procedural 0.260 
2 13 Sample 0.306 
2 35 Sample 0.233 
2 50 Sample 0.143 
2 57 Sample 1.056 
2 69 Matrix 0.165 
4 13 Sample 0.250 
4 35 Sample 0.292 
4 57 Sample 0.215 
4 69 Matrix 0.235 
6 13 Sample 0.246 
6 35 Sample 0.184 
6 57 Sample 0.219 
6 69 Matrix 0.288 
7 13 Sample 0.208 
7 35 Sample 0.190 
7 57 Sample 0.103 
7 69 Procedural 0.238 
8 13 Sample 0.156 
8 35 Sample 0.093 
9 13 Sample 0.272 
9 35 Sample 0.245 
9 57 Sample 0.222 
9 69 Matrix 0.205 
10 13 Sample 0.854 
10 35 Sample 0.688 
10 57 Sample 1.590 
10 69 Procedural 0.913 
11 13 Sample 1.405 
11 69 Procedural 0.305 
19 57 Sample 0.116 
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If present, the amount of carryover from samples and sample blanks was determined by 
comparing the peak area of the IS quantitation ion detected in the fibre blank against the 
peak area from the previous injection.  Some carryover was detected in the earlier batches 
of the study, as shown.  However, no carryover was detected from Batch 12 onwards, except 
for one sample in Batch 19, even though the IS peak area was larger, indicating higher 
method sensitivity and therefore the ability to detect carryover for these later batches.  The 
percentage carryover is measured for each of the fibre blanks and illustrated in Figure 4.26.  
 
Figure 4.26: Percentage carryover determined from fibre blank injections 
Where detected, most carryover was far <1 %.  The overlaid chromatograms in Figure 4.27, 
show how small the IS quantitation peak carried over in the Batch 2 Injection 69 Fibre blank 
(green) is compared to the IS peak in the Injection 68 Matrix blank (orange).  
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Figure 4.27: Zoomed-in IS quantitation ion showing a low percentage carryover  
Overlaid chromatograms of the Batch 6 Injection 56 C2 sample (orange) and subsequent 
Injection 57 Fibre blank (green) are shown in Figure 4.28.  The carryover peak is not visible. 
 
Figure 4.28: Zoomed-out IS quantitation ion showing a low percentage carryover of the IS 
Even carryover present in Batches 10 and 11 were lower than 1.6 % and this level was 
deemed acceptable.  Those blanks that detected carryover >1 % were mostly analysed after 
the analysis of samples with a high specific gravity.  This means that they are more 
concentrated and likely to contain a higher concentration of analytes that could cause 
carryover.  Considering the concentration of the IS and the level of carryover of this less 
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volatile analyte seen throughout the batches, the potential level of carryover from sample to 
sample was deemed acceptable for this study.  Further method validation would include the 
monitoring of carryover from injection-to-injection with even more use of blanks, 
particularly for more concentrated urine samples with high specific gravity which are more 
likely to cause carryover.     
4.2.1.7 Replicate bladder cancer and control sample analyses 
Where there was sufficient quantity of sample provided, participants’ samples were 
analysed in triplicate.  This was useful for several reasons: 
• In the event of sample acquisition failure, it was still highly likely to have at least 
one data file per participant for disease classification. 
• It provided a reproducibility check for consecutive injections and for injections 
distributed throughout a batch and between batches. 
The value of evaluating the reproducibility of the retention time, peak area and SN ratio, 
using the IS, have previously been discussed.  This section will focus on the visual 
reproducibility of the IS in sample chromatograms.  As most samples were acquired in 
triplicate there is far too much data to show; therefore, some good and poor chromatograms 
have been selected as exemplars.  The overlaid IS quantitation ion for three consecutive 
injections in Batch 9 of a C3 sample is shown in Figure 4.29. 
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Figure 4.29: IS quantitation ion for consecutive injections of a C3 sample from Batch 9 
The IS peak (2) is coeluting with a neighbouring sample peak (3).  As can be seen in  Figure 
4.27, this peak is not seen in the sample blanks.  For each injection, the IS retention times 
and peak responses are very similar.  A summary of the IS retention times and quantitation 
ion areas is given in Table 4-9. 
Table 4-9: IS results for consecutive injections of a C3 sample from Batch 9 
Replicate Retention time (s) Peak area (arbitrary units) 
1 610.7 33856439 
2 610.8 32530947 
3 610.8 32758993 
Average: 610.77 33048793.0 
RSD (%): 0.009 2.14 
The reproducibility of the replicate injections is less than that seen for in-batch sample 
blanks.  As previously discussed, Batch 3 had problems with sensitivity and thus the whole 
batch was re-analysed.  However, despite the lack of sensitivity, relatively good 
reproducibility for three consecutive injections was produced, as shown for a Batch 3 C1 
sample in Figure 4.30. 
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Figure 4.30: IS quantitation ion for consecutive injections of a C1 sample in Batch 3 
As is shown from the data summarised in Table 4-10, the retention time of each injection is 
the same.  The peak areas are relatively close, even though they are gradually reducing.  
Generally, smaller peaks tend to show poorer peak area reproducibility, partly due to the 
reproducibility of the integration and the lack of resolution of the IS peak (1) from the matrix 
peak (2). 
Table 4-10: IS results for consecutive injections of a C1 control sample in Batch 3 
Replicate Retention time (s) Peak area (arbitrary units) 
1 611.4 221373 
2 611.4 197315 
3 611.4 176272 
Average: 611.4 198320.0 
RSD (%): 0.00 11.38 
Full chromatograms of three consecutive injections of a TCC3 sample in Batch 20 is shown 
in Figure 4.31.  
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Figure 4.31: Overlaid TICs of three consecutive injections of a TCC3 sample in Batch 20 
The chromatograms of the three consecutive injections are very similar.  The largest 
variability is in the more volatile region, where the solvent background peaks seen in the 
sample blanks is present.   
The overlaid IS quantitation ion for the replicate Injections 19, 50 and 58 of a C1 sample 
scattered throughout Batch 12 is shown in Figure 4.32.  The peak area and retention time 
results can be seen in Table 4-11.   
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Figure 4.32: IS quantitation ion for in-batch replicate injections of a C1 sample in Batch 12  
The IS elutes earlier in the first injection (orange) compared to the later injections, however 
it is almost identical in size to the third injection (blue). 
Table 4-11: IS results for in-batch replicate injections of a C1 sample in Batch 12 
Batch injection no. Retention time (s) Peak area (arbitrary units) 
19 610.4 21631334 
50 611.4 28460583 
58 611.3 22228171 
Average: 611.03 24106696.0 
RSD (%): 0.09 15.69 
The in-batch replicates data shown here, is no worse than that seen for the in-batch sample 
blanks.  This indicates that the variability is due to random error rather than being matrix-
related.  Full chromatograms of a TCC1 sample in Batch 10, Injections 39, 50 and 55 is 
shown in Figure 4.33.  There is a very slight variation in response for each injection.  
However, this is for all peaks including the IS and therefore any differences can be 
normalised against the IS. 
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Figure 4.33: Overlaid TICs of three in-batch injections of a TCC1 sample in Batch 10 
The third reproducibility check was through analysing replicate samples scattered between 
multiple batches.  The overlaid IS quantitation ion for the between-batch replicates of a C1 
sample analysed in Batches 9, 13 and 14 as Injections 17, 61 and 36 respectively is shown 
in Figure 4.34. 
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Figure 4.34: IS quantitation ion for between-batch injections of a C1 sample in Batches 9, 
13 & 14    
The reproducibility is good, with similar areas and retention times, which is corroborated in 
the results shown in Table 4-12.  The IS elutes slightly later in Batch 9 (orange).  The peak 
area RSD (%) is better than has been shown for some in-batch sample blanks. 
Table 4-12: IS results for between-batch injection of a C1 sample in Batches 9, 13 & 14 
Batch no. Injection no. Retention time (s) Peak area (arbitrary units) 
9 17 610.8 45142407 
13 61 610.4 42060356 
14 36 610.5 42996074 
 Average: 610.57 43399612.3 
 RSD (%): 0.034 3.64 
Full chromatograms of a TCC2 sample in Batches 1, 7 and 18, Injections 41, 33 and 39 
respectively is shown in Figure 4.35.  Batch 18 was analysed two months after Batch 1, 
therefore some variability could be expected.  There was some variability in the sample 
peaks.  However, on comparison to the IS variability a similar pattern was seen, indicating 
that differences could be removed by normalising against the IS. 
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Figure 4.35: Overlaid TCC2 sample TICs of between-batch injections in Batches 1, 7 & 18 
4.2.1.7 Comparison of the acquisition outliers to the chemometric analysis 
outlier removal 
Throughout the discussion in this section, numerous data files have been identified from the 
performance data that are potential outliers.  For example, those data files where the IS 
retention time has greatly differed, as seen in Figure 4.4, or the IS quantitation ion peak area 
has changed more than average, as seen in Figure 4.7. 
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The next step would be to see if the outliers identified from the performance data compared 
significantly to those outliers identified by Cranfield University in the chemometric analysis.  
This would be a great test to see if the data processing steps flagged inconsistencies in the 
acquisition of those data files.  Unfortunately, due to the closure of the bioinformatics group 
at Cranfield University some time ago, we have been unable to access the data to make this 
comparison.  Dr Michael Cauchi has very recently (Autumn 2016) taken up a new position 
at the University of Limerick and hopes to both have access to the processed data and to 
process it further in the future. 
4.2.2 Statistical analysis of the full bladder cancer data set 
The full set of data files that had been uploaded to the servers at Cranfield University, as 
described in Table 4-1, were first normalised against the IS.  Any data files that did not 
contain the correct number of scans of approximately 8,700 were removed at this point.  The 
next step was exploratory analysis using PCA and HCA.  A summarising table of the 
statistical terms used throughout this section can be found in Table 2-1. 
4.2.2.1 Exploratory analysis using PCA and HCA 
The unsupervised, independent exploratory techniques PCA and HCA were used to 
determine if there were any natural groupings of the data in the data set.  The first three PCs 
didn’t show any separation of the data files according to their cancer status when using PCA, 
and not even when investigating past the first three PCs responsible for the greatest part of 
the variance.  The dendrogram from HCA also didn’t show any natural groupings.  Outliers 
identified by the PCA were removed at this point, leaving the number of participants and 
samples for classification as previously described in Table 4-1. 
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4.2.2.2 Pattern recognition through PLS-DA and SVM-LIN 
The remaining data set, with the outliers removed, was divided into the different categories 
based on their clinical classification.  Pattern recognition was then performed between the 
following pairs of categories: 
• C1 vs. TCC (all three categories combined) 
• C2 vs. TCC (all three categories combined) 
• C3 vs. TCC (all three categories combined) 
• C3 vs. TCC1 
• C3 vs. TCC2 
• C3 vs. TCC3 
Different types of scaling were investigated, including auto-scaling (AS), mean-centred 
(MC), no scaling, normalised (Norm), pareto, range-scaled (RS) (-1 to 1) and (0 to 1).  
Feature selection was also investigated, with the results from no feature selection, feature 
selection using the Wilcoxon t-test (WTT) and Student t-test (STT) being compared.  These 
were then compared using the two classifiers PLS-DA and SVM-LIN.   
Only the results for the best scaling technique, with and without feature selection, are shown 
for each classifier.  The results shown in the following tables are the mean of all models 
produced, therefore selecting the best performing model would give better results than the 
performance shown here.   
Results from classification of C1, C2 or C3 against TCC 
The summary of the results for the comparisons of each control (C1, C2, C3) against all of 
the cancer samples (TCC) are shown in Table 4-13, Table 4-14 and Table 4-15, respectively.  
In these results, all the C3 controls are used, they are not age-matched.  The results from the 
mean of the classification models produced for C1 vs. TCC is shown in Table 4-13. 
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Table 4-13: C1 vs. TCC results for PLS-DA and SVM-LIN  
Classifier PLS-DA SVM-LIN 
Feature 
selection* 
None WTT 
p=0.05 
STT 
p=0.05 
None WTT 
p=0.05 
STT    
p=0.05 
No. scans 8721 1458 1067 8721 1458 1067 
Scaling** AS Norm Pareto AS Norm RS (-1 to 1) 
%CC 87.53 87.48 84.29 88.99 88.82 88.05 
%Spec 87.23 85.06 83.37 88.84 86.37 86.97 
%Sens 87.82 89.79 85.17 89.13 91.15 89.07 
%NPV 87.45 89.05 84.49 88.83 90.45 88.56 
%PPV 87.94 86.46 84.47 89.48 87.66 87.93 
%FDR 12.06 13.54 15.53 10.52 12.34 12.07 
LV 16 19 9 1 1 1 
AUROC 0.9055 0.9124 0.9040 0.9350 0.9170 0.9281 
*WTT = Wilcoxon t-test; STT = Student t-test; **Norm = normalised; RS = Range-scaled; 
MC = mean-centred; AS = auto-scaled. 
The performance for C1 controls against all TCC samples gives similar results for both PLS-
DA and SVM-LIN, with SVM-LIN performing slightly better.  Auto-scaling with no feature 
selection gave the best classification results for both classifiers, using the maximum number 
of scans of 8,721.   
C1 controls are from healthy participants, therefore it should be relatively easy to 
differentiate these data sets from TCC and the results clearly show this, even though the 
performance of the algorithms are not 100 %.  There are a multitude of parameters in the 
analysis of these samples, as previously discussed in Chapter 3.  1D GC identified over 900 
individual analytes in the headspace above urine, whereas 2D GC identified over 3,000; 
therefore, it is probable that not all the analytes that can differentiate the controls from the 
cancer patients can be seen using the TIC in this 1D GC method.  The chemometrics analysis 
also has many parameters to be optimised, which is very much limited by computer 
processing power.  It is possible that even the best performing models are not fully optimised 
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for these data sets and more could be achieved.  In addition, the samples themselves and the 
impact of the metadata has not been assessed, as it was beyond the scope of this project, but 
it should be investigated further in the future.   
The AUROC values are all above 0.9, meaning very good from Table 1-3; the total correctly 
classified, sensitivity, specificity, negative and positive predictive values are all above 87 %; 
and the false discover rate is 12 % or less.  
The results from the mean of the classification models produced for C2 controls against the 
total TCC is shown in Table 4-14.   
Table 4-14: C2 vs. TCC results for PLS-DA and SVM-LIN  
Classifier PLS-DA SVM-LIN 
Feature 
selection 
None WTT 
p=0.05
STT 
p=0.05
None WTT 
p=0.05 
STT    
p=0.05 
No. scans 8721 4274 4119 8721 4274 4119 
Scaling AS MC Pareto RS (0 to 1) RS (-1 to 1) RS (-1 to 1) 
%CC 88.35 85.09 85.26 89.18 87.82 88.10 
%Spec 88.21 83.03 84.83 88.00 86.43 87.57 
%Sens 88.48 87.08 85.68 90.33 89.17 88.61 
%NPV 88.30 86.43 85.34 90.01 88.73 88.36 
%PPV 88.71 84.29 85.54 88.74 87.30 88.21 
%FDR 11.29 15.71 14.46 11.26 12.70 11.79 
LV 12 19 15 1 1 1 
AUROC 0.9276 0.9087 0.9058 0.9220 0.9223 0.8795 
Again, the performance for C2 controls against all TCC samples gives similar results for 
both PLS-DA and SVM-LIN.  Auto-scaling with no feature selection again gave the best 
classification results for PLS-DA; whereas, range scaling was the best technique for SVM-
LIN, with again no feature selection and therefore using the maximum of 8,721 scans.  C2 
controls are from participants with a urine abnormality that could be caused by menstruation, 
urinary tract infections, pregnancy, dermatological conditions, diabetes and other non-
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cancerous, non-serious illnesses.  Symptoms such as blood in the urine of bladder cancer 
patients is quite common, as can be seen from Table 4-1.  Therefore, it would be thought to 
be more difficult to differentiate TCC samples from C2 controls than it was from C1 controls.  
However, the AUROC values are all above 0.9, meaning very good; the total correctly 
classified, sensitivity, specificity, negative and positive predictive values are all above 88 %; 
and the false discover rate is 11 %.  Therefore, classification of the C2 controls from the 
TCC samples resulted in generated models giving slightly better performance than when 
comparing C1 controls and TCC samples. 
The results from the mean of the classification models produced for all the C3 controls 
(C3(full)), with no age-matching, against the total TCC is shown in Table 4-15.   
Table 4-15: C3(full) vs. TCC results for PLS-DA and SVM-LIN  
Classifier PLS-DA SVM-LIN 
Feature 
selection 
None WTT 
p=0.05 
STT 
p=0.05 
None WTT 
p=0.05 
STT    
p=0.05 
No. scans 8721 553 2641 8721 553 2641 
Scaling Norm RS (-1 to 1) AS AS AS AS 
%CC 76.85 70.24 71.77 78.78 71.74 74.02 
%Spec 74.41 63.40 65.56 74.51 59.65 60.60 
%Sens 78.95 76.14 77.14 82.46 82.18 85.61 
%NPV 75.58 69.87 71.48 78.90 74.93 78.93 
%PPV 78.33 70.85 72.47 79.18 70.45 71.81 
%FDR 21.67 29.15 27.53 20.82 29.55 28.19 
LV 15 13 20 1 1 1 
AUROC 0.8399 0.7550 0.7788 0.8332 0.7825 0.8330 
Again, the performance for all C3 controls against all TCC samples gives similar results for 
both PLS-DA and SVM-LIN, with similar specificity and AUROC values.  However, SVM-
LIN gave slightly better sensitivity, a slightly higher overall correct classification and 
therefore a slightly lower false discovery rate.  Auto-scaling (with no feature selection) again 
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gave the best classification results for SVM-LIN, whereas normalised scaling was the best 
technique for PLS-DA (with no feature selection).   
C3 controls are from patients with a urological disorder requiring hospital treatment.  Urine 
abnormalities may or may not be apparent, as previously indicated in Table 4-1.  These 
patients do not have bladder cancer but do have disorders which can give similar symptoms; 
for example, kidney stones, renal cysts, urethral stricture or chronic urinary tract infections.  
Therefore, out of the three different control categories this is the most likely group to be 
more difficult to classify from the TCC patient samples.  These results were not age-
matched.  
As expected, the classification performance results are not quite as good as for the C1 or C2 
control samples.   The AUROC values for both classifiers were both above 0.83 and are 
therefore still classed as good.  The specificity was >74%; the total correctly classified, 
sensitivity, specificity, negative and positive predictive values all above 78 % for SVM-LIN 
and 75 % for PLS-DA.  The FDR is 20 % for SVM-LIN and 21 % for PLS-DA; which are 
all still classed as good.   
Results from classification of C3(full) against TCC1, TCC2 and TCC3 individually 
In the initial studies, TCC samples were combined and the performance of the models were 
determined for each of the three control categories.  Combining the TCC categories would 
have included samples from patients with both low-grade and high-grade tumours.  As the 
TCC samples had been sub-categorised into TCC1 to TCC3, the next step was to classify 
each of these sub-sets against the C3(full) set, the most difficult control group. 
It was expected that the two most difficult categories to classify, across all the control groups 
and the TCC sub-categories, would be the TCC1 vs. C3, that is low-grade tumour cancer 
patients against the C3 patients with non-cancerous urological disorders.  Many of the urine 
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abnormalities on the dipstick are similar but do vary for both groups, this warrants 
comparison against the results as future work.  The results from the mean of the classification 
models produced for C3(full) vs. TCC1 can be seen in Table 4-16. 
Table 4-16: C3(full) vs. TCC1 results for PLS-DA and SVM-LIN  
Classifier PLS-DA SVM-LIN 
Feature 
selection 
None WTT 
p=0.05 
STT 
p=0.05 
None WTT 
p=0.05 
STT    
p=0.05 
No. scans 8721 917 218 8721 917 208 
Scaling AS MC RS (-1 to 1) Norm RS (0 to 1) RS (0 to 1) 
%CC 75.78 68.71 74.01 80.47 78.17 79.84 
%Spec 80.91 78.75 85.93 97.94 99.54 99.20 
%Sens 57.50 32.96 31.54 18.25 2.042 10.88 
%NPV 87.37 80.76 81.75 81.08 78.36 79.88 
%PPV 46.62 30.58 40.64 68.05 22.94 71.81 
%FDR 53.38 69.42 59.36 31.95 77.06 28.19 
LV 20 3 3 1 1 1 
AUROC 0.6193 0.5899 0.5907 0.6079 0.4706 0.5777 
Although the AUROC value is similar for both the PLS-DA and SVM-LIN classifiers, there 
is a lot of variability in the other performance metrics.  Again, both classifiers performed 
best with no feature selection, so that all 8721 scans were used in the classification.  Auto-
scaling gave the best results for PLS-DA and normalised scaling for SVM-LIN. 
Overall, the performance for classifying C3 against TCC1 is not as good as when classifying 
C3 against all TCC samples.  This is to be expected, as the two sets of data would be far 
more similar as one might expect them to be clinically more similar and therefore the 
chemical profile should be more similar.  The AUROC values for both classifiers are both 
above 0.6, this is a poor result but not a fail.  Although the total correctly classified, the 
specificity, the positive predictive value and false discovery rate is better for SVM-LIN than 
PLS-DA, the sensitivity is very poor at only 18 % compared to 57 % for PLS-DA.  Use of 
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the SVM-LIN classifier would result in high specificity at 98 % but poor sensitivity at only 
18 %.   
These results emphasise that when comparing the performance of different classifiers and 
different models, selection of the best classifier, as well as the best scaling technique cannot 
be based on just one performance metric, for example the AUROC value.  Calculation of 
different performance monitors, comparison and consideration of the impact that high or low 
values of each has, should also be made.   
From a clinicians’ point of view, the most important performance metrics of a test are the 
NPV and PPV, meaning a calculation of the likelihood of a given negative or positive test 
result for the patient to be correct.  The PLS-DA is good at giving a correct negative test 
result but not positive with 87.37 % and 46.61 % NPV and PPV respectively.  Whereas 
SVM-LIN with STT feature selection is almost equally good at correct positive and negative 
results with 71.81 % and 79.88 % PPV and NPV values, respectively.    
Overall, for classification of C3 against TCC1, the PLS-DA classifier gave the best 
performance, with 81 % specificity, 57 % sensitivity and an AUROC value of 0.62.  The 
specificity is slightly less than conventional urine cytology which is > 90 %.  However, for 
low-grade tumours, this classifier gave better sensitivity at 57 % compared to 20-50 % 
(Bassi, et al., 2005).  Once again it should be noted that these results are based on the mean 
value of the all the classification models and so some the models developed actually perform 
better, this will be discussed in more detail later in this chapter. 
The results from the mean of the classification models produced for the comparison of all 
the C3 controls against the TCC2 moderate-grade tumours can be seen in Table 4-17. 
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Table 4-17: C3(full) vs. TCC2 results for PLS-DA and SVM-LIN  
Classifier PLS-DA SVM-LIN 
Feature 
selection 
None WTT 
p=0.05 
STT 
p=0.05 
None WTT 
p=0.05 
STT    
p=0.05 
No. scans 8721 389 629 8721 389 629 
Scaling Norm AS RS (0 to 1) Norm Norm Norm 
%CC 78.37 79.78 66.71 78.60 80.76 71.82 
%Spec 79.81 84.21 67.63  93.16 94.69 95.58 
%Sens 75.21 70.05 64.72 46.69 50.21 19.74 
%NPV 87.77 86.22 81.31 79.46 80.81 72.35 
%PPV 63.38 67.58 47.82 76.90 82.42 68.46 
%FDR 36.62 32.42 52.18 23.10 17.58 31.54 
LV 16 6 20 1 1 1 
AUROC 0.8134 0.7961 0.7115 0.7256 0.7509 0.5742 
TCC2 patients have moderate-grade tumours that have grown into the muscle and therefore 
should be easier to detect than TCC1 low-grade tumours.  The cancer is more established 
and biologically active and could be potentially producing more metabolites that could be 
used as biomarkers or could be producing a higher increase or reduction in other metabolite 
concentrations.  This is reflected in the results, with an AUROC value of greater than 0.8 for 
PLS-DA, meaning good.  Both classifiers performed better with no feature selection, using 
the full 8721 scans, and with normalised scaling.  The PLS-DA classifier performed better 
overall than SVM-LIN.  SVM-LIN again had better specificity, but poor sensitivity.  PLS-
DA had sensitivity, specificity, total correct classification and negative predictive values all 
above 75 %, which is good.  However, the model was not so good at predicting positives 
correctly, with a lower PPV and had a higher false discovery rate.  The results from the mean 
of the classification models produced for the comparison of all the C3 controls against the 
TCC3 high-grade tumours can be seen in Table 4-18. 
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Table 4-18: C3(full) vs. TCC3 results for PLS-DA and SVM-LIN 
Classifier PLS-DA SVM-LIN 
Feature 
selection 
None WTT 
p=0.05 
STT 
p=0.05 
None WTT 
p=0.05 
STT    
p=0.05 
No. scans 8721 1548 992 8721 1548 992 
Scaling AS AS AS RS (0 to 1) RS (-1 to 1) RS (-1 to 1) 
%CC 80.75 75.99 74.15 82.67 76.17 73.32 
%Spec 84.94 77.33 74.74 94.28 93.99 95.58 
%Sens 71.20 72.93 72.80 56.19 35.55 22.56 
%NPV 87.27 86.86 86.50 83.26 77.14 73.91 
%PPV 67.97 59.00 56.21 82.25 75.21 73.99 
%FDR 32.03 41.00 43.79 17.75 24.79 26.01 
LV 7 18 20 1 1 1 
AUROC 0.8592 0.7916 0.7789 0.8122 0.7081 0.5950 
When classifying the TCC3 against C3 controls, again, the best results for both classifiers 
were with no feature selection, using the full 8721 scans.  Auto-scale was best for the PLS-
DA classifier and range scaling for SVM-LIN.  As found for the TCC1 and TCC2, the best 
overall results were using PLS-DA, with SVM-LIN giving better specificity but a much 
lower sensitivity.  
The ability to classify TCC3 patients with high-grade tumours against the full C3 control 
data set, was expected to be easier than when classifying TCC1 or TCC2.  The cancer is 
large and fully established both inside and outside of the bladder and therefore would be 
thought to significantly change the metabolites concentration when compared to a patient 
without TCC.  This is again reflected in the results, with slightly better classification for 
C3(full) vs. TCC3 than for C3(full) vs. TCC2.   Using the PLS-DA classifier, an AUROC 
value of greater than 0.85 was obtained, meaning good; the total correctly classified, 
specificity and negative predictive value were all better than 80 %; the sensitivity better than 
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70% compared to only 56 % for SVM-LIN; but again, the positive predictive value and false 
discovery rates didn’t perform as well. 
A discussion of the classifications using PLS-DA and SVM-LIN 
These summaries show the importance of optimising the scaling and whether to use feature 
selection.  Feature selection, using the Wilcoxon t-test or the Student t-test methods, reduces 
the number of features or scans that are used by the classifier, by only selecting the ones that 
appear to have the most significance.  In the GC-MS data files, there were over 8700 scans 
(mass spectra).  The abundancies of the m/z at each scan had been summed to produce the 
TIC, which is two-dimensional data, for multivariate data analysis to be performed.  Feature 
selection reduced these 8700+ scan numbers down to 200 in some cases, indicating that 
classification between the data sets could be performed by only considering some peaks in 
the chromatograms, which could lead to identification of biomarkers. 
However, when examining each of the data sets that had been compared, reducing the 
number of features using either the Wilcoxon t-test or Student t-test methods, reduced the 
accuracy of the models for both the classifiers used.  This indicates that all data points need 
to be considered to obtain the best accuracy of classification.  Therefore, the differences 
between the cancer and control data sets cannot be reduced to such a low number of features 
and indicates that the whole profile must be considered.  Subsequently, feature selection was 
no longer used for data analysis.   
It should also be noted that within this chemometric data analysis, the use of the TIC is 
already a significant reduction in the data potentially available for the classification model.  
Effectively, this does not allow individual fragment ions and therefore co-eluting compounds 
to be monitored.  Unfortunately, this was dictated by the computing processing power; 
however, in the future this should become less of an issue and therefore the existing 
analytical data sets may still have the potential to produce even better clinical performances.  
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In addition, if the issues with processing power and COW alignment can be overcome then 
GCxGC opens even greater potential for better clinical diagnostic performance.    
Permutation density plots for the PLS-DA, SVM-LIN and Random Forest classifiers 
The Random Forests (RFs) machine learning algorithm is useful in creating models with low 
variance that don’t overfit the training set.  Classification using RFs was compared to 
classification using PLS-DA and SVM-LIN.  No feature selection was performed and the 
results using the best scaling technique for each classifier is presented. 
Previously, we have compared the performance of the different classifiers by summarising 
the results in tables.  It is easier to compare visually the success of the three different 
classifiers, PLS-DA, SVM-LIN and RFs and the different models that they have generated.  
The performance tables previously reported, showed the data from the peak maxima of these 
permutation density plots.  Effectively, this is the mean performance of all the models 
generated by the classifier.  For each model the files selected to develop the training set 
changed each time; whereas, some of the individual analysis models performed better than 
the values previously reported.  So, if you were to take the algorithms generated for any one 
of these better preforming models and apply it to real world samples then you might get 
better results than previously reported.   
The permutation density plots, shown in Figure 4.36 to Figure 4.39, show the frequency 
distribution of the overall number of samples correctly classified out of all the samples (% 
CC) for the 150 classification models in red.  The bars in blue show the distribution of the 
overall percentage classified after randomised assignation of clinical classes to the samples, 
to generate the 300 null models.   
It is important to generate many null models and compare them to the classification models.  
The likelihood of correctly identifying a sample as positive or negative, by randomly 
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assigning it a value, is the same as correctly guessing heads or tails when flipping a coin.  At 
first, you may be lucky or unlucky in guessing it correctly; however, over many guesses it 
should average out as 50 % correct and 50 % incorrect guesses, if the coin and the flipping 
of the coin have no bias.  Therefore, by producing many null models, the chemometric 
techniques and models used in the data analysis can be checked for any bias. 
Most of the null models (blue) show a tight distribution around the 50 % mark.  In the null 
hypothesis, each sample is randomly assigned as being a cancer sample or a cancer free 
sample before the model is built, therefore there is a 50 % chance of the assignment being 
correct.  This was repeated 300 times to generate 300 individual null models.  For example, 
in Figure 4.36, the distribution on the left are the null models (n = 300); the black vertical 
line is the mean; the green dashed vertical lines either side of the mean are the standard 
deviation (STDDEV); the blue vertical lines either side are two times the STDDEV. 
There were 150 classification models (red) generated using the clinical classification data, 
where the category was known.  Each model was produced by randomly selecting data files 
for the training set used to generate the model and the remainder used to test the model.  For 
each model a different set of data files were randomly selected for the training set, from all 
the possible data files.  As discussed previously in this chapter, the data files that had been 
acquired showed slight variations.  By randomising these data files and using 70 % for the 
training set and 30 % for the testing of the model, ensured the models were not generated 
using only the ‘best’ data files or the testing of the performance of the model carried out 
using the ‘best’ samples.  There will always be some data files that are of higher diagnostic 
quality than others and some samples that are more representative of the category than 
others; therefore, by generating 150 models using the best and the worst data there will be a 
spread in the performance of the models, but these are more representative of real-world 
samples.  In Figure 4.36, the distribution on the right are the classification models (n = 150); 
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the black vertical line is the mean; the cyan dashed vertical lines either side of the mean are 
the STDDEV; the purple vertical lines either side are two times the STDDEV. 
A comparison of the three different classifiers for the classification of C1 against TCC is 
shown in Figure 4.36.   There is complete separation between all null models (blue) and 
analysis models (red).  The SVM-LIN classifier (Figure 4.36(b)) produces the best 
performance: the null models are more tightly clustered around 50 %; the mean for the 
analysis models is 89 %; and the models are more tightly clustered around that mean.  The 
best performing models are at 96 %.  It is the means for these models that is shown in the 
tables and previously discussed earlier in this chapter. 
The comparison of the three different classifiers for the classification of C2 against TCC is 
shown in Figure 4.37.   Once again there is complete separation between all null models 
(blue) and analysis models (red).  The SVM-LIN classifier again (Figure 4.37 (b)) produces 
the best performance: the null models are more tightly clustered around 50 % showing no 
bias; the mean for the analysis models at 89 %; and the models are more tightly clustered 
around that mean.  The best performing models are at 96 %, meaning that these randomly 
selected training sets better captured the variability in the TIC of cancer positive samples 
than the less well performing models.  
Comparing the null and classification models for C2 vs. TCC very similar profiles are shown 
to those of the C1 vs. TCC.  C2 controls had produced a positive dipstick reading and could 
have been suffering from, for example urinary tract infections.  This could make it more 
difficult to differentiate them from the cancer samples, however neither the PLS-DA 
classifier, the SVM-LIN classifier nor the RFs classifier had any more difficulty than when 
differentiating the cancer samples from the healthy C1 controls.  
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Figure 4.36:  Permutation density plots for C1 vs. TCC using (a) PLS-DA, (b) SVM-LIN, (c) 
RFs 
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Figure 4.37: Permutation density plots for C2 vs. TCC using (a) PLS-DA, (b) SVM-LIN, (c) 
RFs 
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The comparison of the three different classifiers for the classification of C3 against TCC is 
shown in Figure 4.38.   As expected, it was more difficult to separate the cancer samples 
from the C3 control samples from patients suffering from other non-cancerous urological 
diseases, as expected.   Once again there is complete separation between all null models 
(blue) and analysis models (red); however, the RFs classifier does not produce such a large 
separation for this classification and was the worst performing classifier.  The PLS-DA and 
SVM-LIN classifiers gave very similar results but the SVM-LIN (Figure 4.38 (b)) produced 
a slightly narrower distribution of the null models, but a slightly wider distribution of the 
classification models, whereas the PLS-DA classifier had the opposite problem.  The SVM-
LIN classifier produced a mean for the analysis models of 79 % with the best performing 
models at 86 %.   
However, the mean of the null models is around 53% rather than 51% for PLS-DA, showing 
there is some bias in the classification models.  But it is more tightly clustered around that 
mean than PLS-DA which has some null models up to 58%.  Up until this point, SVM-LIN 
appears to be the better classifier visually, but it is struggling more with the classification of 
C3 controls against TCC samples. 
An overview of all the permutation density plots for %CC generated for each of the 
classifiers for each of the control categories vs. TIC (combined) can be seen in Figure 4.39.   
Comparing the PLS-DA, SVM-LIN and RFs classifiers for each control category against all 
TCC samples, they gave a very similar performance, although the RFs is not quite as good 
as the PLS-DA or SVM-LIN.  
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Figure 4.38: Permutation density plots for C3(full) vs. TCC using (a) PLS-DA, (b) SVM-
LIN, (c) RFs 
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Figure 4.39: Density plots of TCC vs. C1/C2/C3 for PLS-DA, SVM-LIN and RFs
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The greatest difference in %CC between the null and the analysis models is between the C1 
controls and the TCC samples for all classifiers, as expected, as it is much easier to 
distinguish between healthy and diseased samples.  Many of the early publications in disease 
diagnosis have used controls from healthy participants or have not specified what types have 
controls have been used, leading to the conclusion that they had been from healthy 
participants (Issaq, et al., 2008), (Pasikanti, et al., 2010).  In the real world, the models they 
generated would not work, as usually tests are performed because the patient is unwell and 
is therefore likely to have conditions such as those present in the C2 and C3 controls. 
The next stage was to compare each of the TCC categories individually against the C3(full) 
controls, this can be seen in Figure 4.40 to Figure 4.43.  The most difficult categories to 
separate are the more complex C3 control samples with non-cancerous urological diseases 
against the TCC1 early stage cancer sufferers, Figure 4.40 (a), (b) and (c).  The analysis 
models and the null models completely overlap for the SVM-LIN and RFs classifiers.  PLS-
DA gives a better separation but still has overlapping distributions, with a mean of 76 % for 
the analysis and 69 % for the null models.  The best performing analysis models are at 87 % 
which are separate from the worst performing null models.  The null models are more tightly 
clustered for SVM-LIN and RFs, with the mean at 78 % and 76 % respectively.  The best 
performing analysis models are at 87 % and 89 % respectively.  However, as discussed 
before, this does not reflect the very poor sensitivity of the SVM-LIN classifier for this 
classification and so these visual representations of the density plots of %CC must also be 
regarded as indicative. 
There is more difficulty in distinguishing these two similar groups, C3 and TCC1, suggesting 
that a more rigorous modelling algorithm or machine learning technique is required for this 
data.  In addition, the GC-MS data needs to be modelled using all fragment ions rather than 
just the TIC, especially as the data is already available.  Also, GCxGC-ToFMS data could 
be used, provided the issues described previously are resolved. 
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Figure 4.40: Permutation density plots for C3(full) vs. TCC1 using (a) PLS-DA, (b) SVM-
LIN, (c) RFs 
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The permutation density plots of C3(full) against TCC2 are shown in Figure 4.41.  PLS-DA 
shows complete separation of the null and analysis models, with the mean of the null models 
at 61 % and the analysis models at 78 %.  The best performing models were at 89 %.  
Although having null models more tightly clustered, the SVM-LIN and RFs classifiers gave 
mean null models of 68 % and 65 % respectively, both of which overlapped with the analysis 
models distribution.  Therefore visually, as well as examining the performance values of the 
various classifiers for this classification, the best classifier was again PLS-DA. 
Visually, the best classifier for the classification of C3(full) and TCC3 samples was SVM-
LIN, as shown in Figure 4.42.  The null models are more tightly clustered and separate from 
the analysis models; however, all null models have a higher %CC than the other classifiers.  
The mean correctly classified of the 150 analysis models is 85 % with the best performing 
model at 95 %.  The RFs classifier gave similar distributions but not such a good 
performance.  The PLS-DA classifier gave a broader distribution for the null models, 
however the mean of the null models was 63 %, compared to 69 % for SVM-LIN and 65% 
for RFs.  The analysis models gave similar performance to the SVM-LIN.  Again, the total 
correctly classified hides the very poor sensitivity of the SVM-LIN classifier when compared 
to the PLS-DA classifier and therefore the PLS-DA classifier is the better performer overall. 
All nine permutation density plots for the three classification of all the C3 controls against 
the various TCC sub-categories can be seen in Figure 4.43.  The similarities of the 
distributions between C3(full) against TCC2 ((d), (e) and (f)) and TCC3 ((g), (h) and (i)) for 
all three classifiers can easily be seen in (d) to (i).  C3(full) against TCC1 is clearly the most 
difficult to classify, as was also indicated by the performance metrics for the different 
classifiers.  Going from TCC1 to TCC3 the performance of the models improves for all three 
classifiers.  The %CC performance of the classification models are consistent for all TCC 
categories but it is the %CC performance of null models that improve on going from TCC1 
to TCC3.   
282 
 
 
Figure 4.41: Permutation density plots for C3(full) vs. TCC2 using (a) PLS-DA, (b) SVM-
LIN, (c) RFs 
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Figure 4.42: Permutation density plots for C3(full) vs. TCC3 using (a) PLS-DA, (b) SVM-
LIN, (c) RFs 
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This indicates that the data sets and/or chemometric techniques are being influenced by an 
external factor, providing bias and resulting in the null models not clustering around 50 %.  
Moving from TCC1 to TCC3 this has less of an influence.  Further work needs to be carried 
out on the data analysis to determine the source of this bias. 
The use of the RFs classifier has not improved the ability to classify these samples.  
Separation of the distributions is achieved by PLS-DA, but not by the RFs classifier, with 
the SVM-LIN’s performance in-between them.  The RFs classifier may not have been 
optimised, due to very slow processing by the computer, even when choosing small numbers 
of trees.  Eventually, by cropping from greater than 8,700 scans down to 8,500 scans, 
classification models were built using 150 evaluations for 50, 150, 250, 350 and 450 trees 
which enabled processing of the data, but the RFs classifier may not have been fully 
optimised and improved performance may be achieved with a larger number of trees.  
Overall, the PLS-DA classifier appears to give consistence performance, no matter what the 
data sets are. 
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Figure 4.43: Density plots C3(full) vs. TCC1/2/3 for PLS-DA, SVM-LIN and RFs 
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4.2.3 Statistical analysis of the reduced dataset with age-matching 
It was hypothesised that much of the source of the statistical variation between C3 controls 
and TCC samples was potentially thought to be age related.  To test that theory the C3 control 
data set was filtered to only include patients in the same age range as those in the TCC data 
sets.  The number of participants used in the C3 age-matched classification can be seen in 
Table 4-3.  This reduced C3 data set (C3(AM)) was processed as before, using the three 
classifiers PLS-DA, SVM-LIN and RFs for pattern recognition. 
4.2.3.1 Pattern recognition using PLS-DA, SVMs and RFs on aged-
matched samples 
The revised data set C3(AM) was processed against all TCC samples, and individually 
against TCC1, TCC2 and TCC3 using PLS-DA, SVM-LIN and RFs.  As before, the scaling 
method was optimised but feature selection was not tried, due to the poor results obtained 
with the previous data set.  The results from the mean of the classification models are 
summarised in Table 4-19.     
For all data sets, the RFs classifier gave poorer results than the PLS-DA or SVM-LIN.  The 
PLS-DA and SVM-LIN gave similar results for all data sets, with SVM giving slightly better 
results than PLS-DA for most.  The exception was the most difficult data set C3(AM) vs. 
TCC1 where PLS-DA gave a higher overall accuracy of 69 % compared to 67 % for SVM-
LIN and RFs and an AUROC score of 0.74 compared to 0.63 and 0.71, respectively.   
The permutation density plots of the different classifiers and classification models against 
the null models can be visualised in Figure 4.44 to Figure 4.49 for the age-matched C3(AM) 
data set.  As can be seen in Figure 4.44 for C3(AM) vs. TCC, there are overlapping 
distributions at a CI of 95 % for PLS-DA but not for SVM-LIN or RFs.  Again, the 
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classification distributions are very broad and the null models very narrow for the machine 
learning algorithms.  There is overlap for all 3 classifiers for the most difficult comparison 
of C3(AM) vs. TCC1, as shown in Figure 4.45.  However, visually there is improvement in 
the classification of the age related C3(AM) data set when comparing against the full 
C3(full) data set.  For all data sets, RFs again gave the worst performance. 
Table 4-19: Comparison of classification algorithms across all datasets 
Dataset Classifier %CC %Spec %Sens LV or Tree* AUROC
C1 v TCC PLS-DA 87.53 87.23 87.82 16 0.9055 
SVM-LIN 88.99 88.84 89.13 -- 0.9350 
RFs 80.91 80.28 81.75 450 0.892 
C2 v TCC PLS-DA 88.35 88.21 88.48 12 0.9276 
SVM-LIN 89.18 88.00 90.33 -- 0.9220 
RFs 82.70 82.93 82.72 450 0.865 
C3 v TCC PLS-DA 83.01 66.06 88.66 8 0.8680 
SVM-LIN 83.48 44.36 96.52 -- 0.9023 
RFs 83.57 42.90 86.99 150 0.8427 
C3 v TCC1 PLS-DA 69.18 66.18 73.29 13 0.7424 
SVM-LIN 67.30 86.15 41.38 -- 0.6363 
RFs 67.33 77.63 54.03 450 0.7102 
C3 v TCC2 PLS-DA 80.51 71.39 88.23 7 0.8985 
SVM-LIN 81.44 72.15 89.31 -- 0.9040 
RFs 75.87 64.31 86.66 350 0.8642 
C3 v TCC3 PLS-DA 79.70 73.48 85.17 20 0.8580 
SVM-LIN 81.46 73.91 88.11 -- 0.9280 
RFs 74.44 66.76 81.64 350 0.8098 
*Denotes the optimum number of trees for Random Forests. 
Comparing the age-matched data set with the full data set for the comparisons that used the 
C3 control category, as summarised in Table 4-20, for all data set comparisons where the 
mean of all classification models is given, there was an improvement in the AUROC score, 
meaning that the classification system improved on considering the age in selecting the 
control samples for C3. 
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Figure 4.44: Permutation density plots for C3(AM) vs. TCC using (a) PLS-DA, (b) SVM-
LIN, (c) RFs 
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Figure 4.45: Permutation density plots for C3(AM) vs. TCC1 using (a) PLS-DA, (b) SVM-
LIN, (c) RFs 
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Figure 4.46: Permutation density plots for C3(AM) vs. TCC2 using (a) PLS-DA, (b) SVM-
LIN, (c) RFs 
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Figure 4.47: Permutation density plots for C3(AM) vs. TCC3 using (a) PLS-DA, (b) SVM-
LIN, (c) RFs
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Figure 4.48: Permutation density plots of the C3(AM) data set against all TCC data and the TCC1 data set 
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Figure 4.49: Permutation density plots of the C3(AM) data set against the TCC1 and TCC2 data sets  
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Looking at the most difficult comparison of C3 against TCC1 data, the sensitivity was not 
so good for either classifier in the full data set but the specificity was good.  For the age-
matched data set, for example for the PLS-DA, the overall accuracy reduced, the specificity 
reduced but the sensitivity and AUROC scores greatly increased.  This means that the overall 
number of TCC samples correctly classified greatly increased; however, the number of 
C3(AM) samples incorrectly classified as cancer samples slightly increased.  Depending on 
the operational model for the screening programme, this could be considered a benefit, as 
more positive patients would be identified.  Conversely, this would mean that more negative 
patients would receive further tests.    
Table 4-20: Comparison of the results using the C3(full) and C3(AM) data sets 
 Dataset Model %CC %Spec %Sens AUROC 
C3 v TCC Full PLS-DA 76.85 74.41 78.95 0.8399 
 SVM-Lin 78.78 74.51 82.46 0.8332 
 Age-
matched 
PLS-DA 83.01 66.06 88.66 0.8680 
 SVM-Lin 83.48 44.36 96.52 0.9023 
C3 v TCC1 Full PLS-DA 75.78 80.91 57.50 0.6193 
SVM-Lin 80.47 97.94 18.25 0.6079 
 Age-
matched 
PLS-DA 69.18 66.18 73.29 0.7424 
 SVM-Lin 67.30 86.15 41.38 0.6363 
C3 v TCC2 Full PLS-DA 78.37 79.81 75.21 0.8134 
SVM-Lin 78.60 93.16 46.69 0.7256 
 Age-
matched 
PLS-DA 80.51 71.39 88.23 0.8985 
 SVM-Lin 81.44 72.15 89.31 0.9040 
C3 v TCC3 Full PLS-DA 80.75 84.94 71.20 0.8592 
SVM-Lin 82.67 94.28 56.19 0.8122 
 Age-
matched 
PLS-DA 79.70 73.48 85.17 0.8580 
 SVM-Lin 81.46 73.91 88.11 0.9280 
For the other data set comparisons, the overall accuracy stayed the same or improved, the 
specificity slightly reduced but the sensitivity improved.  This shows that the metadata such 
as age, should be taken into consideration when classifying samples.  
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Future work, using this data set alone, would be to explore the influence of other metadata, 
such as smoking status, the presence of blood, glucose and other dipstick text positives on 
the data. 
In future studies, controls should not only be matched in terms of illnesses and other diseases 
that could influence the classification, i.e. samples from healthy individuals should not be 
used or should be used along with other controls, but also, as far as possible, controls should 
be recruited that match the age group of the diseased or cancer positive patients. 
4.2.3.2 Statistical significance 
Visually, significant results had been achieved using the PLS-DA classifier for all age-
matched data set comparisons in Figure 4.44 to Figure 4.47.  This means that the accuracy 
of the classification models (shown as solid black lines in the red distribution) is beyond two 
STDDEVs of the respective null model means (shown as the solid blue lines) and vice versa 
for the null hypothesis models (mean shown as a solid black line in the blue distribution) 
which is beyond two STDDEVs of the classification model means (shown as solid pink line).  
These show that significant results had been achieved at the 95% confidence level, even for 
the age-matched C3(AM) data set against the TCC1 cancer categories, as shown in Figure 
4.45. 
This is further corroborated with the calculation of the statistical significance of the data set 
comparisons, shown in Figure 4.48 and Figure 4.49, for the C3(AM) data set, as summarised 
and shown in Table 4-19.  The significance was determined using the Z-test for overlapping 
distributions using the PLS-DA classifier, which was the most consistent classifier for all 
comparative data sets. 
The p-value was calculated at the 95 % confidence level where α = 0.05 and the results are 
shown in Table 4-21.  The null hypothesis would state that there is no difference between 
296 
 
the two means. However, since the calculated probability is << 0.05 (95%) then the null 
hypothesis is rejected implying statistical significance. 
Table 4-21: Z-test statistical significance for overlapping distributions with PLS-DA  
Data set Overall accuracy (%) 
Z value      
(Zcrit = 1.96) 
p-Value        
(α = 0.05) 
Significant 
difference 
C1 vs TCC 87.53 143.61 <0.0001 Yes 
C2 vs TCC 88.35 147.54 <0.0001 Yes 
C3(AM) vs TCC 83.01 32.02 <0.0001 Yes 
C3(AM) vs TCC1 69.18 24.42 <0.0001 Yes 
C3(AM) vs TCC2 80.51 66.07 <0.0001 Yes 
C3(AM) vs TCC3 79.70 56.70 <0.0001 Yes 
As shown, all the classifications were determined to have significant difference between the 
classification and the null models for PLS-DA, even though there was some overlap for C3 
vs. TCC1.  
4.2.4 Biomarker discovery 
The advantage of the PLS-DA classifier is the ability to view the loadings to reveal possible 
regions of the TIC chromatogram indicative of metabolites or compounds that could be 
potential biomarkers to diagnose TCC.  A PRS PLS-DA Loadings Viewer (Dr Michael 
Cauchi, Bruce Bolt and Philip Spratt, Cranfield University) was used to plot the LV against 
the retention time and suggested the retention times of peaks that provided the largest 
differences between the C3(AM) controls and TCC data sets.  An example is shown in Figure 
4.50 for C3(AM) vs. TCC1.  From there library searches against the NIST (National Institute 
of Standards and Technology, USA) and MassBank (National Institute of Biomedical 
Innovation, Japan) libraries are possible.  The negative peaks indicate a decrease in 
abundance between C3(AM) and TCC1, whereas the positive peaks indicate an increase in 
abundance between C3(AM) and TCC1. 
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Figure 4.50:   PRS PLS-DA Loading Viewer suggesting retention times of key peaks in the 
C3(AM) vs. TCC1 classification 
A summary of possible biomarkers, identified using this viewer, are presented in Table 4-22.  
However, as is shown in Figure 4.50, there are a very large number of negative and positive 
peaks, more than listed in the table.    
When comparing these to the peaks identified in the fibre, matrix and procedural blanks 
there several compounds that were identified in these blanks.  This doesn’t mean that they 
are still not potential biomarkers, but their relevance needs to be investigated, by checking 
retention times to ensure that they were identified as the same compounds and by comparing 
the peak areas in the samples to the blanks.  This should be carried out as future work. 
The remaining metadata has also not been used in the classification and therefore this needs 
to be examined in relation to the peaks shown and identified here.  But even after potentially 
many of these being ruled out, as not being related to the cancer status, it would still leave 
many peaks.  Therefore, reducing the amount of information, by selecting only peaks of 
interest no longer uses pattern recognition for classification, but distinct peaks.  This goes 
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back to the reason that feature selection was determined to give poorer classification results, 
as it reduced the amount of data used in the classification.  
Table 4-22:  Potential biomarkers identified from the PLS-DA loadings after classification.  
Compound Database Change* 
2-Pentanone NIST & MassBank Decrease 
2,3-Butanedione MassBank Decrease 
4-Heptanone MassBank Decrease 
Dimethyl disulphide NIST Decrease 
Hexanal NIST Increase 
Benzaldehyde MassBank Increase 
Butyrophenone MassBank Increase 
3-Hydroxyanthranilic acid MassBank Increase 
Benzoic acid MassBank Increase 
Trans-3-Hexanoic acid MassBank Increase 
Cis-3-Hexanoic acid MassBank Increase 
2-Butanone NIST Increase 
2-Propanol NIST Decrease 
Acetic acid NIST Decrease 
Piperitone MassBank Decrease 
Thujone MassBank Decrease 
*Indicates the increase or decrease of the abundance from C3(AM) to TCC. 
The list of potential biomarkers was compared against bladder cancer publications that 
mention biomarkers, of which there are very few.  The list of potential markers published by 
Pasikanti and colleagues (Pasikanti, et al., 2010), has no overlap, although there are some 
compounds listed in both that are of the same class.  Most metabolites listed by Pasikanti 
and colleagues are volatile acids and we found four acids, although not the same ones.  Tsai 
and colleagues suggested that the listed 3-hydroxyanthranilic acid (3-HAA) is a potential 
biomarker of bladder cancer, with raised levels in those with bladder cancer (Tsai, et al., 
2015).  This was also shown in our results.  Reduced levels of 4-heptanone were also reported 
as a bladder cancer biomarker by Zhu and colleagues (Zhu, et al., 2007).  Therefore, it is 
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possible that some of the biomarkers that we identified are linked to bladder cancer, but this 
requires further investigation.  
4.3 Studies by other groups, since the project analyses 
Since the method was developed and optimised and the analysis of the samples by HS-
SPME-GC-TOFMS was completed, there have been several publications released on 
bladder cancer analysis. 
A GC-sensor device has been proposed along with a statistical model for the identification 
of bladder cancer from urine headspace (Khalid, et al., 2013).  This project studied 24 
patients with bladder cancer and 74 controls.  The urine samples were prepared using sodium 
hydroxide and after placing in a water bath at 60 °C for 50 minutes, a 2 mL aliquot of 
headspace was removed using an unheated, gas-tight syringe and injected into the GC.  The 
VOCs were separated using compressed air as a carrier gas and the eluted peaks were 
detected with a metal oxide sensor.  The total run time was 42 minutes and the data was 
processed using two different methods.  The first using two-group linear discriminant 
analysis with leave-one-out cross-validation (LOO-CV).  This approach resulted in a 
sensitivity of 95.8 % and a specificity of 93.2 %.  The second method used PLS-DA with 10 
latent variables (LVs) and LOO-CV, this resulted in a sensitivity of 95.8 % and a specificity 
of 95.9 %.   
On the face of it these results appear excellent; however, this analysis method takes much 
longer and is more manual than the method developed during my period of study.  There is 
no mention of method controls within the paper to ensure accuracy of the sample analysis, 
even though they mention their instrument as being ‘reliable’.   
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In terms of the participants, the control samples were not categorised.  The 24 bladder cancer 
patients were graded, similarly to my project, however, this resulted in very few participants 
for each type.  As advised by the project partners at Cranfield University, for statistical 
significance, there needs to be a minimum of 30 positive and 30 negative for comparative 
purposes, the small study was acknowledged by the author.  Also, the number of participants 
for each group should be balanced, to reduce bias, which was not the case in this study.  
In terms of the statistical analysis conducted by Khalid and colleagues, both discriminant 
analysis techniques used only LOO-CV with no cross-model validation or permutation 
testing.  This simpler analysis approach has previously been shown to give over-optimistic 
results and a more thorough validation approach should be used, as employed here 
(Westerhuis, et al., 2008). 
The same group then went on to publish a paper on the diagnosis of urological malignancies 
using a GC-sensor system including bladder cancer and prostate cancer (Aggio, et al., 2016).  
The paper will be discussed in the next chapter. 
Studies have also been published on the potential of using polymerase chain reaction (PCR) 
techniques as a non-invasive diagnostic technique for bladder cancer.  Perez and colleagues 
(Perez, et al., 2014) published the results of a pilot study identifying four genes involved in 
differentiating between cancer and non-cancer urinary vesicles.  Since then, there have been 
multiple publications on using multiplex PCR which is described as ‘a useful tool for staging 
and monitoring purposes’ (Leotsakos, et al., 2014) and it has been reported to need more 
research to be carried out using this technique, due to the genomic complexity (Togneri, et 
al., 2016). 
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4.4 Conclusions and future work 
The aims of assessing the performance of the analytical method, by quantifying the IS 
present in every sample and sample blank, was to determine if the HS-SPME-ToFMS 
method developed was reproducible and sensitive enough to enable comparisons of the data 
files of the different types of clinical samples that would show differences in the analytes 
detected due to the differences in the clinical status of the sample rather than instrument 
and/or sample analysis error.  In summary, we can conclude the following: 
• The components of samples given in Table 4-1, for example blood or bilirubin, are 
present in variable amounts both in control and diseased samples and therefore are 
not indicative of the disease state.  Care should be taken to ensure the samples used 
for modelling reflect this variation so that the presence or absence of these 
components do not influence the classification models. 
• The analysis of replicate samples, with consecutive and non-consecutive injections 
in a batch and between-batch replicates showed no reduction in performance between 
these types of replicates.   
• The IS quantitation ion peak areas showed better reproducibility for the replicates 
than it did when comparing the area throughout all samples in a batch or between 
batches, most likely due to drift.   
• When excluding the batches with SPME fibre failure, the RSD of the IS quantitation 
ion peak area was less than 30 % for most batches.   
• The variation in the response of the unknown analytes in the replicate injections 
matched the IS response variation and therefore normalisation against the chosen IS 
would be possible. 
• Assessing the library similarity match of the IS helps to assess the sensitivity of the 
method, alongside the IS peak areas and SN ratio. 
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Therefore, normalisation of the data against the IS is highly recommended: 
• To align the retention times, thus enabling comparison of the peaks in each data file 
based on their scan number. 
• To compare the response of the peaks in each data file more accurately, leading to 
the generation of more significant classification results. 
The PLS-DA classifier produced models that gave a mean accuracy of 80 % or greater for 
C1, C2 or C3 (age-matched controls) vs. all TCC samples and for C3(AM) vs. TCC2 and 
TCC3.  The C2 vs. TCC specificity of 88 % and sensitivity of 89 % was comparable to those 
achieved for high grade tumours using urine cytology of 90 % and 80-90 % respectively.  
However, for low grade tumours, C3 vs. TCC1 gave a sensitivity of 73 % which is much 
better than 20- 50 % obtained when using the urine cytology.  Future work to improve these 
results further is still possible. 
A large amount of high quality data was collected through this study.  However, I feel that a 
large amount of this valuable information has still not been used.  Further chemometric 
analysis of the data should be focused on: 
• Finding out which samples were classified as outliers and investigating the reasons 
why they were classified as such.  Potential reasons could be instrument acquisition 
problems, IS concentration, or it could be related to the metadata from the 
participants. 
• Making more use of the metadata.  Age-matching improved the classification of C3 
controls, in particular against TCC1 cancer participants.  For example, would 
considering the gender of the participants or smoking status improve it further?  
Other metadata would include dipstick test results, drugs taken and even food and 
drink intake.  The previous point may help to determine this.  
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• Investigating if the specific gravity can be successfully used for normalising the urine 
sample concentration.  
• Using three-dimensional data for multivariate analysis of retention time, abundance 
and mass to charge ratio, rather than two-dimensional data of retention time and TIC 
abundance, where the abundance of each mass was summed.  This should be possible 
now, due to improvements in computing power since this data was analysed. 
• Validation of the models created here by analysing and classifying new, independent 
urine samples, both positive and negative.  These had been requested but did not 
materialise before my PhD ended. 
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 Prostate Cancer Study 
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5.1 Introduction 
After the success of training dogs to identify bladder cancer from sniffing the headspace 
above urine (Willis, et al., 2004) and the successful preliminary studies in using SPME-GC-
MS to classify the bladder cancer samples from controls, Willis and colleagues wanted to 
apply these techniques (both dogs and analytical instrumentation) to other cancer studies.  In 
prostate cancer (PC) diagnosis, there is a lack of non-invasive, sensitive and specific 
techniques to identify prostate cancer.  The differentiation between prostate cancer and 
benign prostatic hypertrophy (BPH) is very difficult.   
5.1.1 Participant selection and sample types 
Participants were recruited for both the bladder cancer and prostate cancer studies at the 
same time.  Further details on selecting participants for this study can be found in Section 
4.1.1.  As reported for the bladder cancer data, metadata was collected and urinalysis 
performed.  As can be seen in Figure 5.1 to Figure 5.3, the metadata was extracted, for all 
samples analysed, by highlighting the range of values from each data type, or highlighting 
those that tested positive for a feature.  A screenshot of the sex, age, smoking status and 
dipstick measurements for the PC participants can be seen in Figure 5.1, further information 
on these different urinalysis abnormalities can be found in Section 4.1.3.  A screenshot of 
the diagnosis and the medication taken up to 48 hours before the study sampling for the BPH 
participants can be seen in  Figure 5.2.  A screenshot of the food and drink intake up to 48 
hours before the study sampling for the C4 participants can be seen in Figure 5.3.   
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Figure 5.1: Snapshot of metadata for prostate cancer (PC) participants, showing sex, age, smoker plus urinalysis results 
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Figure 5.2: Snapshot of metadata for BPH participants, showing diagnosis and medication taken within 48 hours prior to study 
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Figure 5.3: Snapshot of metadata for C4 participants, showing food and drink intake during 48 hours prior to study
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All participants were questioned about their intake in the previous 48 hours with a mixture 
of participants having drunk alcohol within 24 hours, most having eaten cooked garlic, raw 
garlic, cooked onion, raw onion, brassicas, mustard, mint, fish, strong cheese or other strong 
flavours, for example ginger and spices.  A handful of participants across all classes had 
eaten asparagus, aniseed or liquorice in the previous 48 hours. 
A summary of the metadata for the participants in this study is provided in Table 5-1 and 
Table 5-2.  The range of values, for each parameter and their relevance is discussed in this 
section.   
All participants in this study were male.  There were three types of samples: those with 
prostate cancer (PC) and two types of controls (BPH and C4).  PC samples were taken from 
patients with new or recurrent prostate cancer and included the recruitment of male patients 
over the age of 18 years.  Based on a review of the urinalysis results and metadata collected 
for each of the patients, we can conclude the following: 
• These were male patients aged between 48-77; a mixture of smokers and non-
smokers.  All PC patients tested negative for bilirubin and nitrite; all had normal 
urobilinogen levels; one had small amounts of ketones in his urine; another had a 
large amount of glucose in his urine; some tested positive for blood, protein and/or 
leucocytes; their urine ranged from pH 5-7.5; their specific gravity ranged from 1.01-
1.03; the majority were taking prescription medication; most were not taking over 
the counter medication but a few had pain relief medication; some were on vitamin 
or mineral supplements; no one had taken recreational drugs. 
For the control samples, it was important to include participants with benign prostatic 
hypertrophy (BPH) to classify cancer samples based purely on the volatiles present rather 
than the volatiles that were not specifically attributed to cancer.  Along with the BPH controls 
another group of controls were identified from the non-cancer participants recruited in the 
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bladder cancer and prostate cancer studies.  The number of participants in the C4 control 
category were selected to match those of the participants in the BPH and PC categories, in 
addition to age range and gender (male).  As is shown in Table 5-2, the median age is very 
similar.  Based on a review of the urinalysis results and metadata collected for each of the 
patients, we can conclude the following: 
• BPH - These were male patients aged between 55-86; a mixture of smokers and non-
smokers.  Some BPH patients had trace amounts of glucose in their urine; one patient 
tested positive for bilirubin; some tested positive for ketones, protein and/or nitrite; 
over half tested positive for leucocytes and/or blood; they all had normal 
urobilinogen levels; their urine ranged from pH 5-8; their specific gravity ranged 
from 1.005-1.03; the majority were taking prescription medication; most were not 
taking over the counter medication but a few had pain relief medication; some were 
on vitamin or mineral supplements; no one had taken recreational drugs. 
• C4 - male participants aged between 54-79; a mixture of smokers and non-smokers.  
C4 controls had normal levels of urobilinogen; were negative for bilirubin, nitrite 
and ketones; one patient had a dipstick test that was strongly positive for glucose, 
another patient had a trace of protein; a fifth had produced a dipstick reading that had 
trace amounts of  leucocytes, and/or moderate amounts of blood; their urine ranged 
from pH 5-7; their specific gravity ranged from 1.005-1.03; they were all taking 
prescription medication; most were not taking over the counter medication but some 
were on pain relief; some on vitamin or mineral supplements; one had taken 
recreational drugs. This category included patients with focal atrophy and chronic 
inflammation only. 
As all control participants were over the age of 32, they were required to have been screened 
with a recent cystoscopy to check that there were no visible signs of bladder cancer, 
otherwise they were excluded.  As all control participants were over the age over 50, they 
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were only included if they had recently been checked for prostate cancer with a negative 
result. 
Participants with current history of malignancy or pre-malignancy elsewhere in the body, a 
pre-malignant urological disease or a history of bladder cancer other than TCC were 
excluded from the study.  Participants who had suffered from a different cancer elsewhere 
in the body more than five years previously and were considered disease-free were included 
in the study.  Participants with mental incapacity or who had participated in another clinical 
trial during the study period and three weeks prior to inclusion were also excluded.   
Table 5-1:  Participants used in the study: prostate cancer (PC) and control (C4 and BPH)  
 Category 
Number: C4 BPH PC 
Participants 39 36 39 
Total samples analysed 117 104 117 
Smokers 4 9 4 
With blood detected 6 (*-***) 23 (*-***) 10 (*-***) 
With glucose detected 1 (***) 2 (*) 1 (***) 
With protein detected 1 (*) 13 (*-**) 4 (*) 
With bilirubin detected 0 1 (*) 0 
With high urobilinogen 0 0 0 
With nitrite detected 0 9 (*-***) 0 
With leucocytes detected 6 (*-**) 21 (*-***) 10 (*-**) 
With ketones detected 0 4 (*-**) 1 (*) 
Total samples data processed  109 99 104 
Participants after outlier removal 38 36 37 
* = trace or small amount, ** = moderate amount, *** = large amount 
Most participants in each category were non-smokers, ranging from 10 to 25 %.  As can be 
seen in Table 5-2, the pH range of the samples for each category was also similar.  The most 
acidic pH for each category was pH 5, whereas the most basic samples ranged from pH 7 in 
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C4 controls to pH 8 in BPH samples.  The specific gravity for each category was normal, 
with all categories within the range of 1.005-1.030. 
Table 5-2:  Participants used in the PC study: age, pH and specific gravity 
Category 
Data C4 BPH PC 
Age range (years) 54-79 55-86 48-77 
Median age (years) 64.2 70.4 66.8 
pH range 5-7 5-8 5-7.5 
Specific gravity 1.005-1.030 1.005-1.030 1.010-1.030 
5.1.2 HS-SPME-GC-ToFMS analysis 
A total of 39 prostate cancer samples along with 75 control samples (39 C4 and 36 BPH) 
were analysed, in triplicate where the quantity of sample allowed.  Analyses were conducted 
along with bladder cancer samples and controls.  As reported in Chapter 4, analyses were 
conducted in 22 batches, including fibre blanks, sample blanks and procedural blanks.  The 
samples were prepared and analysed using HS-SPME-GC-ToFMS as described in Section 
2.2.  The total number of participants and total number of samples analysed, including 
replicates, along with the metadata, has been presented in Table 5-1.  
The data was processed using the statistical methods described in Section 2.4.  To 
summarise: 
• A consistency test was performed on the data files to ensure that they had roughly 
the same number of scans.  Any files that had too few scans for alignment, were 
removed.  Generally, these files were samples that had failed to acquire on the GC-
MS instrument.  This consistency test was performed when importing the data files 
into the data analysis software.   
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• The data was standardised against the IS, phenol-d6, quantitation ion.  Exploratory 
PCA analysis was performed and outliers were removed.  Outlying samples were 
identified visually and statistically, leaving the total number of data files and 
participants for each category as shown in Table 5-1.   
• The chromatographic peaks were aligned using COW.  Different types of scaling and 
feature selection were investigated.  Classification was performed using PLS-DA, 
SVM-LIN and RFs with cross-model validation through bootstrapping with LOO-
CV and LFO-CV.   
Each of these approaches were previously described in Chapter 2. 
5.2 Results and Discussion 
The results and discussion is divided into two sections: 
The raw data that was processed using Leco ChromaTOF software will be discussed in 
Section 5.2.1.  This section will look at the use of the IS for assessing the reproducibility of 
the method.  As both the bladder cancer and prostate cancer study samples were analysed 
together, the results from the use of the IS for both studies were presented in Section 4.2.1, 
as they cannot be separated for certain tests.  In this chapter, only results relevant to the 
prostate cancer study are presented. 
The results of the statistical analysis by Cranfield University will be shown and discussed in 
Section 5.2.2.  This section will give the results from each step of the data processing. 
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5.2.1 Robustness of HS-SPME-GC-TOFMS analysis method for 
prostate cancer samples 
5.2.1.1 Performance assessments using an IS  
The IS was added to all C4, BPH and PC samples analysed in this study.  This enabled an 
assessment of the performance of the method, as well as enabling alignment and 
normalisation of the results in the data processing.  All the prostate cancer study samples 
were analysed in the batches alongside the bladder cancer study samples and blanks.  The 
performance of the method, using the IS, was discussed in Section 4.2.1.  In brief, it 
concluded that retention time reproducibility was very good and normalisation of the 
response against the IS improved the ability to compare data files acquired across many 
batches. 
5.2.1.2 Replicate sample analyses 
As discussed in Chapter 4, replicate sample analysis enabled the reproducibility to be 
assessed.  As most PC study samples were acquired in triplicate there is far too much data 
to show here, therefore I’ve selected some good and poor PC, BPH and C4 chromatogram 
overlays.   
The overlaid IS quantitation ion chromatograms for three consecutive injections in Batch 1 
of a PC sample is shown in Figure 5.4.  The peak shapes, resolution and baseline are very 
similar for all 3 injections, although Injection 2 (green) has a later retention time and 
Injection 1 (orange) has a lower response.     
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Figure 5.4:  IS (peak 2) quantitation ion for consecutive injections of a Batch 1 PC sample 
The results of the IS retention times and quantitation ion areas is given in Table 5-3. 
Table 5-3: IS results for consecutive injections of a PC sample in Batch 1 
Replicate Retention time (s) Peak area (arbitrary units) 
1 610.6 37548690 
2 611.3 52802854 
3 610.5 53093767 
Average: 610.8 47815103.7 
RSD (%): 0.07 18.60 
The retention time reproducibility of these replicate injections, is similar to those seen for 
replicate, in-batch analyses of the sample blanks, as shown in Table 4-6.  The IS peak area 
replicate injections for this sample is less than that seen for in-batch sample blank replicates, 
of around 20 %, as shown in Table 4-7.  The differences are mostly likely caused by 
variations in the extraction and desorption of the fibre or inconsistent spiking of the IS into 
the vials.  Chromatograms from three consecutive injections of a BPH sample in Batch 2 is 
shown Figure 5.5. 
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Figure 5.5: Overlaid TICs of consecutive injections of a BPH sample in Batch 2 
The second injection (green) and third injection (blue) are very similar throughout the 
chromatogram.  The first injection (orange) has a slightly lower response, which is most 
apparent at the front.  It is possible that this sample was more defrosted on transferring to 
the HS vial, losing some volatiles, or there is less solvent contamination, as seen in the 
sample blanks.  On extracting the IS quantitation ion, this also had a slightly lower response, 
therefore, normalisation against the IS should align the intensities for most peaks.  
The peak area and retention time reproducibility can be seen for the analysis of three 
replicate injections of a PC sample scattered throughout a batch.  The IS quantation ions for 
Injections 10, 15 and 45 in Batch are shown in Figure 5.6. 
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Figure 5.6:  IS quantitation ion for in-batch replicates of a PC sample in Batch 2 
The first injection (orange) and second injection (green) are very similar, with almost 
identical retention times and area.  The third injection (blue) that was injected much later in 
the batch shows a little more variation.  The data is summarised in Table 5-4. 
Table 5-4: IS results for in-batch replicate injections of a PC sample in Batch 2 
Batch injection no. Retention time (s) Peak area (arbitrary units) 
10 610.7 31634744 
15 610.7 32150386 
45 610.9 36195805 
Average: 610.8 33326978.3 
RSD (%): 0.02 7.49 
The in-batch replicates data shown here, is better than the data from the consecutive 
injections discussed previously.  This indicates that any changes in repeatability is more 
likely to be due to random error, not through any reduction in sensitivity or carryover 
throughout a batch.  The TICs from in-batch replicates of a C4 sample in Batch 14, Injection 
41, 52 and 64 can be seen in Figure 5.7. 
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Figure 5.7: Overlaid TICs of in-batch replicates of a C4 sample in Batch 14 
From 300 seconds, onwards, the replicates are very similar, with the second injection (green) 
showing a slightly better response.  Once again, at the front of the chromatogram the first 
injection shows a lower baseline, but the peaks are the same size.  Again, the result shows 
that the response does not systematically reduce or increase throughout a batch. 
The reproducibility of the peak area and retention time can be seen for the analysis of three 
replicate injections of a BPH sample scattered between batches.  The IS quantiation ion in 
Batches 8, 11 and 18, respectively, are shown in Figure 5.8. 
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Figure 5.8: IS quantitation ion for between-batch injections of a BPH sample in Batches 8, 
11 & 18 
Slight variability in the retention times can be seen; however, the responses are very similar.  
The results are summarised in Table 5-5. 
Table 5-5: IS results for between-batch replicate injections of a BPH sample 
Batch no. Injection no. Retention time (s) Peak area (arbitrary units) 
8 8 610.9 35917615 
11 59 610.4 33898021 
18 50 610.3 41308831 
 Average: 610.5 37041489.0 
 RSD (%): 0.05 10.34 
The between-batch replicates data shown here, is better than the data from the consecutive 
injections discussed previously.  Again, this indicates that any changes in repeatability is 
more likely to be due to random error, if, prior to analysing a batch, the analytical instrument 
is suitably prepared.  The small reduction in the retention time between batches could 
indicate that there has been column bleed, resulting in a loss in the stationary phase; though 
this would appear to have been more significant between Batches 8 and 11 rather than 
between Batches 11 and 18. 
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Overlaid TICs from Batches 7, 19 and 20 BPH between-batch sample replicates is shown in 
Figure 5.9. 
 
Figure 5.9: Overlaid TICs of between-batch replicates of a BPH sample  
The reproducibility of these replicate injections is good considering they were analysed 
nearly 2 months apart.  Slight variation for injection three (blue) exists towards the end of 
the chromatogram, the main variable is a contamination peak. 
To summarise, the IS measurements between batches are good, if not better than consecutive 
and in-batch replicates, even over 22 batches and over 2 months of continual instrument 
analyses.   
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5.2.2 Statistical analysis of the prostate cancer data set 
The full set of data files that had been uploaded to the servers at Cranfield University, were 
processed as described in Section 2.4, with the steps summarised in the Flow Chart in Figure 
2.8.     
5.2.2.1 Exploratory analysis using PCA and HCA 
The unsupervised, independent exploratory techniques PCA and HCA were used to 
determine if there were any natural groupings in the data sets.  The PCA plot showed no 
linear separation between different types of samples, but it did show that the C4 controls 
were much more tightly clustered than the BPH or PC samples that showed greater variance.  
The HCA dendrogram also showed this, with potential separation of the diseased samples 
from the control categories, that were more tightly clustered.  
Outliers were visually identified from a PCA Scores Plot in conjunction with the Hotelling’s 
T2 statistic (equivalent to a multivariate Student t-test) and were removed at this point, 
leaving the total number of participants and data files for classification as described in Table 
5-1. 
5.2.2.2 Pattern recognition using PLS-DA 
For each sample, the TIC data was extracted into a data matrix and the alignment of the 
chromatographic peaks was performed using COW.  Different types of scaling were 
investigated: auto-scaling (AS), mean-centring (MC), normalisation (Norm) and range-
scaling (RS).     
The data set was divided into the different categories based on their clinical classification.  
Pattern recognition, using PLS-DA, was then performed between the following pairs of 
categories: 
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• C4 vs. PC 
• C4 vs. BPH 
• BPH vs. PC 
The models were built as described in Section 2.4.5.  To summarise, bootstrapping with 
LOO-CV was used, with at least 150 models built.  The required number of latent variables 
(LV) was typically 20, and the lowest number of LVs was chosen for the highest overall 
classification accuracy.   
Permutation testing, through the generation of 300 null models, was also used to test the 
significance of the results and to also check for bias of the models.  Performance metrics 
were then generated.   
5.2.2.3 C4 controls vs. Prostate cancer results 
The permutation density plots for the C4 vs. PC samples is shown in Figure 5.10.  Blue bars 
are the 300 null models; red bars are the 150 analysis models generated. The dotted lines are 
one standard deviation (STDDEV) and solid lines are two STDDEVs at 95% confidence 
interval (CI). 
The null models are tightly clustered around 50 % CC, indicating no bias in the models.  The 
mean performance of the 150 sample analysis models is 72 %, although many models had 
higher performance of up to 83 % CC, within two STDDEVs of the mean at 95 % CI.  The 
analysis models, at this CI, are separate from the null models, indicating significance in the 
results. 
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Figure 5.10:  Permutation density plots for C4 vs. PC using PLS-DA 
5.2.2.4 C4 controls vs. BPH controls results 
The permutation density plots for the C4 vs. BPH samples is shown in Figure 5.11. 
The null models are again tightly clustered around 50 % CC, indicating no bias in the models.  
The mean performance of the 150 sample analysis models is 84 %, although many models 
had higher performance of up to 93 % CC, within two STDDEVs of the mean at 95 % CI.  
The analysis models are all separate from the null models, indicating significance in the 
results and therefore this shows potential as a diagnostic technique. 
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Figure 5.11:  Permutation density plots for C4 vs. BPH using PLS-DA 
5.2.2.5 BPH vs. Prostate cancer results 
The permutation density plots for the BPH vs. PC samples is shown in Figure 5.12.  
The null models are again tightly clustered around 50 % CC, indicating no bias in the models.  
The mean performance of the 150 sample analysis models is 83 %, although many models 
had higher performance of up to 91 % CC, within two STDDEVs of the mean at 95 % CI.  
The analysis models are all separate from the null models, indicating significance in the 
results and therefore this shows potential as a diagnostic technique. 
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Figure 5.12: Permutation density plots for BPH vs. PC using PLS-DA 
5.2.2.6 PLS-DA performance metrics for prostate cancer 
Performance metrics were calculated for the mean of all the classification models generated 
and are presented in Table 5-6.  The definition of each performance metric has been 
discussed previously in Table 2-1. 
Table 5-6: Summary of performance obtained for the mean of the classification models 
 C4 vs. BPH C4 vs. PC BPH vs. PC 
Overall (%CC) 83.5 71.6 82.9 
Specificity (%) 85.8 71.7 81.1 
Sensitivity (%) 80.8 71.5 84.6 
NPV (%) 84.4 73.1 83.7 
PPV (%) 83.3 70.7 83.2 
FDR (%) 16.7 29.3 16.8 
LV 14 19 16 
AUROC 0.903 0.756 0.900 
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Of the three pairs of categories compared, the best performance is produced from the pairs 
including the BPH data set.  The C4 vs. BPH and BPH vs. PC both gave >80 % overall CC, 
specificity, sensitivity, NPV and PPV.  The AUROC values were also greater than 0.9, 
which, from Table 1-3 means very good.  The results from the C4 vs. PC categories was still 
good, with >70 % success rates and an AUROC value of greater than 0.75 meaning fair. 
When a patient is presenting to a GP with symptoms of possible prostate cancer, it is quite 
likely that the patient will have prostate cancer and/or BPH.  Therefore, a test that can 
differentiate between these two conditions with high sensitivity and specificity is important.  
The results shown for BPH vs. PC show the potential for this technique to do that with a 
good prediction.  When comparing these results to the PSA and DRE tests, this technique 
out-performs them both.  The sensitivity and specificity of this method, are much higher than 
the 30-35 % sensitivity and 63 % specificity given by the PSA test and the overall CC is 
higher than that obtained for DRE of 59 % (Thompson, et al., 2004).  Also, these statistical 
models were generated using the TIC and not the full 3D data that is available, due to 
limitations in the computing processing power.  Even better, would be the use of GCxGC-
ToFMS data that can be generated and was discussed in Chapter 3. 
5.3 Studies by other groups, since this project 
In 2012, capillary electrophoresis MS (CE-MS) was shown to be a potentially cost-effective 
method for prostate cancer diagnosis (Schiffer, et al., 2012).  Proteome analysis was 
performed on the urine of 211 patients with suspected prostate cancer.  The data for 184 of 
these patients was received about their cancer status after biopsy (the remaining samples 
were unconfirmed), with 49 positive and 135 prostate cancer negative.  The proteome 
method had correctly identified 42 of the 49 patients with prostate cancer giving a sensitivity 
of 86 %.  For the negative patients, the method identified 79 out of 135 correctly, giving a 
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specificity of 59 %.   Against the results from the biopsy, the proteome method gave a total 
accuracy of 65.7 %, compared to 33.3 % by the PSA test and 42.7 % by the free-PSA test.  
However, this method is still not very specific and would result in many patients undergoing 
unnecessary treatment, despite being negative. 
More recently, GC-MS has been used to analyse the VOCs in the headspace above urine to 
diagnose prostate cancer (Khalid, et al., 2015).  Urine was analysed from 59 prostate cancer 
patients, confirmed by biopsy, and 43 cancer-free controls.  The urine samples were basified 
with sodium hydroxide and heated in a water bath at 60 °C for 30 minutes.  The headspace 
VOCs were extracted using SPME with an 85 µm Carboxen/polydimethylsiloxane fibre that 
was inserted into the headspace for 20 minutes.  The fibre was then desorbed in the GC inlet 
and the VOCs separated and detected by GC-MS.  The GC-MS data was then analysed using 
deconvolution and library searching against a library of 197 VOC metabolites developed 
through the study.  Those compounds found in <20 % or >90 % of all samples were then 
removed from the results.  The remaining data underwent feature selection before being 
processed using the random forests (RFs) and linear discriminant analysis (LDA) 
classification techniques.  Compared to the PSA test with a total accuracy of 62-64 %, a 
classification model based on only four VOCs had a total accuracy of 63-65 %.  When the 
PSA level and the four VOCs data was combined, the RFs classification method gave a total 
accuracy of 71 % after double cross-validation and the LDA method gave 65 % total 
accuracy after double cross-validation.  These results were marginally better than the CE-
MS method but only after combining the data with the PSA level method.  However, 
bootstrapping was not used in the process and the AUROC value was only 0.76 for RFs and 
0.71 for linear discriminant analysis with NPV and PPV percentages not given.   
The same group then went on to publish a paper on the diagnosis of urological malignancies 
using a GC-sensor system (Aggio, et al., 2016).  The statistical analysis was the same as used 
for the analysis of bladder cancer (Khalid, et al., 2013), discussed previously.  This paper 
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analysed urine samples from 58 male patients with prostate cancer, 24 with bladder cancer 
and 73 controls with haematuria (cancer-free).  After analysis by the GC-sensor system, the 
data underwent PCA followed by various methods of classification.  Prostate cancer 
diagnosis with classification against the controls, using a SVM and validation by LOO-CV 
gave 95 % sensitivity and 96 % specificity.  Bladder cancer diagnosis with classification 
against the controls using SVM and validation by LOO-CV gave 96 % sensitivity and 100 
% specificity, whereas using the validation technique repeated double cross validation 
(DoubleCV) reported 87 % sensitivity and 99 % specificity.  Classification of the prostate 
and bladder cancer samples by SVM gave 78 % and 98 % sensitivity respectively, with 
evaluation of the significance of the results using a Monte Carlo simulation reported that the 
results were not due to over fitting of the data.   
However, the number of samples in the control and cancer data sets were very different and 
not balanced, meaning that the models could have learned to recognise the cancer samples 
better than the controls.  LOO-CV was used rather than bootstrapping with LOO-CV, 
meaning that the process was not as thorough and the results can be over-optimistic as the 
subset taken out for evaluation purposes is not random.  Our cross-model validation 
randomly split the data set into a 70 % bootstrap set for training and a 30 % independent set 
for testing.  The bootstrap set was used to develop an optimised model that was tested by 
LOO-CV and then used to classify the testing set.  This process was then repeated 150 times 
to obtain a mean accuracy, specificity, sensitivity, etc. which has been reported, rather than 
the results from the best model.  Our process is more robust than purely using LOO-CV and 
produces more confidence in our results.   
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5.4 Conclusions and future work 
Looking at the replicate sample analysis with consecutive, scattered in-batch and scattered 
between-batch injections, no patterns can be seen to show an increase (from carryover) or 
decline in the method performance.  This indicates that any variability is not systematic and 
is random, even over long periods and so are likely to be due to errors in placing the collected 
sample into the vial, sample preparation or extraction and injection. 
The results for the prostate cancer study look very promising and give higher clinical 
performance than the current gold standards.  It was also concluded that other benign 
genitourinary tract diseases (e.g. BPH) did not affect the performance of the classifier and 
classification of BPH against PC produced equally good performance which can be used for 
the differentiation of these two conditions that cause similar symptoms. 
The possibility of a relatively cheap test, that can be performed non-invasively on the 
production of a urine sample and give good results would be of great benefit as is outlined 
in Figure 5.13.  The Service Blueprint has been developed in consultation with Dr Linda 
Mahon-Daly (Macmillan Cancer Specialist GP) and Dr Malcolm Mason (Wales Cancer 
Bank).
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Figure 5.13: Possible future care pathway for patients with suspected prostate cancer with the HS-SPME-GC-MS chemometric urine sample analysis 
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6.1 Introduction 
The VOCs present in the urine of patients with hepatic disorders has not been investigated 
to the same level as that in breath or blood.  It is logical to think that patients reporting 
changes in their urine as well as in their breath, along with the investigated changes in the 
VOC content in breath and blood will show changes in the VOC content in urine too.  The 
bladder cancer method was developed and optimised to analyse volatile organic compounds 
in the headspace above urine.  Following on from the promising results described in Chapters 
4 and 5, this was thought to be an ideal method to investigate whether there are any changes 
in VOC content and identify possible volatile biomarkers from urine for hepatic disorders.  
6.1.2 Participant selection 
Participants were recruited from the Hepatology Clinic at the John Radcliffe Hospital, 
Oxford.  Patients with non-hepatitis C virus (HCV) liver disease were recruited, along with 
HCV infected patients with cirrhosis.  All who had given written informed consent.   
For comparative control purposes, a similar number of healthy volunteers, without risk 
factors for liver disease were recruited from the laboratory and hospital staff.  A short 
medical history was taken to ensure that they had no risk factors for liver disease. 
Participants completed a Case Report Form (CRF) providing considerable detail about their 
medical, personal and social histories to enable any medical or lifestyle factors to be taken 
into consideration that might influence the chemical composition of their urine.  Samples 
were taken before any surgical or therapeutic intervention and urine cytology and 
biochemistry tests were performed before the sample aliquots were frozen.   
The co-ordination of taking, processing and storing the samples and patient details was 
undertaken by Dr Ellie Barnes at the Nuffield Department of Medicine at Oxford University.  
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This process was described in Section 2.2.2.  The data was then anonymised before 
information and samples were sent to The Open University for analysis. 
6.1.2 Hepatic disorders and control sample types 
The samples for the hepatic disorders study was divided into two classes, those with liver 
cirrhosis (CIR) and controls (CON), with no liver cirrhosis.  The liver cirrhosis class was 
sub-divided into categories, those that were negative for HCV (HepC-ve) and those that were 
positive (HepC+ve).   
For all the samples analysed, the metadata was extracted by highlighting the range of values 
from each data type, or highlighting those that tested positive for a feature.  A screenshot of 
the sex, age, smoking status and dipstick measurements for some of the CIRHepC-ve 
participants can be seen in Figure 6.1.  A screenshot of the fibrosis score and the medication 
taken up to 48 hours before the study sampling for some of the CIR participants (both -ve 
and +ve) can be seen in Figure 6.2.  A screenshot of the food and drink intake up to 48 hours 
before the study sampling for some of the Control participants can be seen in Figure 6.3.   
Most participants had not drunk alcohol but had eaten cooked onion within 48 hours; a third 
had eaten cooked garlic, strong cheese, fish or brassicas; some had eaten raw onion, mustard, 
chilli, curry or mint.  A handful of participants across all classes had eaten raw garlic, 
asparagus, aniseed or liquorice in the previous 48 hours. 
The exact metadata of the participants used in the study is summarised in Table 6-1 and 
Table 6-2.  The different urinalysis abnormalities were previously discussed in Section 4.1.3.   
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Figure 6.1: Snapshot of metadata for CIRHepC-ve participants, showing sex, age, smoker plus urinalysis results 
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Figure 6.2: Snapshot of metadata for CIRHepC-ve and HepC+ve participants, showing fibrosis score and medication taken within 48 hours prior to study 
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Figure 6.3: Snapshot of metadata for some Control participants, showing food and drink intake during 48 hours prior to study
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CIR samples were taken from patients with fibrosis scores of 5 or 6 and included male and 
female patients aged over 28 years.  CIR samples were divided into two categories those 
with and those without HCV.  A review of the metadata and the urinalysis results enabled 
the following conclusions to be drawn about each of the CIR patient categories: 
• CIRHepC-ve – these were 52 male and female patients aged between 28-75; the 
majority were non-smokers.  Over a third of CIRHepC-ve patients had a high level 
of urobilinogen, which is to be expected for those with liver problems; some had 
trace amounts of ketones and some tested positive for nitrite, glucose and/or 
bilirubin; many tested positive for leucocytes, protein and/or blood.  Their urine 
ranged from pH 5-8.5 and specific gravity from 1.000-1.030; the majority were 
taking prescription medication and over the counter pain relief; some were on 
vitamin or mineral supplements; no one had taken recreational drugs. 
• CIRHepC+ve – these were 5 male and 1 female patients aged between 54-62; all 5 
male patients smoked and the female patient was a non-smoker.  Two thirds had high 
urobilinogen levels; all tested negative for blood, protein, nitrite, ketones and 
bilirubin; one had a trace of leucocytes; two thirds had moderate to high levels of 
glucose.  Their urine ranged from pH 5-8 and specific gravity from 1.000-1.010; two 
thirds were taking prescription medication, including insulin for two patients; one 
patient had taken recreational drugs. 
The control samples were collected from relatively healthy patients who did not suffer from 
liver problems.  As with the CIR patient cohort, a review of the metadata enabled the 
following conclusions to be drawn: 
• CON – these were 51 male and female patients aged between 20-63; the majority 
were non-smokers.  A third tested positive for leucocytes; a quarter tested positive 
for protein and/or blood; some tested positive for ketones; two had slightly high 
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levels of urobilinogen; all tested negative for nitrite, glucose and bilirubin.  Their 
urine ranged from pH 5-8 and specific gravity from 1.000-1.030; a third were taking 
prescription medication including hormone replacement therapy, contraceptive pill, 
cholesterol and/or blood pressure medication, anti-epileptic or asthma medication 
and antibiotics used to treat urinary tract infections; no one had taken vitamin or 
mineral supplements or recreational drugs. 
Table 6-1:  Participants used in the study including patients with liver cirrhosis (CIR), with 
and without HCV (HepC+ve or HepC-ve) and control (C) participants 
 Category 
Number of: CON CIRHepC-ve CIRHepC+ve 
Participants 51 50 6 
Total samples analysed 157 151 20 
Smokers 12 13 5 
With blood detected 14 (*-**) 11 (*) 0 
With glucose detected 0 4 (**-***) 4 (**-***) 
With protein detected 12 (*) 10 (*-**) 0 
With bilirubin detected 0 6 (*-**) 0 
With high urobilinogen 2 (*) 19 (*-***) 4 (*) 
With nitrite detected 0 5  0 
With leucocytes detected 16 (*-***) 16 (*-**) 1 (*) 
With ketones detected 3 (*) 6 (*) 0 
Total samples data processed  145 148 18 
Participants after outlier removal 49 50 6 
* = trace or small amount, ** = moderate amount, *** = large amount 
Table 6-2: Participants used in the hepatic disorders study: age, pH and specific gravity 
Category 
Data CON CIRHepC-ve CIRHepC+ve 
Age range (years) 20-63 28-75 54-62 
Median age (years) 39.2 58.7 59.2 
pH range 5-8 5-8.5 5-8 
Specific gravity 1.000-1.030 1.000-1.030 1.000-1.010 
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6.1.3 Sample and data analysis 
Samples from a total of 51 controls, 50 CIRHepC-ve and 6 CIRHepC+ve participants were 
analysed in triplicate.  Analyses were conducted in 6 batches, including fibre blanks and 
procedural blanks.  Problems in the analysis of one batch, resulted in more than three 
analyses for some samples, this is discussed later.  The samples were prepared and analysed 
using HS-GC-MS as described in Section 2.2.  The total number of samples analysed is 
shown in Table 6-1. 
The data was processed using the methods described in Section 2.4.  First, a consistency test 
was performed on the data files to ensure that they had roughly the same number of scans, a 
total of 8,708.  Any files that had too few scans for alignment were removed.  Generally, 
these files were samples that had failed to acquire on the GC-MS instrument.  This 
consistency test was performed when importing the data files into the data analysis software.   
Next, the data was normalised against the IS, phenol-d6, quantitation ion.  This was also 
performed as the data was imported.  Exploratory PCA analysis was performed and outliers 
were removed.  Outlying samples were identified visually and statistically via Hotelling’s 
T2, leaving the total number of data files and participants for each category as shown in Table 
6-1. 
The chromatographic peaks in the TICs were aligned using COW.  Feature selection was 
investigated using the Wilcoxon t-test.  Classification was performed using PLS-DA, SVM 
and ANNs with cross-model validation through bootstrapping with LOO-CV for 
optimisation and different types of scaling were considered.  The final step was permutation 
testing using the best scaling method.  Each of these approaches were previously described 
in Chapter 2 and were implemented in Chapters 4 and 5. 
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6.2 Results and Discussion 
The results and discussion is divided into two sections: 
The raw data that was processed using Leco ChromaTOF will be discussed in Section 6.2.1.  
This data was used to assess the reproducibility of the method across all 6 batches of samples 
and again will illustrate the importance of using an IS.  The different types of blanks are used 
to look for carryover within the analytical instrument as well as the sample preparation. 
Next, the results of the statistical analysis by Cranfield University will be shown and 
discussed in Section 6.2.2.  This section will systematically review the results from each step 
of the data processing. 
6.2.1 Robustness of HS-SPME-GC-TOFMS analysis method in 
the hepatic disorders sample batches 
Fibre and procedural blanks were analysed within the batches and along with the addition of 
IS to all samples and sample blanks, the performance of the analyses was assessed.  
6.2.1.1 IS identification 
A summary of the results for the identification of the IS, across the six batches, is shown in 
Table 6-3.  The retention times are earlier than that seen in the bladder and prostate cancer 
studies, of 610-611 seconds.  This is to be expected, as these samples were analysed more 
than a year later, using the same column.  In this period, the column had undergone several 
maintenance procedures, mainly in the form of column trimming.  It has also been used for 
a range of other studies. 
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Table 6-3: Summary of the IS identification results 
Batch 
number 
Number 
sample* 
data files  
Average 
retention 
time (s) 
Retention 
time RSD 
(%) 
Average 
similarity 
match  
Similarity 
RSD        
(%) 
1 64 596.71 0.016 831.2 4.29 
2 64 596.64 0.014 824.1 4.86 
3 68 596.51 0.023 826.4 6.37 
4 64 596.39 0.014 821.5 4.96 
5 60 596.36 0.020 823.2 6.73 
6 33 595.58 0.027 700.6 10.68 
Average 
for all 
samples 
353 596.44 0.054 813.7 7.47 
* Refers to hepatic disorders, control samples, matrix and procedural blanks 
A plot of the retention time of the IS in all samples in each batch is shown in Figure 6.4.  
Batches 1-5 show good reproducibility, with a gradual decline of retention time through each 
batch and a gradual decline from batch-to-batch.  This is to be expected, as the column 
stationary phase is always bleeding, resulting in less retention with each injection.   
 
Figure 6.4: Plot of IS retention time for all samples  
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Batch 3 had a few outliers around Injection 40, but there were a few problems with the 
analysis in Batch 3, as is discussed later.  Batch 6 didn’t follow the trends and resulted in an 
earlier retention time of approximately 1 second.  This was probably because of essential 
column maintenance deemed necessary after Batch 5. 
6.2.1.2 IS response 
A summary of the response of the IS quantitation ion for each batch is shown in Table 6-4. 
Table 6-4: Summary of the IS abundance and SN ratio data 
Batch number Average peak area 
(arbitrary units) 
Area RSD 
(%) 
Average SN 
ratio 
SN ratio 
RSD (%) 
1 32897544.6 40.32 52480.2 37.28 
2 70345484.7 26.94 107329.6 27.71 
3 74697253.9 23.43 107467.9 25.57 
4 90888220.7 17.35 130079.0 17.01 
5 58903673.5 19.55 96402.2 20.64 
6 2288556.0 32.31 8909.4 31.94 
Average for all 
samples 
59811773.4 50.20 90727.4 46.67 
Batch 1 has the greatest variability, followed by Batch 6.  A plot of all the IS quantitation 
ion areas is shown in Figure 6.5.  The IS had a much lower response in Batch 6 than in the 
other batches.  This was later determined to be a problem with the MS filament.  As discussed 
in previous chapters, greater variability is shown in data files where the peak is smaller and 
this is seen when comparing the Batch 6 responses to those seen in Batches 2-5.  However, 
these data files can still be used in the data analysis, as sensitivity issues can be overcome 
by normalising against the IS. 
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Figure 6.5: Variation in the peak area of the IS quantitation ion for all samples 
Examining the Batch 1 data, there are no overall outliers, just a gradual increase in response, 
as shown in Figure 6.6.  These are possibly due to the variability in the sensitivity of the 
Leco ToFMS.  It is known to have poor sensitivity if not used for a period of time, as was 
the case before this study.  This is well documented and has been identified in other studies 
within the laboratory and for other laboratories.  Its cause is not clear, but is thought to be a 
build-up of contamination within the ion source or detector, that the manufacturer 
recommends not to clean.  On use, this contamination gradually disappears, as was seen in 
the analysis of subsequent Batches 2-4 that show an improvement, up to a certain point 
before filament problems occurred in Batch 6.  Again, normalisation of the data file against 
the IS during the data processing, overcomes this detector drift. 
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Figure 6.6: IS peak area for Batch 1 with an exponential trendline fitted 
6.2.1.3 Performance checks of procedural blank samples 
A summary of the performance data for the identification of the IS in the sample blanks run 
in each batch is shown in Table 6-5. 
Table 6-5: Summary of the sample blanks IS identification results 
Batch 
number 
Number 
sample 
blanks 
Average 
retention 
time (s) 
Retention 
time RSD 
(%) 
Average 
similarity 
match  
Similarity 
RSD (%) 
1 4 596.70 0.024 860.0 2.28 
2 4 596.60 0.024 815.3 2.50 
3 5 596.46 0.015 844.6 4.33 
4 4 596.35 0.010 837.5 3.41 
5 5 596.28 0.018 862.6 2.23 
6 2 595.70 0.000 756.5 13.93 
Average 
for all 
samples 
24 596.40 0.047 837.5 5.18 
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A SPME fibre failure during Batch 3, resulted in an additional procedural blank to be 
analysed, along with additional samples, as shown in Table 6-3.  The procedural blanks 
showed a similar trend to the full sample data, with Batch 6 producing poorer similarity 
reproducibility, due to the smaller peaks.   
A summary of the response of the IS quantitation ion in the procedural blanks is shown in 
Table 6-6. 
Table 6-6: Summary of the sample blanks IS abundance and SN ratio data 
Batch number Average peak area 
(arbitrary units) 
Area RSD 
(%) 
Average SN 
ratio 
SN ratio 
RSD (%) 
1 33434429.8 61.28 49831.3 53.43 
2 46969414.8 44.95 61349.8 47.44 
3 60935877.0 41.43 80062.2 38.90 
4 91853567.5 42.18 122332.0 40.07 
5 53442773.2 40.30 81623.4 37.68 
6 2277856.5 78.57 7329.9 87.58 
Average for all 
samples 
52728275.5 62.13 73214.2 57.84 
As the procedural blanks are scattered throughout a batch, the variability in response through 
a batch, as previously described, is enhanced when taking this small number of samples into 
account.  As is shown in Figure 6.7, the sensitivity improves through the batch.  However, 
as is apparent from the plots for all samples, the last procedural blank at the end of the batch 
reduces in sensitivity again.  This requires further investigation, most likely it is an error in 
preparing the IS injection, potentially an issue with the syringe. 
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Figure 6.7: IS quantitation ion peak area for procedural blanks 
6.2.1.4 Comparisons between different blanks 
Within the study two different types of blanks were acquired: 
• Fibre blanks: to check for carryover or contamination within the SPME-GC-
ToFMS system. 
• Procedural blanks: to check for contamination from sample collection through 
analysis. 
By comparing these blanks analysed at different times, sources of contamination can be 
determined.  As contamination peaks were identified and the source discussed in Section 
4.2.1.5, only additional contaminant peaks found in this study will be discussed in this 
section. 
The overlaid Injection 1 Fibre blanks for all batches is shown in Figure 6.8.  As discussed in 
Chapter 4, the peaks identified were siloxane fibre bleed and solvent contaminants.  
However, in this study, a higher abundance of higher MW siloxane peaks were seen than 
before. 
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Figure 6.8: The overlaid TICs of Injection 1 Fibre blanks 
The overlaid Injection 2 Procedural blanks for all batches is shown in Figure 6.9.  The peaks 
identified were again the same as those previously discussed.  The additional peak seen in 
yellow is the solvent contaminant n-hexane, which had a higher concentration for that blank. 
 
Figure 6.9: The overlaid TICs of Injection 2 Procedural blanks 
The remaining peaks were identified in both types of blanks and these were present at similar 
levels in each data file.   
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On comparison to the previous study the same profile was seen, however in this study there 
appeared to be a lower abundance of the solvent contaminants.  This could be due to new 
reagents used, more rigorous protocols used to reduce contamination after the previous 
experiences or a cleaner environment for sample preparation.  No additional contaminants 
were identified from the sample collection. 
6.2.1.5 Fibre blanks and carryover 
As in previous studies, the fibre blanks analysed throughout a batch were used to check for 
and quantify carryover.  The details of where carryover was detected is shown in Table 6-7. 
Table 6-7: Carryover of the IS detected in the fibre blanks 
Batch number Injection no. Injected after: IS similarity 
(out of 1,000) 
Carryover (%) 
1 13 Sample 641 0.366 
1 35 Sample 472 0.361 
1 57 Sample 593 0.304 
1 69 Procedural 544 0.235 
2 13 Sample 722 0.310 
2 35 Sample 687 0.336 
2 57 Sample 516 0.248 
2 69 Procedural 695 0.310 
3 35 Procedural 668 0.351 
3 57 Sample 655 0.268 
3 69 Procedural 644 0.251 
4 35 Sample 752 0.507 
4 57 Sample 723 0.368 
4 69 Procedural 757 0.336 
5 13 Sample 691 0.573 
5 35 Sample 713 0.525 
5 57 Sample 567 0.317 
5 69 Procedural 649 0.289 
6 13 Sample 591 1.236 
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Except for Batch 6, any carryover detected was 0.5 % or less.  The IS detected in the fibre 
blank in Batch 6, was only identified with a mass spectral similarity match of 59 % which is 
borderline for identification purposes, plus the carryover was also still low at 1.2 %, which 
was deemed acceptable.  
6.2.1.6 Replicate hepatic disorder and control sample analyses 
All samples were analysed in triplicate.  Where there were instrumental problems, some 
additional replicates had also been analysed.  As before, there is far too much data to show, 
therefore I’ve selected some good and poor chromatogram overlays. 
The overlaid IS quantitation ion chromatograms for three consecutive injections in Batch 5 
of a CON sample is shown in Figure 6.10. 
 
Figure 6.10: IS quantitation ion for consecutive injections of a CON sample in Batch 5 
The reproducibility of the IS for this sample is excellent.  A summary of the retention time 
and IS peak areas are given in Table 6-8. 
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Table 6-8: IS results for consecutive injections of a CON sample in Batch 5 
Replicate Retention time (s) Peak area (arbitrary units) 
1 596.4 68008859 
2 596.4 63234211 
3 596.3 64893066 
Average: 596.37 65378712.0 
RSD (%): 0.010 3.71 
The results reflect the reproducibility shown in the chromatogram, with good retention time 
and peak area reproducibility.  The coeluting peak also shows a similar profile.  
Chromatograms from three consecutive injections of a CIRHepC-ve sample in Batch 4 is 
shown Figure 6.11. 
 
Figure 6.11: Overlaid TICs of consecutive injections of a CIRHepC-ve sample in Batch 4 
All three injections show good reproducibility with the second injection (green) giving 
slightly better responses for all peaks.  This was also seen for the IS; therefore, normalisation 
would fix this.  The main difference is the large solvent peak in the first injection (orange).  
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As seen and discussed before, this is a contaminant peak which could come from the sample 
collection or preparation steps. 
The overlaid IS quantitation ion chromatograms for replicate injections, scattered throughout 
Batch 1 of a CIRHepC-ve sample, analysed as Injections 15, 53 and 65 is shown in Figure 
6.12. 
 
Figure 6.12: IS quantitation ion for in-batch replicates of a Batch 1 CIRHepC-ve sample 
Although the retention times are reproducible, there is variability in the response from the 
first injection (orange) to the second and third injections (green and blue).  A summary of 
the IS retention times and quantitation ion areas is given in Table 6-9. 
Table 6-9: IS results for in-batch replicates of a CIRHepC-ve sample in Batch 1 
Replicate Retention time (s) Peak area (arbitrary units) 
1 596.7 21875841 
2 596.6 56650971 
3 596.6 49524821 
Average: 596.63 42683877.7 
RSD (%): 0.010 43.04 
The cause of the response variability is most likely instrument related, as discussed earlier 
in this chapter.  The change in response is also reflected in the matrix peaks and therefore 
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can be normalised.  Chromatograms from in-batch replicate injections of a CIRHepC+ve 
sample in Batch 4, analysed as Injections 54, 60 and 67 is shown Figure 6.13. 
 
Figure 6.13: Overlaid TICs of in-batch replicates of a CIRHepC+ve sample in Batch 4 
The response variability appears to be consistent for all peaks in each injection.  However, 
there appears to be more variability of the volatile peaks and less towards the end of the 
chromatogram and therefore this is volatility related.  This could be caused by the sample 
preparation or when aliquoting the samples into vials after collection.  If it is extraction and 
analysis related, then the use of a second IS, eluting towards the front of the chromatogram 
would help to overcome this. 
The overlaid IS quantitation ion chromatograms for replicate injections, scattered between 
Batches 1, 4 and 5 of a CIRHepC-ve sample analysed as Injections 14, 8 and 33 respectively 
is shown in Figure 6.14. 
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Figure 6.14: IS quantitation ion for between-batch replicates of a CIRHepC-ve sample  
Variability can be seen for both the retention time and the response from the first injection 
(orange) to the second (green) and third (blue) injections.  A summary of the IS results is 
given in Table 6-10. 
Table 6-10: IS reproducibility for between-batch replicates of a CIRHepC-ve sample 
Batch no. Injection no. Retention time (s) Peak area (arbitrary units) 
1 14 596.8 31726529 
4 8 596.4 73820208 
5 33 596.4 51992607 
 Average: 596.53 52513114.7 
 RSD (%): 0.039 40.09 
This profile follows the same pattern seen for the in-batch replicates for Batch 1 (Figure 
6.12).  As previously discussed, the instrument sensitivity improvements after Batch 1 
accounts for a large proportion of the variability.  Again, the co-eluting matrix peak shows 
the same variability which will enable normalisation against the IS for better classification 
or these data files.  The TICs of the three replicates of this sample is shown Figure 6.15. 
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Figure 6.15: TICs of between-batch replicates of a CIRHepC-ve sample in Batches 1, 4 & 5 
The between-batch replicate TICs show no greater variation than the in-batch replicates 
shown and discussed in Figure 6.13 and they follow a very similar pattern. 
6.2.2 Statistical analysis of the hepatic disorders data  
The full set of data files that had been uploaded to the servers at Cranfield University, as 
described in Table 6-1, were pre-processed, as described in Section 6.1.3.  During this step, 
15 data files were removed.  This was either due to data files not being acquired, due to the 
software hanging, fibre failure or the file not containing approximately enough scans. 
The next step was exploratory analysis using PCA, before pattern recognition through PLS-
DA, SVM and ANNs. 
6.2.2.1 Exploratory analysis using PCA and HCA 
The unsupervised, independent exploratory technique, PCA, was used to determine if there 
were any natural groupings of the data in the data sets, as in previous studies none were seen.   
Outliers were visually identified from a PCA Scores Plot in conjunction with the Hotelling’s 
T2 statistic (equivalent to a multivariate Student t-test) and were removed at this point, 
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leaving the number of participants and samples for classification as described in Table 6-1.  
Two outliers were identified in the CIRHepC-ve category. 
The data set was then divided into the different categories based on their clinical 
classification.  Feature selection, then pattern recognition, was performed between the 
following pairs of categories: 
• CIRHepC-ve vs. CON, i.e. the HCV negative cirrhotic samples against the controls 
• CIRHepC+ve vs. CON & CIRHepC-ve, i.e. the HCV positive cirrhotic samples 
against the controls plus the HCV negative cirrhotic samples 
6.2.2.2 Pattern recognition using PLS-DA, SVM and ANNs 
For each sample, the TIC data was extracted into a data matrix and alignment of the 
chromatographic peaks was performed using COW.  Feature selection was performed 
through the Wilcoxon t-test (WTT), with optimisation of the P-value, to reduce the number 
of mass spectral scans down to the most significant. 
The models were built as described in Section 2.4.5.  To summarise, bootstrapping with 
LOO-CV for optimisation was used.  Different types of scaling were investigated: auto-
scaling (AS), mean-centring (MC), normalisation (Norm), pareto and range-scaling (RS), 
prior to pattern recognition, using PLS-DA, SVM and ANNs via PNNs.  The required 
number of latent variables was typically 20, and the lowest number of LVs was chosen for 
the highest overall classification accuracy.  At least 150 models were built for each classifier. 
Permutation testing, through the generation of 300 null models, was also used to test the 
significance of the results and to also check for bias of the models.  Performance metrics 
were then generated.   
A summarising table of the terms and calculations used here can be found in Table 2-1. 
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6.2.2.3 CIRHepC-ve vs. CON results 
The results from the mean of all classification models produced for CIRHepC-ve vs. CON, 
using the optimal scaling techniques, is shown in Table 6-11.   
Table 6-11: CIRHepC-ve vs. CON using PLS-DA, SVM and ANNs  
Classifier PLS-DA SVM-LIN SVM-RBF ANNs via PNNs 
Feature 
selection 
None None WTT 
p=0.001 
None WTT 
p=0.001 
No. scans 8708 8708 1403 8708 1403 
Scaling AS RS (0 to 1) AS Norm Norm 
%CC 88.21 89.76 84.04 78.61 81.33 
%Spec 89.92 89.05 83.70 89.59 79.53 
%Sens 86.53 90.46 84.37 67.88 83.10 
%NPV 86.95 90.32 84.28 73.38 82.33 
%PPV 90.00 89.67 84.39 87.17 80.88 
%FDR 10.00 10.33 15.61 12.83 19.12 
LV 9     
AUROC 0.9279 0.9585 0.8958 0.8034 0.8519 
When using the ANNs classifier via PNNs, using all scans with no feature selection gave a 
higher specificity than with feature selection; however, when feature selection was used, 
better sensitivity was achieved.  Overall, reducing the number of mass spectral scans from 
8,708 to 1,403 gave a higher %CC and AUROC value, which signified good from Table 1-3. 
It is worth noting that ANNs via PNNs, with no feature selection and range scaling (-1 to 1) 
gave 100 % specificity and 100 % PPV but poor sensitivity, with an overall result of 55 % 
CC.  This shows that models can be created than give very good performance for some 
performance monitors; however, it is the models that perform the best across multiple 
performance monitors that will give the most robust performance for any sample. 
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Linear SVM with no feature selection and range-scaling (0 to 1) gave better performance for 
all monitors than when using RBF with feature selection.  As seen in Chapters 4 and 5, the 
best performing classifiers were with no feature selection.  Again, SVM-LIN gave very 
similar performance to PLS-DA, with PLS-DA giving very slightly better specificity and 
%PPV.  SVM-LIN gave slightly better overall %CC of 89 % and AUROC value of 0.96, 
meaning very good. 
The permutation testing models are shown in the permutation density plots in Figure 6.16 
for PLS-DA, SVM-LIN and SVM-RBF.  Blue bars are the 300 null models; red bars are the 
150 analysis models.  Dotted lines are one STDDEV and solid lines are two STDDEVs at 
95% CI. 
The null models are clustered around the 50 % CC for all classifiers, with a slightly wider 
distribution for PLS-DA.  There is complete separation of the null and sample models for all 
classifiers.  The sample distributions for the PLS-DA and SVM-LIN are similar, however 
the PLS-DA has a high frequency for the model producing 89 % CC and has the best 
performing model at 97 %.  Whereas SVM-LIN has a slightly higher mean, as shown by the 
data in Table 6-11.  Overall, considering both the data and permutation density plots, PLS-
DA gave the best performance. 
The permutation density plots for ANNs with PNNs, both with and without feature selection, 
is shown in Figure 6.17. 
Again, the null models are clustered around 50 % CC, showing no significant bias in the 
models generated.  The sample models are well separated from the null models.  The 
distribution of sample models is similar to PLS-DA and SVM, however, the performance is 
not as good, with the best performing models below 90 % CC. 
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Figure 6.16: Permutation density plots for CIRHepC-ve vs. CON using (a) PLS-DA, (b) 
SVM-LIN, (c) SVM-RBF 
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Figure 6.17: Permutation density plots for CIRHepC-ve vs. CON using ANNs with PNNs (a) 
without feature selection, (b) with feature selection 
6.2.2.4 CIRHepC+ve vs. CON & CIRHepC-ve results 
Full data set 
The results from the mean of all classification models produced for CIRHepC+ve vs. CON 
& CIRHepC-ve using the optimal scaling techniques and different feature selections is 
shown in Table 6-12. 
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Table 6-12: CIRHepC+ve vs. CON & CIRHepC-ve using PLS-DA, SVM and ANNs  
Classifier PLS-DA SVM-LIN SVM-RBF ANNs via PNNs 
Feature 
selection 
None None WTT 
p=0.01 
WTT 
p=0.05 
None WTT 
p=0.05 
No. scans 8708 8708 217 1353 8708 1353 
Scaling AS RS (-1 to 1) RS (0 to 1) Norm Norm RS (0 to 1) 
%CC 96.28 97.09 95.23 97.30 97.62 97.33 
%Spec 97.42 99.48 99.81 99.92 99.34 99.85 
%Sens 79.56 62.11 28.00 58.89 72.44 60.44 
%NPV 98.61 97.49 95.33 97.29 98.16 97.39 
%PPV 70.80 88.90 77.15 97.44 89.56 96.94 
%FDR 29.20 11.10 22.85 2.563 10.44 3.057 
LV 19      
AUROC 0.9840 0.8228 0.7351 0.9067 0.8290 0.7464 
When using the ANNs classifier via PNNs, both with and without feature selection, gave 
similar for most performance monitors.  However, the sensitivity and AUROC value were 
better when using all scans even though %PPV and %FDR were better when using only 
1,353 scans.  Overall, no feature selection gave a slightly higher %CC and higher AUROC 
value, which signified good. 
Linear SVM (with no feature selection) and SVM-RBF (with feature selection) gave similar 
performance.  SVM-RBF (with 217 scans) gave similar %CC, specificity and %NPV but 
was much poorer for the other performance monitors.  Even though SVM-LIN produced a 
slightly better sensitivity, SVM-RBF (with 1353 scans) produced a better %PPV, %FDR 
and AUROC value of very good.  SVM-RBF gave a similar performance to PLS-DA, with 
SVM-RBF giving very slightly better %CC and specificity and better %PPV and %FDR.  
PLS-DA gave much better sensitivity and gave an AUROC value of 0.98, meaning very 
good. 
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The permutation testing models are shown in the permutation density plots in Figure 6.18 
for PLS-DA, SVM-LIN and SVM-RBF.  As before, blue bars are the null models; red bars 
are the analysis models, dotted lines are one STDDEV and solid lines are two STDDEVs at 
95% CI. 
The classification sample models show a similar distribution to the CIRHepC-ve vs. CON 
and the mean of the models is above 95 % for all classifiers, as shown in the data in Table 
6-12, with the best performing models around 100%. 
However, there are far fewer sample models generated and the null models show a mean of 
85 % or higher, with complete overlapping for SVM, although not for PLS-DA.  This shows 
the importance of not just relying on the best performing model or even the mean of all 
models, but permutation testing is needed to find out really how significant the models are. 
Both can be explained by the small number of data files analysed and used for CIRHepC+ve 
(18) especially when compared to the number of CIRHepC-ve plus CON (293) used for the 
classification.  This lack of balance between the number of controls and diseased samples is 
very apparent in the amount of bias generated by the models.  This is also reflected in the 
permutation density plots for ANNS, shown in Figure 6.19. 
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Figure 6.18: Permutation density plots for CIRHepC+ve vs. CON & CIRHepC-ve using (a) 
PLS-DA, (b) SVM-LIN, (c) SVM-RBF    
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Figure 6.19: Permutation density plots for CIRHepC+ve vs. CON & CIRHepC-ve using 
ANNs with PNNs (a) without feature selection, (b) with feature selection.    
Balanced data set 
Because of the biased results discussed, a smaller, balanced number of controls (CON & 
CIRHepC-ve) were used in the classification against CIRHepC+ve.  The results for the mean 
of the classification models when using the classifiers, PLS-DA, SVM and ANNs, with and 
without feature selection, can be seen in Table 6-13. 
For all three classifiers, feature selection through the Wilcoxon t-test with p=0.05 gave the 
best results, with ANNs consistently producing the highest performance for all monitors, 
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except specificity, where SVM-RBF was slightly better.  SVM-RBF gave a much higher 
performance than SVM-LIN.   
Table 6-13: CIRHepC+ve vs. balanced CON & CIRHepC-ve using PLS-DA, SVM and ANNs  
Classifier PLS-DA SVM-LIN SVM-RBF ANNs via PNNs 
Feature 
selection 
None WTT 
p=0.05 
None WTT 
p=0.05 
None WTT 
p=0.05 
None WTT 
p=0.05 
No. scans 8701 290 8701 290 8701 290 8701 290 
Scaling None Norm MC Norm AS AS Norm RS     
(0 to 1) 
%CC 70.87 73.00 60.13 63.53 65.47 74.6 59.93 82.8 
%Spec 60.13 61.20 56.53 56.93 75.87 75.87 100.00 73.33 
%Sens 81.60 84.80 63.73 70.13 55.07 73.33 19.87 92.27 
%NPV 78.11 81.53 67.09 70.16 66.48 77.09 55.94 92.91 
%PPV 69.27 70.02 57.88 61.55 63.56 72.75 72.00 79.56 
%FDR 30.73 29.98 42.12 38.45 36.44 27.25 28.00 20.44 
LV 11 2       
AUROC 0.8325 0.8564 0.6245 0.6967 0.5056 0.8383 0.5993 0.9501 
The permutation density plots for the three best classifiers of the balanced data sets is shown 
in Figure 6.20.  As before, the performance data from the mean of the models shown in the 
table, does not completely reflect the performance when comparing against the null models.  
When the full control data set was used, the mean of the null models was 85 % or higher, 
showing considerable bias.  For the balanced data sets, the mean of the null models is where 
they should be, centred on 50% CC.   
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Figure 6.20: Permutation density plots for CIRHepC+ve vs. balanced CON & CIRHepC-ve 
using (a) PLS-DA, (b) SVM-RBF, (c) ANNs 
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The distribution of the null models for PLS-DA and ANNs is very similar and quite broad, 
with a few models over 75 %, whereas the SVM-RBF is much narrower, but still has a null 
model at 70 %.  The distribution of the sample classification models is similar for all three 
classifiers, with the worst performing models around 40% and the best near 100 %.  
However, the mean is better for ANNs than the other classifiers.  Although there is no 
complete separation of all models, each classifier produced separation of the mean null and 
mean analysis models at greater than two STDDEV.  Visually, ANNs is still the best 
performing classifier. 
The only way to improve the density plots, is to acquire more CIRHepC+ve samples to 
compare against the control samples.  This will enable more sample models to be generated 
and hopefully narrow the distributions seen while maintaining or improving further the mean 
of and the top performing models. 
6.3 Studies by other groups, since this project 
VOCs in the breath have also been studied pre- and post-liver transplant (Fernández del Río, 
et al., 2015).  First, the alveolar breath from 31 patients with liver cirrhosis and 30 healthy 
controls was analysed by proton transfer reaction-MS (PTR-MS).  PTR-MS is used for the 
real-time monitoring of volatile compounds without any sample preparation or separation.  
The neutral molecules in the breath are ionised through chemical ionisation by reacting with 
protonated water before separating the ion by quadrupole-MS (qMS) or time-of-flight-MS 
(ToFMS).  In this study qMS was used and statistical techniques were used to compare the 
data.  Seven volatiles were found to be at higher concentrations in the liver cirrhosis patients.  
The breaths of 12 of these patients were then analysed after having liver transplants.  Five 
of the previously observed raised volatiles had reduced significantly between pre-transplant 
and post-transplant, with three of these volatiles resulting in an area under a receiver 
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operating characteristic curve (AUROC) of 0.95, a sensitivity of 97 % and a specificity of 
70 %.  On comparing the VOCs identified by Van den Velde (van den Velde, et al., 2008) 
and Fernandez del Rio (Fernández del Río, et al., 2015), three of the four volatiles identified 
in the early study were in the seven volatiles identified in the pre-transplant study by 
Fernandez del Rio and colleagues.  However, only one, 2-pentanone, was in the group of 
three significant VOCs identified post-transplant.  
Also, the analysis of plasma samples by GC-MS has been revisited (Nezami Ranjbar, et al., 
2015).  The plasma from 40 hepatocellular carcinoma (HCC) patients and 49 patients with 
liver cirrhosis were analysed by derivatisation using MSTFA followed by GC-qMS and GC-
ToFMS analysis.  Metabolites were identified by metabolomics libraries and statistical 
analysis using two-way analysis of variance (ANOVA) models to select those metabolites 
with the highest statistical differences, resulting in nine potential biomarkers for HCC with 
false discovery rate (FDR) values of <10 %.  In a similar study, serum was analysed from 
49 HBV, 52 liver cirrhosis (LC), 39 HCC and 61 healthy non-cancer (NC) patients by 
derivatisation with MSTFA followed by GC-ToFMS analysis (Gao, et al., 2015).  The data 
was then analysed using PCA, PLS-DA, RFs and HCA to identify possible metabolites.  
Binary logistic regression of the validation sets gave a classification sensitivity of 100 % and 
specificity of 95.2 % for HBV vs. NC.  A sensitivity of 83.3 % and specificity of 100 % for 
LC vs. HBV.  A sensitivity of 76.9 % and specificity of 83.3 % for HCC vs. LC.  Combined, 
the classification accuracies were 100 % for NC, 94.12 % for HBV, 100 % for LC and 76.92 
% for HCC.  The focus of these studies was the identification of biomarkers for these 
different hepatic disorders.  
The focus of these publications has been the sensitivity and specificity, when from previous 
discussions the performance monitors should also be focussed on the %PPV and %NPV for 
the clinicians along with the AUROC value.  None of the publications mention permutation 
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testing which, from our studies, is very important to determine how significant the results 
really are. 
6.4 Summary and future work 
The results for the hepatic disorders study look even more promising than the two previous 
studies for bladder and prostate cancers.  We could differentiate between those with liver 
cirrhosis and various other illnesses with all performance monitors of 86 % or greater and a 
‘very good’ AUROC score using PLS-DA, which is very similar to other publications.  
However, the excellent results from the permutation testing underlines the significance and 
lack of bias of the models generated by our analyses.     
The ability to differentiate between those with liver cirrhosis caused by HCV and non-HCV 
cirrhosis combined with controls, also looks promising, but far more data is required. 
Biomarker identification on the current data sets, by using the PLS loadings plot to determine 
retention times of potential biomarkers and then performing library searching on their mass 
spectra needs to be performed.  These can then be compared to potential biomarkers 
published by other groups. 
Urine samples are easier to collect, transport and store than breath samples, therefore the 
possibility to identify not only liver cirrhosis but the source of that cirrhosis, particularly for 
HCV would be very beneficial. 
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7.1 Introduction 
Although many of the methods investigated over the past 30 years for the diagnosis of 
bacteria have not made it into the routine lab environment, much of the research was carried 
out using less sensitive instrumentation unable to detect, analyse and identify compounds 
like we can today.  Chemometric techniques, for pattern recognition in complex and large 
data sets, were either not available, or were in their earlier stages of development.  The 
widely-reported potential of HS-GC techniques for identification of bacterial infections, fits 
well with the methods developed in this thesis.  It was also appropriate to explore the 
application of TD as an alternative sampling methodology to HS-SPME.  Therefore, it is 
well worth revisiting this area, especially considering the development of the sample analysis 
techniques performed for bladder and prostate cancers and hepatic disorders studies, as well 
as the chemometric techniques by Dr Michael Cauchi of Cranfield University.  
It was hypothesised that analysis of the headspace above bacterial cultures by GC-ToFMS 
would provide plenty of data to be analysed using chemometric techniques, which we hoped 
would at least confirm the presence or absence of bacteria and hopefully identify the type of 
bacteria the patient is infected with.  Further investigation for the identification of specific 
biomarkers would be advantageous too. 
7.1.1 Proof of concept  
A proof of concept was carried out to determine if this project was worth pursuing.  Although 
protocols are in place to analyse urine samples in the department, the research into 
microbiology samples involved the analysis of the headspace above blood cultures. 
Therefore, considering Health & Safety in addition to practical sampling collection and 
analysis, we decided to analyse some samples, containing a variety of bacteria, in-situ in the 
labs of our project partners, Dr Kevin Fong and Dr Tom Bashford, at University College 
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London Hospital (UCLH), London.  The headspace of the blood cultures could be sampled 
using the following techniques: 
• HS analysis:  this sample had to be taken from the sample bottle and injected straight 
into the GC-MS.  A GC-MS instrument was used in the Biochemistry Department at 
UCLH, but the sampling had to be carried out manually, as a HS autosampler wasn’t 
available. 
• TD analysis: UCLH didn’t have the equipment to perform TD analysis in their labs, 
so the headspace was: sampled onto a clean TD tube and sealed; heated to kill any 
possible bacteria drawn onto the tube; and taken back to The Open University for 
analysis by GC-MS.  One batch (10 tubes) was purchased for the study. 
• SPME analysis: UCLH didn’t have the equipment to perform this in their labs; 
manual sampling would take a long time with a single SPME fibre; the main problem 
was the possible exposure to bacteria.  Therefore, we decided not to investigate this 
technique during the preliminary study. 
Risk assessments were carried out for the analysis of the blood cultures using the two 
techniques applied. 
The objectives of the preliminary study were to: 
• Analyse as many samples using the two techniques in the one day available. 
• Observe any differences in the profile of VOCs in the headspace between blank 
aerobic and anaerobic bottles plus and cultured bacteria samples. 
• Observe any differences between the different types of bacteria. 
• Determine which method was better: HS or TD. 
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7.1.2 Sample recruitment  
Samples were obtained from the Microbiology Department at UCLH.  Prior to analysis it 
was unknown which bacteria, or how many of each type, would be present in any sample on 
any one day.  Therefore, it was very much a matter of luck if there would be enough samples 
giving a positive reading in their BACTECTM system on that or the previous day.  
Microbiologists on the day and the day before the preliminary study, on confirmation of a 
positive result kept samples in the incubator ready for collection.  As it can take 1-2 days for 
the gram stain and subculture to identify the bacterium present, the HS-GC-MS samples 
were analysed blind.  
Anaerobic and Aerobic BACTECTM bottles containing positive samples that had been 
cultured and identified at UCLH were analysed.   
7.1.3 Study samples and analysis methods 
7.1.3.1 Samples and HS-GC-MS method 
There were three different types of bacteria that were analysed by HS-GC-MS following the 
method described in Section 2.3.2.2.  The bacteria were identified as: 
• Escherichia coli (E. coli)  
• Coagulase-negative Staphylococcus (Coag. neg. staph.)  
• Staphylococcus aureus and alpha-haemolytic streptococcus (Staph. aureus & Alpha 
haem. strept.) 
The number of samples analysed from Aerobic and Anaerobic BACTECTM bottles 
containing different bacteria are summarised in Table 7-1. 
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Table 7-1: Summary of number of samples of each type analysed by HS-GC-MS 
Blank or bacteria type Aerobic bottles Anaerobic bottles 
E. coli 3 2 
Coag. neg. staph 0 2 
Staph. aureus & Alpha haem. strept. 1 1 
Failed to grow by GPC 0 1 
Blank bottle 2 2 
The samples, data file names and conditions used in the figures are summarised in Table 7-2.  
As is shown, the samples were analysed randomly (bacteria type unknown) with blanks 
interspersed, including syringe blanks (SyrBlk) of air and BACTECTM bottle blanks (Blank 
or Blk). 
The method was being developed as the samples were injected, hence the variations in the 
incubation temperature, time and split ratio while sampling.  All samples had been incubated 
at 37 °C before being taken to the lab in an insulated bag for analysis. 
After injection of the first sample very few peaks were seen.  It was unknown at the time 
that this sample had also failed to grow by gel-permeation chromatography (GPC), meaning 
that there might not have been any bacteria present in the bottle.  Based on the assumption 
that the cultured bacteria should have been present, the split ratio was reduced from 10:1 to 
5:1 to improve the sensitivity.  The temperature was also changed throughout the process 
from the majority being analysed at room temperature, then incubation at 37 °C and finally 
56 °C to see if more volatiles analytes could be sampled. 
  
376 
 
Table 7-2: Summary of samples and conditions in the analysis by HS-GC-MS 
Inj. no. Data file name Bacteria type Bottle 
Type 
Inc. T 
(°C) 
Inc. time 
(hr) 
Split 
ratio 
2 SyrBlk1 None NA NA NA 10:1 
8 SyrBlk2 None NA NA NA 5:1 
10 Blank_Aerobic None Aerobic Room T 0 5:1 
14 Blk_A_Hot None Aerobic 37 1.5 5:1 
5 X576_A E. coli Aerobic Room T 0 5:1 
11 H38707_Aerobic E. coli Aerobic 37 3 5:1 
15 M41244_A_56 E. coli Aerobic 56 1 5:1 
4 X13_A Staph. aureus + 
alpha haem. strept. 
Aerobic Room T 0 5:1 
7 Blank_An None Anaerobic Room T 0 5:1 
13 Blk_An_Hot None Anaerobic 37 2.25 5:1 
12 H38707_An E. coli Anaerobic 37 3.25 5:1 
16 M42051_An E. coli Anaerobic 56 1.25 5:1 
6 X12_An Coag neg. staph. Anaerobic 37 1 5:1 
9 S12805_An Coag neg. staph. Anaerobic 37 2 5:1 
3 X13_An Staph. aureus + 
alpha haem. strept. 
Anaerobic Room T 0 5:1 
1 T64012_An GPC - failed to 
grow 
Anaerobic Room T 0 10:1 
Shows Injection number (Inj. no.), incubation temperature (Inc. T) and time (Inc. time), inlet 
split ratio (split ratio). 
7.1.3.2 Samples analysed by TD-GC-MS 
There were six different types of bacteria analysed by TD-GC-MS, following the method 
described in Section 2.3.3.3. 
• Escherichia coli (E. coli)  
• Coagulase-negative staphylococcus (Coag. neg. staph.) 
• Staphylococcus aureus and Alpha-haemolytic streptococcus (Staph. aureus & Alpha 
haem. strept.) 
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• Microcococcus species (Micrococcus spp.) 
• Klebsiella pneumoniae 
• Vancomycin-resistant enterococci (Vanc. resistant enterococcus) 
The number of samples analysed from Aerobic and Anaerobic BACTECTM bottles, 
containing the different bacteria, are summarised in Table 7-3. 
 Table 7-3: Summary of number of samples of each type analysed by TD-GC-MS 
Blank or bacteria type Aerobic bottles Anaerobic bottles 
E. coli 1 1 
Coag. neg. staph 1 0 
Micrococcus spp. 1 0 
Staph. aureus & Alpha haem. strept. 1 1 
Klebsiella pneumoniae 1 1 
Vanc. resistant enterococcus 0 1 
Failed to grow by GPC 0 0 
Blank bottle 1 1 
A summary of the samples and their analysis conditions are given in Table 7-4.  
Unfortunately, no replicates for each of the bacteria types, in each of bottles, were available 
for comparison. 
The instrument was checked for contamination by analysing two instrument blanks 
(TD_GCMS_Blk), where the TD trap was fired and the GC-MS acquired the data files.  After 
the first sample (Injection 3) was analysed, the TD tube that had been used was re-analysed 
two further times to check for carryover (Injections 4 and 5).  No carryover was seen and 
therefore the remainder of the samples were analysed randomly.  The TD tube used for 
Injection 10 was again re-analysed (Injections 11 & 12) to confirm the previous findings. 
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Table 7-4: Summary of samples and conditions in the analysis by TD-GC-MS. 
Inj. No. Data file name Bacteria type Bottle Inc. T (°C) Inc. time (hr) Static HS Dynamic HS Used for HS? 
1 TD_GCMS_Blk1 None NA NA NA NA NA NA 
2 TD_GCMS_Blk2 None NA NA NA NA NA NA 
4 Mi167821 None NA NA NA NA NA NA 
5 Mi167821_2 None NA NA NA NA NA NA 
11 Mi167822_1 None NA NA NA NA NA NA 
12 Mi167822_2 None NA NA NA NA NA NA 
18 TD_Blank_A None Aerobic Room temp. NA 10 10 Yes 
14 TD_X576_A E. coli Aerobic 37 4.25 10 0 Yes 
7 TD_F66318_A Coag neg staph Aerobic 37 2.75 10 10 No 
8 TD_H39091_A Klebsiella pneumoniae Aerobic 37 3.25 10 10 No 
10 TD_S12901_A Micrococcus spp Aerobic 37 4 10 0 No 
16 TD_X13_A Staph aureus + alpha haem strept Aerobic 56 4.75 10 0 Yes 
17 TD_Blank_An None Anaerobic Room temp. NA 10 10 Yes 
6 TD_M41244_An E. coli Anaerobic 37 2.25 10 10 No 
9 TD_H39091_An Klebsiella pneumoniae Anaerobic 37 3.75 10 0 No 
15 TD_X13_An Staph aureus + alpha haem strept Anaerobic 56 4.5 10 0 Yes 
3 TD_X583_An Vanc resistant Enterococcus Anaerobic 37 2 10 10 No 
13 TD_T64012_An GPC - failed to grow Anaerobic 37 4 10 0 Yes 
Shows: Injection number (Inj. no.), bottle type (Bottle), incubation temperature (Inc. T) and time (Inc. time), how long the bottle was sampled under static 
and dynamic HS conditions; if the sample had previously been analysed by HS-GC-MS.
379 
 
The method was also being developed further while sampling the sample bottles, therefore 
some samples were sampled by: 
• Static HS: where the static volume above the culture in the BACTECTM bottle was 
sampled at 20 mL/min for 10 minutes. 
• Dynamic HS: with 10 minutes of static HS followed by 10 minutes of dynamic HS, 
where the second needle was inserted to draw air through the bottle. 
Full details for both methods were provided in Chapters 2 and 3.  Due to the limited 
availability of samples, some samples collected onto a TD tube had been previously analysed 
by HS-GC-MS. 
7.2 Results and Discussion 
The results and discussion are divided into three sections: 
• The performance of the HS-GC-MS analysis will be discussed in Section 7.2.1, with 
data analysis performed using NIST AMDIS software.  There were no spectral 
libraries present in the Shimadzu software and the data files could not be used with 
Agilent software.  
• The performance of the TD-GC-MS method will be discussed in Section 7.2.2, with 
data analysis performed using Agilent MSD Chemstation software. 
• Chemometric analysis of both data sets by Cranfield University will be discussed and 
compared in Section 7.2.3. 
7.2.1 HS-GC-MS data 
There weren’t many samples to compare or data to generate performance data as this was 
conceived as a proof of concept study.  Contractual issues prevented the larger follow-on 
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study from taking place.  However, blanks were assessed and sample chromatograms 
compared and discussed in this section. 
7.2.1.1 Method performance: blanks 
The syringe blank data file was analysed and along with the air peak the solvents acetone, 
ethanol, n-hexane and cyclohexane were identified, plus some small siloxane peaks.  On 
comparison with the aerobic and anaerobic blank bottles, no additional peaks were identified 
in the aerobic blank bottle except for larger siloxane peaks and ethanol peaks.  In the 
anaerobic blank bottle, 1,3-dimethyl benzene and methyl-cyclopentane were also identified.  
The chromatograms are shown in Figure 7.1. 
 
Figure 7.1: TICs of HS-GC-MS blanks (a) syringe; (b) aerobic bottle; (c) anaerobic bottle 
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7.2.1.2 Sample bottles 
As shown in Figure 7.2, when comparing the aerobic samples to the aerobic blank there was 
very little difference in the chromatograms.  Even when using deconvolution, except for 
siloxane peaks, the only additional peak seen and identified was acetic acid, present in the 
Staph. aureus + alpha haem. strept. sample, with a smaller peak present in an E. coli sample. 
On comparison of the anaerobic samples to the anaerobic blank, again there were no 
significant differences seen, with only slight variations in the solvents and siloxane peaks 
previously discussed for the anaerobic bottle. 
 
Figure 7.2: TICs of HS-GC-MS (a) aerobic blank; (b) aerobic Staph. aureus + alpha haem. 
strept.  
Overall, the HS-GC-MS method showed very poor sensitivity, with very few peaks seen in 
the chromatograms or extracted using deconvolution. 
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7.2.2 TD-GC-MS data 
7.2.2.1 Method performance: blanks 
Manual comparisons and peak identification was made using the instrument software.  
Chromatograms comparing an instrument blank with a TD tube blank, aerobic and anaerobic 
bottle blanks are shown in Figure 7.3. 
Background from the instrument was very low, with only a couple of peaks identified as 
siloxanes and sulphur dioxide, most likely to be artefacts from the TD cold trap sorbent.  
Analysis of a conditioned TD tube produced the same siloxanes and sulphur dioxide at a 
higher abundance, plus the extra peaks: benzene and styrene, which are known artefacts of 
the TD tube sorbents.   
On the analysis of the blank aerobic and anaerobic BACTECTM bottles, with no sample only 
the culture medium, the background was much higher.  This is to be expected, as all tubing 
used in the sampling system, the bottle itself (including septum and the medium) will 
produce volatiles.  For example, both ethanol and acetone were analysed from the culture 
medium, multiple branched and cyclic hydrocarbons from either the medium or the sampling 
parts, low level phthalates and plasticisers from the tubing and bottle septum.  Comparing 
the aerobic and anaerobic bottle chromatograms, the peaks were identified as being the same 
compounds, they were just present at different concentrations.   
Future work, in a larger scale project, would need to include the analysis of multiple blank 
bottles and a comparison between the sample bottles themselves and those bottles that do 
not contain medium, to see how consistent the background signal is.    
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Figure 7.3:  Comparison of Anaerobic (red) and Aerobic (blue) bottle blanks against 
instrument (black) and TD tube (green) blanks 
7.2.2.2 Method performance: carryover 
After the first sample (Vanc. resistant enterococcus from the anaerobic bottle) was analysed, 
the same TD tube was analysed twice more.  This was to determine if there had been any 
carryover.  If in the first desorption, all the analytes from the TD tube had not been fully 
desorbed, or the system had been left contaminated after sample analysis, peaks would still 
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be present on the second desorption of the TD tube.  The third desorption would then show 
fewer peaks again at lower abundancies.  Carryover was checked for, before the remaining 
samples were analysed.  The chromatograms from the sample and subsequent desorptions 
of the TD tube are shown in Figure 7.4.  The second blank desorption chromatogram was 
already compared to an instrument blank and BACTECTM bottle blanks in Figure 7.3. 
Comparing the chromatogram of the sample against the two TD tube blanks, there were 
many large peaks in the sample chromatogram and very few peaks in the TD tube blanks.  
The peaks present in the TD tube blank were also much lower in abundance. Comparing the 
chromatograms of the two TD blank analyses, they are very similar in terms of the number 
of peaks and the abundances of those peaks.  The three chromatograms were integrated using 
the real-time execution (RTE) integrator and the results determine for all peaks present in all 
three chromatograms are presented in Table 7-5. 
The percentage carryover was calculated by comparing the peak areas from the first blank 
TD tube desorption against the areas of the same peaks from the sample analysis.  The areas 
of the first and second blank TD tube desorptions were then compared and presented, where 
a value of 1 means the areas are comparable and 0.5 means the second desorption area is 
half the size of the first desorption area.  Many of the peaks from both desorptions were very 
small, therefore the accuracy of integration, which was not optimised, may cause much of 
the difference. 
The TD tube blanks will never be completely peak-free, due to sorbent heating artefacts, as 
discussed previously.  Out of the 24 integrated peaks, nine had a carryover of < 1 %, a further 
nine had a carryover of < 10 %. 
The peak at 15.58 minutes, tentatively identified as styrene, had a consistent size in all three 
analyses, indicating it must be an artefact of the method, rather than coming from a sample. 
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Figure 7.4: Carryover check for anaerobic bacteria
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Table 7-5:  Carryover peak data 
Sample desorption 2nd desorption 3rd desorption  
Retention 
Time   
(min) 
Area 
(arbitrary 
units) 
Area 
(arbitrary 
units) 
Carryover 
(%) 
Area 
(arbitrary 
units) 
Ratio of 
areas       
3rd cf. 2nd  
Tentative 
Identification 
2.633 1758999 12342 0.70 8764 0.71 Argon 
2.716 2918097 8024 0.27 3674 0.46 
Carbon 
dioxide 
3.37 3027708 692756 22.88 572099 0.83 
Sulphur 
dioxide 
3.805 1328062 74715 5.63 46284 0.62 Acetaldehyde 
3.856 1322680 44578 3.37 33803 0.76 2-Butene 
4.476 25388094 57794 0.23 24130 0.42 Ethanol 
5.141 1069004 27987 2.62 21331 0.76 ? 
5.27 7419961 33672 0.45 5027 0.15 Acetone 
5.944 472322 4105 0.87 7576 1.85 Siloxane 
6.618 7523368 42765 0.57 3773 0.09 Siloxane 
9.015 1262945 5040 0.40 3968 0.79 ? 
9.549 2256760 827250 36.66 658854 0.80 Benzene 
10.034 196186 7870 4.01 0 0.00 ? 
12.453 337902 81324 24.07 25736 0.32 Toluene 
12.615 188026 12302 6.54 27773 2.26 ? 
12.87 108093 9048 8.37 19195 2.12 Siloxane 
13.137 230630868 2271622 0.98 1696316 0.75 Siloxane 
14.793 2417202 63492 2.63 49472 0.78 Ethylbenzene 
15.079 5838192 75523 1.29 34502 0.46 m-Xylene 
15.577 179814 163417 90.88 145433 0.89 Styrene 
15.687 1355468 32704 2.41 8880 0.27 o-Xylene 
16.805 350686968 528199 0.15 387213 0.73 Siloxane 
17.217 114170 19371 16.97 7820 0.40 Benzaldehyde 
19.748 23454253 413114 1.76 314081 0.76 Siloxane 
Two peaks, tentatively identified as sulphur dioxide and benzene, had an initial carryover on 
the first desorption; however, on the second desorption the peak was approximately the same 
size, again meaning that it was likely these compounds were artefacts. 
Two peaks had carryover of 17-24 %, but then reduced again in size by 80 %.  This cannot 
be explained, however, after sampling the headspace from the bacterial culture bottles onto 
the TD tubes, they were sealed with air inside and heated to 60 °C to kill any potential 
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bacteria present.  This would potentially cause some damage to the sorbents due to oxidation 
by the oxygen present and would explain some of these results. 
For future work the damage to the tube on carrying out this process, needs to be investigated, 
by conditioning and then analysing a clean TD tube.  Sampling air onto the tube at the 
flowrate and for the time described in the method.  Sealing the tube and heating to the method 
temperature for the method time.  Then finally analysing the TD tube and comparing to the 
first analysis. 
On comparison of the second and third desorptions of the TD tube against the sample 
desorption, it was deemed that there was negligible carryover caused by the sample analytes 
and therefore the remainder of the samples were analysed as described in Section 2.3.3.2. 
7.2.2.3 Aerobic sample compared to a blank aerobic bottle  
A zoomed in chromatogram of an aerobic sample containing Klebsiella pneumoniae (black 
trace) compared to a blank aerobic bottle (blue trace) is shown in Figure 7.5.  The headspace 
from the sample and blank bottles had both been extracted for a total of 20 minutes.  The 
blank bottle was incubated at room temperature, while the sample bottle was incubated at 37 
°C.  Many small peaks from the blank bottle were much larger from the sample bottle plus 
there were many additional peaks.  For example, the peak at 6.41 minutes was only present 
in the sample trace and was identified through the RTL database as 1-propanol.  Another 
peak at 6.90 minutes was identified as MTBE and 3-methyl hexane at 9.64 minutes.  The 
peak at 4.87 minutes in the sample trace was not identified by the IARTL library.  The mass 
spectrum was therefore sent to the NIST library search algorithm and identified as 2-methyl 
butane.  Going back to the IARTL library this mass spectrum was not present and therefore 
not identified as a target. 
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Figure 7.5: Zoomed in comparison of an aerobic sample vs. blank aerobic bottle by TD-GC-MS
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Identification of the peaks against the retention time locked library means more certainty in 
identification because retention time is used as a qualifier.  A total of 55 target peaks were 
automatically identified using this technique.  However, manual comparison of these peaks 
as well as the manual identification of peaks not identified by this limited library would be 
very lengthy.  Hence, it is much easier to do the comparison using chemometric techniques 
which can also reveal hidden differences between the blanks and samples. 
7.2.2.4 Comparison of all aerobic samples 
An overlay of all five aerobic samples can be seen in Figure 7.6.  As to be expected, in 
general the two samples extracted for a total of 20 minutes showed higher abundances of 
peaks than the three samples extracted for a total of 10 minutes.  However, this was not the 
case for all peaks, with the peak at 3.35 minutes showing a much higher concentration of 
sulphur dioxide for Staph. aureus + Alpha haem. strept. (green trace) compared to other 
samples.  The 1,4-dioxane peak at 10.61 minutes was also higher for this sample.  The Coag. 
neg. staph. (blue trace) appeared to have the highest concentration of peaks.   
7.2.2.5 Anaerobic sample compared to a blank aerobic bottle  
A zoomed in chromatogram of an anaerobic sample containing E. coli (black trace) 
compared to a blank anaerobic bottle (blue trace) is shown in Figure 7.7.  The headspace 
from the sample and blank bottles had both been extracted for a total of 20 minutes.  
However, the blank bottle was incubated at room temperature, while the sample bottle was 
incubated at 37 °C.   
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Figure 7.6: Zoomed in comparison of all aerobic samples by TD-GC-MS 
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Just as for the aerobic bottle comparisons, most small peaks from the blank bottle were much 
larger from the sample bottle plus there were many additional peaks.  For example, the peak 
at 6.41 minutes was only present in the sample trace and was again identified through the 
RTL database as 1-propanol.  Other peaks identified were ethyl acetate (8.01 minutes), 1,1,1-
trichloroethane (9.01 minutes) and 1-butanol (9.09 minutes).  All of them were identified 
through deconvolution in the sample trace but not the bottle blank.  Automatic deconvolution 
and identification against the 171 compound IARTL library identified 58 targets, however 
many of these were present in both sample and bottle blank.   
7.2.2.6 Comparison of all anaerobic samples 
An overlay of all five aerobic samples can be seen in Figure 7.8.   In general, the two samples 
extracted for a total of 20 minutes (black and red traces) showed higher concentrations of 
peaks than the three samples (yellow, green and blue traces) extracted for a total of 10 
minutes.  This is to be expected.  However, this was not the case for all peaks, the peak at 
4.15 minutes, identified by IARTL as methanethiol, was only present in the Klebsiella 
pneumoniae (blue trace) and E. coli (red trace) samples.  The peak at 7.40 minutes, identified 
by IARTL as possibly vinyl acetate, was only present in the Vanc resistant Enterococcus 
(black trace) sample.  1-propanol, at 6.41 minutes was only detectable in the E. coli (red 
trace) as a large peak and Klebsiella pneumoniae (blue trace) as a small peak.  It was not 
detected in the other three samples.  The peak at 11.03 minutes was 3-methyl butanol, which 
was present in all traces except for the GPC (failed to grow) data file.  
Peaks from 14 minutes onwards, were much smaller with the small peaks barely detectable 
for the samples that were extracted for 10 minutes rather than 20 minutes, showing the need 
to optimise this part of the method in the future with real samples rather than just blank 
aerobic and anaerobic bottles in the lab.     
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Figure 7.7: Zoomed in comparison of an anaerobic sample vs. blank anaerobic bottle by TD-GC-MS 
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Figure 7.8: Zoomed in comparison of all anaerobic samples by TD-GC-MS 
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As expected, the failed to grow by GPC sample (green trace) had by far the lowest number 
and lowest abundances of peaks.  The E. coli (red trace) appeared to have the highest number 
and abundances of peaks. 
7.2.3 Exploratory analysis by PCA and HCA 
Data files were uploaded to the servers at Cranfield University, in .CSV format, in the future 
NetCDF format will be used.  Dr Michael Cauchi then processed them using chemometrics 
techniques.  There were not enough data files of any one type to perform supervised learning; 
therefore, only exploratory analysis could be performed to look for any statistical differences 
between the samples. 
The TD-GC-MS data files had a total of ~14,900 scans, far more than the urine study samples 
by HS-SPME-GC-ToFMS of ~8,700.  This was due to the analysis time being longer, 28.5 
compared to 15 minutes.  However, the data files were treated in the same way as for the 
urine analysis. 
The blanks were treated as samples to determine if they could be differentiated from the 
samples through natural groupings.  There was no IS present for normalisation, but for future 
work the TD autosampler has the possibility of using the automatic addition of an IS.  
Usually toluene-d8 is used as it is volatile and not present in the samples.  A TIC trace was 
created by summing the abundances of the m/z, as previously described.  The data files were 
aligned using COW and no feature selection was performed.  Multiple different scaling 
methods were compared, including no scaling, mean-centre, auto-scale, range-scale (0 to 1), 
range-scale (-1 to 1) and normalisation.  HCA was performed using the Euclidean distance 
and Ward linkage methods. 
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7.2.3.1 HS-GC-MS data 
The first 150 scans were removed, as the air peak had a large influence on the data analysis, 
producing no classification.  Through implementing this method, discrimination improved 
and gave similar results for no scaling, mean-centring and range-scaling (0 to 1).  The PCA 
plot with no scaling is shown in Figure 7.9.  See Table 7-2 for the key to data file names. 
 
Figure 7.9: PCA plot of the HS samples 
88 % of the variance in the data set is captured in PC1, with a further 10 % in PC2.  The 
relationship between the samples can more clearly be seen from the HCA dendrogram in 
Figure 7.10, with no scaling. 
There is clearly a relationship between all the aerobic samples and the anaerobic samples, 
except for the anaerobic blank.  However, for some samples that are the same type, for 
example the E. coli aerobic samples H38707 and M41244, they are more similar to the 
blanks than they are to each other.   
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Figure 7.10: HCA dendrogram of the HS samples 
7.2.3.2 TD-GC-MS data 
The resultant PCA plot for the TD samples, with no scaling is shown in Figure 7.11.  See 
Table 7-4 for the key to data file names. 
 
Figure 7.11:  PCA analysis of data files from TD-GC-MS, no scaling 
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91 % of the variance in the data is captured in PC1 and a further 4 % in PC2.  From this plot, 
there are no clear clusters of data.  Any relationships between the samples is easier to 
visualise from the HCA dendrogram, shown in Figure 7.12. 
 
Figure 7.12: HCA dendrogram of the TD samples and blanks 
The different types of samples: instrument blanks, aerobic and anaerobic samples are very 
well clustered together.  However, differences can be seen between the individual samples.  
Unfortunately, there were no duplicates of any bacteria type in the same medium to see if 
they clustered together, as they should. 
7.3 Conclusions and future work 
Although the data set was small, the data analysis using chemometric techniques could 
provide answers to the objectives of the pilot study: 
• We could observe differences in the headspace between the blank aerobic and 
anaerobic bottles using both HS and TD. 
• We could observe differences between the different types of bacteria when using 
TD-GC-MS. 
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• The TD method was far more sensitive than the HS method, showing far more 
differences between the different types of blanks and bacteria and better clustering 
of samples from blanks.  The GC-MS method used also provided around four times 
more scans, providing more data to see any patterns and differentiate between the 
samples. 
The next steps would be to: 
• Seek ethical approval. 
• Decide the key bacteria to focus on and the number of samples and blanks to analyse. 
• Write protocols for sample collection, transportation and analysis. 
• Optimise the TD sampling, desorption and GC-ToFMS analysis, including use of 
automatic IS addition for normalisation.  
• Optimise chemometric techniques and biomarker identification. 
Unfortunately, this project could not be taken any further at the time, despite having secured 
funding for the next study.  More sensitive instrumentation TD-GC-ToFMS had been 
organised with the manufacturer for the sample analysis, along with trained staff to regularly 
sample the BACTECTM bottles over a four-month study.  The plan for this work can be seen 
in Figure 7.13 and Table 7-6.  However, the material transfer agreement for the samples 
could not be agreed upon between The OU and UCLH.  
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Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
May-13   
    1 2 3 4 5 
Sample collection: UCLH
6 7 8 9 10 11 12 
Sample analysis: ALMSCO
13 14 15 16 17 18 19 
Data analysis/report writing: Cranfield
20 21 22 23 24 25 26 
Finalise report: OU 
27 28 29 30 31     
Submit report: ISIC 
   
Jun-13   
          1 2 
3 4 5 6 7 8 9 
10 11 12 13 14 15 16 
17 18 19 20 21 22 23 
24 25 26 27 28 29 30 
   
Jul-13   
1 2 3 4 5 6 7 
8 9 10 11 12 13 14 
15 16 17 18 19 20 21 
22 23 24 25 26 27 28 
29 30 31         
   
Jul-13   
      1 2 3 4 
5 6 7 8 9 10 11 
12 13 14 15 16 17 18 
19 20 21 22 23 24 25 
26 27 28 29 30 31   
Figure 7.13: Timetable for follow-on sepsis study 
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Table 7-6: Plan for follow-on sepsis study  
End of:  Max. no. TD tubes Max. no. samples Min. no. samples 
Week 1 Extract up to 40 samples including max. of 5 no-grows 40 40 15 
Week 2 Extract up to 40 samples including max. of 5 no-grows 80 80 30 
Week 3 Extract up to 40 samples including max. of 5 no-grows & ship to ALMSCO 120 120 45 
Week 4 120 samples analysed by ALMSCO, tubes reconditioned & shipped back 160 
 Extract up to 40 samples including max. of 5 no-grows 40 160 60 
Week 5 Extract up to 40 samples including max. of 5 no-grows 80 200 75 
Week 6 Extract up to 40 samples including max. of 5 no-grows & ship to ALMSCO 120 240 90 
Week 7 120 samples analysed by ALMSCO, tubes reconditioned & shipped back 160 
 Extract up to 40 samples including max. of 5 no-grows 40 280 105 
Week 8 Extract up to 40 samples including max. of 5 no-grows 80 320 120 
Week 9 Extract up to 40 samples including max. of 5 no-grows & ship to ALMSCO 120 360 135 
Week 10 120 samples analysed by ALMSCO, tubes reconditioned & shipped back 160 
 Extract up to 40 samples including max. of 5 no-grows 40 400 150 
Week 11 Extract up to 40 samples including max. of 5 no-grows 80 440 165 
Week 12 Extract up to 40 samples including max. of 5 no-grows & ship to ALMSCO 120 480 180 
Week 13 120 samples analysed by ALMSCO, tubes reconditioned & shipped back  
 
Notes: Up to 40 collected per week - a mixture of bacteria and no-grows (control max. 5 per week) 
 At end of each week all samples headspace is extracted onto TD tubes = max. 40 tubes needed    
 After 3rd extraction all tubes are sent to ALMSCO for analysis, reconditioned and returned, meanwhile spare set of tubes are used 
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402 
 
The aim of the thesis was to develop and evaluate the performance of non-invasive methods 
to characterise the disease states of patients utilising selective discrimination, gas 
chromatography-mass spectrometry and chemometrics. 
The primary analytical method that was investigated was gas chromatography-time-of-flight 
mass spectrometry coupled with headspace solid-phase microextraction (HS-SPME-GC-
ToFMS); in addition, comprehensive gas chromatography (GCxGC) was also evaluated, as 
were headspace (HS) and thermal desorption (TD) sampling techniques.  
The main studies reported evaluations of the profiles of the headspace above urine samples 
to classify the presence or absence of disease, as had previously been demonstrated by dogs.  
Nearly 1,000 volatile organic compounds (VOCs) were observed using 1D GC and over 
3,000 VOCs using GCxGC techniques.  However, the inability to process the large GCxGC 
data files restricted the use of the latter technique.   
Therefore, the main focus of the method development, in Chapter 3, was on HS-SPME-GC-
ToFMS.  A robust and sensitive method was developed by optimisation of all sample 
analysis parameters.  Its application for clinical samples was demonstrated through Chapters 
4, 5 and 6, where the optimised method was evaluated for its suitability for detecting patients 
with bladder cancer, prostate cancer and hepatic disorders.   
The performance of the analytical method was assessed to determine if it was reproducible 
and sensitive enough to enable classification of the different types of clinical samples.  It 
was shown that the differences in the analytes detected were due to the differences in the 
clinical status of the sample, rather than any instrument and/or sample analysis error.  This 
evidence was obtained by quantifying the IS present in every sample and sample blank and 
through the comparison of replicate samples in each study. 
To summarise, the following conclusions were drawn about the method developed and 
applied: 
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• The analysis of replicate samples, with consecutive and non-consecutive injections 
in a batch and between-batch replicates showed no reduction in performance between 
these types of replicates.   
• The variability seen was not systematic, it was random, even over long periods and 
so was likely to be due to errors in placing the collected sample into the vial, sample 
preparation or extraction and injection. 
• The variation in the response of the unknown analytes in the replicate injections 
matched the IS response variation and therefore normalisation against the chosen IS 
was possible. 
• Assessing the library similarity match of the IS enabled an assessment of the 
sensitivity of the method, alongside the IS peak areas and SN ratio. 
Based on these findings, this analytical method was used to explore clinical samples with 
confidence.   A recommendation, for all future work, is that normalisation of the data against 
the IS is necessary and highly recommended: 
• To align the retention times, thus enabling comparison of the peaks in each data file 
based on their scan number. 
• To compare the response of the peaks in each data file more accurately, leading to 
the generation of more significant classification results. 
Further improvements to the sample analysis method, developed in this thesis, would 
include: 
• Using a well-characterised urine sample as a system suitability check before the start 
of each batch.  This would ensure the new SPME fibre is functioning properly as well 
as checking the sensitivity of the whole GC-MS across the full volatility range, rather 
than relying on just the single IS. 
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• Looking into more automated preparation of the internal standard.  The latest CTC 
autosampler enables the automatic changing of the syringe.  This would enable 
automatic addition of the IS prior to SPME analysis and could potentially improve 
reproducibility over the manual method.  However, the piercing of the vial septum 
prior to pre-incubation, could potentially cause losses of some volatile analytes into 
the vial septum, which would have to be investigated.   
• The automatic addition of the acid solution and potentially a concentrated saline 
solution, rather than solid sodium sulphate should be investigated, to automate the 
sample preparation further and potentially reduce contamination.  When to add these 
in the process, for example as soon as the vials are loaded or as they are being 
prepared; the effects of automation on the samples (and vial seals); as well as the 
health and safety implications of the sample on the autosampler before it has been 
neutralised; would all need to be investigated.  Automation could improve 
reproducibility in some ways, but reduce it in other ways. 
Separate analytical methods were developed for the identification of the causative agents of 
sepsis, from the profile of the volatile compounds present in the headspace above culture 
samples, using HS-GC-MS and TD-GC-MS, as discussed in Chapter 7.  Although the pilot 
study was small, it was clear that the TD-GC-MS method provided better sensitivity.  
Contractual issues curtailed the development and so future work should concentrate on 
developing this method further with more samples and instrument time. 
Mathematical models were then developed by Cranfield University for all four studies, to 
determine if the diseased samples could be distinguished from the control samples, or in the 
case of sepsis if the different bacteria could be distinguished from each other. 
The classification results, for all three HS-SPME-GC-ToFMS studies, looked very 
promising:   
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For bladder cancer, the comparison of most categories gave a mean accuracy of 80 % or 
better using the PLS-DA classifier.  For low grade tumours, C3 vs. TCC1 gave a sensitivity 
of 73 % which is much better than 20- 50 % obtained when using the urine cytology.   
The prostate cancer study produced very promising results, with even higher clinical 
performance than the current gold standard diagnosis methods.  Also, other benign 
genitourinary tract diseases (e.g. BPH) did not affect the performance of the classifier and 
classification of BPH against PC produced equally good performance, which has the 
potential to be used for the differentiation of these two conditions that cause similar 
symptoms.  Discussions have begun with clinical partners to take this evaluation forward. 
The results for the hepatic disorders study looked better still, with the ability to differentiate 
between liver cirrhosis and various other illnesses with all performance monitors of 86 % or 
greater and a ‘very good’ AUROC score using PLS-DA.  Those with liver cirrhosis caused 
by HCV could be differentiated from non-HCV cirrhosis and healthy controls; however, far 
more data is required to fully validate the statistical significance of the findings. 
Although only a very small study on sepsis was possible, differences between the different 
types of bacteria when using TD-GC-MS were observed. 
A large amount of high quality data was collected through these studies.  However, I feel 
that a large amount of this valuable information has still not been used.  Further chemometric 
analysis of the data should be focused on: 
• Finding out which samples were classified as outliers and investigating the reasons 
why they were classified as such.  Potential reasons could be instrument acquisition 
problems, IS concentration, or it could be related to the metadata from the 
participants. 
• Making more use of the metadata.   
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• Investigating if the specific gravity can be successfully used for normalising the urine 
sample concentration.  
• Using three-dimensional data for multivariate analysis rather than the two-
dimensional TIC data.  This should be possible now, using the large amounts of high 
quality data already generated, due to improvements in computing power since this 
data was analysed. 
• As all three urine studies used the same analysis method, classification of all these 
samples together. 
To be able to successfully classify and diagnose diseases and disorders, there are two parts 
to the methodology: 
Firstly, a robust, acquisition method to analyse the sample and to produce high quality 
analytical data is required.  This needs stringent quality control, using an IS, to check for 
carryover and to correct for any drift in instrumentation and analyte extraction.  Large, 
balanced data sets are required to consider all differences between the samples and to 
investigate the metadata, where age, smoking status, dipstick test results and even food and 
drink intake may have an influence. 
Secondly, experts in chemometric analysis techniques are required, to develop the data 
processing methodology.  Exploratory algorithms such as PCA and HCA didn’t reveal any 
natural groupings and therefore pattern recognition techniques are required to train the 
algorithms with known data sets, that need to be large enough to have statistical significance.  
The scaling technique needs to be considered and assessed.  Feature selection should be 
considered, although it was generally deemed to be unsuitable, meaning that data reduction 
generated poorer performing models.  Bootstrapping, cross-validation and permutation 
testing, using different classifiers and generating many classification models and null models 
are necessary to thoroughly quantify the data and to make the results significant.   
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Finally, as much data as possible about the samples need to be acquired and used.  For 
example, dogs do not sniff individual compounds, they look at the whole profile.  Putting 
this into the laboratory means that all volatile compounds in the headspace above the sample 
need to be extracted and analysed.  Following on from this, all acquired data, with no data 
reduction, needs to be used in statistical pattern recognition techniques, to obtain the best 
classification of diseased vs. non-diseased samples with the highest accuracy and specificity.  
Identification of potential biomarkers, reveals that there are many compounds, increasing or 
decreasing in abundance throughout the whole analysis that contribute to the classification.  
It would be good to identify, 1 or 10 or 50 biomarkers that enable the diagnosis of the disease, 
but all evidence throughout these studies have revealed that although some compounds may 
have more influence, they do not add up to most of the variance in the data and so the 
comprehensive approach reported in this thesis is essential going forward. 
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Appendix A  Publication 
Evaluation of gas chromatography mass
spectrometry and pattern recognition for the
identiﬁcation of bladder cancer from urine
headspace
M. Cauchi,*a C. M. Weber,a B. J. Bolt,a P. B. Spratt,a C. Bessant,b D. C. Turner,c
C. M. Willis,d L. E. Britton,d C. Turnerc and G. Morganc
Previous studies have indicated that volatile organic compounds speciﬁc to bladder cancer may exist in
urine headspace, raising the possibility that they may be of diagnostic value for this particular cancer. To
further examine this hypothesis, urine samples were collected from patients diagnosed with either
bladder cancer or a non-cancerous urological disease/infection, and from healthy volunteers, from
which the volatile metabolomes were analysed using gas chromatography mass spectrometry. The
acquired data were subjected to a speciﬁcally designed pattern recognition algorithm, involving cross-
model validation. The best diagnostic performance, achieved with independent test data provided by
healthy volunteers and bladder cancer patients, was 89% overall accuracy (90% sensitivity and 88%
speciﬁcity). Permutation tests showed that these were statistically signiﬁcant, providing further evidence
of the potential for volatile biomarkers to form the basis of a non-invasive diagnostic technique.
Introduction
Bladder cancer is the seventh most common cancer in the UK,
with over 10 700 new cases diagnosed in 2012.1 As with most
cancers, early diagnosis greatly increases the chances of
survival; individuals presenting with stage I tumours having
a one year relative survival rate of around 97%, compared to
26% for those with stage IV disease.2 For people exhibiting
symptoms or requiring surveillance, cystoscopy with biopsy
remains the “gold standard” investigative technique for bladder
cancer detection, but is invasive, expensive and time-
consuming. Urine cytology can be a useful non-invasive adjunct
to diagnosis, since it has a high specicity for bladder cancer
(96–98%), but its sensitivity is low (22–52%), especially for low-
grade tumours which shed proportionally fewer cells into the
urine. Furthermore, an experienced cytologist or pathologist is
needed to perform the cytological evaluation, making the test
relatively expensive and slow.3
Utilisation of molecular biomarkers present in urine oﬀers
a promising alternative non-invasive approach to diagnosis,
which if suﬃciently accurate, rapid and cheap has the potential
to be used for mass screening of the population. Of the protein
markers which have so far been investigated in depth, three
have achieved FDA approval as assays for diagnosis and/or
follow-up – nuclear mitotic apparatus protein (NMP22),
complement factor H-related protein and complement factor H
(BTA stat® and BTA TRAK®), and carcinoembryonic antigen
combined with two bladder tumour cell-associated mucins
(ImmunoCyt™/uCyt+™).4,5 Whilst these are more sensitive
than urine cytology, having reported sensitivities of 47–100%,
53–83% and 50–100%, respectively, specicities are signi-
cantly lower at 60–90%, 51–75% and 69–79%, respectively.
Recently, it has been suggested that volatile organic
compounds (VOCs) present in the headspace of urine from
bladder cancer suﬀerers may be used as diagnostic biomarkers.
This concept was initially demonstrated in a canine olfactory
proof-of-principle study by Willis et al.6 and subsequently sup-
ported by ndings using a metal oxide semiconductor (MOS)
and eld eﬀect transistor (MOSFET) gas sensor array,7 where
sensitivity and specicity rates of up to 70% were achieved. A
more recent pilot study by Khalid et al.8 involving 24 bladder
cancer patients and 74 control patients with non-malignant
urological disease, utilised an in-house fabricated combined
gas chromatography (GC) MOS-sensor device with pattern
recognition, reporting accuracies of between 93% and 100% for
the correct assignment of urine samples. Although very prom-
ising, the authors acknowledge that larger sample sizes are
needed to conrm the results.
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Gas sensor arrays undoubtedly oﬀer practical advantages
over trained dogs for the detection of the urinary VOCs associ-
ated with bladder cancer. However, they currently exhibit
performance limitations, including sensor dri and a lack of
inter-device reproducibility, and, furthermore, cannot be used
to identify the chemical nature of individual volatile
biomarkers. In the present study, we apply a more revealing
analytical technique; that of gas chromatography mass spec-
trometry (GC-MS), and further demonstrates the potential for
VOCs as a diagnostic approach to bladder cancer. GC-MS has
already shown promise in the early diagnosis of lung cancer
based on the analysis of VOCs contained in breath samples.9 It
is now an important analytical technique in the eld of
metabolomics due to its high sensitivity, reproducibility and
peak resolution.10 As early as 1980, methods had been estab-
lished that could identify up to 155 metabolites in samples
originating from urine.11,12
A number of diﬀerent mass spectrometry systems are avail-
able for such analysis, including time-of-ight (ToF) and
quadrupoles coupled with a database containing a library of
spectral data for the identication of compounds.13 Recent
advances have been seen in the separation of compounds with
the advent of GCx-GC coupled with ToF-MS.14 In this regard,
copious amounts of data are generated which require a robust
statistical analytical approach, such as chemometrics,15 and, in
particular, multivariate data analysis. This can sometimes
involve an exploratory approach typically using principal
components analysis (PCA) to identify possible trends and
outlying samples16 which is followed by pattern recognition.17
The latter, in the form of multivariate classication with partial
least squares discriminant analysis (PLS-DA), can deduce which
type of class a particular sample belongs to, for example,
healthy or diseased.18,19 Although there are other machine
learning algorithms available, e.g. articial neural networks
(ANNs),20 random forests21 and support vector machines
(SVMs),22,23 PLS-DA permits visualisation of the most signicant
features in a given chromatogram via the PLS loadings.19,24
This paper presents the identication and classication of
bladder cancer via the multivariate statistical technique of
partial least squares discriminant analysis (PLS-DA) and the
machine learning approaches of support vector machines and
random forests, on GC-MS data acquired from urine samples.
Experimental
Reagents
Analytical grade reagents and solvents were employed, unless
otherwise stated.
Participant selection
A total of 72 patients (Table 1) presenting at Buckinghamshire
Healthcare NHS Trust with new or recurrent transitional cell
carcinoma (TCC) of the bladder donated urine prior to surgical
intervention. Grade and stage of the tumour were recorded, and
three groups drawn up based on grade: TCC1 – low grade or well
diﬀerentiated; TCC2 – moderately diﬀerentiated; TCC3 – high
grade or poorly diﬀerentiated. An additional 205 control
subjects, categorised into one of three groups (controls 1, 2 and
3, depending upon age and disease status), also provided urine
samples. The control groups were split as follows: control group
1 (C1) – no urine abnormality on dipstick analysis; Control
group 2 (C2) – any non-urological non-cancerous condition or
disease, and/or one or more positive dipstick ndings of
a minor nature. Menstruating women with blood in their urine
were included in this group, for example, as were individuals
with suspected urinary tract infection, positive for leucocytes,
blood and/or protein.
Control group 3 (C3) – conrmed non-cancerous urological
disease, with or without urine dipstick abnormalities. Urolog-
ical conditions included renal and ureteric stones, renal cysts
and polypoid cystitis.
As criteria for inclusion/exclusion, controls over 32 years of
age were required to have had recent cystoscopy to exclude
visible bladder malignancy. For both controls and the cancer
positive group (TCC), men over 50 years were only included if
recent cancer-negative prostate histology had been demon-
strated. Individuals with pre-malignant urological disease or
a history of urological carcinoma other than TCC were excluded.
A history of malignancy in other organ systems (>5 years
previously) was acceptable, providing the individual was now
considered disease-free. All other past and/or present medical
conditions were permissible. There were no exclusions on the
basis of medication, menstrual cycle, diet, alcohol consump-
tion, or chemical exposure. However, details of all of these
factors were recorded for each participant, should their inu-
ence on the composition and odour of the urine need to be
considered at any stage. Special attention was paid to smoking
habits, with 28% of those with bladder cancer being current
cigarette smokers, as compared to 31% control subjects. Finally,
in order to ensure that age would not be a main contributory
factor when comparing the C3 group against the TCC groups, 18
subjects under the age of 50 were omitted from the C3 group.
The study was given favourable ethical opinion by the Mid
and South Buckinghamshire Local Research Ethics Committee
(04/Q1607/65), and all participants gave written informed
consent; aer samples were taken, they and all subsequent data
were anonymised.
Analysis and processing of urine samples
Following urinalysis (Multistix 10 SG, Bayer Corporation, NY,
USA), fresh urine specimens were refrigerated immediately, and
frozen as soon as possible as 0.5 ml aliquots in glass vials. The
median time interval between refrigeration and freezing was 3
hours (range 1–24 hours). Samples were then stored at 80 C
until required. It was found in a recent study that the eﬀect of
freezing samples had no noticeable eﬀect on the volatile
composition of the samples.25 The use of glass vials has recently
become of concern due to it being able to absorb volatiles.26
However the absorption of analytes onto the glass is dependent
on a very large range of factors including concentration, func-
tional groups, etc. Generally, freezing reduces the likelihood of
interaction with the glass vials. Though reduced surface activity
4038 | Anal. Methods, 2016, 8, 4037–4046 This journal is © The Royal Society of Chemistry 2016
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(RSA) vials are readily available which signicantly reduces
silanols and surface ions on the glass surface,27 they were not
available during the initial stages of the work and thus glass
vials were employed. However, it is stressed that the smallest
glass vials were utilised to minimise the headspace and the
surface area therefore resulting in minimal losses. Incidentally,
plastic vials would not be suitable for GC analyses.
Headspace analysis
Gas chromatography mass spectrometry was used to charac-
terise the VOC (volatile organic compound) content of urine.
Measurements were performed using the following
instrumentation:
 CTC CombiPal Autosampler (CTC Analytics, Switzerland):
to automatically introduce the sample into the inlet.
 Agilent 6890 GC with S/SL inlet (Agilent Technologies, CA,
USA): a gas chromatograph with an injector to introduce the
vaporised sample onto the column.
 Leco Pegasus 4D ToFMS (Leco Corp., MI, USA): a time of
ight mass spectrometer.
A total of 832 urine (C1, C2, C3, TCC1, TCC2 and TCC3)
samples were randomly analysed over 9 batches and inter-
spersed with either a bre blank (no sample) or sample blank
(urine replaced with 0.5 ml deionised water) aer every 5
injections. All samples were prepared by placing a 0.5 ml
sample in a pre-conditioned 10ml headspace vial containing 1 g
anhydrous sodium sulphate (Fisher Scientic UK Ltd., Lough-
borough, UK) conditioned overnight at 100 C and 1.5 ml of 0.1
M hydrochloric acid (Fisher Scientic UK Ltd., Loughborough,
UK). An internal standard in the form of deuterated (d6-) phenol
(ISOTEC, Miamisburg, Ohio, USA) at a concentration of 100 mg
ml1 was spiked (10 ml) into the vial which was immediately
capped. This mixture was pre-equilibrated for 10 minutes at 60
C. A pre-conditioned 75 mm carboxen/PDMS ber (Sigma-
Aldrich, Dorset, UK) was inserted for 5 minutes to extract the
volatile organic compounds and then the ber was exposed in
the GC inlet at 280 C for 2 minutes under splitless conditions
to desorb the analytes onto the column. In this work, only one
column was employed in the GC-ToF-MS instrument. The ana-
lytes were thus separated on a BP624 30 m  0.25 mm internal
diameter with a 1.4 mm lm thickness column (SGE Analytical
Science, Victoria, Australia) with the oven programmed from 30
C (2 minute hold) to 240 C at 20 C min1 (hold 1.5 min). The
data were collected at 10 spectra per second across the mass
range 33–350 m/z. The mass range started at m/z 33 so as to
avoid background interferences and higher baselines from the
oxygen (m/z 32) and nitrogen (m/z 28) and using this headspace
technique in order that analytes with amolecular weight greater
than 350 amu would not be introduced into the GC. The
reproducibility of the method was checked before measure-
ments of the samples were made in triplicate.
Finally, the data were stored in NetCDF format (Network
Common Data Form). These are binary les (i.e. cannot be
opened in a standard text editor, such as NotePad) in which
specic information is stored and all zero values are removed in
order to minimise the storage space used on a hard drive. All
information is stored as row vectors. Information includes
some of the following:
 Total_intensity: the sum of the abundances across all of the
retention times. The length of the vector is the number of
retention time scans.
 Scan_acquisition_time: the vector of retention time values
containing the time values in minutes.
 Scan_index: the index values indicating the starting posi-
tions of each retention time scan in the mass_values and
intensity_values vectors (see below). The length of the vector is
the number of retention time scans.
 Point_index: this gives the number of non-zero data points
for each retention time value. The length of the vector is the
number of retention time scans.
 Mass_values: the actual mass-to-charge (m/z) values corre-
sponding to the non-zero values. The length of the vector is the
sum of all the numerical values in the point_index vector.
 Intensity_values: the corresponding intensity values for
each of the respective mass values. The length of the vector is
the sum of all the numerical values in the point_index vector.
Data analysis
The provided NetCDF data les were processed and analysed
using MATLAB (R2011a, MathWorks Inc, USA). Each le con-
tained the information of the full spectral information of one
sample, a chromatogram, which was stored in a data matrix of
size m/z_values  scans. From a data storage point of view, all
samples build a cube – one chromatogram arranged behind the
other. Every single entry of the data matrix of one sample
represents the abundance of a specic ion at a certain point of
time. Each column in the matrix can be interpreted as a mass
spectrum. A typical mass spectrum is usually represented as
a “stick diagram”, displaying the relative current induced by
ions of alternating mass-to-charge ratio. But when it comes to
Table 1 Baseline characteristics of the subjects within each transitional cell carcinoma of the bladder (TCC) and control (C) group (N ¼ 259)
Group No. of subjects No. of males No. of females Age range (y) Median age (y)
TCC1 17 12 5 59–82 74.0
TCC2 28 19 9 50–86 66.5
TCC3 27 15 12 56–88 75.5
C1 70 29 41 18–31 26.0
C2 71 35 36 18–32 25.0
C3 46 8 38 50–89 66.0
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the storage of the data and the computational data processing
point of view, each mass spectrum is represented as an array of
numbers. The rows of a GC-MS chromatogram represent single
ion count (SIC) chromatograms. This fact allows inferring the
total ion count (TIC) chromatogram by summing up the
columns. This data reduction was necessary, as the majority of
multivariate data analysis techniques require two-dimensional
data.
For each NetCDF data le that was imported into the MAT-
LAB environment, and based on the knowledge of the contents
of the NetCDF le given previously, the GC-MS data matrix was
reconstructed to the order of m/z_values  scans re-inserting
zero values where appropriate into the single ion count (SIC)
chromatograms. All of the abundance values were normalised
against the abundance values of the deuterated (d6-) phenol
internal standard (atm/z 99). Them/z values are summed so that
a row vector is generated whose length is the number of scans
(i.e. the retention time values). The same process is repeated
with the remaining NetCDF les. Finally, all row vectors are
combined into a data matrix of the order samples  scans. Fig. 1
illustrates the relationship among the elements within a single
data matrix and demonstrates the formation of the dataset
containing the TIC of each sample.
As the process required chromatograms to be warped in time
to align corresponding peaks, correlation optimised warping
(COW) was applied28,29 on these data prior to further data
analysis. The “retention time shis” can be caused by physical
changes in the column, mobile phase composition, instru-
mental dri and interaction between analytes, and these must
be corrected.30 Although other warping methods exist,31–34 COW
was employed due to the ability to preserve peak shape and
area, in addition to the ability to deduce the optimal parameters
required for alignment of the retention time peaks.29 The
deduced optimal parameters are the segment (the number of
data points per interval) and the slack (the extent of warping/
shiing of the peaks in any direction). The segment and slack
values attained for C1 v TCC, C2 v TCC, C3 v TCC, C3 v TCC1, C3
v TCC2, and C3 v TCC3 were {31, 1}, {23, 1}, {6, 1}, {23, 1}, {19, 1}
and {6, 1} respectively.
Exploratory data analysis was accomplished via principal
components analysis (PCA) and hierarchical cluster analysis
(HCA), which are the most widely used multivariate statistical
techniques.15,35 This was performed to reveal natural groupings
based on the chromatograms of the GC-MS via the character-
istics that cause the greatest variance in the dataset.
Next, three pattern recognition tools were employed via
custom-written scripts to build classication models using the
cancer status of the samples: partial least squares discriminant
analysis (PLS-DA), random forests (RFs) and support vector
machines (SVMs). For PLS-DA, the PLS Toolbox 3.5 (Eigenvector
Research Inc., USA) was employed in MATLAB R2011a (Math-
Works Inc., Nattick, USA); for SVMs the libsvm3.20 toolbox was
employed; for RFs, MATLAB wasmade to call the RandomForest
package in R (3.0.2). All three techniques call for information
about the parameter of interest (the cancer status) to be known
in order to train the algorithm to identify those molecules that
diﬀerentiate between the classes.
PLS-DA is considered to be a dimensionality reduction
method and can be seen as the regression extension of principal
components analysis.36 Unlike PCA, which attempts to describe
the maximum variation in the measured data, PLS-DA tends to
maximise the covariance between the input data and the output
class. The information returned by PCA is that which was
caused by the attribute with the biggest variance. In contrast,
PLS-DA returns only data that were caused by the property
under investigation.
It is known that PLS-DA is prone to overestimate the accuracy
of classication if it is not accurately validated.37 For this reason
the number of latent variables (LVs) was varied from 1 to 20 in
each test run. Furthermore a very thorough evaluation process –
bootstrapping with optimisation by leave-one-out cross-valida-
tion (LOOCV)38,39 – was implemented to assess the performance
of the PLS-DA classier. In each bootstrap evaluation, the
dataset was randomly split into two subsets: the rst subset was
the bootstrap training set which would be used to determine the
optimum model parameters via LOO-CV and was made up of
70% of the original dataset; the remaining 30% formed the
bootstrap testing set which would be used to evaluate the model
at the determined optimum LV. This whole process was
repeated for the next bootstrap evaluation until all 150 evalua-
tions had taken place. A set of statistical parameters are then
calculated such as the overall accuracy, specicity, sensitivity
and the area under the receiver operating characteristic
(AUROC) curve which uses the trapezoid rule.40 This method
ensures that validation is sequentially performed on each
sample using a model that excludes the data from that sample.
Two machine learning algorithms were also employed:
random forests21 and support vector machines.23 In order to
ensure the optimum number of trees was employed for random
forests, they were varied from 50 up to 450 in steps of 100. The
linear kernel was employed for SVM. During the optimisation
process of the linear kernel the cost values applied were 0.5, 1.0,
2.0, 4.0 and 8.0. These two machine learning approaches were
Fig. 1 Storage of the full spectral information of one GC-MS data
sample. Each column of the data matrix represents a single mass
spectrum. Every row can be seen as a single ion count (SIC) chro-
matogram. Therefore the sum of all columns results in the total ion
count (TIC) chromatogram.
4040 | Anal. Methods, 2016, 8, 4037–4046 This journal is © The Royal Society of Chemistry 2016
Analytical Methods Paper
integrated into the bootstrapping procedures described in the
previous paragraph.
As nal validation of the results, and to attain an indication
of the statistical signicance of the results, permutation testing
involving a Monte Carlo simulation was used to evaluate the
obtained results.38 This involved repeated random sampling. In
this context a null model was generated from a set of data that
was statistically similar to the data under study, but for which it
was not expected to be able to build a meaningful classication
model. For each of the 6 datasets (C1 v TCC, C2 v TCC, C3 v TCC,
C3 v TCC1, C3 v TCC2, and C3 v TCC3), random class assigna-
tions were made to the samples in the datasets 300 times.
Within each random assignation, the datasets were subjected to
the bootstrap procedure described previously. For a disease
discriminating model trained on the real sample classes to be
considered statistically signicant it needs to achieve a classi-
cation accuracy towards the extremities of those produced by
the null models.
Results and discussion
Exploratory analysis via PCA and HCA
The visual outputs of the two independent exploratory tech-
niques of principal components analysis (PCA) and hierarchical
cluster analysis (HCA) did not disclose any separation by cancer
status of the samples, in any of the experiments. Other inu-
ences such as age, diet or gender may be responsible for the
groupings obtained. However, this does not mean that the data
do not contain any information concerning bladder cancer. The
PCA was able to demonstrate that the cancer status was not
responsible for the bigger part of the variance, captured by the
rst two or three principal components (PCs). Nevertheless,
investigating principal components of lower variance did not
lead to an explicitly disease-related diﬀerentiation, either.
Pattern recognition via PLS-DA, SVMs and RFs
Table 2 compares the results attained via the machine learning
algorithms of support vector machines (SVMs) and random
forests (RFs) along with the multivariate statistical technique of
partial least squares discriminant analysis (PLS-DA). Each
chromatogram contained approximately 8400 data points, i.e.
all of the features. This enables multivariate methods such as
PLS-DA to be able to detect “hidden features” that are crucial for
the model to distinguish between cancer and control samples,
which univariate methods are not able to identify properly.
It is clear to see that the C3 v TCC1 dataset has been the most
diﬃcult to classify due to the nature of the datasets: TCC1 being
the low grade and C3 other urological diseases. The random
forests and support vector machines algorithms have not per-
formed as well as the partial least squares discriminant analysis
algorithm in this instance. As far as the classication models
are concerned, the classiers were trained with the two most
disparate groups: control 1 (C1), representing healthy males or
females, and the TCC groups incorporating people suﬀering
from bladder cancer. Since group C1 possesses the most
diﬀerences compared to the cancer group, the classication
outcome of this sample set was expected to be the best. However
this was surprisingly not the case. A mean total accuracy of
87.5%, 89.0% and 80.9% were attained for PLS-DA, SVM and RF
respectively.
Next, the classier with control 2 (C2) and the cancer group
(TCC) data was trained. Urine samples within this control
subgroup showed similar abnormalities on dipstick analysis to
some cancer samples, such as blood, for example, and were
therefore more diﬃcult to distinguish from cancerous samples
than control 1 (C1) samples. However, the achieved specicity
contradicts this (for example, PLS-DA at 88.2% compared with
87.2% for C1). The overall classied accuracies attained were
greater for each classier than C1.
In the third experiment, the classier had to distinguish
between samples with conrmed non-cancerous urological
diseases (control 3) and cancerous samples (TCC). This was
expected to be the most diﬃcult combination, as disease
markers not specic to bladder cancer are likely to be present.
The achieved total accuracies appeared to perform better than
expected as they attained values of 83.0%, 83.5% and 83.6% for
PLS-DA, SVM and RF respectively. However it is noted that the
specicities attained were especially poor for SVM Lin and RF
(<50%) yet PLS-DA was at 66.1% suggesting that PLS-DA is the
better algorithm. The specicity values attained can be attrib-
uted to the unbalanced nature of the data since the TCC
subgroup is far greater (combining TCC1, TCC2 and TCC3) than
the C3 subgroup (Table 1) suggesting that the models learn
better the patterns attributed to the TCC groupmore so than the
C3 group.
The remaining experiments focusing on C3 versus the TCC
cancer grades (TCC1, TCC2 and TCC3) show that SVM-Lin was
better than PLS-DA and RF at discriminating the control (C3)
from the TCC grades due to the overall and sensitivities attained
for C3 v TCC2 and C3 v TCC3 (SVM > PLS-DA > RF). However, for
C3 v TCC1, PLS-DA was shown to be better than SVM and RF,
especially as the latter two only achieved sensitivities of 41.4%
and 54.0% respectively. This suggests that the PLS-DA classier
was able to distinguish to a certain extent the C3 control from
the low grade TCC (TCC1) whilst SVM and RF could not. From
a clinical perspective, the ability to distinguish between the C3
control and TCC1 is of paramount importance.
To assess the signicance of the presented results, permu-
tation testing via a Monte Carlo simulation was carried out.
Fig. 2 shows the results attained for each of the six experiments
each with 300 random runs (dark grey vertical bars) for the PLS-
DA classier. It also shows the respective distributions of the
observed analytical accuracies attained via the 150 classication
models generated (light grey vertical bars) during the analysis.
Although overlap had been observed in the distributions for
C3 v TCC and C3 v TCC1 (Fig. 2), the Z-test41 was carried out to
test for signicance between themeans of the two distributions.
As Table 3 shows, all calculated probability (p) values were lower
than the critical value (a ¼ 0.05) indicating that the means of
the two distributions are statistically signicantly diﬀerent.
This implies that the controls can be distinguished from TCC as
well as C3 against all of the TCC grades. Furthermore, the area
under the receiver operating characteristic (AUROC) curve
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values calculated for each of the experiments (Table 2) give
further support to the ndings with values ranging from 0.93 for
C2 v TCC to 0.74 for C3 v TCC1 for the PLS-DA classier.
Diagnostic potential
By combining gas chromatography mass spectrometry with
pattern recognition techniques, progress towards a new
instrumental method of bladder cancer detection based on
volatile biomarkers has been made. The obtained results
conrm that there is a clear relationship between the acquired
GC-MS data and the cancer status of the respective samples.
This relationship shows promise as the basis of a non-invasive
diagnostic technique. As many as 88.5% of cancer patients and
88.2% of non-cancerous subjects were correctly classied when
the classier was trained with a combination of TCC positive
urine samples and samples from healthy control groups con-
taining patients diagnosed with some form of non-cancerous
disease such as urinary tract infections (C2).
Samples from group C2 showed abnormalities such as
blood, for example haematuria – blood in the urine – is the most
common symptom of bladder cancer. Samples containing
traces of blood therefore represent a challenge for the distinc-
tion between control samples and bladder cancer samples.
However, the major contributor to this classication outcome
was control group 3. All subjects within this subgroup had
conrmed non-cancerous urological disease, the pathological
eﬀects of which are likely to be similar to the secondary eﬀects
of bladder cancer. Within both these groups, varying amounts
of metabolic products associated with inammation, infection
and/or necrosis will almost certainly be present. Because of this,
control 3 samples form the most important control subset and
contain the most relevant information. Training the classier
with this kind of data is therefore fundamental in order to be
able to subtract general disease compounds present in the urine
from those specic for bladder cancer. Accurate diagnosis of the
control subjects is, of course, paramount to this process, since
the inclusion of false negative individuals would lead to incor-
rect classication rules.
Interestingly, within the TCC sample group, the majority of
those incorrectly classied as negative were from patients with
more advanced tumours. In these cases, it is possible that
metabolic products generated secondarily to the tumour may
overwhelm or mask the volatile cancer biomarkers within the
urine, giving rise to a urine headspace more closely resembling
that of control 3 samples. Canine olfactory studies support this
hypothesis; high grade TCCs with a signicant level of invasion
are missed more frequently by trained dogs than low-grade
supercial tumours.42
Fig. 2 also showed the increase in complexity of the control
samples (C1 to C3) as reected in the poorer performing models
with overall classications of 80%, 80% and 73% for C1,
C2 and C3 respectively. In most cases, the best performing
models were shown to achieve an overall classication of 95%
for both C1 and C2, and 92% for C3. More so, Fig. 2 clearly
illustrates the diﬃculty in distinguishing the C3 control group
from the TCC1 cancer group via PLS-DA. This was also observed
via support vector machines (SVMs) and random forests (RFs)
suggesting that a more rigorous modelling algorithm/machine
learning technique is warranted in conjunction with data pre-
processing and pre-treatment methods.
Visualisation of the PLS-DA loadings revealed a number of
possible metabolites/compounds which could be potential
biomarkers for the determination of TCC. These are summar-
ised in Table 4. As is oen the case with complex samples
analysed by GC-MS, the identity of some compounds deter-
mined through using NIST (National Institute of Standards and
Technology) and MassBank (http://www.massbank.jp) is less
Table 2 Performances of machine learning algorithms. LV denotes the best number of latent variables (PLS-DA); tree denotes the optimum
number of trees for Random Forest (RF). Lin denotes Linear kernel for support vector machines (SVMs); TCC implies TCC1, TCC2 and TCC3
combined; AUROC is the area under the receiver operating characteristic curve
Dataset Model comparison % overall % spec % sens LV or tree AUROC
C1 v TCC PLS-DA 87.53 87.23 87.82 16 0.906
SVM Lin 88.99 88.84 89.13 — 0.935
RF 80.91 80.28 81.75 450 0.892
C2 v TCC PLS-DA 88.35 88.21 88.48 12 0.928
SVM Lin 89.18 88.00 90.33 — 0.922
RF 82.70 82.93 82.72 450 0.865
C3 v TCC PLS-DA 83.01 66.06 88.66 8 0.8680
SVM Lin 83.48 44.36 96.52 — 0.9023
RF 83.57 42.90 86.99 150 0.8427
C3 v TCC1 PLS-DA 69.18 66.18 73.29 13 0.7424
SVM Lin 67.30 86.15 41.38 — 0.6363
RF 67.33 77.63 54.03 450 0.7102
C3 v TCC2 PLS-DA 80.51 71.39 88.23 7 0.8985
SVM Lin 81.44 72.15 89.31 — 0.9040
RF 75.87 64.31 86.66 350 0.8642
C3 v TCC3 PLS-DA 79.70 73.48 85.17 20 0.8580
SVM Lin 81.46 73.91 88.11 — 0.9283
RF 74.44 66.76 81.64 350 0.8098
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certain due to incomplete separation and similar library spectra
for diﬀerent (but related) compounds. However, based on the
most likely compound identication, the list does not seem to
concur with the list of biomarkers suggested by Pasikanti et al.43
Yet some of the suggested compounds in Table 4 have been
identied as being signicant in colo-rectal cancer, i.e. 2-pen-
tanone, hexanal and 2,3-butanedione44 (suggested in Table 4 to
decrease from C3 to TCC); 3-hydroxyanthranilic acid has been
found in bladder cancer45 (suggested in Table 4 to increase from
C3 to TCC). In addition, 4-heptanone (suggested in Table 4 to
Fig. 2 Distribution of the overall percentage classiﬁed after randomised assignation of classes to the samples (dark grey vertical bars) corre-
sponding to each of the six experiments via the PLS-DA classiﬁer. Number of runs: 300. The light grey vertical bars denote distribution of the
observed accuracies attained via the classiﬁcation models (150 runs). It can be seen that the respective means of the accuracy attained (the
maxima of the rightmost distribution curve) is beyond two standard deviations of the respective permutation means (the maxima of the leftmost
distribution curve) indicating that statistically signiﬁcant results had been achieved at the 95% conﬁdence level. This is further corroborated in
Table 3. Conﬁdence intervals (CI) for evaluations: (C1 v TCC: mean: 87.5%; CI (95%): 82–94%); (C2 v TCC: mean: 88.4%; CI (95%): 82–95%); (C3 v
TCC: mean: 83.0%; CI (95%): 75–91%); (C3 v TCC1: mean: 69.2%; CI (95%): 54–84%); (C3 v TCC2: mean: 80.5%; CI (95%): 70–90%); (C3 v TCC3:
mean: 79.7%; CI (95%): 68–91%).
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decrease from C3 to TCC) was reported to be a marker for
bladder cancer when human urine was analysed via headspace
GC-MS.46 Other chemicals have been reported in the medical
literature, but not as cancer markers. For example, piperitone
has been reported to inhibit the cervical cancer cell-line
growths,47 benzoic acid (suggested in Table 4 to increase from
C3 to TCC) reduces bladder cancer when as a functional group
within the retinoid-related molecule AGN193198,48 and butyro-
phenone (suggested in Table 4 to increase from C3 to TCC) is
employed in the treatment of schizophrenia and other central
nervous disorders49 though it is unclear if any patients were
taking this medication.
It should be noted that some biomarkers are almost ubiq-
uitous biomarkers and can be seen as volatile compounds
emanating from biological systems; examples include: dimethyl
disulphide, 2-butanone, 2-propanol, acetic acid, etc. However,
their relative concentrations may alter due to the presence of
abnormal metabolism, and this may give information about
changes occurring in that system. Though use of an internal
standard had been employed (deuterated phenol), it may not
have accounted for diﬀering concentrations – where it had been
observed during sample preparation that some urine samples
were very watery whilst others more concentrated. However the
same volume of urine was always taken therefore it is possible
to make use of a naturally occurring internal standard such as
creatinine. Furthermore, the concentration of acetic acid in the
headspace may increase if the pH surrounding a tumour is
lowered because it pushes the chemical equilibrium away from
the acetate ion and to the acetic acid molecule which is much
more volatile and hence detectable by this method. For this
reason, it is quite reasonable that some “cancer biomarkers” are
in fact compounds found under non-cancerous circumstances,
but with varying relative concentrations; these can still form the
basis for a diagnostic test.
Although Pasikanti and colleagues claim 100% sensitivity in
identifying human bladder cancer,43 there is no specic
mention of identifying transitional cell carcinoma (TCC) in
conjunction with applying any retention time shi corrections.
The authors have also not specied the clinical diagnoses of any
of their controls (only that they had bladder cancer symptoms,
but were cystoscopy negative), so the nature, severity or chro-
nicity of their urological conditions are currently not known.
Though the article by Khalid et al.8 reported a success of 96%
accuracy using two alternative statistical approaches, the rst
involving a simple linear discriminant analysis on 9 selected
time points, and the second employing PLS-DA on all time
points, both approaches only employed leave-one-out cross-
validation. This has been shown to give overoptimistic results
and it is thus recommended to employ a more thorough vali-
dation approach employing cross-model validation and
permutation testing37 as has been employed in this work, and
thus permitting greater condence and reliability in the results
presented. Finally, recent work has been reported in which
nanoparticles are employed in conjunction with cystoscopy to
improve the recognition of tumours, for example distinguishing
at lesions from non-malignant cells, yet though outcomes are
positive, there is still an invasive element to the procedure.50
Finally, in a recent paper by Aggio et al., it was reported that
a GC-sensor was able to distinguish in urine prostate cancer
from controls, bladder cancer from controls, and bladder
cancer from prostate cancer via an in-house data processing
and analysis pipeline reporting very high ([90%) accuracies,
sensitivities and specicities.51 It was stated that “diﬀerent
VOCs are associated with the two urological disorders” however
it must be suggested that it is very likely that there will also be
the same VOCs present in both cancers. Both statements can be
corroborated via the use of mass spectrometry in order to
identify compounds, the potential of which have been demon-
strated in this work, and are acknowledged by the authors for
their future work.
Conclusions
PLS-DA-derived models gave a mean accuracy for patients pre-
senting with other non-cancerous urological disease of 88.4%,
with 88.5% sensitivity and 88.2% specicity for C2 versus TCC
(TCC1, TCC2 and TCC3 combined). SVM-derived models had
given a mean accuracy of 89.2%, with a sensitivity of 90.3% and
specicity of 88.0%. Although the specicities achieved were
Table 3 Determination of statistical signiﬁcance via the Z-test for the
overlapping distributions in Fig. 2 (permutation “null” models in dark
grey and observed classiﬁcation in light grey) for PLS-DA. Calculated
p-value is the probability at the 95% conﬁdence level (a ¼ 0.05)
Case
Overall accuracy
(%)
Z value
(Zcrit ¼ 1.96)
p-Value
(a ¼ 0.05)
Signicant
diﬀerence
C1 v TCC 87.53 143.61 <0.0001 Yes
C2 v TCC 88.35 147.54 <0.0001 Yes
C3 v TCC 83.01 32.02 <0.0001 Yes
C3 v TCC1 69.18 24.42 <0.0001 Yes
C3 v TCC2 80.51 66.07 <0.0001 Yes
C3 v TCC3 79.70 56.70 <0.0001 Yes
Table 4 A list of possible biomarkers identiﬁed from the PLS-DA
loadings in conjunction with the NIST and MassBank databases.
Change denotes the median value of abundance from control (C3) to
cancer (TCC)
Compound Database Change
2-Pentanone NIST & MassBank Decrease
2,3-Butanedione MassBank Decrease
4-Heptanone MassBank Decrease
Dimethyl disulphide NIST Decrease
Hexanal NIST Increase
Benzaldehyde MassBank Increase
Butyrophenone MassBank Increase
3-Hydroxyanthranilic acid MassBank Increase
Benzoic acid MassBank Increase
trans-3-Hexanoic acid MassBank Increase
cis-3-Hexanoic acid MassBank Increase
2-Butanone NIST Increase
2-Propanol NIST Decrease
Acetic acid NIST Decrease
Piperitone MassBank Decrease
Thujone MassBank Decrease
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marginally less than that of conventional urine cytology (typi-
cally >90% specicity), sensitivity was very close to typical range
of 80–90% for high-grade tumours52 and thus better than the
typical range of 20–50% for low-grade tumours,3 case in point,
the sensitivity attained for C3 v TCC1 was 73.3% which is
considerably better than the “gold-standard” of 20–50%. Of
course, further improvement is still highly warranted.
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